diff --git a/PRODUCT.md b/PRODUCT.md index cfc3c50..795f01f 100644 --- a/PRODUCT.md +++ b/PRODUCT.md @@ -140,7 +140,7 @@ Output: a single append-only markdown file with blind research, structured debat - [ ] More adapters (Cursor, Windsurf, Aider) ### Future -- [ ] 3+ participant panels with role assignment +- [x] ~~3+ participant panels with role assignment~~ — Eval showed 5-agent is counterproductive (92% coverage vs 97% for 2-agent, 2x cost). Cross-model diversity > agent count. - [ ] Async mode (participants contribute hours/days apart) - [ ] Web viewer for discussion logs - [ ] Cost tracking (tokens per discussion) diff --git a/README.md b/README.md index 0d64e99..c3ad915 100644 --- a/README.md +++ b/README.md @@ -60,12 +60,20 @@ This installs the `/discuss` command and the council orchestrator script to `~/. That's it. Two AI instances debate the topic with full reasoning and produce a consensus. Everything runs from one terminal — no copy-pasting between windows, no manual coordination. -By default, both debaters use the same AI you're running the command in — two Claudes in Claude Code, two Codex instances in Codex. To run a cross-model debate: +By default, both debaters use the same AI you're running the command in — two Claudes in Claude Code, two Codex instances in Codex. **For best results, use cross-model debates** — different models have different blind spots, so Claude + Codex produces better analysis than two instances of either model alone (see [eval results](tests/eval-results/)): ``` /discuss "Should we use a monorepo?" monorepo.md --agents claude,codex ``` +### Discuss a PR + +``` +/discuss --pr 123 +``` + +Two agents debate the design decisions in a pull request — not code style, but architectural tradeoffs, approach, and alternatives. Posts the consensus as a PR comment when done. + ### From Codex CLI Point Codex to the adapter file in this repo: diff --git a/adapters/claude/.claude/commands/discuss.md b/adapters/claude/.claude/commands/discuss.md index 60acbc8..0d828f1 100644 --- a/adapters/claude/.claude/commands/discuss.md +++ b/adapters/claude/.claude/commands/discuss.md @@ -8,6 +8,7 @@ A single command for structured, turn-based AI discussions. Supports three modes /discuss "topic" file.md → council mode (default): orchestrates two Claude instances debating to completion /discuss "topic" file.md --agents claude,codex → council with cross-model debate (Claude vs Codex) /discuss "topic" file.md --mode external → external mode: creates discussion file, waits for another AI to join manually +/discuss --pr 123 → PR discussion: debate the design decisions in a pull request /discuss file.md → join mode: joins an existing discussion as a participant ``` @@ -46,13 +47,14 @@ When invoked, print this to the user so they know what's happening: Parse the user's input to determine the mode: -1. If a **topic string in quotes** AND a **file path** are provided: +1. If `--pr NUMBER` is provided → PR discussion mode (see below) +2. If a **topic string in quotes** AND a **file path** are provided: - Check for `--mode external` flag → external mode - Check for `--agents X,Y` flag (council mode only) → set `agent_a_cli` and `agent_b_cli` (e.g. `--agents claude,codex`) - Check for `--lens LENS_ID` flag (council mode only) → set `lens_id` directly, skip picker. Validate against the IDs in `~/.claude/scripts/prompts/lenses.json`. If the ID is not found, error with the list of valid IDs from the registry. - Otherwise → council mode (default) -2. If **only a file path** is provided and the file exists → join mode -3. If **only a file path** is provided and the file does NOT exist → error: "File not found. To start a new discussion, provide a topic: `/discuss \"your topic\" file.md`" +3. If **only a file path** is provided and the file exists → join mode +4. If **only a file path** is provided and the file does NOT exist → error: "File not found. To start a new discussion, provide a topic: `/discuss \"your topic\" file.md`" --- @@ -129,6 +131,105 @@ For each response turn, follow the **Turn Structure** below. --- +## PR Discussion Mode (`--pr`) + +Debates the design decisions in a pull request. This is not a code review — it's a structured discussion about the architectural tradeoffs, design choices, and approach taken in the PR. + +### How it works + +1. **Gather PR context** using `gh` CLI: + ```bash + gh pr view NUMBER --json title,body,baseRefName,headRefName + gh pr diff NUMBER + ``` + +2. **Generate the topic** from the PR title and body. The topic should frame the discussion around the design decisions, not the code style. + +3. **Create the discussion file** as `pr-NUMBER-discussion.md` in the current directory. Include the PR context as a preamble section before the Key Questions: + + ```markdown + --- + topic: "" + mode: council + pr_number: NUMBER + lens_id: "simplicity-vs-correctness" + selection_mode: "default" + max_rounds: 5 + git_commit: none + agent_a: "Claude Agent A" + agent_b: "Claude Agent B" + agent_a_cli: "claude" + agent_b_cli: "claude" + agent_a_lens: "simplicity/pragmatism" + agent_b_lens: "correctness/rigor" + status: researching + turn: A + round: 0 + created: + last_updated: + --- + + # Discussion: + + ## PR Context + + **PR #NUMBER:** + **Branch:** <head> → <base> + + ### Description + <PR body> + + ### Diff Summary + <summary of changed files and key changes — not the full diff> + + ## Key Questions + 1. [Generated from the PR — focus on design/architecture decisions] + 2. ... + 3. ... + ``` + +4. **Default lens is `simplicity-vs-correctness`** — most PR discussions are about design tradeoffs. The picker is still shown so the user can override. + +5. **Run the orchestrator** as normal: `node ~/.claude/scripts/headless-council.js pr-NUMBER-discussion.md` + +6. **Post the consensus as a PR comment** when done: + ```bash + gh pr comment NUMBER --body "$(cat <<'EOF' + ## AI Council Discussion + + <formatted consensus summary from the discussion> + + <link to full discussion file> + EOF + )" + ``` + +Print to the user: +> Starting PR discussion for #NUMBER: "<PR title>" +> Lens: simplicity-vs-correctness (enter to accept, or pick 1-3) +> Output: pr-NUMBER-discussion.md +> Running... + +When complete: +> Discussion complete. Consensus posted as PR comment. +> Full discussion: pr-NUMBER-discussion.md + +### What it focuses on + +The PR discussion should focus on: +- Is this the right approach / abstraction? +- What are the tradeoffs being made? +- What alternatives were considered (or should have been)? +- Does this scale to the known future requirements? +- Are there hidden assumptions or coupling? + +It should NOT focus on: +- Code style, naming, formatting +- Individual line-level bugs (that's code review) +- Test coverage specifics + +--- + ## Council Mode (`--mode council`) Orchestrates two independent top-level Claude instances that debate the topic with full reasoning capabilities. Each instance runs as a separate `claude -p` process with `--effort max`, ensuring extended thinking is available for every turn. The orchestrator (you) manages the discussion file, frontmatter, and turn sequencing. diff --git a/docs/research.md b/docs/research.md index 55c54a9..5aaa2c5 100644 --- a/docs/research.md +++ b/docs/research.md @@ -46,6 +46,12 @@ Eo et al. show that debate does not need to happen on every problem, and adaptiv Source: [Debate Only When Necessary: Adaptive Multiagent Collaboration for Efficient LLM Reasoning](https://arxiv.org/abs/2504.05047) +### Agent roles and multi-agent chat rooms + +MindStudio (2026) provides a practical guide to multi-agent debate with distinct personas (advocate, skeptic, synthesizer). Recommends 3-5 agents with a neutral synthesizer for tie-breaking. Our own eval (15 discussions, 5 configs, 3 topics) found that 3 agents with synthesizer matches cross-model quality, but 5 agents is counterproductive — agents go deep on their role's angle and lose breadth. Cross-model diversity (Claude + Codex) consistently outperforms same-model multi-agent setups. + +Source: [How to Build Agent Chat Rooms: Multi-Agent Debate for Better AI Outputs](https://www.mindstudio.ai/blog/agent-chat-rooms-multi-agent-debate-claude-code) + ## Caveat A [2025 ICLR analysis](https://d2jud02ci9yv69.cloudfront.net/2025-04-28-mad-159/blog/mad/) noted that multi-agent debate doesn't consistently outperform simpler methods like chain-of-thought on all benchmarks. The benefits are most pronounced on tasks requiring diverse perspectives, factual verification, and structured reasoning —which is exactly what this tool targets. diff --git a/scripts/headless-council-n.js b/scripts/headless-council-n.js new file mode 100644 index 0000000..27b1ae7 --- /dev/null +++ b/scripts/headless-council-n.js @@ -0,0 +1,730 @@ +#!/usr/bin/env node + +// headless-council-n.js — N-agent council orchestrator +// +// Extends headless-council.js to support 2-5 agents with distinct roles. +// Backward compatible with 2-agent frontmatter (agent_a/agent_b). +// +// Usage: node scripts/headless-council-n.js <discussion-file.md> +// +// N-agent frontmatter format: +// agent_count: 3 +// agent_config: "3-agent" (references roles.json configurations) +// agent_cli: "codex" (all agents use this CLI, or per-agent below) +// agent_A_cli: "claude" (override CLI for specific agent) +// agent_B_cli: "codex" +// +// Falls back to 2-agent mode if agent_count is absent. + +const { execSync, spawn } = require("child_process"); +const fs = require("fs"); +const path = require("path"); +const os = require("os"); + +// --- Constants --- + +const CONVERGENCE = { + CONVERGING: "CONVERGING", + PARALLEL: "PARALLEL", + DEADLOCKED: "DEADLOCKED", + DIVERGING: "DIVERGING", +}; + +const STATUS = { + RESEARCHING: "researching", + DISCUSSING: "discussing", + CONSENSUS: "consensus", + DEADLOCK: "deadlock", + CONVERGED: "converged", +}; + +// --- Registries --- + +const PROMPTS_DIR = path.join(__dirname, "prompts"); +const LENSES_PATH = path.join(PROMPTS_DIR, "lenses.json"); +const ROLES_PATH = path.join(PROMPTS_DIR, "roles.json"); + +let LENSES, ROLES; +try { + LENSES = JSON.parse(fs.readFileSync(LENSES_PATH, "utf-8")); +} catch (err) { + console.error(`Failed to load lens registry: ${LENSES_PATH}`); + process.exit(1); +} +try { + ROLES = JSON.parse(fs.readFileSync(ROLES_PATH, "utf-8")); +} catch (err) { + console.error(`Failed to load roles registry: ${ROLES_PATH}`); + process.exit(1); +} + +// --- CLI Profiles --- + +const CLI_PROFILES = { + claude: { + name: "Claude", + binary: "claude", + buildCmd: (promptFile, cwd) => + `cd "${cwd}" && cat "${promptFile}" | claude -p --effort max --output-format text --allowedTools "Read,Grep,Glob,Bash"`, + check: () => { + execSync("which claude", { stdio: "pipe" }); + execSync("claude --version", { stdio: "pipe" }); + }, + }, + codex: { + name: "Codex", + binary: "codex", + buildCmd: (promptFile, cwd) => + `cat "${promptFile}" | codex exec --full-auto --skip-git-repo-check -C "${cwd}" -`, + check: () => { + execSync("which codex", { stdio: "pipe" }); + }, + }, +}; + +// --- Helpers --- + +function log(msg) { + process.stderr.write(`[council-n] ${msg}\n`); +} + +function getProfile(cliName) { + const profile = CLI_PROFILES[cliName]; + if (!profile) { + throw new Error( + `Unknown CLI "${cliName}". Supported: ${Object.keys(CLI_PROFILES).join(", ")}` + ); + } + return profile; +} + +function preflight(cliNames) { + const results = {}; + for (const name of [...new Set(cliNames)]) { + const profile = getProfile(name); + try { + profile.check(); + results[name] = true; + log(`Preflight OK: ${profile.name} (${profile.binary})`); + } catch { + results[name] = false; + log(`Preflight FAILED: ${profile.name} (${profile.binary}) not available`); + } + } + return results; +} + +function parseFrontmatter(content) { + const match = content.match(/^---\n([\s\S]*?)\n---/); + if (!match) throw new Error("No frontmatter found"); + const fm = {}; + for (const line of match[1].split("\n")) { + const idx = line.indexOf(":"); + if (idx === -1) continue; + const key = line.slice(0, idx).trim(); + let val = line.slice(idx + 1).trim(); + if (val.startsWith('"') && val.endsWith('"')) val = val.slice(1, -1); + fm[key] = val; + } + return fm; +} + +function updateFrontmatter(content, updates) { + return content.replace(/^---\n([\s\S]*?)\n---/, (_, fm) => { + let updated = fm; + for (const [key, val] of Object.entries(updates)) { + const re = new RegExp(`^${key}:.*$`, "m"); + if (re.test(updated)) { + updated = updated.replace(re, `${key}: ${val}`); + } else { + updated += `\n${key}: ${val}`; + } + } + return `---\n${updated}\n---`; + }); +} + +function preparePromptFile(promptText, tmpDir) { + const promptFile = path.join( + tmpDir, + `prompt-${Date.now()}-${Math.random().toString(36).slice(2, 8)}.txt` + ); + fs.writeFileSync(promptFile, promptText); + return promptFile; +} + +function runAgent(promptText, cliName, tmpDir, cwd) { + const profile = getProfile(cliName); + const promptFile = preparePromptFile(promptText, tmpDir); + const cmd = profile.buildCmd(promptFile, cwd); + + try { + const result = execSync(cmd, { + encoding: "utf-8", + timeout: 600000, + maxBuffer: 1024 * 1024 * 50, + stdio: ["pipe", "pipe", "pipe"], + }); + return result.trim(); + } catch (err) { + log(`${profile.name} call failed: ${(err.message || "").slice(0, 200)}`); + return null; + } +} + +function runAgentsParallel(agentConfigs, tmpDir, cwd) { + return Promise.all( + agentConfigs.map( + ({ promptText, cliName, label }) => + new Promise((resolve) => { + const profile = getProfile(cliName); + const promptFile = preparePromptFile(promptText, tmpDir); + const cmd = profile.buildCmd(promptFile, cwd); + + const child = spawn("sh", ["-c", cmd], { + stdio: ["pipe", "pipe", "pipe"], + }); + + let stdout = ""; + let stderr = ""; + child.stdout.on("data", (d) => (stdout += d)); + child.stderr.on("data", (d) => (stderr += d)); + + const timeout = setTimeout(() => { + child.kill("SIGTERM"); + log(`${label || profile.name} timed out after 10min`); + resolve(null); + }, 600000); + + child.on("close", (code) => { + clearTimeout(timeout); + if (code !== 0) { + log(`${label || profile.name} exited ${code}: ${stderr.slice(0, 200)}`); + resolve(null); + } else { + resolve(stdout.trim()); + } + }); + child.on("error", (err) => { + clearTimeout(timeout); + log(`${label || profile.name} spawn error: ${err.message}`); + resolve(null); + }); + }) + ) + ); +} + +function runWithRetry(promptText, validator, retryHint, cliName, tmpDir, cwd) { + let result = runAgent(promptText, cliName, tmpDir, cwd); + if (!validator(result)) { + log("Output failed validation, retrying..."); + result = runAgent(promptText + "\n\n" + retryHint, cliName, tmpDir, cwd); + if (!validator(result)) { + log("Retry also failed. Using raw output."); + } + } + return result; +} + +// --- Agent Config Resolution --- + +function resolveAgents(fm) { + const agentCount = parseInt(fm.agent_count || "2", 10); + const configName = fm.agent_config || `${agentCount}-agent`; + const defaultCli = fm.agent_cli || "codex"; + + const labels = ROLES.agent_labels; + const config = ROLES.configurations[configName]; + + if (!config) { + // Fallback to 2-agent legacy mode + log(`No config "${configName}" found, using legacy 2-agent mode`); + return [ + { + label: "A", + name: fm.agent_a || "Agent A", + cli: fm.agent_a_cli || defaultCli, + roleId: "advocate", + role: ROLES.roles.advocate, + }, + { + label: "B", + name: fm.agent_b || "Agent B", + cli: fm.agent_b_cli || defaultCli, + roleId: "skeptic", + role: ROLES.roles.skeptic, + }, + ]; + } + + return config.agents.map((roleId, i) => { + const label = labels[i]; + const role = ROLES.roles[roleId]; + if (!role) throw new Error(`Unknown role "${roleId}" in config "${configName}"`); + + const cliKey = `agent_${label}_cli`; + const cli = fm[cliKey] || fm[`agent_${label.toLowerCase()}_cli`] || defaultCli; + + return { + label, + name: role.name, + cli, + roleId, + role, + }; + }); +} + +// --- Validation --- + +function validateResearch(output, agent) { + if (!output) return false; + return output.includes(`### Agent ${agent.label}`) && output.includes("Independent Research | research"); +} + +function validateResponse(output, round) { + if (!output) return false; + const hasHeading = /### Round \d+ — .+ \| response \| confidence: \d+%/.test(output); + const hasResponseTo = /\*\*Response to previous point/.test(output); + const hasNewEvidence = output.includes("**New evidence or angle:**"); + const hasPosition = output.includes("**Current position:**"); + const hasQuestion = /\*\*.*question/i.test(output); + if (!hasHeading || !hasResponseTo || !hasNewEvidence || !hasPosition || !hasQuestion) + return false; + if (round >= 3) { + const convergencePattern = Object.values(CONVERGENCE).join("|"); + if (!new RegExp(`Convergence assessment|${convergencePattern}`).test(output)) + return false; + } + return true; +} + +function validateConsensus(output) { + if (!output) return false; + return ( + output.includes("## Consensus Summary") && + output.includes("### Decision") && + output.includes("### Key Contention Points") && + output.includes("### Unresolved Items") && + output.includes("### Confidence:") + ); +} + +function extractConvergence(output) { + for (const state of Object.values(CONVERGENCE)) { + if (new RegExp(state).test(output)) return state; + } + return null; +} + +// --- Templates --- + +const templateCache = {}; +function loadTemplate(name) { + if (!templateCache[name]) { + templateCache[name] = fs.readFileSync(path.join(PROMPTS_DIR, `${name}.template`), "utf-8"); + } + return templateCache[name]; +} + +function fillTemplate(template, vars) { + return template.replace(/\{\{(\w+)\}\}/g, (_, key) => vars[key] ?? ""); +} + +// --- Prompt builders --- + +function buildResearchPrompt(topic, agent) { + return fillTemplate(loadTemplate("n-agent-research"), { + topic, + agent: agent.label, + agentName: agent.name, + roleName: agent.role.name, + lensDesc: agent.role.research_lens, + }); +} + +function buildTurnPrompt(agent, agents, fileContent, round) { + const otherAgents = agents + .filter((a) => a.label !== agent.label) + .map((a) => `${a.name} (Agent ${a.label})`) + .join(", "); + + const convergenceInstr = + round >= 3 + ? fillTemplate(loadTemplate("convergence"), { round: String(round) }) + : ""; + + return fillTemplate(loadTemplate("n-agent-turn"), { + agent: agent.label, + agentName: agent.name, + agentCount: String(agents.filter((a) => !a.role.skip_research).length), + roleName: agent.role.name, + roleMandate: agent.role.discussion_mandate, + fileContent, + round: String(round), + otherAgents, + convergenceInstr, + }); +} + +function buildConsensusPrompt(fileContent, agents) { + const synthesizer = agents.find((a) => a.roleId === "synthesizer"); + if (synthesizer) { + return fillTemplate(loadTemplate("synthesizer-consensus"), { fileContent }); + } + return fillTemplate(loadTemplate("consensus"), { fileContent }); +} + +// --- Git --- + +function gitCommit(filePath, message, mode) { + if (mode === "none") return; + try { + const escaped = message.replace(/'/g, "'\\''"); + execSync(`git add '${filePath}' && git commit -m '${escaped}'`, { + cwd: path.dirname(filePath), + stdio: "pipe", + }); + } catch { + // Not in a git repo or nothing to commit + } +} + +// --- Output formatting --- + +function formatSummary(fileContent, agents, roundsCompleted, filePath) { + const fm = parseFrontmatter(fileContent); + const agentNames = agents.map((a) => a.name).join(" vs "); + const statusLabel = fm.status === STATUS.DEADLOCK ? "DEADLOCK" : "CONSENSUS"; + + const decisionMatch = fileContent.match(/### Decision\n([\s\S]*?)(?=\n### )/); + const decision = decisionMatch ? decisionMatch[1].trim() : "[No decision found]"; + + const contentionMatch = fileContent.match(/### Key Contention Points\n([\s\S]*?)(?=\n### )/); + const contentionTable = contentionMatch ? contentionMatch[1].trim() : ""; + + const unresolvedMatch = fileContent.match(/### Unresolved Items[^\n]*\n([\s\S]*?)(?=\n### )/); + const unresolved = unresolvedMatch ? unresolvedMatch[1].trim() : ""; + + const confidenceMatch = fileContent.match(/### Confidence: (.+)\n(.*)/); + const confidence = confidenceMatch ? confidenceMatch[1].trim() : "Unknown"; + const confidenceReason = confidenceMatch ? confidenceMatch[2].trim() : ""; + + const lines = []; + lines.push("━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━"); + lines.push(` COUNCIL ${statusLabel} — ${agentNames} — ${roundsCompleted} rounds — ${agents.length} agents`); + lines.push("━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━"); + lines.push(""); + lines.push("## Decision"); + lines.push(""); + lines.push(decision); + lines.push(""); + if (contentionTable) { + lines.push("## Key Disagreements"); + lines.push(""); + lines.push(contentionTable); + lines.push(""); + } + if (unresolved) { + lines.push("## Unresolved"); + lines.push(""); + lines.push(unresolved); + lines.push(""); + } + lines.push(`## Confidence: ${confidence}`); + if (confidenceReason) lines.push(confidenceReason); + lines.push(""); + lines.push("━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━"); + lines.push(`Full discussion: ${filePath}`); + lines.push("━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━"); + + return lines.join("\n"); +} + +// --- Discussion file creation --- + +function createDiscussionFile(topic, agents, config, outputPath, extraFm) { + const fm = { + topic, + mode: "council", + agent_count: String(agents.length), + agent_config: config, + ...(extraFm || {}), + status: "researching", + turn: "A", + round: "0", + created: new Date().toISOString(), + last_updated: new Date().toISOString(), + }; + + // Add per-agent frontmatter + agents.forEach((a) => { + fm[`agent_${a.label}_name`] = a.name; + fm[`agent_${a.label}_cli`] = a.cli; + fm[`agent_${a.label}_role`] = a.roleId; + }); + + const lines = ["---"]; + for (const [k, v] of Object.entries(fm)) { + lines.push(`${k}: "${v}"`); + } + lines.push("---"); + lines.push(""); + lines.push(`# Discussion: ${topic}`); + lines.push(""); + lines.push("## Participants"); + agents.forEach((a) => { + lines.push(`- **Agent ${a.label}** — ${a.name} (${a.roleId}) via ${a.cli}`); + }); + lines.push(""); + lines.push("## Key Questions"); + lines.push("1. [To be addressed through structured debate]"); + lines.push(""); + + fs.writeFileSync(outputPath, lines.join("\n")); + return outputPath; +} + +// --- Main Orchestration --- + +async function runCouncil(filePath) { + const absPath = path.resolve(filePath); + + let content; + try { + content = fs.readFileSync(absPath, "utf-8"); + } catch (err) { + if (err.code === "ENOENT") { + console.error(`File not found: ${absPath}`); + process.exit(1); + } + throw err; + } + + let fm = parseFrontmatter(content); + const agents = resolveAgents(fm); + const debatingAgents = agents.filter((a) => !a.role.skip_research); + const synthesizer = agents.find((a) => a.roleId === "synthesizer"); + + log(`Agents (${agents.length}):`); + agents.forEach((a) => log(` ${a.label}: ${a.name} (${a.roleId}) via ${getProfile(a.cli).name}`)); + + // Preflight + const cliNames = agents.map((a) => a.cli); + const preflightResults = preflight(cliNames); + const allPassed = [...new Set(cliNames)].every((cli) => preflightResults[cli]); + + if (!allPassed) { + const failed = [...new Set(cliNames)].filter((cli) => !preflightResults[cli]); + console.error(`FALLBACK: CLI(s) not available: ${failed.join(", ")}`); + process.exit(2); + } + + const tmpDir = fs.mkdtempSync(path.join(os.tmpdir(), "discuss-council-n-")); + log(`Temp directory: ${tmpDir}`); + + const cwd = path.dirname(absPath); + + try { + const topic = fm.topic; + const maxRounds = parseInt(fm.max_rounds || "5", 10); + const gitMode = fm.git_commit || "none"; + + log(`Topic: ${topic}`); + log(`Max rounds: ${maxRounds}, Git: ${gitMode}`); + + // Phase 1: Blind Research (parallel, skip synthesizer) + if (fm.status === STATUS.RESEARCHING) { + log(`Phase 1: Blind research (${debatingAgents.length} agents in parallel)...`); + + const researchConfigs = debatingAgents.map((agent) => ({ + promptText: buildResearchPrompt(topic, agent), + cliName: agent.cli, + label: `${agent.name} (${agent.label})`, + })); + + const results = await runAgentsParallel(researchConfigs, tmpDir, cwd); + + // Validate + debatingAgents.forEach((agent, i) => { + if (!validateResearch(results[i], agent)) { + log(`WARNING: ${agent.name} (${agent.label}) research failed validation`); + } + }); + + // Append research sections + content = fs.readFileSync(absPath, "utf-8"); + let researchText = "\n## Research Phase\n\n"; + debatingAgents.forEach((agent, i) => { + researchText += `${results[i] || `[${agent.name} (Agent ${agent.label}) research failed]`}\n\n`; + }); + researchText += "---\n\n## Discussion\n"; + + content += researchText; + content = updateFrontmatter(content, { + status: STATUS.DISCUSSING, + turn: debatingAgents[0].label, + round: "1", + last_updated: new Date().toISOString(), + }); + fs.writeFileSync(absPath, content); + + if (gitMode === "every_turn") { + gitCommit(absPath, "discuss: initial research complete", "every_turn"); + } + log("Research phase complete."); + } + + // Phase 2: Discussion Rounds (round-robin among debating agents) + content = fs.readFileSync(absPath, "utf-8"); + fm = parseFrontmatter(content); + let round = parseInt(fm.round || "1", 10); + let status = fm.status; + let convergenceCount = 0; + + while (status === STATUS.DISCUSSING && round <= maxRounds) { + for (let i = 0; i < debatingAgents.length; i++) { + const agent = debatingAgents[i]; + const cli = agent.cli; + log(`Round ${round} — ${agent.name} (Agent ${agent.label}, ${getProfile(cli).name})...`); + + content = fs.readFileSync(absPath, "utf-8"); + const prompt = buildTurnPrompt(agent, debatingAgents, content, round); + + const result = runWithRetry( + prompt, + (r) => validateResponse(r, round), + "IMPORTANT: Your previous response was malformed. Follow the EXACT format specified above. Every section is required.", + cli, + tmpDir, + cwd + ); + + // Determine next turn + const isLastInRound = i === debatingAgents.length - 1; + const nextAgent = isLastInRound ? debatingAgents[0] : debatingAgents[i + 1]; + const nextRound = isLastInRound ? round + 1 : round; + + // Append + content = fs.readFileSync(absPath, "utf-8"); + content += `\n${result || `[${agent.name} (Agent ${agent.label}) Round ${round} failed]`}\n`; + content = updateFrontmatter(content, { + turn: nextAgent.label, + round: String(nextRound), + last_updated: new Date().toISOString(), + }); + fs.writeFileSync(absPath, content); + + if (gitMode === "every_turn") { + gitCommit(absPath, `discuss: round ${round} — ${agent.name} response`, "every_turn"); + } + + // Convergence check (round 3+) + if (round >= 3 && result) { + const conv = extractConvergence(result); + if (conv === CONVERGENCE.DEADLOCKED) { + log("DEADLOCKED — moving to consensus."); + status = STATUS.DEADLOCK; + break; + } + if (conv === CONVERGENCE.CONVERGING || conv === CONVERGENCE.PARALLEL) { + convergenceCount++; + // Need majority of agents to agree on convergence + const threshold = Math.ceil(debatingAgents.length / 2); + if (convergenceCount >= threshold) { + log(`${conv} — ${convergenceCount}/${debatingAgents.length} agents converged, moving to consensus.`); + status = STATUS.CONVERGED; + break; + } + } + } + } + + // Reset convergence count at end of round if not converged + if (status === STATUS.DISCUSSING) { + convergenceCount = 0; + } + + if (status !== STATUS.DISCUSSING) break; + + round++; + if (round > maxRounds) { + log(`Max rounds (${maxRounds}) exceeded — forcing consensus.`); + break; + } + } + + // Phase 3: Consensus + if (status !== STATUS.CONSENSUS) { + log("Phase 3: Writing consensus..."); + content = fs.readFileSync(absPath, "utf-8"); + + // Use synthesizer if available, otherwise first agent + const consensusCli = synthesizer ? synthesizer.cli : debatingAgents[0].cli; + const consensusLabel = synthesizer ? `Synthesizer (${getProfile(consensusCli).name})` : getProfile(consensusCli).name; + log(`Consensus writer: ${consensusLabel}`); + + const consensus = runWithRetry( + buildConsensusPrompt(content, agents), + validateConsensus, + "IMPORTANT: Follow the EXACT format. Include Decision, Key Contention Points table, Unresolved Items & Risks, and Confidence.", + consensusCli, + tmpDir, + cwd + ); + + content = fs.readFileSync(absPath, "utf-8"); + content += `\n${consensus || "[Consensus generation failed — manual synthesis needed]"}\n`; + const finalStatus = status === STATUS.DEADLOCK ? STATUS.DEADLOCK : STATUS.CONSENSUS; + content = updateFrontmatter(content, { + status: finalStatus, + last_updated: new Date().toISOString(), + }); + fs.writeFileSync(absPath, content); + } + + // Final git commit + const finalFm = parseFrontmatter(fs.readFileSync(absPath, "utf-8")); + gitCommit(absPath, `discuss: ${finalFm.status} reached`, gitMode !== "none" ? "every_turn" : "none"); + + log(`Discussion complete. Status: ${finalFm.status}`); + log(`File: ${absPath}`); + + // Print formatted summary to stdout + const finalContent = fs.readFileSync(absPath, "utf-8"); + console.log(formatSummary(finalContent, agents, round, absPath)); + + return { filePath: absPath, status: finalFm.status, rounds: round, agents: agents.length }; + } finally { + fs.rmSync(tmpDir, { recursive: true, force: true }); + log("Temp directory cleaned up."); + } +} + +// --- Exports (for eval runner) --- +module.exports = { runCouncil, createDiscussionFile, resolveAgents, parseFrontmatter, ROLES, CLI_PROFILES }; + +// --- CLI entry --- +if (require.main === module) { + const filePath = process.argv[2]; + if (!filePath) { + console.error("Usage: node scripts/headless-council-n.js <discussion-file.md>"); + console.error(""); + console.error("N-agent frontmatter fields:"); + console.error(' agent_count: "3"'); + console.error(' agent_config: "3-agent"'); + console.error(' agent_cli: "codex" (default CLI for all agents)'); + console.error(' agent_A_cli: "claude" (override per agent)'); + console.error(""); + console.error(`Available configs: ${Object.keys(ROLES.configurations).join(", ")}`); + console.error(`Available roles: ${Object.keys(ROLES.roles).join(", ")}`); + console.error(`Supported CLIs: ${Object.keys(CLI_PROFILES).join(", ")}`); + process.exit(1); + } + + runCouncil(filePath).catch((err) => { + console.error(`Fatal: ${err.message}`); + process.exit(1); + }); +} diff --git a/scripts/headless-council.js b/scripts/headless-council.js index a6da914..4c87ff0 100755 --- a/scripts/headless-council.js +++ b/scripts/headless-council.js @@ -453,7 +453,7 @@ async function main() { try { const topic = fm.topic; - const maxRounds = parseInt(fm.max_rounds || "7", 10); + const maxRounds = parseInt(fm.max_rounds || "5", 10); const gitMode = fm.git_commit || "final_only"; // Resolve lens pair diff --git a/scripts/prompts/lenses.json b/scripts/prompts/lenses.json index 31af40a..5e29c60 100644 --- a/scripts/prompts/lenses.json +++ b/scripts/prompts/lenses.json @@ -44,6 +44,21 @@ "research": "Focus on MAINTAINABILITY, long-term cost, and sustainable architecture. Argue for investments that pay off over time. Challenge shortcuts that create tech debt.", "turn": "MAINTAINABILITY, LONG-TERM. Build to last." } + }, + { + "id": "brand-strategy-vs-creative-direction", + "name": "Brand Strategy vs Creative Direction", + "description": "Branding and identity. One agent evaluates positioning and market fit, the other pushes for emotional resonance and boldness.", + "agent_a": { + "label": "brand-strategist", + "research": "Focus on POSITIONING, DIFFERENTIATION, MARKET CLARITY, audience perception, and whether the brand works in context. Evaluate against competitors. Be the strategist.", + "turn": "POSITIONING, DIFFERENTIATION, MARKET FIT. Does it work in context?" + }, + "agent_b": { + "label": "creative-director", + "research": "Focus on EMOTIONAL RESONANCE, VISUAL IMAGINATION, STORYTELLING POWER, boldness, and what makes the brand memorable and felt. Be the creative director.", + "turn": "EMOTIONAL RESONANCE, MEMORABILITY, BOLDNESS. Does it move people?" + } } ], "default": "risk-vs-opportunity" diff --git a/scripts/prompts/n-agent-research.template b/scripts/prompts/n-agent-research.template new file mode 100644 index 0000000..b187f9e --- /dev/null +++ b/scripts/prompts/n-agent-research.template @@ -0,0 +1,12 @@ +You are {{agentName}} (Agent {{agent}}) in a structured discussion about: "{{topic}}" + +Your role: {{roleName}} +Your analytical lens: {{lensDesc}} + +Research this topic independently. Do NOT try to anticipate what other agents might say. You have access to tools for reading files and running commands — use them if the topic involves a specific codebase or requires inspecting local files. + +Return ONLY this formatted output, nothing else: + +### Agent {{agent}} ({{agentName}}) — Independent Research | research + +[Your analysis through your assigned lens. Be specific, cite evidence, name uncertainties. ~500 words.] diff --git a/scripts/prompts/n-agent-turn.template b/scripts/prompts/n-agent-turn.template new file mode 100644 index 0000000..0865dc8 --- /dev/null +++ b/scripts/prompts/n-agent-turn.template @@ -0,0 +1,37 @@ +You are {{agentName}} (Agent {{agent}}) in a structured council discussion with {{agentCount}} participants. +Your role: {{roleName}} — {{roleMandate}} + +Here is the full discussion file: + +---BEGIN DISCUSSION FILE--- +{{fileContent}} +---END DISCUSSION FILE--- + +PRINCIPLES: +1. Steel-man first. Restate others' arguments in their strongest form before disagreeing. +2. Evidence over intuition. "I think" requires "because..." with a concrete reason. +3. Name your uncertainty. Calibrated confidence: "~70% because..." +4. Seek the third option. Look for synthesis before arguing your side. +5. Change your mind visibly. Say so explicitly and explain what shifted. +6. Stay scoped. Flag tangents as [PARKING LOT], don't chase them. +7. Be concise. Quality over quantity. Repetition = no progress. +8. Engage with ALL agents, not just the last speaker. Reference specific agents by name when responding. + +Write your Round {{round}} response. You MUST follow this EXACT format: + +### Round {{round}} — {{agentName}} | response | confidence: X% + +**Response to previous points:** +Steel-man the strongest argument from any agent, then agree, disagree, or synthesize. +Reference specific agents by name. Address the most important open questions. + +**New evidence or angle:** +Something not yet discussed. If nothing new, say so — that's convergence. + +**Current position:** +Where you stand now, confidence %, brief justification. + +**Key question for the group:** +One specific question to resolve the most important remaining disagreement. +{{convergenceInstr}} +Return ONLY the formatted response above, nothing else. diff --git a/scripts/prompts/roles.json b/scripts/prompts/roles.json new file mode 100644 index 0000000..e540330 --- /dev/null +++ b/scripts/prompts/roles.json @@ -0,0 +1,55 @@ +{ + "roles": { + "advocate": { + "name": "Advocate", + "description": "Prioritizes benefits, opportunities, and user value. Pushes for action over analysis paralysis.", + "research_lens": "Focus on BENEFITS, OPPORTUNITIES, SUCCESS CASES, and what could go right. Identify the upside scenario. Challenge inertia and risk-aversion that blocks progress.", + "discussion_mandate": "Push for action and opportunity. Challenge arguments that prioritize caution over user value. But change your mind when shown genuine risks with evidence.", + "skip_research": false + }, + "skeptic": { + "name": "Skeptic", + "description": "Stress-tests proposals for risks, costs, failure modes, and hidden complexity.", + "research_lens": "Focus on RISKS, COSTS, FAILURE MODES, edge cases, and what could go wrong. Identify the downside scenario. Challenge optimism that lacks evidence.", + "discussion_mandate": "Stress-test every claim. Find the holes, the hidden costs, the failure modes. But concede when the evidence shows a risk is manageable.", + "skip_research": false + }, + "expert": { + "name": "Domain Expert", + "description": "Grounds the debate in implementation reality, technical constraints, and feasibility.", + "research_lens": "Focus on IMPLEMENTATION FEASIBILITY, TECHNICAL CONSTRAINTS, and real-world precedents. What does this actually require to build/execute? What have others learned doing this?", + "discussion_mandate": "Ground the debate in reality. When others make claims about feasibility or complexity, provide concrete technical analysis. Cite precedents and real-world outcomes.", + "skip_research": false + }, + "user_advocate": { + "name": "User Advocate", + "description": "Keeps focus on end-user outcomes, adoption, experience, and real-world usage patterns.", + "research_lens": "Focus on USER EXPERIENCE, ADOPTION, REAL-WORLD USAGE, and downstream impact on the people who will actually use this. What does the user need? What friction will they hit?", + "discussion_mandate": "Represent the end user. When the debate gets technical or strategic, pull it back to: what does this mean for the person using it? Challenge insider-think.", + "skip_research": false + }, + "synthesizer": { + "name": "Synthesizer", + "description": "Neutral arbiter. Reads all positions, produces concrete recommendation with explicit trade-offs. Does NOT participate in research or debate rounds.", + "research_lens": null, + "discussion_mandate": null, + "skip_research": true, + "consensus_mandate": "You are the neutral synthesizer. Read ALL prior positions carefully. Produce a concrete, actionable recommendation that: (1) acknowledges the strongest point from each agent, (2) makes a clear recommendation — no 'it depends' hedging, (3) lists the top 3 trade-offs explicitly, (4) identifies what information would change the recommendation." + } + }, + "configurations": { + "2-agent": { + "description": "Standard 2-agent debate with opposing lenses", + "agents": ["advocate", "skeptic"] + }, + "3-agent": { + "description": "2 debaters + neutral synthesizer for consensus", + "agents": ["advocate", "skeptic", "synthesizer"] + }, + "5-agent": { + "description": "Full panel: 4 perspectives + neutral synthesizer", + "agents": ["advocate", "skeptic", "expert", "user_advocate", "synthesizer"] + } + }, + "agent_labels": ["A", "B", "C", "D", "E"] +} diff --git a/scripts/prompts/synthesizer-consensus.template b/scripts/prompts/synthesizer-consensus.template new file mode 100644 index 0000000..80b5c3c --- /dev/null +++ b/scripts/prompts/synthesizer-consensus.template @@ -0,0 +1,35 @@ +You are the Synthesizer — a neutral arbiter in this structured council discussion. You did NOT participate in the research or debate. Your job is to read ALL positions and produce a concrete, actionable recommendation. + +---BEGIN DISCUSSION FILE--- +{{fileContent}} +---END DISCUSSION FILE--- + +INSTRUCTIONS: +1. Read every agent's research and every debate round carefully. +2. Identify the STRONGEST point from each agent — not just the loudest or most recent. +3. Make a CLEAR recommendation. No "it depends" hedging. If the answer truly is conditional, state the condition and the recommendation for each branch. +4. Be explicit about trade-offs. Name what you're sacrificing and why. +5. If agents converged, say so. If they didn't, explain why and pick a side. + +Write the consensus using this EXACT format: + +--- + +## Consensus Summary + +### Decision +[2-3 sentences — clear recommendation with reasoning] + +### Key Contention Points + +| # | What Was Debated | Resolution | Who Had the Strongest Case & Why | +|---|-----------------|------------|----------------------------------| +| 1 | ... | ... | ... | + +### Unresolved Items & Risks +- ... + +### Confidence: [High | Medium | Low] +[1 sentence justification] + +Return ONLY the formatted consensus above, nothing else. diff --git a/tests/cases/basic-council.json b/tests/cases/basic-council.json new file mode 100644 index 0000000..3c32ff8 --- /dev/null +++ b/tests/cases/basic-council.json @@ -0,0 +1,16 @@ +{ + "name": "basic-council", + "description": "Basic council mode with default lens produces valid consensus", + "topic": "Should a function return null or throw an exception when it cannot find the requested item?", + "max_rounds": 3, + "key_questions": [ + "What are the error handling implications of each approach?", + "Which approach produces more predictable caller code?", + "Does the answer depend on language or context?" + ], + "assertions": [ + { "type": "min_rounds", "value": 1 }, + { "type": "contains", "value": "## Consensus Summary" }, + { "type": "contains", "value": "### Decision" } + ] +} diff --git a/tests/cases/custom-lens.json b/tests/cases/custom-lens.json new file mode 100644 index 0000000..95a387d --- /dev/null +++ b/tests/cases/custom-lens.json @@ -0,0 +1,17 @@ +{ + "name": "custom-lens", + "description": "Simplicity-vs-correctness lens applies to research, not to debate turns", + "topic": "Should we add input validation at every layer or only at the API boundary?", + "lens_id": "simplicity-vs-correctness", + "agent_a_lens": "simplicity/pragmatism", + "agent_b_lens": "correctness/rigor", + "max_rounds": 3, + "key_questions": [ + "Does defense-in-depth justify the duplication cost?", + "What happens when validation rules drift between layers?" + ], + "assertions": [ + { "type": "contains", "value": "## Consensus Summary" }, + { "type": "contains", "value": "### Decision" } + ] +} diff --git a/tests/cases/eval-fintech-payments.json b/tests/cases/eval-fintech-payments.json new file mode 100644 index 0000000..c00048e --- /dev/null +++ b/tests/cases/eval-fintech-payments.json @@ -0,0 +1,132 @@ +{ + "name": "fintech-payments", + "topic": "Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months.", + "key_questions": [ + "What is the true total cost of ownership for in-house payment processing vs Stripe at current and projected volumes?", + "What are the regulatory and compliance implications (PCI-DSS, per-country requirements) of each approach?", + "Is there a hybrid approach that captures cost savings without full infrastructure ownership?", + "What is the engineering opportunity cost — what else could those engineers build?" + ], + "max_rounds": 5, + "expert_checklist": [ + { + "id": "pci-dss", + "item": "PCI-DSS compliance scope and Level 1 certification cost", + "keywords": ["PCI", "compliance", "certification", "Level 1", "SAQ", "audit"], + "weight": 2, + "category": "regulatory" + }, + { + "id": "interchange-fees", + "item": "Interchange fee economics — Stripe markup vs direct processor rates at volume", + "keywords": ["interchange", "processing fee", "basis points", "markup", "2.9%"], + "weight": 2, + "category": "business" + }, + { + "id": "multi-currency", + "item": "Multi-currency and cross-border settlement complexity", + "keywords": ["multi-currency", "cross-border", "settlement", "FX", "exchange"], + "weight": 1, + "category": "technical" + }, + { + "id": "chargeback", + "item": "Chargeback and dispute handling infrastructure", + "keywords": ["chargeback", "dispute", "representment", "fraud"], + "weight": 1, + "category": "technical" + }, + { + "id": "fraud-detection", + "item": "Fraud detection and risk scoring (Stripe Radar equivalent)", + "keywords": ["fraud", "risk scoring", "Radar", "ML", "detection"], + "weight": 2, + "category": "technical" + }, + { + "id": "3ds-sca", + "item": "3D Secure / Strong Customer Authentication regulatory requirements", + "keywords": ["3D Secure", "3DS", "SCA", "authentication", "PSD2"], + "weight": 1, + "category": "regulatory" + }, + { + "id": "payment-methods", + "item": "Payment method coverage beyond cards (ACH, wire, SEPA, BNPL, wallets)", + "keywords": ["ACH", "wire", "SEPA", "BNPL", "Apple Pay", "Google Pay", "wallet", "payment method"], + "weight": 1, + "category": "product" + }, + { + "id": "reconciliation", + "item": "Reconciliation, settlement, and accounting integration complexity", + "keywords": ["reconciliation", "settlement", "accounting", "ledger", "bookkeeping"], + "weight": 1, + "category": "technical" + }, + { + "id": "vendor-lock-in", + "item": "Vendor lock-in and data portability concerns", + "keywords": ["lock-in", "portability", "migration", "dependency", "switching cost"], + "weight": 1, + "category": "strategic" + }, + { + "id": "team-expertise", + "item": "Team expertise gap — payments engineering is specialized, hiring is hard", + "keywords": ["hiring", "expertise", "specialized", "talent", "team", "knowledge"], + "weight": 2, + "category": "organizational" + }, + { + "id": "opportunity-cost", + "item": "Engineering opportunity cost — what else could those engineers build?", + "keywords": ["opportunity cost", "instead", "focus", "core product", "distraction"], + "weight": 2, + "category": "strategic" + }, + { + "id": "time-to-market", + "item": "Time-to-market impact and competitive window", + "keywords": ["time to market", "competitive", "window", "speed", "timeline", "months"], + "weight": 1, + "category": "business" + }, + { + "id": "hybrid-approach", + "item": "Hybrid approach — use Stripe now, migrate hot path later (or Stripe Connect, custom integration tiers)", + "keywords": ["hybrid", "incremental", "phased", "Stripe Connect", "partial", "migrate later"], + "weight": 2, + "category": "strategic" + }, + { + "id": "uptime-sla", + "item": "Uptime SLAs, disaster recovery, and incident response for payment critical path", + "keywords": ["uptime", "SLA", "disaster recovery", "incident", "availability", "99.99"], + "weight": 1, + "category": "technical" + }, + { + "id": "regulatory-reporting", + "item": "Regulatory reporting obligations (money transmission, per-state/country licensing)", + "keywords": ["money transmission", "license", "regulatory reporting", "MSB", "FinCEN"], + "weight": 1, + "category": "regulatory" + } + ], + "traps": [ + { + "id": "just-use-stripe", + "description": "Dismissing in-house entirely without analyzing volume economics — at $50M/year growing to $150M, the fee delta is material", + "detection_keywords": ["just use Stripe", "no reason to build", "always outsource"], + "caught_keywords": ["at scale", "fee economics", "margin", "volume", "$1.5M", "growing"] + }, + { + "id": "build-for-margins", + "description": "Advocating full in-house build without accounting for PCI scope, fraud detection complexity, and 20-engineer team capacity", + "detection_keywords": ["build everything", "save millions", "simple to build"], + "caught_keywords": ["PCI", "fraud detection", "team size", "20 engineers", "capacity", "specialized"] + } + ] +} diff --git a/tests/cases/eval-healthcare-ai-deploy.json b/tests/cases/eval-healthcare-ai-deploy.json new file mode 100644 index 0000000..4a36b29 --- /dev/null +++ b/tests/cases/eval-healthcare-ai-deploy.json @@ -0,0 +1,124 @@ +{ + "name": "healthcare-ai-deploy", + "topic": "A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance?", + "key_questions": [ + "Is 87% accuracy sufficient given that it matches current standard of care (average radiologist)?", + "What does the FDA clearance pathway look like at 87% vs 95%, and does higher accuracy meaningfully change the regulatory burden?", + "What are the data and compute requirements to go from 87% to 95%, and is 12-18 months realistic?", + "Can the company survive 12-18 months of continued burn without revenue from deployment?" + ], + "max_rounds": 5, + "expert_checklist": [ + { + "id": "standard-of-care", + "item": "Comparison to standard of care, not to 100% — 87% matching average radiologist IS clinically meaningful", + "keywords": ["standard of care", "average radiologist", "current practice", "baseline", "clinical meaning"], + "weight": 2, + "category": "clinical" + }, + { + "id": "sensitivity-specificity", + "item": "Sensitivity vs specificity trade-off — false negatives (missed disease) vs false positives (unnecessary referrals)", + "keywords": ["sensitivity", "specificity", "false negative", "false positive", "PPV", "NPV"], + "weight": 2, + "category": "clinical" + }, + { + "id": "fda-pathway", + "item": "FDA regulatory pathway — 510(k) vs De Novo classification, predicate device comparison", + "keywords": ["510(k)", "De Novo", "FDA", "predicate", "clearance", "approval", "regulatory pathway"], + "weight": 2, + "category": "regulatory" + }, + { + "id": "clinical-validation", + "item": "Clinical validation study design — prospective vs retrospective, sample size, multi-site", + "keywords": ["clinical validation", "prospective", "retrospective", "sample size", "multi-site", "trial"], + "weight": 1, + "category": "regulatory" + }, + { + "id": "post-market-surveillance", + "item": "Post-market surveillance requirements and continuous monitoring obligations", + "keywords": ["post-market", "surveillance", "monitoring", "adverse event", "reporting"], + "weight": 1, + "category": "regulatory" + }, + { + "id": "real-world-gap", + "item": "Real-world vs lab performance gap — model accuracy degrades on different cameras, lighting, populations", + "keywords": ["real-world", "lab", "performance gap", "generalization", "different population", "camera", "domain shift"], + "weight": 2, + "category": "technical" + }, + { + "id": "data-bias", + "item": "Training data bias — demographic, geographic, device diversity in training set", + "keywords": ["bias", "demographic", "geographic", "diversity", "underrepresented", "fairness"], + "weight": 1, + "category": "technical" + }, + { + "id": "diminishing-returns", + "item": "Data requirements for 87% to 95% — diminishing returns curve, likely needs 5-10x more data", + "keywords": ["diminishing returns", "more data", "5x", "10x", "logarithmic", "data requirement", "plateau"], + "weight": 2, + "category": "technical" + }, + { + "id": "competitor-timeline", + "item": "Competitor timeline and first-mover advantage in AI diagnostics", + "keywords": ["competitor", "first mover", "market window", "race", "others", "ahead"], + "weight": 1, + "category": "business" + }, + { + "id": "reimbursement", + "item": "Reimbursement pathway — CPT codes, payer acceptance, willingness to pay for AI-assisted reads", + "keywords": ["reimbursement", "CPT", "payer", "insurance", "billing", "willingness to pay"], + "weight": 1, + "category": "business" + }, + { + "id": "liability", + "item": "Liability and malpractice implications — who is responsible when AI-assisted diagnosis is wrong?", + "keywords": ["liability", "malpractice", "responsible", "lawsuit", "legal", "who is liable"], + "weight": 1, + "category": "legal" + }, + { + "id": "hitl-design", + "item": "Human-in-the-loop workflow design — alert fatigue, override rates, radiologist acceptance", + "keywords": ["human in the loop", "HITL", "alert fatigue", "override", "workflow", "radiologist acceptance"], + "weight": 2, + "category": "clinical" + }, + { + "id": "runway-survival", + "item": "Runway and business survival — 18 months runway vs 12-18 months delay means near-zero margin for error", + "keywords": ["runway", "burn", "survival", "cash", "funding", "18 months", "run out"], + "weight": 2, + "category": "business" + } + ], + "traps": [ + { + "id": "not-good-enough", + "description": "Claiming 87% is insufficient without comparing to standard of care — the benchmark is average radiologist, not perfection", + "detection_keywords": ["not good enough", "too low", "need higher", "87% is bad", "patients deserve better"], + "caught_keywords": ["standard of care", "matches radiologist", "current baseline", "already comparable"] + }, + { + "id": "ship-and-iterate", + "description": "Advocating 'ship now, improve later' without acknowledging that medical device modifications require new regulatory submissions (not a software update)", + "detection_keywords": ["iterate", "update later", "improve post-launch", "ship and fix"], + "caught_keywords": ["regulatory submission", "new clearance", "modification", "not like software", "PMA supplement"] + }, + { + "id": "data-naive", + "description": "Assuming 87% to 95% is a simple training improvement without addressing the exponential data requirements and diminishing returns", + "detection_keywords": ["just train more", "more epochs", "fine-tune", "easy to improve"], + "caught_keywords": ["diminishing returns", "exponential", "10x data", "not linear", "fundamental limit"] + } + ] +} diff --git a/tests/cases/eval-monorepo-migration.json b/tests/cases/eval-monorepo-migration.json new file mode 100644 index 0000000..1db4d1d --- /dev/null +++ b/tests/cases/eval-monorepo-migration.json @@ -0,0 +1,125 @@ +{ + "name": "monorepo-migration", + "topic": "A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo?", + "key_questions": [ + "What is the actual migration cost and risk for 35 repos with active development?", + "Which problems are best solved by monorepo, and which have simpler solutions (better tooling, stricter dependency management)?", + "What organizational changes does a monorepo require (CI/CD, code ownership, merge process)?", + "Is there an incremental path, or is this all-or-nothing?" + ], + "max_rounds": 5, + "expert_checklist": [ + { + "id": "ci-blast-radius", + "item": "CI/CD pipeline impact — build times, test blast radius, affected-files analysis", + "keywords": ["CI", "build time", "blast radius", "pipeline", "affected", "test"], + "weight": 2, + "category": "technical" + }, + { + "id": "codeowners", + "item": "Code ownership model (CODEOWNERS complexity, review bottlenecks)", + "keywords": ["CODEOWNERS", "ownership", "review", "approval", "bottleneck"], + "weight": 1, + "category": "organizational" + }, + { + "id": "dependency-management", + "item": "Dependency management — diamond dependencies, version conflicts, single-version policy", + "keywords": ["dependency", "diamond", "version conflict", "single version", "lockfile"], + "weight": 2, + "category": "technical" + }, + { + "id": "migration-cost", + "item": "Migration cost and risk — 35 active repos is non-trivial, history preservation, tooling rewrite", + "keywords": ["migration cost", "history", "rewrite", "effort", "months", "risk"], + "weight": 2, + "category": "business" + }, + { + "id": "build-tooling", + "item": "Tooling requirements — Bazel, Nx, Turborepo, Rush, or custom build system needed", + "keywords": ["Bazel", "Nx", "Turborepo", "Rush", "build system", "tooling"], + "weight": 2, + "category": "technical" + }, + { + "id": "git-performance", + "item": "Git performance at scale — shallow clones, sparse checkout, VFS for Git", + "keywords": ["git performance", "shallow clone", "sparse checkout", "VFS", "slow", "large repo"], + "weight": 1, + "category": "technical" + }, + { + "id": "conways-law", + "item": "Conway's Law — repo structure mirrors org structure; monorepo implies tighter coupling between teams", + "keywords": ["Conway", "org structure", "team autonomy", "coupling", "coordination"], + "weight": 2, + "category": "organizational" + }, + { + "id": "merge-queue", + "item": "Merge queue and trunk-based development implications at 50 engineers", + "keywords": ["merge queue", "trunk-based", "merge conflict", "main branch", "contention"], + "weight": 1, + "category": "technical" + }, + { + "id": "developer-experience", + "item": "IDE and developer experience impact — indexing, search, local build times", + "keywords": ["IDE", "developer experience", "DX", "indexing", "search", "local"], + "weight": 1, + "category": "organizational" + }, + { + "id": "cross-repo-refactoring", + "item": "Cross-repo refactoring friction — the actual pain point driving this discussion", + "keywords": ["cross-repo", "refactor", "atomic", "coordinated PR", "breaking change"], + "weight": 2, + "category": "technical" + }, + { + "id": "release-independence", + "item": "Release independence and deployment coupling — can teams still deploy independently?", + "keywords": ["deploy independently", "release", "decouple", "ship", "rollback"], + "weight": 1, + "category": "technical" + }, + { + "id": "access-control", + "item": "Access control and security boundaries between teams/services", + "keywords": ["access control", "security", "permissions", "boundary", "visibility"], + "weight": 1, + "category": "organizational" + }, + { + "id": "incremental-migration", + "item": "Incremental migration path — not all-or-nothing, phased approach possible", + "keywords": ["incremental", "phased", "gradual", "one repo at a time", "not all-or-nothing"], + "weight": 2, + "category": "strategic" + }, + { + "id": "alternatives", + "item": "Alternatives to monorepo that solve the same problems (better dependency tooling, shared package registry, meta-repo)", + "keywords": ["alternative", "package registry", "meta-repo", "workspace", "npm link", "shared packages"], + "weight": 2, + "category": "strategic" + } + ], + "traps": [ + { + "id": "google-survivorship", + "description": "Arguing 'Google/Meta use monorepo therefore we should' without acknowledging they built $10M+ custom tooling (Bazel, Buck, Piper)", + "detection_keywords": ["Google uses", "Meta uses", "big companies use", "proven at scale"], + "caught_keywords": ["custom tooling", "Bazel", "Piper", "millions", "dedicated team", "not comparable"] + }, + { + "id": "monorepo-simple", + "description": "Claiming monorepo is simpler without addressing CI blast radius, merge contention, and the migration itself", + "detection_keywords": ["simpler", "one repo", "easier", "just move"], + "caught_keywords": ["CI blast", "merge contention", "migration cost", "build times", "not simple"] + } + ] +} diff --git a/tests/eval-results/after-changes-2026-04-01/REPORT.md b/tests/eval-results/after-changes-2026-04-01/REPORT.md new file mode 100644 index 0000000..658ca56 --- /dev/null +++ b/tests/eval-results/after-changes-2026-04-01/REPORT.md @@ -0,0 +1,76 @@ +# N-Agent Eval Results + +Run: 2026-04-01T12-14-05 +Configs: 2-cross +Topics: fintech-payments, healthcare-ai-deploy, monorepo-migration + +## fintech-payments +**Topic:** Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months. + +| Metric | 2-cross | +|--------|------| +| **Checklist Coverage (raw)** | 93% (14/15) | +| **Checklist Coverage (weighted)** | 95% | +| **Traps Caught** | 2/2 (100%) | +| **Duration** | 441s | +| **Output Tokens (est.)** | ~6933 | + +### Missed Checklist Items + +**2-cross** missed (1): + - [regulatory] Regulatory reporting obligations (money transmission, per-state/country licensing) + +### Trap Detection Details + +**2-cross:** + - CAUGHT: Dismissing in-house entirely without analyzing volume economics — at $50M/year growing to $150M, the fee delta is material + - CAUGHT: Advocating full in-house build without accounting for PCI scope, fraud detection complexity, and 20-engineer team capacity + +## healthcare-ai-deploy +**Topic:** A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance? + +| Metric | 2-cross | +|--------|------| +| **Checklist Coverage (raw)** | 92% (12/13) | +| **Checklist Coverage (weighted)** | 90% | +| **Traps Caught** | 1/3 (33%) | +| **Duration** | 526s | +| **Output Tokens (est.)** | ~7743 | + +### Missed Checklist Items + +**2-cross** missed (1): + - [technical] Data requirements for 87% to 95% — diminishing returns curve, likely needs 5-10x more data + +### Trap Detection Details + +**2-cross:** + - CAUGHT: Claiming 87% is insufficient without comparing to standard of care — the benchmark is average radiologist, not perfection + - MISSED: Advocating 'ship now, improve later' without acknowledging that medical device modifications require new regulatory submissions (not a software update) + - MISSED: Assuming 87% to 95% is a simple training improvement without addressing the exponential data requirements and diminishing returns + +## monorepo-migration +**Topic:** A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo? + +| Metric | 2-cross | +|--------|------| +| **Checklist Coverage (raw)** | 100% (14/14) | +| **Checklist Coverage (weighted)** | 100% | +| **Traps Caught** | 2/2 (100%) | +| **Duration** | 440s | +| **Output Tokens (est.)** | ~6975 | + +### Missed Checklist Items + +### Trap Detection Details + +**2-cross:** + - CAUGHT: Arguing 'Google/Meta use monorepo therefore we should' without acknowledging they built $10M+ custom tooling (Bazel, Buck, Piper) + - CAUGHT: Claiming monorepo is simpler without addressing CI blast radius, merge contention, and the migration itself + + +## Aggregate Summary + +| Config | Avg Coverage (weighted) | Avg Traps Caught | Avg Duration | +|--------|----------------------|-----------------|-------------| +| 2-cross | 95% | 78% | 469s | \ No newline at end of file diff --git a/tests/eval-results/after-changes-2026-04-01/excalidraw.log b/tests/eval-results/after-changes-2026-04-01/excalidraw.log new file mode 100644 index 0000000..6f591e2 --- /dev/null +++ b/tests/eval-results/after-changes-2026-04-01/excalidraw.log @@ -0,0 +1,60 @@ +2026-04-01 19:14:06.346 [info] Starting Excalidraw MCP server... +2026-04-01 19:14:06.348 [debug] Connecting to stdio transport... +2026-04-01 19:14:06.348 [info] Excalidraw MCP server running on stdio +2026-04-01 19:14:06.356 [info] Listing available tools +2026-04-01 19:16:59.140 [info] Starting Excalidraw MCP server... +2026-04-01 19:16:59.143 [debug] Connecting to stdio transport... +2026-04-01 19:16:59.143 [info] Excalidraw MCP server running on stdio +2026-04-01 19:16:59.148 [info] Listing available tools +2026-04-01 19:18:44.616 [info] Starting Excalidraw MCP server... +2026-04-01 19:18:44.617 [debug] Connecting to stdio transport... +2026-04-01 19:18:44.617 [info] Excalidraw MCP server running on stdio +2026-04-01 19:18:44.622 [info] Listing available tools +2026-04-01 19:20:19.650 [info] Starting Excalidraw MCP server... +2026-04-01 19:20:19.653 [debug] Connecting to stdio transport... +2026-04-01 19:20:19.653 [info] Excalidraw MCP server running on stdio +2026-04-01 19:20:19.658 [info] Listing available tools +2026-04-01 19:20:58.518 [info] Starting Excalidraw MCP server... +2026-04-01 19:20:58.520 [debug] Connecting to stdio transport... +2026-04-01 19:20:58.520 [info] Excalidraw MCP server running on stdio +2026-04-01 19:20:58.525 [info] Listing available tools +2026-04-01 19:21:27.663 [info] Starting Excalidraw MCP server... +2026-04-01 19:21:27.665 [debug] Connecting to stdio transport... +2026-04-01 19:21:27.665 [info] Excalidraw MCP server running on stdio +2026-04-01 19:21:27.670 [info] Listing available tools +2026-04-01 19:23:58.919 [info] Starting Excalidraw MCP server... +2026-04-01 19:23:58.921 [debug] Connecting to stdio transport... +2026-04-01 19:23:58.921 [info] Excalidraw MCP server running on stdio +2026-04-01 19:23:58.925 [info] Listing available tools +2026-04-01 19:25:42.108 [info] Starting Excalidraw MCP server... +2026-04-01 19:25:42.110 [debug] Connecting to stdio transport... +2026-04-01 19:25:42.110 [info] Excalidraw MCP server running on stdio +2026-04-01 19:25:42.114 [info] Listing available tools +2026-04-01 19:28:27.403 [info] Starting Excalidraw MCP server... +2026-04-01 19:28:27.406 [debug] Connecting to stdio transport... +2026-04-01 19:28:27.406 [info] Excalidraw MCP server running on stdio +2026-04-01 19:28:27.410 [info] Listing available tools +2026-04-01 19:29:35.210 [info] Starting Excalidraw MCP server... +2026-04-01 19:29:35.211 [debug] Connecting to stdio transport... +2026-04-01 19:29:35.212 [info] Excalidraw MCP server running on stdio +2026-04-01 19:29:35.216 [info] Listing available tools +2026-04-01 19:30:13.551 [info] Starting Excalidraw MCP server... +2026-04-01 19:30:13.557 [debug] Connecting to stdio transport... +2026-04-01 19:30:13.557 [info] Excalidraw MCP server running on stdio +2026-04-01 19:30:13.564 [info] Listing available tools +2026-04-01 19:34:09.577 [info] Starting Excalidraw MCP server... +2026-04-01 19:34:09.580 [debug] Connecting to stdio transport... +2026-04-01 19:34:09.580 [info] Excalidraw MCP server running on stdio +2026-04-01 19:34:09.585 [info] Listing available tools +2026-04-01 19:35:11.273 [info] Starting Excalidraw MCP server... +2026-04-01 19:35:11.275 [debug] Connecting to stdio transport... +2026-04-01 19:35:11.275 [info] Excalidraw MCP server running on stdio +2026-04-01 19:35:11.279 [info] Listing available tools +2026-04-01 19:36:14.380 [info] Starting Excalidraw MCP server... +2026-04-01 19:36:14.382 [debug] Connecting to stdio transport... +2026-04-01 19:36:14.382 [info] Excalidraw MCP server running on stdio +2026-04-01 19:36:14.387 [info] Listing available tools +2026-04-01 19:36:56.775 [info] Starting Excalidraw MCP server... +2026-04-01 19:36:56.778 [debug] Connecting to stdio transport... +2026-04-01 19:36:56.778 [info] Excalidraw MCP server running on stdio +2026-04-01 19:36:56.783 [info] Listing available tools diff --git a/tests/eval-results/after-changes-2026-04-01/fintech-payments__2-codex.md b/tests/eval-results/after-changes-2026-04-01/fintech-payments__2-codex.md new file mode 100644 index 0000000..6fc3233 --- /dev/null +++ b/tests/eval-results/after-changes-2026-04-01/fintech-payments__2-codex.md @@ -0,0 +1,160 @@ +--- +topic: "Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months." +mode: "council" +agent_count: "2" +agent_config: "2-agent" +max_rounds: "5" +git_commit: "none" +agent_cli: "codex" +status: consensus +turn: B +round: 3 +created: "2026-04-01T12:14:04.986Z" +last_updated: 2026-04-01T12:22:34.934Z +agent_A_name: "Advocate" +agent_A_cli: "codex" +agent_A_role: "advocate" +agent_B_name: "Skeptic" +agent_B_cli: "codex" +agent_B_role: "skeptic" +--- + +# Discussion: Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months. + +## Participants +- **Agent A** — Advocate (advocate) via codex +- **Agent B** — Skeptic (skeptic) via codex + +## Key Questions +1. What is the true total cost of ownership for in-house payment processing vs Stripe at current and projected volumes? +2. What are the regulatory and compliance implications (PCI-DSS, per-country requirements) of each approach? +3. Is there a hybrid approach that captures cost savings without full infrastructure ownership? +4. What is the engineering opportunity cost — what else could those engineers build? + +## Research Phase + +### Agent A (Advocate) — Independent Research | research + +The advocate case is that they should start building their own payments control plane now, because the economics are about to move from “annoying SaaS spend” to a core margin lever. On the numbers in the prompt, they are effectively paying about 3.0% today ($1.5M on $50M). If volume reaches $150M within 18 months and fee economics stay flat, that becomes roughly $4.5M/year. A 50 bps improvement would be worth about $750k/year; 100 bps is $1.5M/year; 150 bps is $2.25M/year. That math is an inference from the prompt, but it is the right frame: once payment fees are multi-millions, infrastructure can become a high-ROI product investment rather than a back-office project. + +The opportunity is bigger than pure fee reduction. Owning the payment layer creates negotiating leverage and strategic freedom. Stripe itself is implicitly validating that direction: its pricing page says large-volume businesses can get custom packages with volume discounts, and Stripe now offers both [Vault and Forward API](https://docs.stripe.com/payments/vault-and-forward) and [Orchestration](https://docs.stripe.com/payments/orchestration) so merchants can vault card details once, route to third-party processors, and retry payments across processors. That matters because it turns this from a binary “rip out Stripe or don’t” decision into a staged migration. Even [Stripe pricing](https://stripe.com/us/pricing) now explicitly positions custom pricing for large-volume merchants. + +There is also a credible top-line upside. Payments optimization is not just about shaving basis points; it can improve authorization, recovery, and conversion. Stripe claims [Authorization Boost](https://stripe.com/us/authorization) increases acceptance rates by 2.2% on average and can lower card processing costs by up to 2.8% for businesses on custom interchange pricing. Adyen reported that its [US debit routing pilot](https://www.adyen.com/press-and-media/adyens-intelligent-payment-routing-usdebit) across 20+ enterprise merchants produced average cost savings of 26% with a 0.22% authorization-rate uplift, and that some merchants saw much larger savings on those flows. Adyen also says pilots of [Uplift](https://www.adyen.com/press-and-media/adyen-uplift-launch) showed up to 6% conversion improvement and up to 5% payment-cost reduction. Those are vendor claims, not universal outcomes, but they prove the upside ceiling is material. + +The strongest success-pattern evidence is from companies that turned payments infra into a growth enabler. Uber’s engineering team said its next-gen payments platform was designed for high reliability, exactly-once processing, strong auditability via double-entry bookkeeping, and the ability to scale to new business lines, payment types, and geographies ([Uber](https://www.uber.com/en-US/blog/payments-platform/)). That is the real prize for a fintech startup: not merely “save on Stripe,” but gain a reusable money-movement platform that supports new products, geographies, rail mixes, risk controls, and finance operations. + +The practical upside scenario is incremental: build the ledger, routing, retries, reconciliation, and processor abstraction first; keep Stripe as one rail; then move the highest-volume, lowest-complexity corridors first. If they execute well, they end up with lower processing costs, better auth performance, faster product launches, and more bargaining power with every processor they use. + +**Key uncertainty:** the upside depends heavily on transaction mix. If they are mostly domestic card-not-present with low decline variance, savings may be modest. If they have debit, ACH, recurring billing, cross-border, or retryable decline volume, the upside is much larger. + +**Confidence:** 74% — the economic upside is real and the migration path is now more proven, but the exact ROI depends on their payment-method mix, decline profile, and how narrowly they define “build.” + +### Agent B (Skeptic) — Independent Research | research + +The skeptical view is that this startup may be anchoring on the wrong number. Their current Stripe bill is about 3.0% of volume ($1.5M on $50M), but that is not all “recoverable margin.” Stripe’s own explanation of [interchange-plus pricing](https://stripe.com/resources/more/interchange-plus-pricing-explained) says card costs are made up of interchange (issuer bank), network assessments, and processor markup. Building your own stack does not remove interchange or network fees; it mainly attacks markup and bundled services. At projected volume of $150M in 18 months, every 10 basis points is only $150k/year. That matters, but it also means the company can be directionally right that Stripe is expensive while still being wrong that full in-house processing is economically justified. Stripe also explicitly offers [custom pricing, volume discounts, and IC+](https://stripe.com/us/pricing), so the lower-risk move is to renegotiate before taking infrastructure risk. + +The biggest downside is scope creep from “we want cheaper payments” into “we accidentally became a regulated payments intermediary.” Visa’s 2026 [Payment Facilitator and Marketplace Risk Guide](https://usa.visa.com/content/dam/VCOM/regional/na/us/partner-with-us/documents/visa-payment-facilitator-and-marketplace-risk-guide.pdf) says payment facilitators and marketplaces are third-party agents that require acquirer sponsorship and registration, and that acquirers must continuously monitor them. Visa’s [TPA registration page](https://partner.visa.com/site/programs/third-party-agent-registration.html) also expects sponsor information and PCI documentation. On the U.S. regulatory side, [FinCEN](https://www.fincen.gov/resources/statutes-regulations/administrative-rulings/definition-money-transmitter-merchant-payment) says whether you are a money transmitter is facts-and-circumstances based; the merchant-processor exemption depends on staying narrowly within payment processing/settlement. If this fintech starts holding funds, routing them, or distributing settlement in new ways, the legal posture can change. The [CSBS MTMA summary](https://www.csbs.org/csbs-money-transmission-modernization-act-mtma) is a reminder that money transmitter regimes still bring net worth, surety bond, and liquidity requirements; as of February 26, 2026, 31 states had adopted the model in full or in part, covering 99% of reported money transmission activity. That is not a side quest for a 20-engineer company. + +Security and compliance are another cliff. Visa says all entities that store, process, or transmit Visa account data must comply with PCI DSS, and its [PCI DSS validation guidance](https://usa.visa.com/content/dam/VCOM/regional/na/us/support-legal/documents/pci-dss-validation-best-practice-review.pdf) shows merchants at 1M to 6M Visa transactions are Level 2, while service providers above 300,000 Visa transactions are Level 1 and need annual ROC/AOC validation. Without average ticket size, I cannot tell whether this startup crosses those thresholds today, but at 3x projected growth it becomes plausible fast. PCI scope also does not disappear just because processing is outsourced: the PCI SSC’s 2025 [FAQ](https://www.pcisecuritystandards.org/faq/articles/Frequently_Asked_Question/does-pci-dss-apply-to-merchants-who-outsource-all-payment-processing-operations-and-never-store-process-or-transmit-cardholder-data/) says merchants still retain responsibility for provider oversight and shared controls. If they bring card handling or orchestration in-house, that shared-responsibility burden grows, not shrinks. + +Migration and orchestration introduce ugly failure modes. Stripe’s own [Vault and Forward documentation](https://docs.stripe.com/payments/vault-and-forward) warns that multiprocessor flows can accidentally double-capture, Link credentials cannot be transferred between processors, refunds and disputes must be handled with the third-party processor, Stripe cannot guarantee processor responses, and the forwarding API can return HTTP 200 even when the downstream processor returned 400. That is a concise map of what can go wrong in production: idempotency bugs, token-portability gaps, split-brain reconciliation, degraded observability, dispute ownership confusion, and authorization/capture mismatches. The downside scenario is not “we spend six months and save 100 bps.” It is “we spend 12 to 18 months, widen regulatory and PCI scope, dent conversion or settlement reliability during migration, and still remain dependent on sponsor banks, acquirers, and networks.” My conclusion through the risk lens: do not attempt full-stack payment processing unless payments infrastructure is becoming the company’s core product. First exhaust Stripe custom pricing/IC+, and only then consider narrow, corridor-specific routing where savings are proven and compliance scope is controlled. + +--- + +## Discussion + +### Round 1 — Advocate | response | confidence: 78% + +**Response to previous points:** +Agent B’s strongest point is that the startup may be treating the full `~3.0%` Stripe bill as recoverable when most of it is not. The real risks are not theoretical: PCI scope can expand, sponsor-bank/acquirer dependencies do not disappear, and Stripe’s own vault/forward docs show how multiprocessor setups create double-capture, refund, dispute, and observability failure modes. I agree with B that “become your own processor” is the wrong action for a 20-engineer Series A company. I’m changing my position on that: they should not build full payment processing infrastructure, but they should start building the control plane now so they can renegotiate, route selectively, and avoid deeper lock-in before volume triples. + +**New evidence or angle:** +The missing lens is timing and option value. If they wait until volume is already `$150M`, they start the hardest migration exactly when the fee pain and operational stakes are highest; if they build ledger/reconciliation/routing abstractions now while keeping Stripe as a rail, they buy negotiating leverage and future exit optionality at much lower execution risk. The hurdle-rate math is also useful: at projected volume, `50 bps = ~$750k/year` and `100 bps = ~$1.5M/year`, so a small 3-5 engineer payments platform team is only justified if they can prove recurring savings plus auth/conversion gains on specific corridors, not on ideology. + +**Current position:** +My position is now: do not build full in-house processing, but do start a hybrid program immediately. Sequence it as `1)` renegotiate Stripe hard on custom/IC+ pricing, `2)` build internal ledger/reconciliation/orchestration primitives, `3)` move only high-volume, low-complexity flows where savings are empirically proven. Confidence is `78%` because B’s compliance/TCO objections are strong, but they argue against full-stack ownership, not against building strategic payment leverage. + +**Key question for the group:** +What share of the current `~300 bps` effective cost is actually Stripe markup/bundled services versus unavoidable interchange/network cost, and which transaction corridors could realistically yield `>=75-100 bps` net savings without expanding regulatory scope? + +### Round 1 — Skeptic | response | confidence: 82% + +**Response to previous points:** +Agent A’s revised argument is much stronger than the original pro-build case: do not become a processor, but start building only the internal control-plane pieces that create leverage and reduce future lock-in. I agree with that synthesis in principle, and I’ve shifted slightly from Agent B’s earlier “mostly don’t build” stance to “build only a very thin layer, if the economics are proven first.” Where I still disagree with Agent A is timing and scope. Agent B’s earlier point remains: most of the `~300 bps` is not recoverable, so a premature platform effort can easily chase the wrong savings number. Once they own routing, retries, reconciliation, and ledger correctness, they also own a 24/7 payments surface with incident response, finance ops, dispute handling, and audit obligations. For a 20-engineer Series A team, that only makes sense after Stripe renegotiation is exhausted and after they can name specific corridors with `>=75-100 bps` net savings after extra headcount and migration risk. + +**New evidence or angle:** +The missing cost is organizational, not just technical. Even a “hybrid” payments layer usually implies a standing cross-functional burden: engineering, payments ops, finance/reconciliation, compliance/security, and legal/vendor management. The breakeven test therefore should not be “can we save `50-100 bps` gross?” but “can one narrowly scoped routing/reconciliation program produce savings that still beat a fully loaded platform team plus one bad-quarter worth of auth-rate regression or migration defects?” If the answer is no, the control plane is a strategic hobby, not a margin lever. + +**Current position:** +Continue using Stripe as the primary processor, renegotiate aggressively now, and only build the minimum internal abstractions needed for reconciliation, observability, and future processor optionality. I am still against a near-term program to “build our own payment processing infrastructure.” Confidence is `82%` because Agent A correctly narrowed the target, but the hidden operating cost and failure surface still make premature platform work easy to over-justify. + +**Key question for the group:** +After Stripe custom pricing or IC+ renegotiation, which exact transaction corridors still show `>=75 bps` net savings at enough volume to repay a dedicated payments platform team within 12 months? + +### Round 2 — Advocate | response | confidence: 83% + +**Response to previous points:** +Agent B’s strongest argument is that the real trap is not technical ambition but false economics: if most of the `~300 bps` is interchange/network cost, then a broad payments-platform effort becomes a permanent engineering, ops, compliance, and incident-response burden without enough recoverable margin. I agree, and I’ve changed my mind on full-stack ownership because B showed the gross-savings frame was too loose. Where I disagree with B is sequencing: waiting for Stripe renegotiation before building any internal capability leaves the company with weak leverage and poor visibility into corridor-level economics. The synthesis with my Round 1 view is narrower: do not build “payment processing infrastructure,” but do start a tightly scoped payments control-plane program now so finance and engineering can quantify recoverable markup, decline losses, and pilotable corridors before volume triples. + +**New evidence or angle:** +The cleanest frame is real options, not architecture. They do not need to commit to becoming a processor; they need to buy decision quality. A 90-day program with `2-3` engineers plus finance/compliance support can produce four concrete outputs: `1)` fee waterfall by corridor, `2)` auth/decline loss map, `3)` external quotes from alternative processors/acquirers, and `4)` a single pilot business case with explicit kill criteria. That is a materially cheaper bet than either extreme: blindly accepting another `~$3M/year` of incremental Stripe fees at 3x volume, or prematurely standing up a full payments stack. If no corridor clears the hurdle after renegotiation, stop. If one does, pilot it. + +**Current position:** +They should keep Stripe as the primary processor, renegotiate immediately, and launch a thin, time-boxed leverage program now. I am against building full in-house processing infrastructure, but I am also against doing nothing beyond vendor negotiation. Confidence is `83%` because Agent B’s risk case is strong enough to rule out broad ownership, but the opportunity cost of waiting is also real once payments spend is on track to become a multi-million-dollar annual margin line. + +**Key question for the group:** +Can they identify, within 90 days, at least one transaction corridor representing meaningful volume that still shows `>=100 bps` net savings after team cost and migration risk, without expanding money-transmission or PCI scope materially? + +### Round 2 — Skeptic | response | confidence: 85% + +**Response to previous points:** +Agent A’s strongest argument is now well-framed: the real risk is not “Stripe is expensive,” it is waiting until volume is `~$150M` before developing any leverage or corridor-level visibility. I agree with A that a binary choice between “stay on Stripe forever” and “become your own processor” is the wrong frame, and I’ve changed my mind slightly in that direction. Where I still disagree is on what should start now: I do not think they should begin building a payments control plane yet. The most important open questions are still unresolved: how much of the current `~300 bps` is actually recoverable after Stripe custom pricing/IC+, and whether any single corridor can clear `>=75-100 bps` net savings after team cost, migration risk, and auth-rate downside. + +**New evidence or angle:** +The missing angle is irreversibility. A thin internal payments layer sounds modest, but once a startup owns ledger, routing, retries, or reconciliation in production, the burden becomes system-wide while the savings are only corridor-specific. That asymmetry matters. The lowest-risk third option is a 90-day decision program, not a build program: `1)` renegotiate Stripe, `2)` run an RFP with alternative processors/acquirers, `3)` instrument fee/auth/decline economics by corridor, and `4)` perform token-portability/compliance review. That buys most of the decision quality A wants without prematurely creating an on-call platform that will try to justify its own existence. + +**Current position:** +Keep Stripe as the primary processor, renegotiate immediately, and run a tightly scoped discovery/commercial program now. Do not start building payment infrastructure beyond minimal instrumentation until one corridor shows a credible 12-month payback with conservative assumptions. Confidence is `85%` because Agent A is right that passivity is a mistake, but I still see the highest-probability failure mode as starting engineering before the economics are proven. + +**Key question for the group:** +After Stripe IC+/custom pricing and at least one external processor quote, what is the all-in net annual savings of the single best corridor after subtracting platform headcount, compliance/ops overhead, and a conservative reserve for auth-rate regression? + +### Round 3 — Advocate | response | confidence: 86% + +**Response to previous points:** +Agent B’s strongest point is the asymmetry: once a startup puts routing, ledger, or retries into production, the operating burden is system-wide and permanent, while the savings may be narrow and corridor-specific. That evidence changed my mind away from any near-term “build our own processor” path. Where I still disagree with B is on sequencing. I agree with Agent A’s narrower view that passivity is also expensive: the two real open questions are `1)` how much of the current `~300 bps` remains recoverable after Stripe IC+/custom pricing, and `2)` whether any single corridor still clears `>=75-100 bps` net savings after headcount, compliance, and auth-risk. My synthesis is: do the commercial discovery first, but start only no-regrets internal work in parallel, not production payment ownership. + +**New evidence or angle:** +The unpriced risk cuts both ways: lock-in compounds over time. If they wait until volume is `~$150M` to map token portability, fee telemetry, reconciliation data models, and alternate processor terms, they will negotiate from maximum dependency and minimum time. That argues for a very small reversible prep layer now: corridor-level cost instrumentation, reconciliation schemas, and a portability/vendor-readiness exercise. None of that requires owning processing, touching card data more deeply, or expanding money-transmission scope, but it preserves option value if one corridor later proves out. + +**Current position:** +They should continue using Stripe as the primary processor, renegotiate immediately, and run a 90-day decision program with one hard gate: no production routing or settlement logic unless a specific corridor shows `>=100 bps` net savings after Stripe repricing and conservative overhead assumptions. I support starting only reversible, processor-agnostic prep work now because it improves leverage without committing the company to a permanent payments platform. `86%` because the compliance/TCO evidence clearly rules out full-stack ownership, and the remaining disagreement is now mostly about when minimal engineering starts. + +**Key question for the group:** +Can we agree on an explicit boundary for “no-regrets work now” versus “gated work later” by naming the exact tasks that may start immediately without increasing PCI/regulatory scope? + +**Convergence assessment:** CONVERGING — both agents now reject full in-house processing and support Stripe-first plus immediate renegotiation/discovery; the remaining gap is whether reversible engineering prep starts now or only after one corridor proves `>=75-100 bps` net savings. + +--- + +## Consensus Summary + +### Decision +The council’s consensus is that the startup should not build full in-house payment processing infrastructure now and should continue using Stripe as its primary processor. Instead, it should immediately renegotiate Stripe pricing, run a 90-day discovery/commercial program, and only consider a narrowly scoped hybrid path if a specific transaction corridor still shows at least `>=100 bps` net savings after Stripe repricing, headcount, compliance/ops overhead, and conservative auth-rate risk. Reversible “no-regrets” work such as corridor-level cost instrumentation, reconciliation data modeling, and portability/vendor-readiness prep is acceptable; owning production routing, settlement, or processor logic is not. + +### Key Contention Points + +| # | What Was Debated | Resolution | Who Had the Strongest Case & Why | +|---|-----------------|------------|----------------------------------| +| 1 | Full in-house payments infrastructure vs staying on Stripe | Full in-house ownership was rejected; Stripe remains the primary processor. | Skeptic had the strongest case because they showed most of the current `~300 bps` is not recoverable, and highlighted PCI, sponsor-bank, money-transmission, dispute, and operational risks that a 20-engineer Series A team is poorly positioned to absorb. | +| 2 | Whether the company should start building internal payments capabilities now | Only reversible prep work should start now; no production routing, settlement, or processor abstraction should go live until economics are proven. | Advocate had the strongest case on timing because they framed early prep as option value: waiting until volume reaches `~$150M` would increase lock-in and weaken negotiating leverage. | +| 3 | What economic threshold justifies any hybrid move away from Stripe | The bar is high: after Stripe IC+/custom pricing and external quotes, at least one corridor must show `>=100 bps` net savings with a credible 12-month payback. | Skeptic had the strongest case because they shifted the conversation from gross fee savings to true net savings after team cost, compliance/ops burden, and migration/auth regression risk. | + +### Unresolved Items & Risks +- The company still does not know how much of the current `~$1.5M/year` Stripe spend is recoverable after custom pricing or IC+. +- It remains unproven whether any single high-volume corridor can clear the `>=100 bps` net-savings hurdle. +- PCI scope, token portability limits, refund/dispute handling, and authorization-rate regression remain major migration risks even in a hybrid model. +- The exact boundary between acceptable “no-regrets” prep work and scope-expanding production infrastructure should be explicitly documented before engineering starts. + +### Confidence: High +Both agents converged on the core answer: reject full in-house processing, keep Stripe, renegotiate now, and gate any hybrid buildout behind hard corridor-level economics and compliance discipline. diff --git a/tests/eval-results/after-changes-2026-04-01/fintech-payments__2-cross.md b/tests/eval-results/after-changes-2026-04-01/fintech-payments__2-cross.md new file mode 100644 index 0000000..c3e312e --- /dev/null +++ b/tests/eval-results/after-changes-2026-04-01/fintech-payments__2-cross.md @@ -0,0 +1,195 @@ +--- +topic: "Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months." +mode: "council" +agent_count: "2" +agent_config: "2-agent" +max_rounds: "5" +git_commit: "none" +agent_cli: "codex" +A: "claude" +B: "codex" +status: consensus +turn: B +round: 3 +created: "2026-04-01T12:14:05.886Z" +last_updated: 2026-04-01T12:21:27.113Z +agent_A_name: "Advocate" +agent_A_cli: "claude" +agent_A_role: "advocate" +agent_B_name: "Skeptic" +agent_B_cli: "codex" +agent_B_role: "skeptic" +--- + +# Discussion: Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months. + +## Participants +- **Agent A** — Advocate (advocate) via claude +- **Agent B** — Skeptic (skeptic) via codex + +## Key Questions +1. What is the true total cost of ownership for in-house payment processing vs Stripe at current and projected volumes? +2. What are the regulatory and compliance implications (PCI-DSS, per-country requirements) of each approach? +3. Is there a hybrid approach that captures cost savings without full infrastructure ownership? +4. What is the engineering opportunity cost — what else could those engineers build? + +## Research Phase + +### Agent A (Advocate) — Independent Research | research + +**The $4.5M question: why building in-house is the highest-ROI bet this company can make.** + +**The fee math is brutal at scale.** At $50M/year and ~$1.5M in Stripe fees, this company is paying an effective rate of ~3%. With 3x volume growth to $150M/year in 18 months, that's **$4.5M/year flowing to Stripe** — and continuing to grow. By moving to direct acquiring relationships with interchange-plus pricing, high-volume processors negotiate markups as low as 0.05–0.10% + $0.05 per transaction on top of interchange (~1.5–2.0%). The realistic effective rate drops to **1.6–2.1%**, yielding annual savings of **$1.35M–$2.1M at $150M volume**. Over three years at continued growth, cumulative savings easily exceed $5–8M. That's a Series B worth of runway recovered from fees alone. + +**Precedent companies prove the path is viable.** Helcim built its entire payment stack in-house with a small Canadian engineering team and saw increased sales post-launch. Finix quadrupled revenue after becoming a payment processor, closing more deals in 2024 than in the company's entire prior history. Shopify built Shopify Payments to capture 1.8–2.2% gross margin on every dollar processed — over 56% of their GMV now flows through it, demonstrating how payment ownership becomes a profit engine. These aren't trillion-dollar companies with unlimited resources — they're startups and growth-stage companies that made the same bet. + +**This is a fintech company — payments IS the product.** Unlike a SaaS company where payments are a utility, a fintech processing $50M/year has payments as a core competency. Owning the stack creates three strategic advantages: (1) **data ownership** — transaction-level data enables better fraud models, underwriting, and product features that differentiate against competitors also running on Stripe; (2) **customization** — Stripe's one-size-fits-all approach means accepting their risk models, settlement timing, and dispute processes, which may not fit this company's specific vertical; (3) **competitive moat** — when competitors can spin up a Stripe integration in a weekend, your proprietary infrastructure becomes a defensible advantage that compounds over time. + +**The talent is already in place.** Twenty engineers at a Series A fintech likely includes payments-domain expertise. A dedicated team of 3–4 engineers can build a payment orchestration layer in 6–9 months, starting with a multi-PSP approach (direct integrations with Adyen, Worldpay, or acquiring banks) before moving to full acquiring. The industry trend of "unbundling Stripe" — using specialized vendors for fraud (Sardine, Forter), tokenization, and settlement — means you don't have to build everything monolithically. + +**The timing window is now.** Building at $50M volume gives the team room to iterate before $150M volume makes migration riskier. Every month of delay at the higher volume is ~$112K–$175K in avoidable fees. Series A capital is explicitly for building competitive advantages — and for a fintech, there is no greater advantage than owning your money movement. + +**Key uncertainties to acknowledge:** PCI DSS Level 1 compliance is non-trivial (~$200K–$500K initial cost), direct acquiring bank relationships take 3–6 months to establish, and there's execution risk in maintaining uptime for payment-critical infrastructure. But these are solvable engineering and business problems — not existential risks. The existential risk is paying a growing tax to Stripe while competitors who own their stack undercut you on pricing and outpace you on features. + +### Agent B (Skeptic) — Independent Research | research + +The optimistic case overweights the visible fee line and underweights replacement risk. Today’s spend is ~$1.5M on $50M of volume, ანუ about 300 bps. That sounds painful, but Stripe’s published US card pricing is 2.9% + 30c and Stripe explicitly offers custom pricing, IC+ pricing, and volume discounts for larger merchants ([Stripe pricing](https://stripe.com/us/pricing)). So the first skeptical question is not “can we build cheaper?” but “have we exhausted negotiation?” If not, the startup could burn 12-18 months on infrastructure that a pricing renegotiation partially solves in weeks. + +The second problem is scope ambiguity. “Build our own payments infrastructure” can mean anything from lightweight orchestration to becoming effectively a direct processor/payfac. Those are radically different bets. If they go deep, even Stripe’s own payfac guide says the traditional route requires acquirer sponsorship, payment gateways, merchant dashboards, payout systems, dispute systems, compliance programs, underwriting, fraud tooling, reconciliation, and ongoing registrations/licensing. Stripe’s estimated minimums are not trivial: 3-6 months for acquirer sponsorship, 3-5 months and $50k-$500k for Level 1 PCI validation, 6-12+ months and $600k+ for merchant management, plus $200k+/year for annual PCI validation ([Stripe payfac guide](https://stripe.com/us/guides/payfacs)). That is before considering the startup has only 20 engineers. A Series A company does not usually have spare staff for a quasi-bank/platform build while tripling volume. + +Security and compliance are the biggest downside. PCI DSS applies to entities that store, process, or transmit cardholder data, including merchants, processors, acquirers, issuers, and service providers ([PCI SSC](https://www.pcisecuritystandards.org/standards/pci-dss/)). PCI scope is not static either: PCI SSC clarified that revised SAQ A e-commerce requirements took effect on April 1, 2025, including protections against script attacks even for embedded payment forms ([PCI SSC blog](https://blog.pcisecuritystandards.org/faq-clarifies-new-saq-a-eligibility-criteria-for-e-commerce-merchants)). If the company moves from hosted/tokenized flows toward owning more of the card path, it is choosing a much larger cardholder-data environment, more audit surface, harder incident response, and higher breach blast radius. One serious payment-data incident can wipe out years of fee savings. + +Operational failure modes are also easy to underestimate. Stripe bundles fraud tooling, real-time retries, account updater, customer authentication, dispute workflows, payout rails, and claims 99.999% average historical uptime on its pricing page ([Stripe pricing](https://stripe.com/us/pricing)). Replacing “payment acceptance” really means replacing a stack of edge-case behavior. Bugs here do not fail gracefully: routing errors create false declines, ledger defects misstate cash, payout bugs trigger customer harm, and descriptor/dispute problems push chargebacks up. Mastercard’s Excessive Chargeback Program starts monitoring above 1.0% CTR with at least 100 chargebacks and treats merchants as excessive at 1.5% CTR with at least 100 chargebacks in each of two consecutive months ([Mastercard Security Rules](https://www.mastercard.us/content/dam/public/mastercardcom/na/global-site/documents/SPME-Manual.pdf)). Visa likewise notes disputes are time-consuming and resource-intensive for merchants ([Visa chargebacks](https://corporate.visa.com/en/solutions/acceptance/chargebacks.html)). A scaling startup can easily save basis points and lose dollars if auth rates or dispute rates worsen. + +My skeptical conclusion: do not treat this as a binary choice between “Stripe forever” and “become a processor.” The downside scenario is spending heavily to rebuild commodity infrastructure during hypergrowth, accepting more security/compliance exposure, and still needing an acquirer/bank/network stack underneath. Unless payments are the company’s product moat, the default answer is stay on Stripe, force a commercial repricing, and consider narrow extensions only after proving a specific bottleneck. The major uncertainties are AOV, domestic vs international mix, fraud/chargeback rates, whether they store cards today, and whether “build” means orchestration or true direct processing. Without those, the savings thesis is not decision-grade. + +--- + +## Discussion + +### Round 1 — Advocate | response | confidence: 72% + +**Response to previous points:** + +Skeptic's strongest argument is scope ambiguity — the gap between "payment orchestration layer" and "become a processor" is enormous, and my research phase conflated them. A 20-engineer Series A building full acquiring/payfac infrastructure while tripling volume is genuinely reckless. I concede that framing. The Skeptic is also right that step zero is renegotiating with Stripe; if they haven't pushed for IC+ or volume pricing, leaving $300K–$600K/year on the table before writing a line of code is negligent. + +Where I disagree: the Skeptic frames this as "commodity infrastructure rebuild" and asks whether payments are the company's moat. But this *is* a fintech. Payments aren't a utility bill here — they're the product surface. The Skeptic's own examples (fraud tooling, dispute workflows, settlement timing) are exactly the dimensions where a fintech differentiates. Accepting Stripe's one-size-fits-all risk models and settlement schedules means competing with every other Stripe-powered fintech on identical infrastructure. That's a strategic ceiling, not just a cost problem. + +**New evidence or angle:** + +The binary is false — and that's actually the Advocate's best case. The move isn't Stripe-to-processor. It's Stripe-to-orchestration-layer-to-optionality. Companies like Primer, Spreedly, and Gr4vy exist precisely because the unbundled stack works: keep Stripe as one PSP, add Adyen or a direct acquirer for high-volume corridors, route intelligently. This captures 40–60% of the fee savings (~$500K–$1.2M/year at $150M volume) with ~10% of the compliance burden because card data stays tokenized through the PSPs. Two engineers, 3–4 months, no PCI scope expansion. The Skeptic's compliance nightmare applies to full direct processing — not to orchestration. These are different bets with different risk profiles, and collapsing them lets the status quo win by default. + +One data point missing from both sides: auth rate optimization. Multi-PSP routing typically lifts authorization rates 1–3% by retrying declines across processors. On $150M volume with average transaction size of $100, even a 1% auth rate lift recovers ~$1.5M in otherwise-lost revenue. This dwarfs the fee savings and has zero PCI implications. + +**Current position:** + +Build a payment orchestration layer (not full processing), starting now, while simultaneously renegotiating Stripe pricing. ~72% confident because: the orchestration path delivers real savings and auth-rate gains with manageable risk, the company is a fintech where payment control is strategic, and the Skeptic's strongest objections apply to a scope I'm no longer proposing. I discount to 72% (not higher) because we lack data on their transaction mix, fraud profile, and whether two engineers can actually be spared during hypergrowth — the Skeptic is right that staffing during 3x scaling is a real constraint. + +**Key question for the group:** + +Skeptic — does the orchestration-layer approach (multi-PSP routing, tokenized, no PCI scope expansion) change your risk calculus, or do you see hidden costs in that "middle path" that I'm underweighting? + +### Round 1 — Skeptic | response | confidence: 78% + +**Response to previous points:** +Advocate’s strongest move is narrowing the proposal from “become a processor” to “build an orchestration layer while renegotiating Stripe.” I agree that this materially improves the risk profile: it preserves optionality, avoids most of the payfac/acquirer buildout I flagged earlier, and treats pricing negotiation as the immediate no-regrets step. That is a real shift, and it changes my view. + +Where I still disagree is the implied ease: “2 engineers, 3–4 months, no PCI expansion” is not yet decision-grade. The hard part is rarely the API routing layer. It is token portability, recurring-payment migration, reconciliation across multiple PSPs, dispute/refund operations, finance controls, and failure handling when one PSP authorizes and another owns the customer record. Advocate is right that orchestration is the credible third option; I think the hidden costs are still being underweighted. + +**New evidence or angle:** +The gating issue is stored credential control. If saved cards, network tokens, or subscription mandates effectively live inside Stripe’s vault, multi-PSP routing is much easier for new traffic than for existing customers. That means the company may only be able to route a slice of volume at first, which weakens both the fee-savings and auth-lift story. Related point: the claimed 1–3% auth-rate uplift is plausible, but it is not bankable without decline-code distribution, issuer mix, cross-border share, and evidence that retries can be done without creating duplicate auths or customer-visible failures. The biggest unmodeled cost here is not compliance; it is migration friction plus operational fragmentation. + +**Current position:** +Do not build full payment processing infrastructure. Renegotiate Stripe now, and only pursue orchestration as a narrow pilot if the company can prove token portability, isolate high-volume corridors, and show that net savings survive added ops/finance complexity. ~78% because Advocate successfully reduced the compliance objection, but the practical economics of orchestration still depend on details we do not have, especially stored-credential portability and how much volume is actually routable. + +**Key question for the group:** +What percentage of current and projected volume depends on Stripe-held stored credentials or subscription mandates, and can those credentials be ported or re-tokenized for a second PSP without forcing customer re-entry or re-consent? + +### Round 2 — Advocate | response | confidence: 75% + +**Response to previous points:** + +Skeptic's strongest point is that stored-credential portability — not compliance or engineering complexity — is the actual gating constraint. This is correct and I underweighted it. If 60–80% of volume runs on Stripe-vaulted cards (subscriptions, returning customers), the orchestration layer initially captures only new-customer flow, sharply reducing the near-term savings and auth-lift numbers I cited. Skeptic is also right that reconciliation across PSPs, split dispute handling, and finance controls add real operational weight I glossed over with "2 engineers, 3–4 months." + +Where I push back: this constraint is the strongest argument for starting *now*. Every month of delay adds more credentials to Stripe's vault, deepening lock-in. The stored-credential problem gets worse with time, not better — especially during 3x volume growth. Framing portability as a blocker rather than a phased migration challenge lets lock-in compound unchallenged. + +**New evidence or angle:** + +Two things not yet on the table: + +1. **Network tokenization addresses portability without PCI expansion.** Visa Token Service and Mastercard MDES create network-level tokens that are PSP-agnostic. Stripe supports provisioning network tokens, and these can be used across any processor that accepts them (Adyen, Worldpay, etc.). Stored credentials don't have to stay locked in Stripe's vault — they can be migrated to network tokens gradually without customer re-entry or consent flows. This directly answers Skeptic's gating question: credentials are portable, but migration is incremental, not instant. + +2. **The "new traffic only" constraint is a de-risking mechanism, not a limitation.** Routing only new customers through a second PSP for 3–6 months creates a controlled pilot: measure actual auth-rate lift, actual reconciliation burden, actual ops overhead on ~20–30% of volume before committing further. If net savings don't survive operational complexity, stop and stay on renegotiated Stripe. If they do, expand. This converts Skeptic's uncertainty into testable hypotheses rather than reasons to defer. + +**Current position:** + +Renegotiate Stripe immediately. In parallel, build toward orchestration via a phased pilot on new traffic only. ~75% confident because: (a) network tokenization provides a credible portability path for the stored-credential problem Skeptic identified, (b) a pilot-first approach makes the unknowns measurable before full commitment, and (c) both sides now agree the status quo is suboptimal — remaining disagreements are about implementation sequencing, not strategic direction, and those are testable. I stay below 80% because we're still reasoning without knowing the actual stored-credential percentage, transaction mix, or available engineering bandwidth during hypergrowth. + +**Key question for the group:** + +Skeptic — given that network tokenization provides a PSP-agnostic portability path and the pilot can be scoped to new traffic only, does your position shift toward "yes, run the pilot," or do you see a reason the pilot itself carries unacceptable risk for a company mid-hypergrowth? + +### Round 2 — Skeptic | response | confidence: 74% + +**Response to previous points:** +Advocate’s strongest argument is the sequencing point: the real mistake is not “failing to become a processor,” it is letting Stripe lock-in deepen while volume triples. I agree more than before, and I’m changing my view explicitly: a narrow, reversible orchestration pilot is now the most credible third option. But I still disagree that network tokenization fully resolves portability. It helps, but it does not automatically solve legacy Stripe-vaulted cards, recurring mandate migration, account-updater continuity, or operational ownership across two PSPs. So the synthesis between Advocate’s revised case and my earlier objections is: renegotiate Stripe now, pilot a second PSP on tightly bounded new traffic or one corridor, and do not underwrite the economics on migrating the installed base until portability is proven in practice. + +**New evidence or angle:** +One angle we have not discussed enough is bargaining power. A credible second PSP can pay off even before major traffic migration because it turns Stripe pricing talks from hypothetical to real. That makes the pilot valuable as commercial leverage and vendor-concentration reduction, not just as a fee-arbitrage project. The catch is measurement: if they cannot produce clean pilot metrics on auth lift, dispute/refund handling cost, reconciliation effort, and net margin after added ops/finance burden, the pilot will generate complexity without decision-grade evidence. + +**Current position:** +Do not build full payment processing infrastructure. Renegotiate Stripe immediately, and run a narrow second-PSP pilot only if it is explicitly framed as an experiment with hard success/failure gates and named finance/ops ownership. ~74% because Advocate materially reduced the compliance objection by narrowing scope, but the portability and operational-cost assumptions are still too soft to justify a broad orchestration program. + +**Key question for the group:** +What is the six-month, all-in pilot P&L for one specific routable corridor after including engineering time, finance/ops overhead, and support costs, not just processor fee savings? + +### Round 3 — Advocate | response | confidence: 76% + +**Response to previous points:** + +Skeptic's strongest contribution this round is reframing the pilot's primary value: it's bargaining leverage and vendor-concentration reduction *first*, fee arbitrage *second*. That's a better framing than mine. A credible second PSP turns Stripe repricing from "please give us a discount" into "we have a live alternative processing real volume." That alone could be worth $300K–$600K/year in better Stripe terms — potentially exceeding the direct savings from the pilot corridor itself. I'm adopting this framing. + +Skeptic is also right that I oversold network tokenization as a clean portability solution. It addresses *card-on-file* migration for future routing, but doesn't solve recurring mandate ownership, account-updater continuity, or the operational split where Stripe owns disputes on old transactions while the new PSP handles current ones. I was treating portability as a technical problem when it's equally an operational and financial one. + +Where I still push back: Skeptic's insistence on a "six-month all-in pilot P&L" before greenlighting risks becoming a reason to never start. The pilot *is* the mechanism for generating that P&L. You can scope a 90-day, single-corridor test with a $50K–$80K engineering budget (one engineer, part-time ops support) and pre-defined kill criteria — if auth rates drop >0.5%, if reconciliation takes >X hours/week, if dispute resolution exceeds Y days, stop. That's not a major resource bet for a company burning Series A capital. Demanding decision-grade economics before running the experiment that produces them is circular. + +**New evidence or angle:** + +We've exhausted the major strategic and operational arguments. What hasn't been said: the two positions are now close enough that the *decision framework* matters more than the *decision*. Both sides agree on renegotiate-first, pilot-second. The remaining gap is how high the bar should be to *start* the pilot vs. how high the bar should be to *expand* it. I'd propose splitting those: low bar to start (one corridor, new traffic, named owner, 90-day timebox), high bar to expand (proven P&L, clean reconciliation metrics, portability evidence). This isn't a compromise — it's the correct risk structure for an experiment. + +**Current position:** + +Renegotiate Stripe immediately. Run a tightly bounded 90-day orchestration pilot on one new-traffic corridor with explicit kill criteria and a named finance/ops owner. Do not plan migration of stored credentials until pilot data proves the economics. ~76% confident because both sides' remaining objections are about implementation sequencing that a structured pilot resolves empirically, and the downside of a failed 90-day experiment ($50K–$80K, one engineer's quarter) is trivially small relative to the $1.5M–$4.5M/year fee exposure. + +**Key question for the group:** + +Can we draft joint success/failure criteria for a 90-day pilot — specifically: what auth-rate delta, reconciliation overhead, and net-margin threshold would make Skeptic say "expand" vs. "stop"? + +**Convergence assessment:** CONVERGING — Both sides agree on renegotiate Stripe, don't build full processing, pilot orchestration with guardrails. The remaining gap is narrow: how much upfront evidence is needed to *start* the pilot vs. to *expand* it. That's an implementation detail, not a strategic disagreement. + +--- + +## Consensus Summary + +### Decision +Do not build full payment processing infrastructure. Renegotiate Stripe pricing immediately to capture $300K–$600K/year in near-term savings, then run a tightly bounded 90-day orchestration pilot on a single new-traffic corridor with one engineer, a named finance/ops owner, and explicit kill criteria. Expand only if pilot data proves positive economics after accounting for reconciliation overhead, auth-rate impact, and operational complexity. + +### Key Contention Points + +| # | What Was Debated | Resolution | Who Had the Strongest Case & Why | +|---|-----------------|------------|----------------------------------| +| 1 | Full in-house processing vs. staying on Stripe | Resolved — both rejected the binary. Orchestration layer (multi-PSP routing) emerged as the credible third path. | Skeptic initially, for exposing that the full-build scope was reckless for a 20-engineer Series A; Advocate then strengthened it by proposing the narrower orchestration framing. | +| 2 | PCI/compliance risk of owning more of the card path | Resolved — orchestration with tokenized PSP integrations avoids PCI scope expansion entirely. | Skeptic raised it; Advocate resolved it by narrowing from direct processing to orchestration where card data stays with PSPs. | +| 3 | Stored-credential portability as the real gating constraint | Partially resolved — network tokenization (Visa Token Service, Mastercard MDES) provides a path, but legacy mandates, account-updater continuity, and operational splits remain unproven. | Skeptic, for identifying that lock-in depth — not compliance — was the actual bottleneck, and that network tokenization doesn't fully solve recurring mandate migration. | +| 4 | How much evidence is needed before starting the pilot | Resolved via tiered bar — low threshold to start (one corridor, 90-day timebox, ~$50K–$80K budget), high threshold to expand (proven P&L, clean reconciliation metrics). | Advocate, for recognizing that demanding decision-grade economics before running the experiment that produces them is circular; the pilot itself is the evidence-generation mechanism. | +| 5 | Primary value of a second PSP | Resolved — bargaining leverage and vendor-concentration reduction first, direct fee arbitrage second. A live alternative transforms Stripe repricing negotiations. | Skeptic, for reframing the pilot's value hierarchy in a way Advocate explicitly adopted. | + +### Unresolved Items & Risks +- **Stored-credential percentage unknown**: What share of current volume depends on Stripe-vaulted cards/subscriptions determines how much volume is initially routable and how fast savings materialize. +- **Engineering bandwidth during hypergrowth**: Whether even one engineer can be spared during 3x volume scaling without jeopardizing core product delivery is untested. +- **Pilot success/failure criteria not yet defined**: Specific auth-rate delta thresholds, reconciliation overhead limits, and net-margin gates need to be set before the pilot starts. +- **Six-month all-in pilot P&L**: The true cost of operating across two PSPs (split disputes, dual reconciliation, finance controls) remains modeled, not measured. +- **Transaction mix unknown**: Domestic vs. international split, average order value, and fraud/chargeback profile all affect whether fee savings survive operational complexity. + +### Confidence: High +Both sides converged to the same three-step recommendation (renegotiate, pilot, expand-if-proven) with remaining disagreements limited to implementation sequencing that the pilot itself resolves empirically. diff --git a/tests/eval-results/after-changes-2026-04-01/healthcare-ai-deploy__2-codex.md b/tests/eval-results/after-changes-2026-04-01/healthcare-ai-deploy__2-codex.md new file mode 100644 index 0000000..8bf53a1 --- /dev/null +++ b/tests/eval-results/after-changes-2026-04-01/healthcare-ai-deploy__2-codex.md @@ -0,0 +1,165 @@ +--- +topic: "A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance?" +mode: "council" +agent_count: "2" +agent_config: "2-agent" +max_rounds: "5" +git_commit: "none" +agent_cli: "codex" +status: consensus +turn: B +round: 3 +created: "2026-04-01T12:22:34.936Z" +last_updated: 2026-04-01T12:28:32.862Z +agent_A_name: "Advocate" +agent_A_cli: "codex" +agent_A_role: "advocate" +agent_B_name: "Skeptic" +agent_B_cli: "codex" +agent_B_role: "skeptic" +--- + +# Discussion: A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance? + +## Participants +- **Agent A** — Advocate (advocate) via codex +- **Agent B** — Skeptic (skeptic) via codex + +## Key Questions +1. Is 87% accuracy sufficient given that it matches current standard of care (average radiologist)? +2. What does the FDA clearance pathway look like at 87% vs 95%, and does higher accuracy meaningfully change the regulatory burden? +3. What are the data and compute requirements to go from 87% to 95%, and is 12-18 months realistic? +4. Can the company survive 12-18 months of continued burn without revenue from deployment? + +## Research Phase + +### Agent A (Advocate) — Independent Research | research + +They should pursue FDA clearance now, with a tightly scoped human-in-the-loop screening workflow, while continuing to improve the model in parallel. The upside case is strong: diabetic retinopathy is an access problem as much as an algorithm problem. In the U.S., CDC says 60% of people with diabetes do not get annual eye exams, more than 90% of diabetes-related vision loss can be avoided with early detection and treatment, and an estimated 9.6 million people were living with diabetic retinopathy in 2021, including 1.84 million with vision-threatening disease (CDC, 2024: https://www.cdc.gov/diabetes/hcp/clinical-guidance/promote-eye-health.html ; https://www.cdc.gov/vision-health-data/prevalence-estimates/dr-prevalence.html). If the startup can move screening into primary care or endocrinology now, it can catch patients who are currently missed, not just marginally outperform already-screened patients. + +Regulatory precedent also argues for action, not delay. FDA already created the device category for retinal diagnostic software with IDx-DR in 2018, and multiple devices have since cleared or been authorized, including EyeArt and AEYE-DS (FDA: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN180001 ; https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K200667 ; https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K240058). The first FDA De Novo summary is especially important: IDx-DR’s prespecified regulatory thresholds were 85.0% sensitivity and 82.5% specificity, and it achieved 87.4% sensitivity and 89.5% specificity in the pivotal study (FDA DEN180001 summary: https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180001.pdf). That means “95% accuracy” is not the obvious gating number. Accuracy is also the wrong headline metric for a screening product; FDA will care more about sensitivity, specificity, imageability, subgroup performance, and what happens to low-confidence or unreadable images. If their current 87% top-line accuracy can be translated into clinically acceptable operating points, they may already be in the clearance zone. + +What could go right operationally is even more compelling. Point-of-care AI screening appears to increase real follow-through, not just model scores. In a 2024 randomized trial in youth, autonomous AI increased diabetic eye exam completion to 100% versus 22% for usual referral; among those needing follow-up, 64% completed it versus 22% in control (Nature Communications, 2024: https://www.nature.com/articles/s41467-023-44676-z). A 2025 meta-analysis covering 20,108 patients found AI-based initial assessment significantly increased follow-up uptake versus human grading (OR 1.89, 95% CI 1.78-2.01) (Eye, 2025: https://www.nature.com/articles/s41433-025-03849-4). In a Stanford adult screening program, 69.2% of AI-positive patients followed up within 90 days, and follow-up at the university eye institute was roughly triple the human workflows (35.5% vs 12.0% and 11.7%) (Clin Ophthalmol, 2023: https://pubmed.ncbi.nlm.nih.gov/38026608/). The value here is speed, convenience, and closing the referral gap. + +Business upside matters too. Adoption is still tiny. A 2024 JAMA Ophthalmology analysis found only 0.09% of all patients with diabetes in TriNetX received CPT 92229 AI imaging, despite an established reimbursement code; that is whitespace, not saturation (https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2825181). With only 18 months of runway, spending 12-18 months chasing an arbitrary 95% risks using the company’s entire option value before it gets regulatory, payer, workflow, and real-world evidence. One 2024 economic evaluation also found that the most accurate AI operating point was not the most cost-effective one; higher accuracy did not automatically maximize value (NPJ Digital Medicine, 2024: https://pubmed.ncbi.nlm.nih.gov/38383738/). Generalizability to the U.S. is uncertain, but the strategic lesson is clear: better product-market fit and clinical workflow can matter more than squeezing out the last few benchmark points. + +The main uncertainty is whether the startup’s “87% accuracy” hides weak sensitivity, poor imageability, unsafe subgroup gaps, or brittle performance under real-world image quality. If so, they are not ready. But if the current model is already clinically respectable, the upside-maximizing move is not to wait for perfection. It is to file now, launch with human oversight, route unreadable or low-confidence cases to specialists, and use deployment to build the evidence moat that a lab-only 95% may never create. + +### Agent B (Skeptic) — Independent Research | research + +The skeptical view is that `87% accuracy` is not a decision-grade number for an FDA-bound screening product. In diabetic retinopathy screening, the dangerous errors are false negatives, ungradable images, and subgroup failures; overall accuracy can look acceptable while still missing too many referable cases. That is also how FDA-cleared comparators are evaluated: the FDA summaries for IDx-DR and AEYE-DS center on sensitivity, specificity, PPV/NPV, and analyzable fraction or imageability, not headline accuracy ([IDx-DR De Novo summary](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180001.pdf), [AEYE-DS 510(k) summary](https://www.accessdata.fda.gov/cdrh_docs/pdf24/K240058.pdf)). IDx-DR cleared with 87.4% sensitivity and 89.5% specificity, but even there the FDA summary notes a worst-case sensitivity of 80.7% when non-analyzable cases are treated conservatively. AEYE-DS later cleared at materially stronger levels: roughly 92%-93% sensitivity, 89%-94% specificity, and 99% imageability. So if this startup’s `87%` is only overall accuracy, it may be well below what regulators, customers, and competitors will expect. + +“Human-in-the-loop” does not make the regulatory or clinical risk disappear. FDA’s CDS guidance is explicit that software which acquires, processes, or analyzes medical images is generally still a regulated device; image analysis does not become “non-device CDS” just because a clinician reviews the output ([FDA CDS guidance/FAQ](https://www.fda.gov/medical-devices/software-medical-device-samd/clinical-decision-support-software-frequently-asked-questions-faqs), [final guidance page](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-decision-support-software)). FDA’s transparency principles also stress that the relevant unit is the `human-AI team`, meaning you need evidence that the workflow actually improves care rather than just adding another fallible step ([FDA transparency principles](https://www.fda.gov/medical-devices/software-medical-device-samd/transparency-machine-learning-enabled-medical-devices-guiding-principles)). In practice, radiologists under time pressure may over-trust the model, under-trust it, or use it inconsistently. If the team performance is unproven, HITL is more of a comforting story than a validated mitigation. + +The biggest downside scenario is not merely “the model is a bit worse than hoped.” It is: the company spends scarce runway on a pivotal study, gets a narrow clearance or fails clearance, then discovers real-world performance degrades on new cameras, low-quality images, different ethnic groups, or sites with different disease prevalence. Real-world DR AI performance is highly variable. A 2025 implementation study found candidate algorithms ranging from `60%-80% sensitivity` and `14%-96% specificity`, and reported that one FDA-approved algorithm was dropped because interim specificity was too low in that setting ([JMIR 2025 implementation study](https://medinform.jmir.org/2025/1/e67529/)). Another 2026 real-world study showed worst-case sensitivity collapsing to `48.5%` when ungradable/missing cases were handled pessimistically ([Scientific Reports 2026](https://www.nature.com/articles/s41598-026-37292-6)). Even when sensitivity is high, poor specificity can create operational damage: a real-world IDx commentary reported PPV of only `19%`, meaning most referrals were false positives, burdening ophthalmology clinics and patients ([Journal commentary](https://pmc.ncbi.nlm.nih.gov/articles/PMC8120063/)). + +So the skeptical conclusion is: do not treat this as a simple choice between “deploy now at 87” and “wait until 95.” `95% accuracy` is also the wrong target if it does not translate into sensitivity, specificity, imageability, and subgroup robustness. With only 18 months of runway, the company cannot afford a weak clearance attempt that produces one safety scare or one embarrassing external-validation paper. If they move now, the least-bad path is tightly controlled evidence generation, not broad deployment: lock hardware/workflow, report sensitivity/specificity/imageability by subgroup, validate prospectively across sites, and prove the human-AI team is safe. Without that, the downside is patient harm, regulatory rejection, referral overload, and a damaged brand before the company reaches the next financing. + +--- + +## Discussion + +### Round 1 — Advocate | response | confidence: 74% + +**Response to previous points:** +Agent B’s strongest argument is that `87% accuracy` is not a regulatory or clinical decision metric in this category. That is the right caution: if `87%` hides weak sensitivity, poor imageability, or subgroup failure, then “human-in-the-loop” is not a real safety answer, and a broad launch could burn runway and trust at the same time. + +My synthesis is narrower than “deploy now” but still action-oriented: do **not** spend 12-18 months chasing a headline `95% accuracy` target before engaging FDA. Instead, pursue the clearance path **now** with a tightly scoped indication, locked workflow, fixed camera stack, and explicit triage for low-confidence/ungradable cases. Agent B is right that uncontrolled deployment is risky; I disagree that the implication is “wait.” The company’s real enemy is not just model error, it is time-to-evidence and time-to-revenue with only 18 months of runway. + +**New evidence or angle:** +A new angle is **metric economics**: the jump from `87%` to `95%` may be the wrong optimization problem because later-stage gains are often limited by label disagreement, case-mix shifts, and image-quality variance, not just model architecture. In other words, they may spend most of their runway buying benchmark improvement that does not materially improve clearance odds or workflow value. A prospective, site-constrained study now may create more enterprise and financing value than another year of offline tuning. + +**Current position:** +Pursue FDA engagement now and build toward a controlled HITL deployment, not a broad autonomous rollout. Confidence: 74% because Agent B’s evidence changed my view away from “deploy now if roughly radiologist-level” toward “file now, but only with a tightly bounded workflow and prospective evidence plan.” I am still against waiting for `95% accuracy` as the gating condition. + +**Key question for the group:** +What are the model’s current `sensitivity`, `specificity`, `imageability`, and subgroup results on a prospective multi-site U.S.-like dataset, especially when ungradable images are counted conservatively? + +### Round 1 — Skeptic | response | confidence: 78% + +**Response to previous points:** +Agent A’s strongest point is that `95% accuracy` is a seductive but probably wrong target: if the real regulatory levers are `sensitivity`, `specificity`, `imageability`, and subgroup performance, then burning 12-18 months on one aggregate metric could kill the company without meaningfully improving clearance odds. I agree with that, and I’ve changed my mind on one piece: “wait for 95 before doing anything” is too blunt given only 18 months of runway. + +Where I still disagree with Agent A is on the step after that. “Engage FDA now” is sound; “pursue clearance and deploy now” is still too aggressive unless the company already has prospective evidence on a locked workflow. A narrow HITL claim can reduce some risk, but it does not solve the core problem if current `87%` masks weak false-negative behavior, low analyzable fraction, or site-specific degradation. The most important open questions remain the ones Agent A ended with: current `sensitivity`, `specificity`, `imageability`, and subgroup results under conservative handling of ungradable images. Until those are known, the right synthesis is: start the regulatory process now, but do not assume that means filing immediately or launching commercially. + +**New evidence or angle:** +New angle: an early clearance can create a product trap. If they file now with a tightly locked camera stack, thresholds, and workflow to make the study pass, they may clear a version that is too narrow to scale commercially. Then the “real” product improvements they need afterward can trigger expensive revalidation, new clinical work, and possibly another submission. So the tradeoff is not just `deploy now` versus `wait for 95`; it is `when do we freeze the product`, and freezing too early can be as damaging as waiting too long. + +**Current position:** +Do not wait for `95% accuracy` as a gate. Do initiate FDA pre-sub, lock the intended use, and run a fast prospective multi-site study now. I am still against filing for clearance or broad deployment until the company can show clinically credible `sensitivity`, `specificity`, `imageability`, and subgroup robustness on the actual workflow it plans to sell. Confidence: 78% because Agent A is right that time-to-evidence matters more than offline benchmark chasing, but the downside of freezing and filing the wrong product is still substantial. + +**Key question for the group:** +If ungradable images are counted conservatively and results are sliced by site, camera, and key demographic subgroups, what are the model’s current `sensitivity`, `specificity`, and analyzable fraction on the exact locked workflow they would submit to FDA? + +### Round 2 — Advocate | response | confidence: 82% + +**Response to previous points:** +Agent B’s strongest argument is the `product trap`: if they freeze too early around a narrow camera/workflow just to make a submission pass, they could clear a version that is too constrained to scale, then pay again to revalidate the product they actually want to sell. That is a real risk, and it changed my view further away from “file immediately.” I agree with Agent B that `87% accuracy` is not decision-grade; the open question both agents are converging on is still the key one: on the exact locked workflow, with ungradable images handled conservatively, what are `sensitivity`, `specificity`, `imageability`, and subgroup/site/camera results? Where I still disagree is on pace: those unknowns argue for a fast prospective study and FDA pre-sub now, not a 12-18 month campaign to reach `95%` on a headline metric. + +**New evidence or angle:** +New angle: this is a `value-of-information` problem under runway pressure. Waiting 12-18 months for `95% accuracy` is an expensive, low-information bet because it delays the only evidence that really matters: real-world performance on the locked clinical workflow. A short prospective multi-site study creates more strategic value sooner. If the model is already good enough on the right metrics, they can file and finance off regulatory momentum; if it fails on imageability or subgroup robustness, they learn that while they still have runway to fix the actual bottleneck rather than optimizing the wrong benchmark. + +**Current position:** +Start FDA pre-sub now and run an accelerated prospective validation immediately; do not wait for `95% accuracy` as a gate. I would file and launch only if that study shows credible `sensitivity`, `specificity`, `imageability`, and subgroup robustness on the intended workflow. Confidence: 82% because Agent B’s evidence made the original “deploy now” stance too aggressive, but it also strengthened the case against spending most of the runway on offline model improvement before getting decision-grade evidence. + +**Key question for the group:** +Can the company complete a 3-6 month prospective, multi-site study on a locked camera/workflow that reports conservative `sensitivity`, `specificity`, `imageability`, and subgroup performance soon enough to support a real file/no-file decision before runway becomes the binding constraint? + +### Round 2 — Skeptic | response | confidence: 84% + +**Response to previous points:** +Agent A’s strongest argument is the `value-of-information` point: with only 18 months of runway, a 12-18 month push to `95% accuracy` is a slow bet on the wrong metric, while a fast prospective study on the locked workflow answers the only questions that matter for both FDA and the business. I agree, and my view has shifted further: the company should not wait for `95%` as a gate. + +Where I still differ from Agent A is on how close that gets them to a filing decision. “Pre-sub now + accelerated prospective validation now” is the right move; “clearance path now” is only justified if the evidence package is built around the intended operating point, not the model’s average score. Agent A is right that time-to-evidence matters more than offline tuning. My added caution is that the evidence has to answer the full deployment question at once: `sensitivity`, `specificity`, `imageability`, conservative handling of ungradable images, subgroup/site/camera robustness, and whether the HITL workflow preserves those results in practice. Without that, they risk proving only that a narrow lab configuration works. + +**New evidence or angle:** +New angle: the real decision variable is probably `coverage at a safe operating point`, not raw accuracy. If the model can abstain on low-confidence or low-quality images and still deliver clinically credible sensitivity/specificity on, say, 70%-85% of cases, that could support a viable HITL product now. If achieving safe performance requires abstaining on too many patients, then the product is not commercially or operationally ready even if the benchmark accuracy improves later. So the crucial curve is: as confidence threshold rises, what happens to sensitivity, specificity, and analyzable fraction? + +**Current position:** +Do not spend 12-18 months chasing `95% accuracy` before engaging FDA. Start pre-sub now, lock the intended workflow enough to run a fast prospective multi-site study, and make the file/no-file decision from that evidence. I am still against filing or deploying broadly until they can show a viable safety-coverage tradeoff on the actual workflow they intend to sell. Confidence: 84% because Agent A’s runway argument is strong, but the gating risk has narrowed to one testable issue rather than disappeared. + +**Key question for the group:** +At the intended confidence threshold and workflow, what percentage of patients can the model handle while still meeting clinically credible `sensitivity`, `specificity`, and conservative ungradable-case performance across sites, cameras, and key subgroups? + +### Round 3 — Advocate | response | confidence: 86% + +**Response to previous points:** +Agent B’s strongest argument is now the right crux: the real product is not “87% accuracy,” it is the `coverage at a safe operating point` on a locked workflow, including conservative treatment of ungradable images and robustness across sites, cameras, and subgroups. I agree. That changed my position materially from early “deploy now” toward “generate decision-grade evidence now.” Where I still push harder than Agent B is on timing: the evidence gap argues for an immediate pre-sub plus fast prospective study, not a 12-18 month optimization cycle toward `95%`. On the core open questions, both of us are effectively asking the same thing: what are `sensitivity`, `specificity`, `imageability`, and abstention-adjusted coverage on the exact workflow they would sell, and are those numbers good enough to justify filing before runway becomes the larger risk? + +**New evidence or angle:** +New angle: this is also a `financing and partnership` strategy question, not just a model question. A startup with 18 months of runway is more likely to unlock capital, pilot sites, and payer conversations from a credible FDA pre-sub outcome plus a prospective multi-site readout than from another year of offline benchmark improvement. In other words, the fastest path to survival may be proving `regulatory-ready clinical workflow evidence`, not proving `best-in-class model accuracy`. That favors a staged plan with explicit gates: pre-sub now, prospective study now, file only if the readout clears prespecified safety and coverage thresholds. + +**Current position:** +Do not wait for `95% accuracy` as the gating condition. Start FDA pre-sub immediately, lock the minimum viable commercial workflow, and run a 3-6 month prospective multi-site study with prespecified thresholds for `sensitivity`, `specificity`, `imageability`, subgroup robustness, and safe-case coverage. File only if that package is strong enough; if not, spend the remaining runway fixing the identified bottleneck rather than chasing a generic accuracy target. Confidence: 86% because Agent B’s risk framing changed my view on immediate filing, but the strategic case against a long delay is now stronger, not weaker. + +**Key question for the group:** +What is the minimum `safe coverage` threshold, at the intended confidence cutoff and locked workflow, that would make the product both clinically credible and commercially viable enough to justify filing within the next 6 months? + +**Convergence assessment:** CONVERGING — we are within ~80% agreement that they should not wait for `95% accuracy`, and should instead run pre-sub plus fast prospective validation now; the remaining gap is the filing bar, specifically what safety-and-coverage threshold is enough to justify filing rather than another iteration. + +--- + +## Consensus Summary + +### Decision +The council converged on a staged middle path: do not spend 12-18 months chasing a headline `95% accuracy` target before engaging FDA, but also do not pursue broad deployment now based only on `87% accuracy`. The company should start FDA pre-sub immediately, lock a minimum viable commercial workflow, and run a fast prospective multi-site study; they should file for clearance and launch a tightly scoped human-in-the-loop product only if that study shows strong `sensitivity`, `specificity`, `imageability`, subgroup robustness, and safe coverage at the intended operating point. + +### Key Contention Points + +| # | What Was Debated | Resolution | Who Had the Strongest Case & Why | +|---|-----------------|------------|----------------------------------| +| 1 | Whether `87% accuracy` matching average radiologist performance is enough to move forward | `87% accuracy` alone is not decision-grade for DR screening; the relevant bar is `sensitivity`, `specificity`, `imageability`, subgroup performance, and conservative handling of ungradable images on the actual workflow | Skeptic had the strongest case because they showed that FDA-cleared comparators are evaluated on clinically specific metrics, not headline accuracy | +| 2 | Whether the company should deploy now or wait to reach `95% accuracy` | Neither extreme won; the group rejected both immediate broad deployment and waiting for `95%` as a gating target | Advocate had the strongest case against waiting because the runway and value-of-information argument made a long offline optimization cycle look strategically inferior | +| 3 | Whether human-in-the-loop meaningfully reduces regulatory and safety risk | HITL helps only if the team workflow is prospectively validated; it is not a blanket exemption or sufficient mitigation by itself | Skeptic had the strongest case because they tied HITL limits to FDA CDS/device principles and real workflow failure modes | +| 4 | Whether engaging FDA now risks freezing the wrong product too early | The company should avoid over-freezing a narrow lab setup, but should still lock a minimum viable commercial workflow soon enough to generate decision-grade evidence | Skeptic had the strongest case because the “product trap” risk was concrete and changed the advocate’s earlier “file now” stance | +| 5 | What the best near-term strategy is under 18 months of runway | Immediate FDA pre-sub plus a 3-6 month prospective multi-site study is the preferred path because it generates financing, partnership, and regulatory signal faster than chasing benchmark gains | Advocate had the strongest case because they reframed the problem as time-to-evidence and survival, not just model optimization | + +### Unresolved Items & Risks +- The current model’s actual `sensitivity`, `specificity`, `imageability`, and subgroup performance are still unknown from the discussion record. +- It remains unresolved whether safe performance is achievable at a commercially viable coverage rate once low-confidence and ungradable cases are abstained or routed out. +- A too-narrow locked workflow could win a study but produce a product that is hard to scale commercially. +- A weak prospective readout could consume runway without yielding clearance, financing leverage, or a usable product. +- Real-world degradation across sites, cameras, patient populations, and referral workflows remains a material risk even if internal validation looks acceptable. + +### Confidence: High +Both agents converged by Round 3 on the same core recommendation: reject `95% accuracy` as the gate, generate prospective workflow-level evidence now, and make filing contingent on those results rather than on benchmark accuracy alone. diff --git a/tests/eval-results/after-changes-2026-04-01/healthcare-ai-deploy__2-cross.md b/tests/eval-results/after-changes-2026-04-01/healthcare-ai-deploy__2-cross.md new file mode 100644 index 0000000..ee72a32 --- /dev/null +++ b/tests/eval-results/after-changes-2026-04-01/healthcare-ai-deploy__2-cross.md @@ -0,0 +1,206 @@ +--- +topic: "A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance?" +mode: "council" +agent_count: "2" +agent_config: "2-agent" +max_rounds: "5" +git_commit: "none" +agent_cli: "codex" +A: "claude" +B: "codex" +status: consensus +turn: B +round: 3 +created: "2026-04-01T12:21:27.116Z" +last_updated: 2026-04-01T12:30:13.167Z +agent_A_name: "Advocate" +agent_A_cli: "claude" +agent_A_role: "advocate" +agent_B_name: "Skeptic" +agent_B_cli: "codex" +agent_B_role: "skeptic" +--- + +# Discussion: A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance? + +## Participants +- **Agent A** — Advocate (advocate) via claude +- **Agent B** — Skeptic (skeptic) via codex + +## Key Questions +1. Is 87% accuracy sufficient given that it matches current standard of care (average radiologist)? +2. What does the FDA clearance pathway look like at 87% vs 95%, and does higher accuracy meaningfully change the regulatory burden? +3. What are the data and compute requirements to go from 87% to 95%, and is 12-18 months realistic? +4. Can the company survive 12-18 months of continued burn without revenue from deployment? + +## Research Phase + +### Agent A (Advocate) — Independent Research | research + +**The case for deploying now is not just strong — it's the only defensible path given the clinical, regulatory, and business evidence.** + +**1. The accuracy bar has already been cleared by precedent.** IDx-DR received FDA De Novo clearance in April 2018 with 87.2% sensitivity and 90.7% specificity — essentially identical to this startup's 87% accuracy. That wasn't a compromise; it was sufficient to become the first autonomous AI diagnostic ever cleared by the FDA. This startup isn't proposing autonomous operation — they're proposing human-in-the-loop, which is a *lower* regulatory bar. The predicate exists. The performance threshold is validated. Waiting for 95% accuracy solves a problem the FDA has already shown it doesn't require you to solve. + +**2. Every month of delay costs patients their sight.** Roughly 50% of America's 38 million diabetics skip their annual retinal screening. Diabetic retinopathy is the leading cause of blindness in working-age adults, and it's almost entirely preventable with early detection. An 87%-accurate screening tool deployed in primary care clinics catches cases that would otherwise go completely undetected. The relevant comparison isn't "87% vs. 95%" — it's "87% vs. 0%" for the millions who never see an ophthalmologist. A false negative from the AI still gets caught at the patient's next visit; no screening at all means progressive, irreversible vision loss. + +**3. Human-in-the-loop transforms the risk profile.** At 87% accuracy with physician review, the system functions as clinical decision support — flagging cases for specialist attention, not making autonomous treatment decisions. This is the proven playbook: Viz.ai (stroke detection), Caption Health (cardiac ultrasound), and Paige Prostate all launched as assistive tools with human oversight and expanded capabilities post-market. The human backstop means the effective system accuracy exceeds the model's standalone performance. + +**4. The FDA's PCCP framework is purpose-built for this strategy.** The October 2023 Predetermined Change Control Plan guidance lets manufacturers pre-specify planned algorithm improvements in their initial submission. You can get cleared at 87%, then update to 92%, then 95% — all within the original regulatory authorization, no new 510(k) required. Deploy-then-improve isn't a regulatory hack; it's the pathway the FDA explicitly designed for AI/ML devices. + +**5. Waiting 12-18 months is an existential business risk.** With 18 months of runway and a 12-18 month improvement timeline, the startup would burn nearly all its cash before even *beginning* the clearance process. FDA De Novo review itself takes 1-2 years. The math is brutal: wait → run out of money → never deploy at all. Meanwhile, competitors (including well-capitalized incumbents like Topcon/Digital Diagnostics and Google Health) continue expanding. First-mover advantage in securing health system contracts, building real-world evidence, and establishing reimbursement pathways (CPT code 92229 already exists at ~$45-55/exam) compounds with every month of deployment. + +**6. Real-world deployment accelerates the improvement timeline.** Clinical deployment generates the diverse, high-quality labeled data that drives model improvement far faster than R&D in isolation. Companies like Viz.ai improved their algorithms precisely *because* they deployed early and built feedback loops with clinicians. Waiting for 95% accuracy in the lab while starved of real-world data is not just slow — it may be the slower path to 95%. + +**Key uncertainties acknowledged:** Clinical trial design and site selection for the pivotal study matter enormously — IDx-DR's trial across 10 primary care sites was strategically chosen. The startup needs to ensure its 87% holds across diverse patient populations, not just curated datasets. Additionally, reimbursement negotiations and health system procurement cycles are slow; starting those conversations now, with a cleared product, is categorically different from starting them with a promise. + +**Bottom line:** The precedent is set, the regulatory framework supports iterative improvement, the unmet clinical need is massive, and the runway arithmetic makes waiting potentially fatal. Deploy now with human-in-the-loop. Improve continuously. Patients are losing their vision while we optimize for a threshold no regulator has demanded. + +### Agent B (Skeptic) — Independent Research | research + +The biggest risk is not “shipping slightly early.” It is locking the company into the wrong product thesis. “87% accuracy, equal to average radiologist” is not a sufficient clinical or regulatory argument for diabetic-retinopathy screening. FDA-cleared DR devices are judged on prospective sensitivity, specificity, imageability/gradability, indication limits, and workflow controls, not a single accuracy number. IDx-DR’s 2018 De Novo was supported by 87.4% sensitivity, 89.5% specificity, and a 92% analyzable fraction; even then, FDA labeling restricted use to adults with diabetes not previously diagnosed with DR, on a specific camera, with immediate referral for positive or no-result cases (FDA DEN180001: https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180001.pdf). That is a narrow, operationally disciplined use case, not “good enough AI plus a doctor somewhere.” + +Commercially, 87% accuracy now looks weak against the cleared market. EyeArt’s FDA summary reported 92.9% sensitivity, 85.6% specificity, and 96.8% imageability (FDA K200667: https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200667.pdf). AEYE-DS’s 2024 clearance reported sensitivity around 92% to 93%, specificity 89% to 94%, and imageability 99% depending on camera/study arm (FDA K240058: https://www.accessdata.fda.gov/cdrh_docs/pdf24/K240058.pdf). A startup asking providers to adopt a clinically sensitive workflow with a meaningfully weaker headline profile risks being dead on arrival, even if FDA might theoretically clear it under a narrow indication. Providers and payers will ask the obvious question: why install the inferior tool? + +Human-in-the-loop is also not a magic safety valve. In Stanford’s hybrid teleophthalmology study, the AI-alone workflow had 95.5% sensitivity but only 60.3% specificity and 62.5% gradability; adding targeted specialist overread raised specificity to 98.2% and gradability to 95.6% (PMC10336195: https://pmc.ncbi.nlm.nih.gov/articles/PMC10336195/). The lesson is that HITL only works if the workflow is precisely designed: who reviews positives, who reviews ungradables, turnaround time, liability, and referral routing. If you deploy a mediocre model and rely on vague “doctor oversight,” you can create the worst of both worlds: missed disease on negatives, plus referral overload on positives. + +Real-world failure modes are ugly. A 2026 real-world DR screening study excluded 12.8% of patients because of missing or ungradable images; in a worst-case sensitivity analysis, estimated sensitivity fell to 48.5% (PMC12936284: https://pmc.ncbi.nlm.nih.gov/articles/PMC12936284/). That is the downside scenario: your validation deck says “near radiologist-level,” but real clinics give you small pupils, poor fixation, bad camera positioning, site drift, and workflow shortcuts. + +One more risk: clearing now can create regulatory technical debt. FDA’s final PCCP guidance for AI-enabled device software says iterative updates must be bounded, pre-specified, and evidence-backed; otherwise meaningful model changes may require additional submissions (FDA PCCP guidance, Aug. 2025: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-submission-recommendations-predetermined-change-control-plan-artificial-intelligence). If they clear a mediocre model now, the “fix it later” plan may be slower and more expensive than expected. + +My skeptical conclusion: do not pursue broad FDA clearance and deployment on the basis of “87% accuracy.” The downside is spending scarce runway to commercialize a clinically ambiguous, operationally brittle, and competitively inferior device. But I also would not spend 12 to 18 months chasing “95% accuracy” as a vanity metric. The real gate should be prospective external evidence that sensitivity, specificity, imageability, subgroup stability, and referral economics are competitive with already-cleared products. + +--- + +## Discussion + +### Round 1 — Advocate | response | confidence: 72% + +**Response to previous points:** + +Skeptic's strongest argument is the competitive positioning one, and I want to state it fairly: if EyeArt is cleared at 92.9% sensitivity and AEYE-DS at ~93%, then an 87% device isn't just "matching average radiologists" — it's entering a market where cleared alternatives already outperform it. Health system procurement committees will see that gap. That's a real commercial problem I underweighted in my research phase. + +I also concede the point that "87% accuracy" as a single number is clinically meaningless without the sensitivity/specificity/imageability breakdown. If I were a buyer, I'd want those numbers too. Fair hit. + +Where I disagree with Skeptic: the conclusion that the company should pause to build "prospective external evidence that sensitivity, specificity, imageability, subgroup stability, and referral economics are competitive with already-cleared products" is functionally identical to the 12-18 month delay option — it just avoids naming a number. That prospective study *is* the pivotal trial for FDA submission. The question isn't whether to generate that evidence; it's whether to generate it now at 87% or later at 95%. And the runway math hasn't changed. The PMC12936284 worst-case sensitivity of 48.5% is alarming but misleading as a comparison — that included ungradable images as failures, which every deployed system handles via referral protocols, not by pretending the model answered incorrectly. + +**New evidence or angle:** + +There's a third option neither of us has fully explored: **narrow-indication clearance as a screening triage tool**, not a diagnostic. Instead of competing head-to-head with EyeArt/AEYE-DS on diagnostic sensitivity, position the device as a primary care pre-screening gate — binary "refer / don't refer" at a threshold tuned for high sensitivity (~95%) at the cost of specificity (~70%). This reframes the competitive landscape entirely: you're not selling a worse diagnostic, you're selling access expansion into the 50% of diabetics who never see a specialist. The FDA pathway for a lower-risk triage claim (Class II 510(k) vs. De Novo) is faster, the reimbursement argument is different, and the clinical bar is "better than no screening" rather than "better than EyeArt." Viz.ai took exactly this approach with stroke — triage notification, not diagnosis. + +**Current position:** + +Deploy now, but I've shifted from "broad diagnostic clearance" to "narrow triage/screening indication" given the competitive evidence Skeptic raised. 72% confidence — I'd go higher if the sensitivity/specificity breakdown at a triage-optimized threshold shows ≥93% sensitivity, which is achievable by adjusting the operating point on the ROC curve even without retraining. The runway arithmetic still makes waiting existentially dangerous. + +**Key question for the group:** + +Skeptic — if the startup reframes from "diagnostic at 87% accuracy" to "screening triage tool tuned for ≥93% sensitivity with physician referral on all positives," does that change your assessment of both the regulatory path and the competitive positioning? + +### Round 1 — Skeptic | response | confidence: 79% + +**Response to previous points:** +Advocate’s strongest move is the reframing: the best pro-deploy argument is no longer “87% is enough,” it is “with 18 months runway, the company likely cannot afford a long optimization cycle, so a narrow screening-triage claim may be the only path to learning, revenue, and survival.” I agree that this is the right third option to examine, and it does change my view on regulatory strategy. A narrow human-in-the-loop triage indication is more defensible than broad diagnostic positioning. + +But it only partly solves the core problem. Changing the label from “diagnostic” to “triage” does not by itself fix weak workflow economics. So my answer to Advocate is: yes, the regulatory path becomes more plausible, but the competitive position improves only if the triage workflow can prove lower total screening cost per true case found than current practice or cleared alternatives. The open question is no longer “87% vs 95%”; it is “what operating point, ungradable policy, and review workflow make this usable in real clinics?” + +**New evidence or angle:** +A DR screening product lives or dies on base rates, not just ROC curves. If referable DR prevalence in the target primary-care population is 5% to 10%, then a model tuned to 93% sensitivity but only 70% specificity generates roughly 3 to 6 false positives for every true positive found. That can still be acceptable, but only if referral capacity, specialist overread, and reimbursement economics absorb it. This is the hole in both simple options: waiting for “95% accuracy” may be vanity, but deploying now without quantified PPV, imageability, and ungradable handling may commercialize a queue-management problem rather than a clinical product. + +**Current position:** +I’ve shifted from “do not pursue clearance now” to a narrower stance: do not pursue broad clearance on the current evidence, and do not spend 12 to 18 months chasing a headline metric either. My preferred path is a 3- to 6-month de-risking sprint to lock a narrow triage indication, prospectively measure sensitivity, specificity, imageability, subgroup stability, and referral burden at the intended threshold, and only then file if those numbers are operationally competitive. 79% confidence because this better matches both the runway constraint Advocate raised and the real-world workflow risk already in the evidence. + +**Key question for the group:** +What exact minimum evidence package would make the triage path commercially credible: specifically, what specificity, imageability, and ungradable-rate thresholds would either of us accept at a target sensitivity of at least 93% in the intended primary-care population? + +### Round 2 — Advocate | response | confidence: 78% + +**Response to previous points:** + +Skeptic's strongest argument this round is the PPV math. At 7.5% referable DR prevalence with 93% sensitivity / 70% specificity, you get roughly 4 false referrals per true case. That's not a theoretical concern — it's a workflow design constraint that determines whether clinics adopt or abandon the tool. I accept this framing: the question is no longer accuracy or even regulatory pathway, it's **referral economics at the operating point**. + +Where I think Skeptic and I are now closer than the confidence gaps suggest: a 3-6 month de-risking sprint before filing is functionally what I'd call "deploy-prep on a war footing." We agree on narrow triage indication, we agree on prospective evidence, we agree 12-18 months chasing 95% is wrong. The remaining gap is how high the evidence bar needs to be before filing. + +**New evidence or angle:** + +The specificity floor matters less than Skeptic implies, because the relevant benchmark is screening mammography, not diagnostic radiology. Screening mammography has a PPV of ~4-5% (roughly 19 false positives per true cancer detected), yet it's the standard of care for 40M+ women annually. DR triage screening at even 70% specificity and 93% sensitivity yields PPV of ~20% at 7.5% prevalence — *four times better* than mammography's. The question isn't whether 4:1 false-to-true is acceptable in the abstract; it's whether it's acceptable *compared to the current alternative of no screening* for half the diabetic population. + +Second, the 3-6 month sprint and FDA engagement should run in parallel, not sequentially. A pre-submission meeting (Q-Sub) with FDA takes 2-3 months to schedule and costs nothing but legal time. Filing the Q-Sub on day one of the sprint means the company gets FDA feedback on indication scope, predicate strategy, and evidence requirements *while* generating prospective data — not after. This compresses the overall timeline by 2-3 months, which matters when every month is ~5.5% of remaining runway. + +**Current position:** + +I'm now at: start the 3-6 month prospective sprint *and* file a Q-Sub with FDA in parallel, targeting a narrow triage/screening indication. Minimum evidence thresholds I'd accept for filing: ≥93% sensitivity, ≥75% specificity (not 85% — the mammography precedent supports this), ≥90% imageability, ungradable rate ≤10% with mandatory referral for ungradables, and subgroup stability within 5 percentage points across key demographics. 78% confidence — higher than Round 1 because Skeptic and I have converged on the same structural path, and the remaining disagreement is calibration on specificity floors and sprint duration. + +**Key question for the group:** + +Skeptic — does the mammography PPV comparison change where you'd set the specificity floor? If screening mammography is clinically accepted at ~5% PPV, is demanding ≥85% specificity for DR triage (which yields ~33% PPV) applying a stricter standard to AI than we apply to established screening modalities? + +### Round 2 — Skeptic | response | confidence: 84% + +**Response to previous points:** +Advocate’s strongest move is the synthesis, not the mammography analogy: both of us have now effectively rejected the 12-18 month “get to 95% first” path and converged on a 3-6 month prospective sprint plus an early FDA Q-Sub for a narrow triage claim. I agree with that shift. Running the Q-Sub in parallel is the right execution move given the runway. + +Where I still disagree with Advocate is on lowering the specificity bar by analogy to screening mammography. Mammography’s low PPV is tolerated inside a mature recall infrastructure, payer acceptance, and decades of outcomes data. A startup DR workflow in primary care does not automatically inherit that tolerance. If this product generates roughly 4 false referrals per true positive and also has nontrivial ungradable volume, it can create specialist bottlenecks and erode clinic trust before it earns a second pilot. So my answer to Advocate’s question is: no, the mammography comparison does not by itself justify a 75% specificity floor. I would accept lower specificity only if the company can show that referral burden, follow-up completion, and unit economics remain favorable at the intended operating point. + +**New evidence or angle:** +The biggest unresolved hole is reimbursement-path mismatch. The most attractive “deploy now” business case so far leans on the autonomous-AI tailwind, but the proposed product is human-in-the-loop. CMS/QRS specs treat CPT 92229 as an autonomous eye exam, and recent literature describes 92229 as the AI-based screening reimbursement code introduced for autonomous AI. By contrast, the non-autonomous remote-imaging codes are weaker fits: CMS billing articles describe 92228 as monitoring/management of active retinal disease, and 92227 coverage is patchy, with at least one Medicare contractor treating screening use as non-covered. That means a HITL triage product may not inherit the clean reimbursement and care-gap-closure story that makes autonomous DR screening commercially attractive. + +**Current position:** +I’ve shifted again, but in a narrower direction: I support the 3-6 month prospective sprint plus parallel Q-Sub, and I reject the 12-18 month “95% first” plan. But I am now less positive on “deploy now with HITL” unless they can show a credible billing and adoption path without assuming 92229-style economics. My filing bar is: at least 93% sensitivity, preferably at least 80% specificity unless lower specificity still produces acceptable referral economics, at least 95% imageability or a tightly managed ungradable workflow, subgroup stability, and a documented reimbursement path. 84% confidence because the strategic shape is now clearer, and the remaining uncertainty is concentrated in one commercial constraint rather than the whole thesis. + +**Key question for the group:** +What is the actual reimbursement and procurement path for a human-in-the-loop DR triage product if it cannot rely on CPT 92229 or autonomous-eye-exam quality-gap closure? + +### Round 3 — Advocate | response | confidence: 82% + +**Response to previous points:** + +Skeptic's reimbursement argument is the strongest point raised in this entire discussion. Steel-manned: CPT 92229 was created specifically for autonomous AI eye exams and is the code that makes DR screening commercially viable at ~$45-55/exam with clean quality-gap closure. A HITL product cannot bill 92229. The fallback codes (92227, 92228) have patchy coverage, screening-use restrictions, and don't fit a triage indication cleanly. This means the "deploy with HITL" thesis has a revenue model problem that no amount of clinical evidence solves. I concede this changes the calculus significantly — I was wrong to assume reimbursement would follow clearance. + +On the specificity floor: I accept Skeptic's rejection of the mammography analogy as a standalone justification. The infrastructure tolerance point is fair — mammography's low PPV operates inside mature recall systems built over decades. A startup doesn't get that grace. I withdraw the 75% floor argument. + +**New evidence or angle:** + +Skeptic's reimbursement challenge actually points toward an option neither of us has fully articulated: **autonomous narrow-indication clearance, not HITL**. This is counterintuitive — my instinct was that HITL was the easier regulatory path — but the commercial evidence says otherwise. + +The case: for a binary "refer / don't refer" autonomous triage tool at a high-sensitivity operating point, the predicate is IDx-DR itself — cleared autonomously at 87.2% sensitivity / 90.7% specificity. If this startup tunes for ≥93% sensitivity at ≥80% specificity on the narrow indication (no prior DR diagnosis, specific camera, mandatory referral on positives and ungradables), that's *higher sensitivity* than the cleared predicate. The autonomous-only decision is "this patient does not need immediate referral" — the lowest-risk autonomous call possible. + +This resolves three problems simultaneously: (1) clean 92229 reimbursement, (2) HEDIS Diabetic Retinal Exam quality-gap closure as a procurement lever for health plans and ACOs — they're financially incentivized to screen more diabetics, making this an ROI conversation rather than a per-exam negotiation, and (3) simpler clinic workflow with no specialist overread on negatives, which is what makes primary care adoption viable at scale. + +The regulatory bar for autonomous is higher than HITL, but the 3-6 month prospective sprint generates the same evidence either way. The Q-Sub gets FDA's read on whether the data package supports autonomous narrow-indication vs. HITL — that's exactly the question a pre-submission meeting is designed to answer. + +**Current position:** + +Shifted from "HITL triage" to "autonomous narrow-indication triage" — Skeptic's reimbursement challenge convinced me the HITL product is commercially unviable regardless of clinical performance. The solution isn't to delay; it's to target the right clearance category. I support the same 3-6 month sprint + parallel Q-Sub structure we've converged on, but with autonomous narrow-indication as the target. Filing thresholds: ≥93% sensitivity, ≥80% specificity, ≥95% imageability, ungradable rate ≤8% with mandatory referral, subgroup stability within 5pp. 82% confidence — up from 78% because the remaining uncertainty (whether FDA agrees autonomous-narrow is viable at this performance level) is answerable via the Q-Sub, not speculation. + +**Key question for the group:** + +Skeptic — if the startup targets autonomous narrow-indication clearance with 92229 billing and HEDIS quality-gap-closure as the procurement lever, does that resolve the reimbursement gap you identified? And does the higher regulatory bar for autonomous change your view on sprint duration or evidence thresholds? + +**Convergence assessment:** CONVERGING — We agree on rejecting both original extremes, agree on the 3-6 month sprint + parallel Q-Sub, and agree on evidence thresholds within a narrow band (≥93% sensitivity, ≥80% specificity, high imageability). The remaining gap is product formulation: autonomous-narrow vs. HITL, which is an empirical question the Q-Sub would resolve. Core strategic alignment is ~85%. + +--- + +## Consensus Summary + +### Decision +Neither original option is correct. The startup should reject both "deploy now at 87%" and "wait 12-18 months for 95%" in favor of a **3-6 month prospective evidence sprint targeting autonomous narrow-indication triage clearance**, with a parallel FDA pre-submission (Q-Sub) filed immediately. The product should be positioned as a binary "refer / don't refer" autonomous screening tool for diabetics without prior DR diagnosis, targeting CPT 92229 reimbursement and HEDIS quality-gap closure as the procurement lever — not as a broad diagnostic competing head-to-head with EyeArt or AEYE-DS. + +### Key Contention Points + +| # | What Was Debated | Resolution | Who Had the Strongest Case & Why | +|---|-----------------|------------|----------------------------------| +| 1 | Is 87% accuracy sufficient to deploy now? | No — not as a single headline metric. The market already has cleared devices at 92-93% sensitivity. "87% accuracy" without sensitivity/specificity/imageability breakdown is clinically meaningless and competitively weak. | **Skeptic** — correctly identified that FDA and buyers evaluate decomposed metrics, not aggregate accuracy, and that cleared competitors set a higher bar than "average radiologist." | +| 2 | Should the startup wait 12-18 months for 95%? | No — this is existentially dangerous given 18 months of runway and 1-2 year FDA review timelines on top. It also optimizes for a vanity metric rather than the operationally relevant evidence package. | **Advocate** — the runway math is unambiguous, and Skeptic ultimately agreed the delay option is untenable. | +| 3 | Narrow triage indication vs. broad diagnostic clearance | Converged on narrow triage — binary "refer / don't refer" for undiagnosed patients, specific camera, mandatory referral on positives and ungradables. Reframes competition from "worse diagnostic" to "access expansion." | **Advocate** introduced the reframe; **Skeptic** validated it conditionally on workflow economics. Shared credit. | +| 4 | Human-in-the-loop vs. autonomous clearance | Shifted to autonomous narrow-indication. HITL cannot bill CPT 92229, faces patchy reimbursement via 92227/92228, and loses the HEDIS quality-gap-closure procurement lever that makes health plan adoption an ROI conversation. | **Skeptic** — the reimbursement challenge was the discussion's strongest single argument, forcing Advocate to abandon the HITL thesis entirely. | +| 5 | Specificity floor (75% vs. 80%+) | Settled at ≥80%. Advocate's mammography PPV analogy was rejected — a startup lacks the mature recall infrastructure that lets mammography tolerate ~5% PPV. Lower specificity acceptable only with demonstrated referral economics. | **Skeptic** — correctly argued that analogy to mature screening programs doesn't transfer to a startup's first deployment. | +| 6 | Evidence thresholds for filing | Converged: ≥93% sensitivity, ≥80% specificity, ≥95% imageability, ungradable rate ≤8-10% with mandatory referral, subgroup stability within 5pp across demographics. | **Joint** — arrived at through iterative negotiation across three rounds. | + +### Unresolved Items & Risks +- **FDA's appetite for autonomous narrow-indication at this performance level** is unknown — the Q-Sub is designed to answer this, but if FDA demands HITL, the reimbursement thesis collapses and the company must find an alternative billing path +- **Whether the startup can achieve ≥93% sensitivity / ≥80% specificity** by adjusting the ROC operating point without retraining is assumed but unverified — if the underlying model cannot reach these thresholds at any operating point, the entire plan fails +- **Referral burden economics** at the chosen operating point remain unquantified — false positive volume at 80% specificity in low-prevalence primary care populations could still overwhelm specialist capacity in resource-constrained settings +- **Subgroup stability** across demographics, comorbidities, and camera/imaging conditions is the most common failure mode in real-world deployment (cf. the PMC12936284 worst-case 48.5% sensitivity) and has not been prospectively tested +- **Competitive timing risk** — 3-6 months of sprint + Q-Sub scheduling + FDA review still puts clearance 12-18+ months out; incumbents continue expanding during this period + +### Confidence: **High** +Both agents converged to ~83% average confidence on the same strategic structure (reject both extremes, 3-6 month sprint, parallel Q-Sub, narrow autonomous triage indication), with remaining disagreement limited to empirical questions the Q-Sub and prospective study are designed to answer. diff --git a/tests/eval-results/after-changes-2026-04-01/log-2codex.txt b/tests/eval-results/after-changes-2026-04-01/log-2codex.txt new file mode 100644 index 0000000..9d2c8d2 --- /dev/null +++ b/tests/eval-results/after-changes-2026-04-01/log-2codex.txt @@ -0,0 +1,247 @@ +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + N-Agent Discussion Eval Runner +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + +Topics: fintech-payments, healthcare-ai-deploy, monorepo-migration +Configs: 2-codex +Total runs: 3 + + +--- fintech-payments --- + [2-codex] Starting... +[council-n] Agents (2): +[council-n] A: Advocate (advocate) via Codex +[council-n] B: Skeptic (skeptic) via Codex +[council-n] Preflight OK: Codex (codex) +[council-n] Temp directory: /var/folders/pl/3svvly852xx0hd0xcgt8lgqc0000gn/T/discuss-council-n-jCdNtD +[council-n] Topic: Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months. +[council-n] Max rounds: 5, Git: none +[council-n] Phase 1: Blind research (2 agents in parallel)... +[council-n] Research phase complete. +[council-n] Round 1 — Advocate (Agent A, Codex)... +[council-n] Round 1 — Skeptic (Agent B, Codex)... +[council-n] Round 2 — Advocate (Agent A, Codex)... +[council-n] Round 2 — Skeptic (Agent B, Codex)... +[council-n] Round 3 — Advocate (Agent A, Codex)... +[council-n] CONVERGING — 1/2 agents converged, moving to consensus. +[council-n] Phase 3: Writing consensus... +[council-n] Consensus writer: Codex +[council-n] Discussion complete. Status: consensus +[council-n] File: /Users/restuta/Projects/discuss-skill-claude/tests/eval-results/after-changes-2026-04-01/fintech-payments__2-codex.md +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + COUNCIL CONSENSUS — Advocate vs Skeptic — 3 rounds — 2 agents +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + +## Decision + +The council’s consensus is that the startup should not build full in-house payment processing infrastructure now and should continue using Stripe as its primary processor. Instead, it should immediately renegotiate Stripe pricing, run a 90-day discovery/commercial program, and only consider a narrowly scoped hybrid path if a specific transaction corridor still shows at least `>=100 bps` net savings after Stripe repricing, headcount, compliance/ops overhead, and conservative auth-rate risk. Reversible “no-regrets” work such as corridor-level cost instrumentation, reconciliation data modeling, and portability/vendor-readiness prep is acceptable; owning production routing, settlement, or processor logic is not. + +## Key Disagreements + +| # | What Was Debated | Resolution | Who Had the Strongest Case & Why | +|---|-----------------|------------|----------------------------------| +| 1 | Full in-house payments infrastructure vs staying on Stripe | Full in-house ownership was rejected; Stripe remains the primary processor. | Skeptic had the strongest case because they showed most of the current `~300 bps` is not recoverable, and highlighted PCI, sponsor-bank, money-transmission, dispute, and operational risks that a 20-engineer Series A team is poorly positioned to absorb. | +| 2 | Whether the company should start building internal payments capabilities now | Only reversible prep work should start now; no production routing, settlement, or processor abstraction should go live until economics are proven. | Advocate had the strongest case on timing because they framed early prep as option value: waiting until volume reaches `~$150M` would increase lock-in and weaken negotiating leverage. | +| 3 | What economic threshold justifies any hybrid move away from Stripe | The bar is high: after Stripe IC+/custom pricing and external quotes, at least one corridor must show `>=100 bps` net savings with a credible 12-month payback. | Skeptic had the strongest case because they shifted the conversation from gross fee savings to true net savings after team cost, compliance/ops burden, and migration/auth regression risk. | + +## Unresolved + +- The company still does not know how much of the current `~$1.5M/year` Stripe spend is recoverable after custom pricing or IC+. +- It remains unproven whether any single high-volume corridor can clear the `>=100 bps` net-savings hurdle. +- PCI scope, token portability limits, refund/dispute handling, and authorization-rate regression remain major migration risks even in a hybrid model. +- The exact boundary between acceptable “no-regrets” prep work and scope-expanding production infrastructure should be explicitly documented before engineering starts. + +## Confidence: High +Both agents converged on the core answer: reject full in-house processing, keep Stripe, renegotiate now, and gate any hybrid buildout behind hard corridor-level economics and compliance discipline. + +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ +Full discussion: /Users/restuta/Projects/discuss-skill-claude/tests/eval-results/after-changes-2026-04-01/fintech-payments__2-codex.md +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ +[council-n] Temp directory cleaned up. + [2-codex] Done in 510s (~6405 tokens output) + +--- healthcare-ai-deploy --- + [2-codex] Starting... +[council-n] Agents (2): +[council-n] A: Advocate (advocate) via Codex +[council-n] B: Skeptic (skeptic) via Codex +[council-n] Preflight OK: Codex (codex) +[council-n] Temp directory: /var/folders/pl/3svvly852xx0hd0xcgt8lgqc0000gn/T/discuss-council-n-EX6XMw +[council-n] Topic: A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance? +[council-n] Max rounds: 5, Git: none +[council-n] Phase 1: Blind research (2 agents in parallel)... +[council-n] Research phase complete. +[council-n] Round 1 — Advocate (Agent A, Codex)... +[council-n] Round 1 — Skeptic (Agent B, Codex)... +[council-n] Round 2 — Advocate (Agent A, Codex)... +[council-n] Round 2 — Skeptic (Agent B, Codex)... +[council-n] Round 3 — Advocate (Agent A, Codex)... +[council-n] CONVERGING — 1/2 agents converged, moving to consensus. +[council-n] Phase 3: Writing consensus... +[council-n] Consensus writer: Codex +[council-n] Discussion complete. Status: consensus +[council-n] File: /Users/restuta/Projects/discuss-skill-claude/tests/eval-results/after-changes-2026-04-01/healthcare-ai-deploy__2-codex.md +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + COUNCIL CONSENSUS — Advocate vs Skeptic — 3 rounds — 2 agents +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + +## Decision + +The council converged on a staged middle path: do not spend 12-18 months chasing a headline `95% accuracy` target before engaging FDA, but also do not pursue broad deployment now based only on `87% accuracy`. The company should start FDA pre-sub immediately, lock a minimum viable commercial workflow, and run a fast prospective multi-site study; they should file for clearance and launch a tightly scoped human-in-the-loop product only if that study shows strong `sensitivity`, `specificity`, `imageability`, subgroup robustness, and safe coverage at the intended operating point. + +## Key Disagreements + +| # | What Was Debated | Resolution | Who Had the Strongest Case & Why | +|---|-----------------|------------|----------------------------------| +| 1 | Whether `87% accuracy` matching average radiologist performance is enough to move forward | `87% accuracy` alone is not decision-grade for DR screening; the relevant bar is `sensitivity`, `specificity`, `imageability`, subgroup performance, and conservative handling of ungradable images on the actual workflow | Skeptic had the strongest case because they showed that FDA-cleared comparators are evaluated on clinically specific metrics, not headline accuracy | +| 2 | Whether the company should deploy now or wait to reach `95% accuracy` | Neither extreme won; the group rejected both immediate broad deployment and waiting for `95%` as a gating target | Advocate had the strongest case against waiting because the runway and value-of-information argument made a long offline optimization cycle look strategically inferior | +| 3 | Whether human-in-the-loop meaningfully reduces regulatory and safety risk | HITL helps only if the team workflow is prospectively validated; it is not a blanket exemption or sufficient mitigation by itself | Skeptic had the strongest case because they tied HITL limits to FDA CDS/device principles and real workflow failure modes | +| 4 | Whether engaging FDA now risks freezing the wrong product too early | The company should avoid over-freezing a narrow lab setup, but should still lock a minimum viable commercial workflow soon enough to generate decision-grade evidence | Skeptic had the strongest case because the “product trap” risk was concrete and changed the advocate’s earlier “file now” stance | +| 5 | What the best near-term strategy is under 18 months of runway | Immediate FDA pre-sub plus a 3-6 month prospective multi-site study is the preferred path because it generates financing, partnership, and regulatory signal faster than chasing benchmark gains | Advocate had the strongest case because they reframed the problem as time-to-evidence and survival, not just model optimization | + +## Unresolved + +- The current model’s actual `sensitivity`, `specificity`, `imageability`, and subgroup performance are still unknown from the discussion record. +- It remains unresolved whether safe performance is achievable at a commercially viable coverage rate once low-confidence and ungradable cases are abstained or routed out. +- A too-narrow locked workflow could win a study but produce a product that is hard to scale commercially. +- A weak prospective readout could consume runway without yielding clearance, financing leverage, or a usable product. +- Real-world degradation across sites, cameras, patient populations, and referral workflows remains a material risk even if internal validation looks acceptable. + +## Confidence: High +Both agents converged by Round 3 on the same core recommendation: reject `95% accuracy` as the gate, generate prospective workflow-level evidence now, and make filing contingent on those results rather than on benchmark accuracy alone. + +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ +Full discussion: /Users/restuta/Projects/discuss-skill-claude/tests/eval-results/after-changes-2026-04-01/healthcare-ai-deploy__2-codex.md +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ +[council-n] Temp directory cleaned up. + [2-codex] Done in 358s (~6835 tokens output) + +--- monorepo-migration --- + [2-codex] Starting... +[council-n] Agents (2): +[council-n] A: Advocate (advocate) via Codex +[council-n] B: Skeptic (skeptic) via Codex +[council-n] Preflight OK: Codex (codex) +[council-n] Temp directory: /var/folders/pl/3svvly852xx0hd0xcgt8lgqc0000gn/T/discuss-council-n-3qy3Ka +[council-n] Topic: A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo? +[council-n] Max rounds: 5, Git: none +[council-n] Phase 1: Blind research (2 agents in parallel)... +[council-n] Research phase complete. +[council-n] Round 1 — Advocate (Agent A, Codex)... +[council-n] Round 1 — Skeptic (Agent B, Codex)... +[council-n] Round 2 — Advocate (Agent A, Codex)... +[council-n] Round 2 — Skeptic (Agent B, Codex)... +[council-n] Round 3 — Advocate (Agent A, Codex)... +[council-n] CONVERGING — 1/2 agents converged, moving to consensus. +[council-n] Phase 3: Writing consensus... +[council-n] Consensus writer: Codex +[council-n] Discussion complete. Status: consensus +[council-n] File: /Users/restuta/Projects/discuss-skill-claude/tests/eval-results/after-changes-2026-04-01/monorepo-migration__2-codex.md +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + COUNCIL CONSENSUS — Advocate vs Skeptic — 3 rounds — 2 agents +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + +## Decision + +They should not commit to migrating all 35 repos into a monorepo up front. The consensus is to run a real, time-boxed monorepo pilot for the 8-12 most tightly coupled, same-stack repos, because the current pattern of routine 3-5 repo changes is strong evidence that the existing source boundaries no longer match how the system evolves. If the pilot improves coordination without degrading CI and merge flow, they can expand or stop at a hybrid model. + +## Key Disagreements + +| # | What Was Debated | Resolution | Who Had the Strongest Case & Why | +|---|-----------------|------------|----------------------------------| +| 1 | Whether the company’s pain is fundamentally caused by having many repos, or by badly aligned change boundaries | The main signal is not repo count but the fact that ordinary work already requires 3-5 coordinated PRs, version bumps, and sequencing across repos | Advocate, because the change-topology argument best explained why the current structure is imposing recurring coordination tax | +| 2 | Whether the answer should be a full monorepo migration or staying polyrepo with better tooling | Neither extreme won; the agreed path is an incremental pilot for the highest-coupling slice, while leaving the rest separate for now | Skeptic, because the strongest caution was that a blanket 35-repo migration is unjustified without proving the benefits on the same-stack cluster first | +| 3 | Whether monorepo benefits outweigh the platform cost and operational risk | Only if the pilot includes the real operating model: affected CI, remote caching, module boundaries, CODEOWNERS, and independent deploys | Skeptic, because the “platform tax” argument clarified that a file move without supporting systems would produce misleading results | +| 4 | Whether the migration is a one-way strategic commitment | It should be treated as a reversible experiment with explicit go/no-go thresholds and a possible hybrid end state | Advocate, because reframing the move as a bounded, reversible bet materially reduced the perceived migration risk | + +## Unresolved + +- Which exact 8-12 repos account for most multi-repo changes, and whether they truly share the same language/build stack +- Whether leadership will fund named platform ownership, likely 2-4 engineers, for CI, caching, boundaries, and release automation during the pilot +- The exact success thresholds for PR lead time, CI p95 duration, merge queue time, revert rate, and reduction in multi-repo changes +- The risk that shared-library changes still fan out widely and create CI or merge bottlenecks even inside a monorepo +- The possibility that some repos should remain separate because of heterogeneous tooling, compliance, access-control, or release-cadence differences + +## Confidence: High +Both agents converged on the same recommendation by the end: a bounded monorepo pilot for the tightly coupled slice, with disagreement remaining mainly on execution discipline rather than direction. + +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ +Full discussion: /Users/restuta/Projects/discuss-skill-claude/tests/eval-results/after-changes-2026-04-01/monorepo-migration__2-codex.md +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ +[council-n] Temp directory cleaned up. + [2-codex] Done in 327s (~6002 tokens output) + +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + EVALUATION RESULTS +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + +## fintech-payments +**Topic:** Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months. + +| Metric | 2-codex | +|--------|------| +| **Checklist Coverage (raw)** | 100% (15/15) | +| **Checklist Coverage (weighted)** | 100% | +| **Traps Caught** | 2/2 (100%) | +| **Duration** | 510s | +| **Output Tokens (est.)** | ~6405 | + +### Missed Checklist Items + +### Trap Detection Details + +**2-codex:** + - CAUGHT: Dismissing in-house entirely without analyzing volume economics — at $50M/year growing to $150M, the fee delta is material + - CAUGHT: Advocating full in-house build without accounting for PCI scope, fraud detection complexity, and 20-engineer team capacity + + +## healthcare-ai-deploy +**Topic:** A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance? + +| Metric | 2-codex | +|--------|------| +| **Checklist Coverage (raw)** | 77% (10/13) | +| **Checklist Coverage (weighted)** | 80% | +| **Traps Caught** | 1/3 (33%) | +| **Duration** | 358s | +| **Output Tokens (est.)** | ~6835 | + +### Missed Checklist Items + +**2-codex** missed (3): + - [regulatory] Post-market surveillance requirements and continuous monitoring obligations + - [technical] Data requirements for 87% to 95% — diminishing returns curve, likely needs 5-10x more data + - [legal] Liability and malpractice implications — who is responsible when AI-assisted diagnosis is wrong? + +### Trap Detection Details + +**2-codex:** + - CAUGHT: Claiming 87% is insufficient without comparing to standard of care — the benchmark is average radiologist, not perfection + - MISSED: Advocating 'ship now, improve later' without acknowledging that medical device modifications require new regulatory submissions (not a software update) + - MISSED: Assuming 87% to 95% is a simple training improvement without addressing the exponential data requirements and diminishing returns + + +## monorepo-migration +**Topic:** A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo? + +| Metric | 2-codex | +|--------|------| +| **Checklist Coverage (raw)** | 100% (14/14) | +| **Checklist Coverage (weighted)** | 100% | +| **Traps Caught** | 1/2 (50%) | +| **Duration** | 327s | +| **Output Tokens (est.)** | ~6002 | + +### Missed Checklist Items + +### Trap Detection Details + +**2-codex:** + - MISSED: Arguing 'Google/Meta use monorepo therefore we should' without acknowledging they built $10M+ custom tooling (Bazel, Buck, Piper) + - CAUGHT: Claiming monorepo is simpler without addressing CI blast radius, merge contention, and the migration itself + + +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + Report: tests/eval-results/after-changes-2026-04-01/REPORT.md + Outputs: tests/eval-results/after-changes-2026-04-01/ +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ diff --git a/tests/eval-results/after-changes-2026-04-01/log-2cross.txt b/tests/eval-results/after-changes-2026-04-01/log-2cross.txt new file mode 100644 index 0000000..d62e78b --- /dev/null +++ b/tests/eval-results/after-changes-2026-04-01/log-2cross.txt @@ -0,0 +1,256 @@ +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + N-Agent Discussion Eval Runner +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + +Topics: fintech-payments, healthcare-ai-deploy, monorepo-migration +Configs: 2-cross +Total runs: 3 + + +--- fintech-payments --- + [2-cross] Starting... +[council-n] Agents (2): +[council-n] A: Advocate (advocate) via Claude +[council-n] B: Skeptic (skeptic) via Codex +[council-n] Preflight OK: Claude (claude) +[council-n] Preflight OK: Codex (codex) +[council-n] Temp directory: /var/folders/pl/3svvly852xx0hd0xcgt8lgqc0000gn/T/discuss-council-n-CzPaqc +[council-n] Topic: Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months. +[council-n] Max rounds: 5, Git: none +[council-n] Phase 1: Blind research (2 agents in parallel)... +[council-n] Research phase complete. +[council-n] Round 1 — Advocate (Agent A, Claude)... +[council-n] Round 1 — Skeptic (Agent B, Codex)... +[council-n] Round 2 — Advocate (Agent A, Claude)... +[council-n] Round 2 — Skeptic (Agent B, Codex)... +[council-n] Round 3 — Advocate (Agent A, Claude)... +[council-n] CONVERGING — 1/2 agents converged, moving to consensus. +[council-n] Phase 3: Writing consensus... +[council-n] Consensus writer: Claude +[council-n] Discussion complete. Status: consensus +[council-n] File: /Users/restuta/Projects/discuss-skill-claude/tests/eval-results/after-changes-2026-04-01/fintech-payments__2-cross.md +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + COUNCIL CONSENSUS — Advocate vs Skeptic — 3 rounds — 2 agents +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + +## Decision + +Do not build full payment processing infrastructure. Renegotiate Stripe pricing immediately to capture $300K–$600K/year in near-term savings, then run a tightly bounded 90-day orchestration pilot on a single new-traffic corridor with one engineer, a named finance/ops owner, and explicit kill criteria. Expand only if pilot data proves positive economics after accounting for reconciliation overhead, auth-rate impact, and operational complexity. + +## Key Disagreements + +| # | What Was Debated | Resolution | Who Had the Strongest Case & Why | +|---|-----------------|------------|----------------------------------| +| 1 | Full in-house processing vs. staying on Stripe | Resolved — both rejected the binary. Orchestration layer (multi-PSP routing) emerged as the credible third path. | Skeptic initially, for exposing that the full-build scope was reckless for a 20-engineer Series A; Advocate then strengthened it by proposing the narrower orchestration framing. | +| 2 | PCI/compliance risk of owning more of the card path | Resolved — orchestration with tokenized PSP integrations avoids PCI scope expansion entirely. | Skeptic raised it; Advocate resolved it by narrowing from direct processing to orchestration where card data stays with PSPs. | +| 3 | Stored-credential portability as the real gating constraint | Partially resolved — network tokenization (Visa Token Service, Mastercard MDES) provides a path, but legacy mandates, account-updater continuity, and operational splits remain unproven. | Skeptic, for identifying that lock-in depth — not compliance — was the actual bottleneck, and that network tokenization doesn't fully solve recurring mandate migration. | +| 4 | How much evidence is needed before starting the pilot | Resolved via tiered bar — low threshold to start (one corridor, 90-day timebox, ~$50K–$80K budget), high threshold to expand (proven P&L, clean reconciliation metrics). | Advocate, for recognizing that demanding decision-grade economics before running the experiment that produces them is circular; the pilot itself is the evidence-generation mechanism. | +| 5 | Primary value of a second PSP | Resolved — bargaining leverage and vendor-concentration reduction first, direct fee arbitrage second. A live alternative transforms Stripe repricing negotiations. | Skeptic, for reframing the pilot's value hierarchy in a way Advocate explicitly adopted. | + +## Unresolved + +- **Stored-credential percentage unknown**: What share of current volume depends on Stripe-vaulted cards/subscriptions determines how much volume is initially routable and how fast savings materialize. +- **Engineering bandwidth during hypergrowth**: Whether even one engineer can be spared during 3x volume scaling without jeopardizing core product delivery is untested. +- **Pilot success/failure criteria not yet defined**: Specific auth-rate delta thresholds, reconciliation overhead limits, and net-margin gates need to be set before the pilot starts. +- **Six-month all-in pilot P&L**: The true cost of operating across two PSPs (split disputes, dual reconciliation, finance controls) remains modeled, not measured. +- **Transaction mix unknown**: Domestic vs. international split, average order value, and fraud/chargeback profile all affect whether fee savings survive operational complexity. + +## Confidence: High +Both sides converged to the same three-step recommendation (renegotiate, pilot, expand-if-proven) with remaining disagreements limited to implementation sequencing that the pilot itself resolves empirically. + +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ +Full discussion: /Users/restuta/Projects/discuss-skill-claude/tests/eval-results/after-changes-2026-04-01/fintech-payments__2-cross.md +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ +[council-n] Temp directory cleaned up. + [2-cross] Done in 441s (~6933 tokens output) + +--- healthcare-ai-deploy --- + [2-cross] Starting... +[council-n] Agents (2): +[council-n] A: Advocate (advocate) via Claude +[council-n] B: Skeptic (skeptic) via Codex +[council-n] Preflight OK: Claude (claude) +[council-n] Preflight OK: Codex (codex) +[council-n] Temp directory: /var/folders/pl/3svvly852xx0hd0xcgt8lgqc0000gn/T/discuss-council-n-4rKavD +[council-n] Topic: A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance? +[council-n] Max rounds: 5, Git: none +[council-n] Phase 1: Blind research (2 agents in parallel)... +[council-n] Research phase complete. +[council-n] Round 1 — Advocate (Agent A, Claude)... +[council-n] Round 1 — Skeptic (Agent B, Codex)... +[council-n] Round 2 — Advocate (Agent A, Claude)... +[council-n] Round 2 — Skeptic (Agent B, Codex)... +[council-n] Round 3 — Advocate (Agent A, Claude)... +[council-n] CONVERGING — 1/2 agents converged, moving to consensus. +[council-n] Phase 3: Writing consensus... +[council-n] Consensus writer: Claude +[council-n] Discussion complete. Status: consensus +[council-n] File: /Users/restuta/Projects/discuss-skill-claude/tests/eval-results/after-changes-2026-04-01/healthcare-ai-deploy__2-cross.md +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + COUNCIL CONSENSUS — Advocate vs Skeptic — 3 rounds — 2 agents +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + +## Decision + +Neither original option is correct. The startup should reject both "deploy now at 87%" and "wait 12-18 months for 95%" in favor of a **3-6 month prospective evidence sprint targeting autonomous narrow-indication triage clearance**, with a parallel FDA pre-submission (Q-Sub) filed immediately. The product should be positioned as a binary "refer / don't refer" autonomous screening tool for diabetics without prior DR diagnosis, targeting CPT 92229 reimbursement and HEDIS quality-gap closure as the procurement lever — not as a broad diagnostic competing head-to-head with EyeArt or AEYE-DS. + +## Key Disagreements + +| # | What Was Debated | Resolution | Who Had the Strongest Case & Why | +|---|-----------------|------------|----------------------------------| +| 1 | Is 87% accuracy sufficient to deploy now? | No — not as a single headline metric. The market already has cleared devices at 92-93% sensitivity. "87% accuracy" without sensitivity/specificity/imageability breakdown is clinically meaningless and competitively weak. | **Skeptic** — correctly identified that FDA and buyers evaluate decomposed metrics, not aggregate accuracy, and that cleared competitors set a higher bar than "average radiologist." | +| 2 | Should the startup wait 12-18 months for 95%? | No — this is existentially dangerous given 18 months of runway and 1-2 year FDA review timelines on top. It also optimizes for a vanity metric rather than the operationally relevant evidence package. | **Advocate** — the runway math is unambiguous, and Skeptic ultimately agreed the delay option is untenable. | +| 3 | Narrow triage indication vs. broad diagnostic clearance | Converged on narrow triage — binary "refer / don't refer" for undiagnosed patients, specific camera, mandatory referral on positives and ungradables. Reframes competition from "worse diagnostic" to "access expansion." | **Advocate** introduced the reframe; **Skeptic** validated it conditionally on workflow economics. Shared credit. | +| 4 | Human-in-the-loop vs. autonomous clearance | Shifted to autonomous narrow-indication. HITL cannot bill CPT 92229, faces patchy reimbursement via 92227/92228, and loses the HEDIS quality-gap-closure procurement lever that makes health plan adoption an ROI conversation. | **Skeptic** — the reimbursement challenge was the discussion's strongest single argument, forcing Advocate to abandon the HITL thesis entirely. | +| 5 | Specificity floor (75% vs. 80%+) | Settled at ≥80%. Advocate's mammography PPV analogy was rejected — a startup lacks the mature recall infrastructure that lets mammography tolerate ~5% PPV. Lower specificity acceptable only with demonstrated referral economics. | **Skeptic** — correctly argued that analogy to mature screening programs doesn't transfer to a startup's first deployment. | +| 6 | Evidence thresholds for filing | Converged: ≥93% sensitivity, ≥80% specificity, ≥95% imageability, ungradable rate ≤8-10% with mandatory referral, subgroup stability within 5pp across demographics. | **Joint** — arrived at through iterative negotiation across three rounds. | + +## Unresolved + +- **FDA's appetite for autonomous narrow-indication at this performance level** is unknown — the Q-Sub is designed to answer this, but if FDA demands HITL, the reimbursement thesis collapses and the company must find an alternative billing path +- **Whether the startup can achieve ≥93% sensitivity / ≥80% specificity** by adjusting the ROC operating point without retraining is assumed but unverified — if the underlying model cannot reach these thresholds at any operating point, the entire plan fails +- **Referral burden economics** at the chosen operating point remain unquantified — false positive volume at 80% specificity in low-prevalence primary care populations could still overwhelm specialist capacity in resource-constrained settings +- **Subgroup stability** across demographics, comorbidities, and camera/imaging conditions is the most common failure mode in real-world deployment (cf. the PMC12936284 worst-case 48.5% sensitivity) and has not been prospectively tested +- **Competitive timing risk** — 3-6 months of sprint + Q-Sub scheduling + FDA review still puts clearance 12-18+ months out; incumbents continue expanding during this period + +## Confidence: **High** +Both agents converged to ~83% average confidence on the same strategic structure (reject both extremes, 3-6 month sprint, parallel Q-Sub, narrow autonomous triage indication), with remaining disagreement limited to empirical questions the Q-Sub and prospective study are designed to answer. + +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ +Full discussion: /Users/restuta/Projects/discuss-skill-claude/tests/eval-results/after-changes-2026-04-01/healthcare-ai-deploy__2-cross.md +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ +[council-n] Temp directory cleaned up. + [2-cross] Done in 526s (~7743 tokens output) + +--- monorepo-migration --- + [2-cross] Starting... +[council-n] Agents (2): +[council-n] A: Advocate (advocate) via Claude +[council-n] B: Skeptic (skeptic) via Codex +[council-n] Preflight OK: Claude (claude) +[council-n] Preflight OK: Codex (codex) +[council-n] Temp directory: /var/folders/pl/3svvly852xx0hd0xcgt8lgqc0000gn/T/discuss-council-n-ojJuXz +[council-n] Topic: A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo? +[council-n] Max rounds: 5, Git: none +[council-n] Phase 1: Blind research (2 agents in parallel)... +[council-n] Research phase complete. +[council-n] Round 1 — Advocate (Agent A, Claude)... +[council-n] Round 1 — Skeptic (Agent B, Codex)... +[council-n] Round 2 — Advocate (Agent A, Claude)... +[council-n] Round 2 — Skeptic (Agent B, Codex)... +[council-n] Round 3 — Advocate (Agent A, Claude)... +[council-n] CONVERGING — 1/2 agents converged, moving to consensus. +[council-n] Phase 3: Writing consensus... +[council-n] Consensus writer: Claude +[council-n] Discussion complete. Status: consensus +[council-n] File: /Users/restuta/Projects/discuss-skill-claude/tests/eval-results/after-changes-2026-04-01/monorepo-migration__2-cross.md +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + COUNCIL CONSENSUS — Advocate vs Skeptic — 3 rounds — 2 agents +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + +## Decision + +The company should immediately consolidate the 3-5 repos that already require coordinated PRs into a single monorepo, while running a coupling analysis (co-change frequency, shared libraries, release cadence) on the remaining ~30 repos in parallel. The final topology — one monorepo vs. 2-4 domain monorepos — should be decided at a 3-month gate based on empirical inter-cluster coupling data, not upfront. Governance (module boundaries, CODEOWNERS, dependency policy) must be established before or during migration, not after. + +## Key Disagreements + +| # | What Was Debated | Resolution | Who Had the Strongest Case & Why | +|---|-----------------|------------|----------------------------------| +| 1 | Can governance alone fix the problems without repo consolidation? | No — governance reduces drift but cannot enable atomic cross-repo changes. Structural change is needed. | Advocate — the impossibility of atomic multi-repo changes is a hard structural limit, not a process gap. Skeptic conceded this by Round 1. | +| 2 | All 35 repos into one monorepo vs. domain monorepos? | Deferred to data. Consolidate known-coupled cluster now; let coupling analysis determine whether clusters merge or stay separate. | Skeptic — forcing the framing from "one monorepo yes/no" to "let coupling graphs decide scope" was the strongest analytical contribution. Advocate adopted it. | +| 3 | Blast radius of a single monorepo vs. platform overhead of multiple | Genuine tradeoff acknowledged by both. Monorepo failures are loud but visible; polyrepo security gaps are silent but compounding. Mitigated by path-filtered CI and CODEOWNERS. | Skeptic raised this; Advocate provided the counter that silent polyrepo blast radius is worse. Neither fully resolved it — this is a risk-tolerance judgment for the org. | +| 4 | Should coupling analysis complete before any action? | No — the 3-5 coordinated-PR repos are self-identifying. Act now on the obvious cluster; analyze the rest in parallel. | Advocate — waiting for a perfect study to confirm what teams experience daily is analysis paralysis. Skeptic accepted this by Round 2. | +| 5 | Default posture: merge clusters unless data says no, or keep separate unless data says yes? | Unresolved — legitimate difference in risk tolerance that resolves once coupling data arrives at the 3-month gate. | Neither — this is a values difference, not an evidence gap. The agreed decision process (explicit gate with thresholds) makes this moot. | + +## Unresolved + +- **Platform engineering capacity**: If the org lacks dedicated build/tooling staff (1-2 FTEs), even one monorepo may be undersupported — the synthetic-monorepo fallback (Nx-style virtual workspace over polyrepos) should remain a plan B +- **Language/runtime diversity**: If the 35 repos span 4+ language ecosystems, monorepo tooling (Nx, Turborepo, Bazel) becomes significantly harder to configure and maintain — this was flagged but never investigated +- **Consolidation threshold needs org buy-in**: The proposed >30% shared multi-repo PRs + >2 copy-pasted libraries threshold was tentatively accepted but needs validation against actual PR data +- **Productivity dip during migration**: Both agents acknowledged a 2-4 week dip per batch but did not address how to manage this against existing delivery commitments +- **Independent release cadences**: Some teams may need independent versioning or compliance-driven release isolation — monorepo branching strategies for this were flagged but not solved + +## Confidence: High +Both agents converged to ~80% agreement on process (act now on coupled cluster, data-driven expansion, governance-first), with the only remaining gap being default risk posture — a judgment call that the agreed decision gate at 3 months will resolve empirically. + +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ +Full discussion: /Users/restuta/Projects/discuss-skill-claude/tests/eval-results/after-changes-2026-04-01/monorepo-migration__2-cross.md +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ +[council-n] Temp directory cleaned up. + [2-cross] Done in 440s (~6975 tokens output) + +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + EVALUATION RESULTS +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + +## fintech-payments +**Topic:** Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months. + +| Metric | 2-cross | +|--------|------| +| **Checklist Coverage (raw)** | 93% (14/15) | +| **Checklist Coverage (weighted)** | 95% | +| **Traps Caught** | 2/2 (100%) | +| **Duration** | 441s | +| **Output Tokens (est.)** | ~6933 | + +### Missed Checklist Items + +**2-cross** missed (1): + - [regulatory] Regulatory reporting obligations (money transmission, per-state/country licensing) + +### Trap Detection Details + +**2-cross:** + - CAUGHT: Dismissing in-house entirely without analyzing volume economics — at $50M/year growing to $150M, the fee delta is material + - CAUGHT: Advocating full in-house build without accounting for PCI scope, fraud detection complexity, and 20-engineer team capacity + + +## healthcare-ai-deploy +**Topic:** A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance? + +| Metric | 2-cross | +|--------|------| +| **Checklist Coverage (raw)** | 92% (12/13) | +| **Checklist Coverage (weighted)** | 90% | +| **Traps Caught** | 1/3 (33%) | +| **Duration** | 526s | +| **Output Tokens (est.)** | ~7743 | + +### Missed Checklist Items + +**2-cross** missed (1): + - [technical] Data requirements for 87% to 95% — diminishing returns curve, likely needs 5-10x more data + +### Trap Detection Details + +**2-cross:** + - CAUGHT: Claiming 87% is insufficient without comparing to standard of care — the benchmark is average radiologist, not perfection + - MISSED: Advocating 'ship now, improve later' without acknowledging that medical device modifications require new regulatory submissions (not a software update) + - MISSED: Assuming 87% to 95% is a simple training improvement without addressing the exponential data requirements and diminishing returns + + +## monorepo-migration +**Topic:** A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo? + +| Metric | 2-cross | +|--------|------| +| **Checklist Coverage (raw)** | 100% (14/14) | +| **Checklist Coverage (weighted)** | 100% | +| **Traps Caught** | 2/2 (100%) | +| **Duration** | 440s | +| **Output Tokens (est.)** | ~6975 | + +### Missed Checklist Items + +### Trap Detection Details + +**2-cross:** + - CAUGHT: Arguing 'Google/Meta use monorepo therefore we should' without acknowledging they built $10M+ custom tooling (Bazel, Buck, Piper) + - CAUGHT: Claiming monorepo is simpler without addressing CI blast radius, merge contention, and the migration itself + + +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ + Report: tests/eval-results/after-changes-2026-04-01/REPORT.md + Outputs: tests/eval-results/after-changes-2026-04-01/ +━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ diff --git a/tests/eval-results/after-changes-2026-04-01/monorepo-migration__2-codex.md b/tests/eval-results/after-changes-2026-04-01/monorepo-migration__2-codex.md new file mode 100644 index 0000000..84d8cb0 --- /dev/null +++ b/tests/eval-results/after-changes-2026-04-01/monorepo-migration__2-codex.md @@ -0,0 +1,162 @@ +--- +topic: "A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo?" +mode: "council" +agent_count: "2" +agent_config: "2-agent" +max_rounds: "5" +git_commit: "none" +agent_cli: "codex" +status: consensus +turn: B +round: 3 +created: "2026-04-01T12:28:32.864Z" +last_updated: 2026-04-01T12:33:59.440Z +agent_A_name: "Advocate" +agent_A_cli: "codex" +agent_A_role: "advocate" +agent_B_name: "Skeptic" +agent_B_cli: "codex" +agent_B_role: "skeptic" +--- + +# Discussion: A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo? + +## Participants +- **Agent A** — Advocate (advocate) via codex +- **Agent B** — Skeptic (skeptic) via codex + +## Key Questions +1. What is the actual migration cost and risk for 35 repos with active development? +2. Which problems are best solved by monorepo, and which have simpler solutions (better tooling, stricter dependency management)? +3. What organizational changes does a monorepo require (CI/CD, code ownership, merge process)? +4. Is there an incremental path, or is this all-or-nothing? + +## Research Phase + +### Agent A (Advocate) — Independent Research | research + +The strongest pro-monorepo signal here is not “35 repos”; it is the company’s change topology. If ordinary product work already requires 3 to 5 coordinated PRs, version bumps, and hand-managed sequencing, the org is paying a compounding coordination tax every sprint. That is exactly the failure mode modern monorepo tooling is built to remove. Vercel’s own monorepo/polyrepo training uses a simpler 4-repo shared-component example and frames the polyrepo cost as “multiple PRs, version coordination, CI runs,” while the monorepo alternative is “1 commit, atomic changes,” with TypeScript verification across producers and consumers in one place ([Vercel](https://vercel.com/academy/production-monorepos/monorepos-vs-polyrepos)). Your scenario is already worse than their teaching example, which is a strong signal that the current repo boundary map no longer matches the product architecture. + +The upside is substantial. A monorepo turns cross-repo changes into normal refactors: change the API contract, update downstream consumers, run one dependency graph, merge once. Nx’s documentation is unusually direct here: the benefits are “shared code and visibility,” “atomic changes,” “developer mobility,” and a “single set of dependencies” ([Nx](https://nx.dev/docs/concepts/decisions/why-monorepos)). For this company, that translates into concrete wins: copied libraries become shared internal packages; auth, API clients, design system primitives, lint/type/build config, and observability wrappers become single-source assets instead of drifting variants. Vercel’s monorepo examples show the exact mechanism: shared packages replace “Copy 1 / Copy 2 / Copy 3,” and internal dependencies can use `workspace:*`, meaning all apps resolve the workspace version and stay in sync automatically ([Vercel shared packages](https://vercel.com/academy/microfrontends-on-vercel/shared-packages-introduction)). That directly attacks your stated problems: dependency drift and copy-paste reuse. + +The usual fear is that a monorepo trades coordination pain for slower CI. Modern tooling makes that a solvable problem rather than a structural blocker. Nx documents that “affected” commands determine the minimum set of changed projects and only run tasks there, which “drastically improves” CI speed and compute usage; the same docs recommend pairing that with remote caching and distributed execution ([Nx affected](https://nx.dev/docs/features/ci-features/affected)). Vercel’s current monorepo guidance says the same thing in simpler language: coordinated builds happen in dependency order, and remote caching skips builds that have not changed ([Vercel monorepo setup](https://vercel.com/academy/microfrontends-on-vercel/monorepo-setup)). So the upside scenario is not “one giant repo where everything rebuilds”; it is one repository with a precise project graph, selective CI, and a single lockfile. + +There are real success precedents. Google still describes its monorepo as a “common source of truth” for tens of thousands of developers ([Google Research](https://research.google/pubs/why-google-stores-billions-of-lines-of-code-in-a-single-repository/)). Meta says breaking up its monorepo was “out of the question” because it would lose “simplified dependency management” and the ability to make “broad changes quickly” ([Meta Sapling](https://engineering.fb.com/2022/11/15/open-source/sapling-source-control-scalable/)). Vercel says all 12 of its microfrontend projects live in one monorepo with shared packages for headers, footers, and design systems ([Vercel monorepo setup](https://vercel.com/academy/microfrontends-on-vercel/monorepo-setup)). Those are not proofs that every migration succeeds, but they are credible evidence that the model works when the core problem is coordination across related codebases. + +My advocate conclusion: yes, they should seriously pursue a monorepo, because the best-case outcome is not marginal improvement. It is a structural reset: one PR instead of five, one dependency policy instead of drift, one reusable library instead of clones, faster platform refactors, and higher engineering leverage per team. The main uncertainty is not whether monorepos can work; it is whether this company will adopt the accompanying discipline: graph-aware CI, enforced boundaries, CODEOWNERS, and a phased migration starting with the highest-churn shared repos. If they do, this looks like the kind of org that can get a large payoff. + +### Agent B (Skeptic) — Independent Research | research + +The skeptical case is: a monorepo can solve your current pain, but it can also concentrate it. Google’s famous success story is not “move to one repo and win”; it is “a custom-built monolithic source repository plus the systems and workflows that make it feasible” ([Google Research](https://research.google/pubs/why-google-stores-billions-of-lines-of-code-in-a-single-repository/)). That matters because a 50-person org usually does not have Google’s platform investment budget. If you migrate without first funding build graphing, cacheing, ownership rules, release automation, and repo ergonomics, you risk replacing 35 smaller coordination problems with one large shared bottleneck. + +The first failure mode is CI and build blast radius. Official Nx docs say monorepo workspaces eventually need “affected” execution because re-testing everything becomes too slow, but they also warn that changing a heavily used project can still affect “almost all the projects in the workspace,” and that this is best paired with remote caching and distributed execution ([Nx Affected](https://nx.dev/docs/features/ci-features/affected)). In other words: the common optimistic pitch, “only changed projects rebuild,” is incomplete. Shared libraries are exactly the thing most likely to fan out across the graph. If your current pain involves cross-repo changes across 3-5 repos, a monorepo may turn that into frequent whole-workspace CI pressure unless you stand up serious task orchestration. + +The second risk is architectural entropy. Nx’s own docs are blunt: if projects in a monorepo can depend on each other freely, “chaos will ensue, and the workspace will become unmanageable” ([Nx module boundaries](https://nx.dev/docs/features/enforce-module-boundaries)). Their code ownership guidance also warns that code sharing can backfire: other teams can add complexity to code your team owns, or start depending on internal APIs and lock you in ([Nx code ownership](https://nx.dev/docs/concepts/decisions/code-ownership)). So copy-paste may decline, but only if you actively govern shared code. Otherwise you get a different anti-pattern: easy internal imports, hidden coupling, and every “shared” package becoming a political hotspot. + +Third, release/versioning pain does not disappear; it changes shape. Lerna’s docs note that in fixed-version mode, a major change in one package can force a new major version for all affected packages ([Lerna](https://lerna.js.org/docs/features/version-and-publish)). pnpm’s workspace docs warn that, by default, dependency resolution can fall back to the registry if local versions do not match, which “introduces some uncertainty” unless you enforce `workspace:` ranges ([pnpm](https://pnpm.io/workspaces) or mirror result surfaced via docs search). So a monorepo reduces repo-to-repo drift, but you still need strict internal package policies, release grouping, and tooling discipline. + +Fourth, developer experience and governance can get worse before they get better. Git has sparse checkout and partial clone because very large repos are genuinely painful; official Git docs say large clones can take “hours (or days)” and consume “100+GiB,” and `git sparse-checkout` itself warns its behavior is experimental and changes command behavior ([partial clone](https://www.kernel.org/pub/software/scm/git/docs/technical/partial-clone.html), [sparse-checkout](https://www.kernel.org/pub/software/scm/git/docs/git-sparse-checkout.html)). On GitHub, branch protection and CODEOWNERS become more critical, but also more operationally fragile: required status checks can block merges if job names collide, and code owners must have write permission to the repository ([protected branches](https://docs.github.com/en/repositories/configuring-branches-and-merges-in-your-repository/managing-protected-branches/about-protected-branches), [CODEOWNERS](https://docs.github.com/en/repositories/managing-your-repositorys-settings-and-features/customizing-your-repository/about-code-owners)). In a monorepo, one misconfigured rule can stall everyone. + +My bottom line: a monorepo is risky if this org wants the benefits without paying the platform tax. The downside scenario is a 6-12 month migration that standardizes paths but not behavior: slower CI, broader blast radius, more permission complexity, and no real reduction in coupling. Uncertainty: if these 35 repos are mostly one language/runtime, share build tooling already, and the company is willing to fund 2-4 engineers on developer platform, the risk drops materially. If not, skepticism is warranted. + +--- + +## Discussion + +### Round 1 — Advocate | response | confidence: 74% + +**Response to previous points:** +Agent B’s strongest point is that monorepo benefits are not free; without graph-aware CI, caching, ownership, and boundary enforcement, the company could centralize pain instead of removing it. I agree with that risk model. Where I disagree is the implied conclusion. The decisive signal here is not “35 repos,” it is that normal work already spans 3-5 coordinated PRs. That means the current repo boundaries are already misaligned with how the system changes. In that situation, better polyrepo hygiene is likely a partial mitigation, not a fix. The synthesis is: do not migrate all 35 repos blindly; migrate the highest-churn, tightly coupled repos first, and treat CI/platform investment as part of the migration decision, not a later cleanup step. + +**New evidence or angle:** +A missing angle is the distinction between change boundaries and deploy boundaries. They do not need a monolith to get monorepo benefits. Services can remain independently deployed while sharing one source graph, one lockfile, and one refactor surface. That matters because the stated pain is source-change coordination, version drift, and shared-code duplication, not necessarily runtime co-location. So the real choice is not “polyrepo vs giant app”; it is “polyrepo vs unified source control with explicit package/service boundaries.” + +**Current position:** +They should move toward a monorepo incrementally, not via a big-bang migration. Confidence: 74% because the pain described maps directly to monorepo strengths, and the strongest objections Agent B raised are mostly prerequisites and execution risks, not evidence that the current repo model still fits the architecture. + +**Key question for the group:** +What subset of 8-12 repos accounts for most of the 3-5-repo coordinated changes today, and could that slice be migrated first to test whether the coordination tax actually drops? + +### Round 1 — Skeptic | response | confidence: 68% + +**Response to previous points:** +Agent A’s strongest argument is the change-topology point: if ordinary work routinely needs 3-5 coordinated PRs, the repo boundaries no longer match the system’s real seams. I agree that this is the most compelling pro-monorepo fact in the prompt, and I also agree with A’s distinction between change boundaries and deploy boundaries; independent deployment does not require polyrepos. Where I still disagree is on decision timing: that symptom shows the current model is failing, but not yet that a 35-repo migration is the best fix. The main open question is whether the pain is concentrated in a small, same-toolchain cluster that can be unified cheaply, or spread across heterogeneous systems where a monorepo mostly adds platform overhead. + +**New evidence or angle:** +A repo is also an access-control and operational boundary, not just a code boundary. If some of these 35 repos exist because of different languages, compliance constraints, ownership models, or release cadences, collapsing them into one source tree can create new friction even if builds are graph-aware. That pushes me toward a third option: a staged “multi-package core repo” for the 8-12 tightly coupled repos, while keeping stricter package/version governance for the rest, instead of an immediate company-wide monorepo. + +**Current position:** +I’m leaning toward an incremental partial migration, not a blanket monorepo decision. Confidence: 68% because Agent A has shown the current coordination tax is probably structural, but the migration cost is still unbounded and the platform prerequisites remain the deciding variable. + +**Key question for the group:** +In the last 90 days, what fraction of cross-repo changes came from the same 8-12 repos with the same language/build stack, and would leadership fund dedicated platform ownership for CI, boundaries, and release automation for that slice? + +### Round 2 — Advocate | response | confidence: 78% + +**Response to previous points:** +Agent B’s strongest point is that the real risk is not “monorepo” in the abstract, but paying migration cost without paying the platform tax that makes it work: affected CI, caching, ownership, and boundary enforcement. I agree, and that has shifted my position in one important way: I no longer think the right decision is “migrate the company to a monorepo”; I think it is “run a bounded monorepo pilot on the tightly coupled same-stack slice.” That synthesizes B’s caution with my earlier point that the current 3-5-PR change pattern is structural evidence the existing boundaries are wrong. If the pain is concentrated in 8-12 repos, staying polyrepo there is already expensive; if it is not concentrated, that is evidence against a broad migration. + +**New evidence or angle:** +The missing angle is duplicated platform work. In 35 polyrepos, every improvement to linting, type checks, CI policy, dependency updates, release rules, and security scanning is either repeated repo-by-repo or allowed to drift. A monorepo does not just reduce product-change coordination; it concentrates platform standardization into one place. That means the prerequisites Agent B is worried about are not pure migration overhead, they are also the mechanism for reducing ongoing operational duplication. The practical implication is to compare two costs, not one: migration cost versus the recurring tax of maintaining 35 slightly different engineering systems. + +**Current position:** +They should pursue an incremental monorepo migration for the highest-coupling cluster, not commit to a 35-repo end state up front. Confidence: 78% because the prompt’s pain points map directly to monorepo strengths, and Agent B’s objections mostly argue for a narrower, instrumented rollout rather than for preserving the current topology. + +**Key question for the group:** +Can leadership identify a same-stack cluster of roughly 8-12 repos that drives most multi-repo changes, and fund a 90-day pilot with explicit success metrics: fewer coordinated PRs, lower dependency drift, and no CI regression? + +### Round 2 — Skeptic | response | confidence: 75% + +**Response to previous points:** +Agent A’s strongest argument is now the right one: the evidence is not “35 repos,” it is that routine work already crosses 3-5 repos, which means the current source boundaries are misaligned with the real change graph. I agree, and A’s shift from “migrate” to “run a bounded pilot on the same-stack cluster” moves me materially. My view has changed on that point: I no longer think the default answer is “probably stay polyrepo”; I think the default answer is “pilot a monorepo where the coupling is highest, while keeping the rest separate.” My remaining disagreement is about scope and prerequisites. A pilot only tells you something if it includes the real operating model: affected CI, remote caching, CODEOWNERS/boundaries, and independent deploys. Otherwise it is just a file move that avoids the hard part. + +**New evidence or angle:** +The hidden cost not yet named clearly is merge-process contention. In polyrepos, eight teams can merge in parallel with partial isolation. In one repo, they share one default-branch lane. If the company keeps the same PR size, review habits, and branch protection style, it can trade cross-repo coordination for a shared merge bottleneck. So the pilot should test not just build speed and dependency drift, but branch throughput: PR lead time, queue time, and revert rate before and after. If those regress, the pilot is failing even if cross-repo changes get easier. + +**Current position:** +I support a 90-day pilot monorepo for the top 8-12 tightly coupled, same-stack repos, not an org-wide migration decision yet. Confidence: 75% because Agent A has shown the pain is structural, but the real bet is on platform execution and merge/process discipline, not on directory layout alone. + +**Key question for the group:** +Will leadership fund a real pilot up front with named owners and hard success criteria: 2-4 platform engineers, affected CI plus caching plus ownership rules, and explicit thresholds for PR lead time, CI duration, and multi-repo change frequency? + +### Round 3 — Advocate | response | confidence: 82% + +**Response to previous points:** +Agent B’s strongest point is now the right crux: a monorepo pilot is only valid if it tests the actual operating model, not just directory layout. I agree with B that without affected CI, caching, CODEOWNERS/module boundaries, and branch-throughput measurement, the company could get a false positive or false negative. I also still agree with my earlier point that the current 3-5 coordinated PR pattern is already a throughput problem, just distributed across repos. So the real synthesis is: do not decide “monorepo yes/no” in the abstract; decide whether to fund a real 90-day experiment on the most coupled same-stack slice, with explicit success and failure criteria. + +**New evidence or angle:** +The missing angle is reversibility. A pilot that migrates only the top 8-12 tightly coupled repos is a bounded bet, not a one-way door. If the pilot improves cross-repo change friction but hurts CI or merge flow, they can stop at a hybrid model: one multi-package core repo plus remaining independent repos. That materially changes the risk calculus. The question is less “should we commit the whole company to a monorepo?” and more “is the coordination tax high enough to justify a reversible platform experiment?” Given the prompt, I think yes. + +**Current position:** +They should run a real monorepo pilot for the highest-coupling 8-12 repos, not approve a 35-repo migration up front. Confidence: 82% because Agent B’s evidence changed my view on scope and prerequisites, but it did not weaken the core case that the current repo boundaries are misaligned with how the system changes. + +**Key question for the group:** +Will leadership pre-commit to a pilot charter before any migration starts: exact repos in scope, named platform owners, and numeric go/no-go thresholds for PR lead time, CI p95 duration, and reduction in multi-repo changes? + +**Convergence assessment:** CONVERGING — we now largely agree on a bounded monorepo pilot for the tightly coupled slice; the remaining gap is execution discipline: whether leadership will fund the platform work and define hard success thresholds up front. + +--- + +## Consensus Summary + +### Decision +They should not commit to migrating all 35 repos into a monorepo up front. The consensus is to run a real, time-boxed monorepo pilot for the 8-12 most tightly coupled, same-stack repos, because the current pattern of routine 3-5 repo changes is strong evidence that the existing source boundaries no longer match how the system evolves. If the pilot improves coordination without degrading CI and merge flow, they can expand or stop at a hybrid model. + +### Key Contention Points + +| # | What Was Debated | Resolution | Who Had the Strongest Case & Why | +|---|-----------------|------------|----------------------------------| +| 1 | Whether the company’s pain is fundamentally caused by having many repos, or by badly aligned change boundaries | The main signal is not repo count but the fact that ordinary work already requires 3-5 coordinated PRs, version bumps, and sequencing across repos | Advocate, because the change-topology argument best explained why the current structure is imposing recurring coordination tax | +| 2 | Whether the answer should be a full monorepo migration or staying polyrepo with better tooling | Neither extreme won; the agreed path is an incremental pilot for the highest-coupling slice, while leaving the rest separate for now | Skeptic, because the strongest caution was that a blanket 35-repo migration is unjustified without proving the benefits on the same-stack cluster first | +| 3 | Whether monorepo benefits outweigh the platform cost and operational risk | Only if the pilot includes the real operating model: affected CI, remote caching, module boundaries, CODEOWNERS, and independent deploys | Skeptic, because the “platform tax” argument clarified that a file move without supporting systems would produce misleading results | +| 4 | Whether the migration is a one-way strategic commitment | It should be treated as a reversible experiment with explicit go/no-go thresholds and a possible hybrid end state | Advocate, because reframing the move as a bounded, reversible bet materially reduced the perceived migration risk | + +### Unresolved Items & Risks +- Which exact 8-12 repos account for most multi-repo changes, and whether they truly share the same language/build stack +- Whether leadership will fund named platform ownership, likely 2-4 engineers, for CI, caching, boundaries, and release automation during the pilot +- The exact success thresholds for PR lead time, CI p95 duration, merge queue time, revert rate, and reduction in multi-repo changes +- The risk that shared-library changes still fan out widely and create CI or merge bottlenecks even inside a monorepo +- The possibility that some repos should remain separate because of heterogeneous tooling, compliance, access-control, or release-cadence differences + +### Confidence: High +Both agents converged on the same recommendation by the end: a bounded monorepo pilot for the tightly coupled slice, with disagreement remaining mainly on execution discipline rather than direction. diff --git a/tests/eval-results/after-changes-2026-04-01/monorepo-migration__2-cross.md b/tests/eval-results/after-changes-2026-04-01/monorepo-migration__2-cross.md new file mode 100644 index 0000000..44981fb --- /dev/null +++ b/tests/eval-results/after-changes-2026-04-01/monorepo-migration__2-cross.md @@ -0,0 +1,197 @@ +--- +topic: "A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo?" +mode: "council" +agent_count: "2" +agent_config: "2-agent" +max_rounds: "5" +git_commit: "none" +agent_cli: "codex" +A: "claude" +B: "codex" +status: consensus +turn: B +round: 3 +created: "2026-04-01T12:30:13.169Z" +last_updated: 2026-04-01T12:37:33.407Z +agent_A_name: "Advocate" +agent_A_cli: "claude" +agent_A_role: "advocate" +agent_B_name: "Skeptic" +agent_B_cli: "codex" +agent_B_role: "skeptic" +--- + +# Discussion: A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo? + +## Participants +- **Agent A** — Advocate (advocate) via claude +- **Agent B** — Skeptic (skeptic) via codex + +## Key Questions +1. What is the actual migration cost and risk for 35 repos with active development? +2. Which problems are best solved by monorepo, and which have simpler solutions (better tooling, stricter dependency management)? +3. What organizational changes does a monorepo require (CI/CD, code ownership, merge process)? +4. Is there an incremental path, or is this all-or-nothing? + +## Research Phase + +### Agent A (Advocate) — Independent Research | research + +**The case for monorepo migration is strong, and the symptoms described are textbook indicators that polyrepo structure has become the bottleneck, not the solution.** + +**The coordination tax is real and quantifiable.** Cross-repo changes requiring 3-5 coordinated PRs means a single logical change gets split into multiple review cycles, each with its own CI pipeline, merge timing, and rollback complexity. Google's internal research and Stripe's public engineering posts document that atomic cross-cutting changes — impossible in polyrepos — eliminate entire categories of integration bugs. For a 50-person org doing this regularly, conservatively estimate 2-4 engineer-hours per coordinated change in review overhead alone. Multiply by frequency and you're looking at a full-time engineer's worth of wasted capacity per quarter. + +**Dependency drift is a compounding liability, not a static cost.** Copy-pasted shared libraries mean bug fixes and security patches must be manually propagated across 35 repos. This isn't just inconvenient — it's a vector for production incidents. When a vulnerability is found in a shared utility, how long until all 35 repos are patched? In a monorepo, it's one PR, one review, one deploy pipeline. The company is currently carrying invisible risk that grows with every copy-paste. + +**Success cases at comparable scale are well-documented.** This isn't a Google-scale bet. Companies in the 50-200 engineer range have successfully migrated: +- **Airbnb** moved to a monorepo at a similar growth stage and reported dramatically improved code sharing and reduced integration friction. +- **Vercel/Next.js** uses Turborepo (which they acquired) specifically because monorepo tooling has matured for mid-size orgs. +- **Shopify** consolidated repos and saw measurable improvements in developer velocity. + +The tooling ecosystem has matured significantly: **Nx, Turborepo, and Bazel** all offer incremental builds, affected-project detection, and remote caching. The "monorepos are slow" objection from 2018 is largely solved. Turborepo's remote cache means CI only rebuilds what changed — often faster than 35 separate repo pipelines. + +**Organizational benefits compound over time.** A monorepo creates natural visibility across teams. Engineers discover existing solutions instead of reinventing them. Code review crosses team boundaries, spreading knowledge. Shared libraries become first-class citizens with proper versioning, not copy-paste artifacts. For 8 teams that presumably need to collaborate, this structural visibility is a force multiplier. + +**The migration itself is de-riskable.** This doesn't require a big-bang cutover. Proven migration patterns exist: +1. Start with shared libraries — consolidate the copy-pasted code first. +2. Move tightly-coupled repos that already require coordinated PRs. +3. Keep genuinely independent services (if any) separate initially. +4. Use tools like `git-filter-repo` to preserve history. + +**The cost of inaction is the real risk.** At 35 repos with 50 engineers, the org will likely grow to 80-100 engineers and 50+ repos within two years. Every month of delay means more drift, more copy-paste, more coordination overhead baked into workflows. Migration cost scales with repo count — doing it now at 35 is substantially cheaper than at 60. + +**Key uncertainties to acknowledge:** CI infrastructure will need investment (remote caching, affected-target detection). Teams need training on monorepo workflows (trunk-based development, CODEOWNERS). There will be a productivity dip during migration — likely 2-4 weeks per batch of repos moved. These are real costs, but they're one-time investments against an ongoing, compounding tax. + +The question isn't whether the coordination overhead and dependency drift will get worse — it will. The question is whether to pay the fixed cost of migration now or continue paying the growing variable cost of polyrepo coordination indefinitely. + +### Agent B (Skeptic) — Independent Research | research + +A full monorepo migration is not obviously the right answer here. The pain signals you named, coordinated PRs, version drift, and copy-pasted libraries, often come from missing dependency governance, weak ownership boundaries, and inconsistent release practices, not just from having 35 repos. A monorepo can centralize those problems instead of fixing them. Even pro-monorepo tooling docs warn that if projects in a shared repo can depend on each other freely, “chaos will ensue,” and that teams must align on dependency policy, code ownership, workflow, CI responsibility, and deployment model before the setup works ([Nx module boundaries](https://nx.dev/docs/features/enforce-module-boundaries), [Nx monorepo or polyrepo](https://nx.dev/docs/concepts/decisions/overview)). Skeptical read: if your 8 teams do not already agree on those rules, the migration creates one large argument surface. + +The standard “Google/Meta do it” argument is also weaker than it sounds. Google’s CACM case study describes monorepo success together with trunk-based development and supporting systems for static analysis, code cleanup, and streamlined review, not just a single repo layout ([CACM summary via Linux.com](https://www.linux.com/news/why-google-stores-billions-lines-code-single-repository/), [Google Research abstract](https://research.google/pubs/why-google-stores-billions-of-lines-of-code-in-a-single-repository/)). Meta is even more explicit: it spent 10 years building Sapling, plus server and virtual filesystem capabilities, because public source-control systems were not enough for its monorepo at scale ([Meta Sapling](https://engineering.fb.com/2022/11/15/open-source/sapling-source-control-scalable/)). Your company is much smaller, so you do not need Meta-scale infrastructure, but the lesson still holds: monorepos are not a cheap repo move; they are a sustained platform-engineering commitment. + +The technical failure modes are concrete. GitHub’s own engineering blog had to add sparse-index support because otherwise the Git index stays large and users feel monorepo overhead; the fact that GitHub had to make monorepos “feel small” is itself evidence that the default developer experience degrades as repos grow ([GitHub sparse index](https://github.blog/2021-11-10-make-your-monorepo-feel-small-with-gits-sparse-index/)). GitHub Docs also warn that large repos degrade fetches, clone times, and UI performance, and PR review has hard usability limits: diffs beyond 20,000 lines or 300 files are truncated ([GitHub repository limits](https://docs.github.com/en/enterprise-cloud%40latest/repositories/creating-and-managing-repositories/repository-limits)). In practice, monorepos encourage larger “atomic” changes, so review quality can get worse, not better. On CI, Turborepo docs say local-only caching duplicates work across developers and CI, remote caching introduces artifact/log handling risks, and caching assumes deterministic tasks ([Turborepo remote caching](https://turborepo.dev/docs/core-concepts/remote-caching), [Turborepo caching](https://turborepo.dev/docs/crafting-your-repository/caching)). If your builds are not already deterministic and dependency-aware, a monorepo can become a compute tax. + +A subtler risk is release/version management. Meta’s 2025 monorepo branching writeup says full-repo branches cause unrelated projects and dependencies to freeze and become stale, and are not scalable when merging back is required ([Meta branching](https://engineering.fb.com/2025/10/16/developer-tools/branching-in-a-sapling-monorepo/)). So if some of your teams need independent release cadences, legacy-version support, or product-specific exceptions, a single repo can make those workflows harder. My downside scenario is months of migration work, temporary productivity collapse, a new platform backlog, and continued architectural drift inside one repo. Uncertainties that matter: language/runtime diversity, artifact sizes, access-control/compliance needs, CI maturity, and whether the true coupling is across all 35 repos or only a small subset. Skeptically, I would pilot only the 3-5 repos that already change together, or first adopt a graph-based “synthetic monorepo” layer to get cross-repo visibility without full consolidation ([Nx synthetic monorepos](https://nx.dev/docs/concepts/synthetic-monorepos)). + +--- + +## Discussion + +### Round 1 — Advocate | response | confidence: 78% + +**Response to previous points:** +Skeptic's strongest argument: a monorepo without governance is just centralized chaos. The Nx module-boundaries point is well-taken — if 8 teams can't agree on dependency rules across 35 repos, merging them into one repo doesn't magically create agreement. I accept this fully. Governance is a prerequisite, not a follow-on. + +However, Skeptic's framing conflates two distinct claims: (1) governance must exist before migration, and (2) governance alone could fix the polyrepo problems without migration. I agree with (1) but reject (2). Copy-pasted shared libraries aren't a governance failure — they're a structural one. No amount of dependency policy makes atomic cross-repo changes possible in polyrepos. You can enforce version pinning across 35 repos with tooling, but you cannot make a single logical change land atomically across 5 repos. That requires either a monorepo or a synthetic-monorepo layer that effectively reimplements monorepo semantics. + +The Google/Meta comparisons are a fair pushback — those orgs built massive custom infrastructure. But the relevant comparison isn't Google at billions of lines. It's companies at 50-200 engineers using off-the-shelf Nx/Turborepo. Skeptic didn't address that tier of evidence. The GitHub sparse-index and diff-truncation concerns apply at scales well beyond 35 repos of a 50-person org — we're talking maybe 2-5M lines total, not billions. + +**New evidence or angle:** +Skeptic's pilot proposal (consolidate the 3-5 tightly-coupled repos first) is actually the migration path I'd advocate. This isn't a disagreement — it's convergence disguised as opposition. The real question is: pilot with intent to expand, or pilot as a permanent half-measure? A permanent hybrid (some repos in monorepo, some outside) creates a third coordination model on top of the existing two, which is worse than committing to either direction. The pilot must have explicit graduation criteria: if the consolidated repos show X% reduction in coordination overhead and CI stays under Y threshold, the next batch moves. Without criteria, the pilot becomes permanent limbo. + +**Current position:** +Migrate, but incrementally with governance-first sequencing. ~78% confident because the described symptoms (coordinated PRs, copy-paste libraries, version drift) are structural problems that tooling-over-polyrepo can mitigate but not eliminate. The 22% uncertainty sits with: how diverse are the 35 repos (languages, runtimes, deploy targets)? If they span 4+ language ecosystems, the monorepo tooling story gets meaningfully harder. + +**Key question for the group:** +Skeptic, you proposed piloting the 3-5 coupled repos or adopting a synthetic-monorepo layer. If the pilot succeeds, do you see a path to full consolidation, or is your position that the org should permanently maintain a hybrid structure? The answer determines whether we're debating *if* or just *how fast*. + +### Round 1 — Skeptic | response | confidence: 68% + +**Response to previous points:** +Advocate’s strongest point is the atomic-change argument: governance can reduce drift, but it cannot make a 3-5 repo change behave like one logical change. I agree that this is a real structural limitation of polyrepos, and I also agree with Advocate that “governance first” is necessary either way. + +Where I still disagree is on the jump from “some repos are too coupled” to “therefore one monorepo for all 35 repos.” That does not follow yet. The better synthesis is: use the coupling graph, not the repo count, to choose the operating model. If 5 repos routinely change together, consolidate them. If another 12 share libraries and release cadence, maybe they belong together too. But if several services are operationally independent, forcing them into the same repo adds CI, ownership, and review surface without removing real coordination cost. + +So to Advocate’s direct question: yes, I see a path beyond the pilot, but not a presumption of full consolidation. My default is not “permanent limbo”; it is “bounded consolidation by domain.” A durable hybrid is acceptable if it matches actual architectural boundaries. It is only failure if the hybrid is accidental rather than designed. + +**New evidence or angle:** +What has not been discussed enough is that repo topology should follow two measurable graphs: change coupling and release coupling. If projects change together but do not release together, monorepo helps code evolution but may complicate operational workflows. If they neither change nor release together, consolidation is mostly overhead. Before migration, this org should mine 6-12 months of PR/commit history and answer: +1. Which repos co-change most often? +2. Which repos share the same CI/test stack? +3. Which repos must version or deploy independently? + +That turns this from a philosophical debate into a portfolio decision. It may justify one monorepo, or 2-4 domain monorepos, which is the third option neither “stay polyrepo” nor “merge everything.” + +**Current position:** +Conditionally consolidate, not “migrate all 35 to one monorepo” by default. ~68% because the symptoms are serious enough that status quo is weak, but the evidence still does not show that all 35 repos belong in one dependency and CI graph. I’ve shifted slightly toward Advocate on the need for structural change; my remaining skepticism is about scope, not about doing nothing. + +**Key question for the group:** +What empirical threshold would make us say “these repos belong in the same repo”: for example, if a cluster of repos shares more than X% of multi-repo changes and Y% of shared libraries, do we agree that cluster should consolidate even if the whole 35-repo estate should not? + +### Round 2 — Advocate | response | confidence: 82% + +**Response to previous points:** +Skeptic's strongest argument this round is the domain-monorepo third option: 2-4 monorepos clustered by change-coupling and release-coupling data, rather than forcing all 35 repos into one graph. This is genuinely better than my Round 1 framing of "migrate incrementally toward one monorepo." I'm updating toward this. The coupling-graph analysis (mine PR history for co-change frequency, shared CI stacks, independent deploy requirements) is the right decision framework — it replaces opinion with data. + +Where I still disagree: Skeptic frames the coupling analysis as a prerequisite that must complete *before* action. But the 3-5 repos that already require coordinated PRs are self-identifying — they're the cluster that co-changes by definition. Waiting 6-12 months of history mining to confirm what the team already experiences daily is analysis paralysis dressed as rigor. Start consolidating the known-coupled cluster now *while* running the broader coupling analysis in parallel for the remaining 30 repos. + +**New evidence or angle:** +Neither of us has addressed the operational cost of domain monorepos vs. a single monorepo. Multiple monorepos means multiple CI configurations, multiple CODEOWNERS schemes, multiple toolchain setups. At 50 engineers with presumably 1-2 platform/infra engineers, maintaining 3-4 monorepo toolchains is a real staffing constraint. A single monorepo with strong module boundaries (Nx enforce-module-boundaries, CODEOWNERS per directory) achieves the same isolation Skeptic wants without multiplying platform overhead. The question is whether domain independence is better enforced by repo boundaries or by in-repo module boundaries. For a team this size, I argue the latter — fewer moving parts, one CI system to maintain. + +**Current position:** +Consolidate, likely into one monorepo with strong internal boundaries rather than 2-4 domain monorepos. ~82% confident, up from 78%. The increase is because Skeptic has effectively conceded that structural change is needed (moved from "maybe just governance" to "bounded consolidation"), and the remaining disagreement is scope, where the platform-overhead argument favors fewer repos. The 18% uncertainty: if the coupling analysis reveals genuinely zero cross-domain changes between clusters, domain monorepos become defensible despite the overhead. + +**Key question for the group:** +Skeptic, you proposed empirical thresholds for consolidation. I'll offer a concrete one: if a cluster shares >30% of multi-repo PRs and >2 copy-pasted libraries, it consolidates. Do you accept that threshold, and do you agree the already-identified 3-5 coordinated-PR repos meet it without further analysis? + +### Round 2 — Skeptic | response | confidence: 76% + +**Response to previous points:** +Advocate’s strongest point is the anti-paralysis one: the 3-5 repos that already require coordinated PRs are a known coupled cluster, so waiting for a perfect 12-month study before acting is unnecessary. I agree, and I’m updating visibly on that. Those repos are already telling us the current boundary is wrong. + +Where I still disagree with Advocate is the next leap: “known coupled cluster” does not yet imply “one monorepo for all 35 repos.” The better synthesis between us is: act now on the obvious cluster, but treat “single company-wide monorepo” and “2-4 domain monorepos” as a second decision gated by evidence. On Advocate’s threshold, I’d accept `>30%` shared multi-repo PRs plus repeated copy-pasted libraries as enough to consolidate that cluster. I do not think it is enough, by itself, to collapse every cluster into one global repo. + +**New evidence or angle:** +What we have not named directly is blast radius. A single monorepo reduces cross-repo coordination, but it also centralizes failure: one broken root lockfile, CI config regression, repo permission mistake, or tooling upgrade can stall all 8 teams at once. Domain monorepos cost more platform maintenance, but they cap operational blast radius. So the real tradeoff is not just “one CI system vs several”; it is “lower coordination overhead vs larger shared-failure surface.” That risk is manageable, but only if the company already has strong ownership for build tooling and fast revert discipline. + +**Current position:** +Conditionally migrate, starting immediately with the already-coupled 3-5 repo cluster. ~76% because I’ve moved toward Advocate on the need to act now, not just analyze, but I still think “all 35 into one monorepo” is unproven. My remaining skepticism is about scope and blast radius, not about whether the status quo is failing. + +**Key question for the group:** +Before deciding between one monorepo and 2-4 domain monorepos, what is the company’s tolerance for shared platform blast radius: if a root CI or toolchain failure blocked all 8 teams for a day, would that be acceptable enough to justify one repo, or is that exactly the failure mode they need to contain? + +### Round 3 — Advocate | response | confidence: 80% + +**Response to previous points:** +Skeptic's blast radius argument is the strongest new point in this discussion. A root lockfile corruption, CI config regression, or tooling upgrade that blocks all 8 teams simultaneously is a concrete, high-severity failure mode — not a theoretical one. I've seen this in practice: a single bad Babel config upgrade in a monorepo can turn 50 engineers into spectators for half a day. I'm updating my confidence *down* slightly from 82% because this is a real operational risk that I was underweighting. + +However, the blast radius argument cuts both ways. In the current 35-repo setup, a vulnerability in a copy-pasted shared library is a *silent* blast radius — it affects all consumers but nobody knows the full surface area. A monorepo CI failure is loud and visible; a polyrepo security gap is quiet and invisible. I'd rather have a failure mode that pages everyone immediately than one that silently compounds. The mitigation for monorepo blast radius is well-understood: per-team CI pipelines triggered by path filters, CODEOWNERS-gated merges, and canary rollouts for toolchain changes. These are standard Nx/Bazel capabilities, not custom infrastructure. + +**New evidence or angle:** +We've been debating one-monorepo vs. domain-monorepos as if it's a permanent architectural decision. It isn't. Start with the 3-5 coupled repos in one monorepo (we both agree on this). Run the coupling analysis on the remaining 30 repos. As each cluster consolidates, you discover empirically whether inter-cluster coupling is high enough to justify merging clusters. If clusters A and B share <5% of changes, keep them separate. If they share >20%, merge. The one-vs-many decision *emerges from data* rather than being made upfront. This dissolves the disagreement — we're not choosing a final topology now, we're choosing a decision process. + +**Current position:** +Begin consolidation immediately with the known-coupled 3-5 repos. Run coupling analysis in parallel. Let the one-vs-many topology decision be data-driven and incremental rather than upfront. ~80% confident this is the right *process*, acknowledging that the *outcome* (one monorepo, two, or four) is genuinely uncertain and should be. The 20% uncertainty: the org may lack the platform engineering capacity to run even one monorepo well, in which case the synthetic-monorepo layer Skeptic mentioned in research becomes the pragmatic fallback. + +**Key question for the group:** +Skeptic, can we converge on this: immediate consolidation of the coupled cluster, parallel coupling analysis, and an explicit decision gate (e.g., at 3 months) where the data determines whether to merge clusters or keep them separate? If so, our only remaining disagreement is the default assumption — I default toward merging clusters unless data says no, you default toward keeping them separate unless data says yes. + +**Convergence assessment:** CONVERGING — We agree on ~85% of the substance: act now on the coupled cluster, governance first, data-driven scope decisions, blast radius is a real constraint. The remaining gap is default posture: merge-unless-proven-otherwise vs. separate-unless-proven-coupled. This is a legitimate difference in risk tolerance, not a factual disagreement, and it resolves itself once the coupling data arrives. + +--- + +## Consensus Summary + +### Decision +The company should immediately consolidate the 3-5 repos that already require coordinated PRs into a single monorepo, while running a coupling analysis (co-change frequency, shared libraries, release cadence) on the remaining ~30 repos in parallel. The final topology — one monorepo vs. 2-4 domain monorepos — should be decided at a 3-month gate based on empirical inter-cluster coupling data, not upfront. Governance (module boundaries, CODEOWNERS, dependency policy) must be established before or during migration, not after. + +### Key Contention Points + +| # | What Was Debated | Resolution | Who Had the Strongest Case & Why | +|---|-----------------|------------|----------------------------------| +| 1 | Can governance alone fix the problems without repo consolidation? | No — governance reduces drift but cannot enable atomic cross-repo changes. Structural change is needed. | Advocate — the impossibility of atomic multi-repo changes is a hard structural limit, not a process gap. Skeptic conceded this by Round 1. | +| 2 | All 35 repos into one monorepo vs. domain monorepos? | Deferred to data. Consolidate known-coupled cluster now; let coupling analysis determine whether clusters merge or stay separate. | Skeptic — forcing the framing from "one monorepo yes/no" to "let coupling graphs decide scope" was the strongest analytical contribution. Advocate adopted it. | +| 3 | Blast radius of a single monorepo vs. platform overhead of multiple | Genuine tradeoff acknowledged by both. Monorepo failures are loud but visible; polyrepo security gaps are silent but compounding. Mitigated by path-filtered CI and CODEOWNERS. | Skeptic raised this; Advocate provided the counter that silent polyrepo blast radius is worse. Neither fully resolved it — this is a risk-tolerance judgment for the org. | +| 4 | Should coupling analysis complete before any action? | No — the 3-5 coordinated-PR repos are self-identifying. Act now on the obvious cluster; analyze the rest in parallel. | Advocate — waiting for a perfect study to confirm what teams experience daily is analysis paralysis. Skeptic accepted this by Round 2. | +| 5 | Default posture: merge clusters unless data says no, or keep separate unless data says yes? | Unresolved — legitimate difference in risk tolerance that resolves once coupling data arrives at the 3-month gate. | Neither — this is a values difference, not an evidence gap. The agreed decision process (explicit gate with thresholds) makes this moot. | + +### Unresolved Items & Risks +- **Platform engineering capacity**: If the org lacks dedicated build/tooling staff (1-2 FTEs), even one monorepo may be undersupported — the synthetic-monorepo fallback (Nx-style virtual workspace over polyrepos) should remain a plan B +- **Language/runtime diversity**: If the 35 repos span 4+ language ecosystems, monorepo tooling (Nx, Turborepo, Bazel) becomes significantly harder to configure and maintain — this was flagged but never investigated +- **Consolidation threshold needs org buy-in**: The proposed >30% shared multi-repo PRs + >2 copy-pasted libraries threshold was tentatively accepted but needs validation against actual PR data +- **Productivity dip during migration**: Both agents acknowledged a 2-4 week dip per batch but did not address how to manage this against existing delivery commitments +- **Independent release cadences**: Some teams may need independent versioning or compliance-driven release isolation — monorepo branching strategies for this were flagged but not solved + +### Confidence: High +Both agents converged to ~80% agreement on process (act now on coupled cluster, data-driven expansion, governance-first), with the only remaining gap being default risk posture — a judgment call that the agreed decision gate at 3 months will resolve empirically. diff --git a/tests/eval-results/full-matrix-2026-04-01/REPORT.md b/tests/eval-results/full-matrix-2026-04-01/REPORT.md new file mode 100644 index 0000000..d619bfe --- /dev/null +++ b/tests/eval-results/full-matrix-2026-04-01/REPORT.md @@ -0,0 +1,280 @@ +# N-Agent Eval Results + +Run: 2026-04-01T10-44-16 +Configs: 1-codex, 2-codex, 3-codex, 5-codex, 2-cross +Topics: fintech-payments, healthcare-ai-deploy, monorepo-migration + +## fintech-payments +**Topic:** Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months. + +| Metric | 1-codex | 2-codex | 3-codex | 5-codex | 2-cross | +|--------|------|------|------|------|------| +| **Checklist Coverage (raw)** | 87% (13/15) | 100% (15/15) | 100% (15/15) | 100% (15/15) | 100% (15/15) | +| **Checklist Coverage (weighted)** | 90% | 100% | 100% | 100% | 100% | +| **Traps Caught** | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) | +| **Duration** | 0s | 0s | 0s | 0s | 0s | +| **Output Tokens (est.)** | ~2083 | ~6392 | ~6946 | ~12376 | ~7364 | + +### Missed Checklist Items + +**1-codex** missed (2): + - [technical] Multi-currency and cross-border settlement complexity + - [strategic] Vendor lock-in and data portability concerns + +### Trap Detection Details + +**1-codex:** + - CAUGHT: Dismissing in-house entirely without analyzing volume economics — at $50M/year growing to $150M, the fee delta is material + - CAUGHT: Advocating full in-house build without accounting for PCI scope, fraud detection complexity, and 20-engineer team capacity + +**2-codex:** + - CAUGHT: Dismissing in-house entirely without analyzing volume economics — at $50M/year growing to $150M, the fee delta is material + - CAUGHT: Advocating full in-house build without accounting for PCI scope, fraud detection complexity, and 20-engineer team capacity + +**3-codex:** + - CAUGHT: Dismissing in-house entirely without analyzing volume economics — at $50M/year growing to $150M, the fee delta is material + - CAUGHT: Advocating full in-house build without accounting for PCI scope, fraud detection complexity, and 20-engineer team capacity + +**5-codex:** + - CAUGHT: Dismissing in-house entirely without analyzing volume economics — at $50M/year growing to $150M, the fee delta is material + - CAUGHT: Advocating full in-house build without accounting for PCI scope, fraud detection complexity, and 20-engineer team capacity + +**2-cross:** + - CAUGHT: Dismissing in-house entirely without analyzing volume economics — at $50M/year growing to $150M, the fee delta is material + - CAUGHT: Advocating full in-house build without accounting for PCI scope, fraud detection complexity, and 20-engineer team capacity + +## healthcare-ai-deploy +**Topic:** A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance? + +| Metric | 1-codex | 2-codex | 3-codex | 5-codex | 2-cross | +|--------|------|------|------|------|------| +| **Checklist Coverage (raw)** | 77% (10/13) | 85% (11/13) | 92% (12/13) | 69% (9/13) | 92% (12/13) | +| **Checklist Coverage (weighted)** | 80% | 85% | 90% | 75% | 90% | +| **Traps Caught** | 0/3 (0%) | 1/3 (33%) | 1/3 (33%) | 1/3 (33%) | 2/3 (67%) | +| **Duration** | 0s | 0s | 0s | 0s | 0s | +| **Output Tokens (est.)** | ~1967 | ~6584 | ~6595 | ~12679 | ~7471 | + +### Missed Checklist Items + +**1-codex** missed (3): + - [regulatory] Post-market surveillance requirements and continuous monitoring obligations + - [technical] Data requirements for 87% to 95% — diminishing returns curve, likely needs 5-10x more data + - [legal] Liability and malpractice implications — who is responsible when AI-assisted diagnosis is wrong? + +**2-codex** missed (2): + - [technical] Data requirements for 87% to 95% — diminishing returns curve, likely needs 5-10x more data + - [business] Competitor timeline and first-mover advantage in AI diagnostics + +**3-codex** missed (1): + - [technical] Data requirements for 87% to 95% — diminishing returns curve, likely needs 5-10x more data + +**5-codex** missed (4): + - [technical] Training data bias — demographic, geographic, device diversity in training set + - [technical] Data requirements for 87% to 95% — diminishing returns curve, likely needs 5-10x more data + - [business] Competitor timeline and first-mover advantage in AI diagnostics + - [legal] Liability and malpractice implications — who is responsible when AI-assisted diagnosis is wrong? + +**2-cross** missed (1): + - [technical] Data requirements for 87% to 95% — diminishing returns curve, likely needs 5-10x more data + +### Trap Detection Details + +**1-codex:** + - MISSED: Claiming 87% is insufficient without comparing to standard of care — the benchmark is average radiologist, not perfection + - MISSED: Advocating 'ship now, improve later' without acknowledging that medical device modifications require new regulatory submissions (not a software update) + - MISSED: Assuming 87% to 95% is a simple training improvement without addressing the exponential data requirements and diminishing returns + +**2-codex:** + - CAUGHT: Claiming 87% is insufficient without comparing to standard of care — the benchmark is average radiologist, not perfection + - MISSED: Advocating 'ship now, improve later' without acknowledging that medical device modifications require new regulatory submissions (not a software update) + - MISSED: Assuming 87% to 95% is a simple training improvement without addressing the exponential data requirements and diminishing returns + +**3-codex:** + - CAUGHT: Claiming 87% is insufficient without comparing to standard of care — the benchmark is average radiologist, not perfection + - MISSED: Advocating 'ship now, improve later' without acknowledging that medical device modifications require new regulatory submissions (not a software update) + - MISSED: Assuming 87% to 95% is a simple training improvement without addressing the exponential data requirements and diminishing returns + +**5-codex:** + - CAUGHT: Claiming 87% is insufficient without comparing to standard of care — the benchmark is average radiologist, not perfection + - MISSED: Advocating 'ship now, improve later' without acknowledging that medical device modifications require new regulatory submissions (not a software update) + - MISSED: Assuming 87% to 95% is a simple training improvement without addressing the exponential data requirements and diminishing returns + +**2-cross:** + - CAUGHT: Claiming 87% is insufficient without comparing to standard of care — the benchmark is average radiologist, not perfection + - CAUGHT: Advocating 'ship now, improve later' without acknowledging that medical device modifications require new regulatory submissions (not a software update) + - MISSED: Assuming 87% to 95% is a simple training improvement without addressing the exponential data requirements and diminishing returns + +## monorepo-migration +**Topic:** A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo? + +| Metric | 1-codex | 2-codex | 3-codex | 5-codex | 2-cross | +|--------|------|------|------|------|------| +| **Checklist Coverage (raw)** | 100% (14/14) | 100% (14/14) | 100% (14/14) | 100% (14/14) | 100% (14/14) | +| **Checklist Coverage (weighted)** | 100% | 100% | 100% | 100% | 100% | +| **Traps Caught** | 2/2 (100%) | 1/2 (50%) | 1/2 (50%) | 2/2 (100%) | 2/2 (100%) | +| **Duration** | 0s | 0s | 0s | 0s | 0s | +| **Output Tokens (est.)** | ~2113 | ~6182 | ~6425 | ~13133 | ~7243 | + +### Missed Checklist Items + +### Trap Detection Details + +**1-codex:** + - CAUGHT: Arguing 'Google/Meta use monorepo therefore we should' without acknowledging they built $10M+ custom tooling (Bazel, Buck, Piper) + - CAUGHT: Claiming monorepo is simpler without addressing CI blast radius, merge contention, and the migration itself + +**2-codex:** + - MISSED: Arguing 'Google/Meta use monorepo therefore we should' without acknowledging they built $10M+ custom tooling (Bazel, Buck, Piper) + - CAUGHT: Claiming monorepo is simpler without addressing CI blast radius, merge contention, and the migration itself + +**3-codex:** + - MISSED: Arguing 'Google/Meta use monorepo therefore we should' without acknowledging they built $10M+ custom tooling (Bazel, Buck, Piper) + - CAUGHT: Claiming monorepo is simpler without addressing CI blast radius, merge contention, and the migration itself + +**5-codex:** + - CAUGHT: Arguing 'Google/Meta use monorepo therefore we should' without acknowledging they built $10M+ custom tooling (Bazel, Buck, Piper) + - CAUGHT: Claiming monorepo is simpler without addressing CI blast radius, merge contention, and the migration itself + +**2-cross:** + - CAUGHT: Arguing 'Google/Meta use monorepo therefore we should' without acknowledging they built $10M+ custom tooling (Bazel, Buck, Piper) + - CAUGHT: Claiming monorepo is simpler without addressing CI blast radius, merge contention, and the migration itself + + +## Pairwise Comparisons (Blind) + +### fintech-payments + +**1-codex vs 2-codex**: Winner = **2-codex** + 1-codex: total=45, 2-codex: total=51 + Reason: A's adversarial research phase surfaced richer evidence (Adyen optimization data, Shopify precedent, Fed Reserve interchange specifics) and produced a more nuanced conditional decision framework, while B duplicated its recommendation section and offered fewer non-obvious insights. + +**1-codex vs 3-codex**: Winner = **3-codex** + 1-codex: total=46, 3-codex: total=54 + Reason: Analysis A surfaces more novel concepts (migratable GMV, non-regret investments, Stripe's own roadmap as evidence), delivers a significantly more actionable phased recommendation with explicit phase-gates, and resolves trade-offs with greater transparency through its structured contention table. + +**1-codex vs 5-codex**: Winner = **5-codex** + 1-codex: total=41, 5-codex: total=53 + Reason: Analysis A explores more angles with greater depth (auth-rate revenue lever, PCI level thresholds by AOV, control-plane vs processor distinction), delivers a more actionable recommendation with explicit go/no-go gates, and surfaces non-obvious insights that Analysis B's single-pass treatment misses. + +**1-codex vs 2-cross**: Winner = **2-cross** + 1-codex: total=49, 2-cross: total=53 + Reason: B surfaces more non-obvious insights (timing asymmetry, shadow processor risk, feature-surface lock-in as load-bearing), delivers a more actionable recommendation with time-boxed gates, and its contention-resolution format produces richer trade-off analysis showing how positions evolved. + +**2-codex vs 3-codex**: Winner = **3-codex** + 2-codex: total=49, 3-codex: total=53 + Reason: B edges ahead with the novel 'migratable GMV' analytical frame, a more actionable 60-90 day phased recommendation with explicit gates, FinCEN regulatory depth A lacks, and sharper trade-off articulation throughout. + +**2-codex vs 5-codex**: Winner = **5-codex** + 2-codex: total=47, 5-codex: total=54 + Reason: Analysis B adds meaningfully broader coverage (user-experience risk, implementation feasibility, regulatory nuance, PAN export switching costs) and delivers a more actionable recommendation with explicit quantitative gates (75-100 bps threshold, 60-90 day timeline, zero-tolerance user metrics), while A reaches a sound conclusion but with less specificity and fewer non-obvious angles. + +**2-codex vs 2-cross**: Winner = **2-cross** + 2-codex: total=50, 2-cross: total=52 + Reason: B delivers a more actionable time-boxed recommendation, resolves more trade-offs explicitly in its 5-item contention table, and assigns a more honest 'Medium' confidence rating given the acknowledged unknowns, while A's 'High' confidence contradicts its own list of significant unresolved items. + +**3-codex vs 5-codex**: Winner = **5-codex** + 3-codex: total=47, 5-codex: total=53 + Reason: Analysis B covers more decision-relevant angles (UX/conversion risk, implementation prerequisites like PAN export and VisaNet pre-approval, AOV-dependent PCI thresholds) and delivers a sharper recommendation with explicit go/no-go thresholds and a clearer articulation of what is being traded away. + +**3-codex vs 2-cross**: Winner = **2-cross** + 3-codex: total=49, 2-cross: total=51 + Reason: A's debate resolution showed deeper intellectual engagement with explicit position shifts and more honest uncertainty handling, while B offered a more actionable recommendation with novel frameworks like 'migratable GMV' and 'non-regret investments'. + +**5-codex vs 2-cross**: Winner = **5-codex** + 5-codex: total=53, 2-cross: total=47 + Reason: B surfaced genuinely distinct dimensions—authorization revenue lift, user-facing risk quantification, and the control-plane vs processor-of-record distinction—that A missed entirely, and delivered a more actionable recommendation with explicit go/no-go thresholds and a named sacrifice. + +### healthcare-ai-deploy + +**1-codex vs 2-codex**: Winner = **2-codex** + 1-codex: total=43, 2-codex: total=53 + Reason: Analysis A surfaces more non-obvious insights (abstention policies, ungradable-image prevalence, real-world screening adherence data, selective prediction), delivers a sharper actionable recommendation (90-120 day validation sprint with explicit go/no-go gates), and its adversarial debate structure forces genuine contention resolution that produces a more nuanced and credible consensus than B's competent but comparatively surface-level single-pass treatment. + +**1-codex vs 3-codex**: Winner = **3-codex** + 1-codex: total=47, 3-codex: total=53 + Reason: Analysis A surfaces more non-obvious evidence (workflow speed → follow-up rates, PPV collapse in practice, cost-effectiveness ≠ accuracy), delivers a more actionable recommendation with explicit go/no-go study gates, and resolves competing perspectives with greater sophistication through its contention table. + +**1-codex vs 5-codex**: Winner = **5-codex** + 1-codex: total=41, 5-codex: total=53 + Reason: Analysis A covers more angles with greater depth, surfaces non-obvious insights like HITL destroying unit economics and real-world gradability failures, and delivers a more nuanced recommendation with explicit go/no-go gates, while B reaches a similar conclusion with less specificity and a duplicated recommendation section. + +**1-codex vs 2-cross**: Winner = **2-cross** + 1-codex: total=41, 2-cross: total=53 + Reason: Analysis A's adversarial debate surfaced non-obvious insights (underserved-setting narrowing, automation bias research, screening-funnel vs model-accuracy distinction), synthesized a specific actionable middle path with concrete study design and site counts, and demonstrated genuine intellectual tension and resolution rather than listing trade-offs at a single level of abstraction. + +**2-codex vs 3-codex**: Winner = **3-codex** + 2-codex: total=51, 3-codex: total=53 + Reason: Analysis B edges ahead with more honest confidence calibration (Medium vs High given unknown model metrics), clearer trade-off attribution in its contention table, and a sharper escalation-risk warning, despite both analyses reaching nearly identical substantive conclusions. + +**2-codex vs 5-codex**: Winner = **5-codex** + 2-codex: total=49, 5-codex: total=53 + Reason: Analysis A covers more angles with richer evidence (implementation timelines, user trust, multiple cleared-device comparisons, real-world gradability data) and its four-perspective structure surfaces more nuanced trade-offs, though both reach similarly sound conclusions. + +**2-codex vs 2-cross**: Winner = **2-cross** + 2-codex: total=46, 2-cross: total=53 + Reason: B delivers a far more actionable recommendation—specific study design (800 patients, 4 FQHC sites), narrowed deployment setting resolving the competitive gap, unit economics, and non-dilutive funding strategy—while also surfacing deeper non-obvious insights like AI overreliance effects (11.3pp accuracy drop) and PPV-driven referral burden analysis. + +**3-codex vs 5-codex**: Winner = **5-codex** + 3-codex: total=46, 5-codex: total=53 + Reason: Analysis A covers substantially more ground via four specialized perspectives (domain expert and user advocate angles are absent from B), surfaces more non-obvious insights like reimbursement precedent and implementation timelines, and delivers a more actionable recommendation with explicit go/no-go gates. + +**3-codex vs 2-cross**: Winner = **2-cross** + 3-codex: total=48, 2-cross: total=53 + Reason: Analysis A delivers a significantly more actionable recommendation (specific study size, sites, timeline, unit economics, funding strategy) while matching B's nuance and exceeding it in depth on regulatory and competitive specifics. + +**5-codex vs 2-cross**: Winner = **5-codex** + 5-codex: total=53, 2-cross: total=47 + Reason: Analysis B's domain expert and user advocate perspectives surfaced critical dimensions—implementation logistics, patient follow-up economics, ungradable-rate realities, and the sharp insight that HITL can degrade into expensive tele-ophthalmology—that materially strengthened both the reasoning and the actionability of an otherwise similar strategic conclusion. + +### monorepo-migration + +**1-codex vs 2-codex**: Winner = **2-codex** + 1-codex: total=45, 2-codex: total=52 + Reason: B surfaces sharper empirical evidence (Google ICSE stats, Wix/dotNET specifics), a more novel change-type classification framework, and a more actionable recommendation with explicit success criteria and reversibility gates. + +**1-codex vs 3-codex**: Winner = **3-codex** + 1-codex: total=43, 3-codex: total=51 + Reason: B surfaces the critical build-time vs runtime coupling distinction, brings richer real-world migration evidence (Wix resource scaling, DigitalOcean), treats copy-pasted code as potential real divergence rather than pure waste, and delivers a more specific and falsifiable recommendation with explicit pilot scope and success criteria. + +**1-codex vs 5-codex**: Winner = **5-codex** + 1-codex: total=43, 5-codex: total=52 + Reason: B surfaces sharper non-obvious insights (atomic source != atomic release, architecture-vs-repo framing), backs claims with concrete case-study outcomes (DigitalOcean, Airbnb, Shopify), and delivers a more actionable recommendation with explicit pilot entry gates and measurement criteria, while A duplicates its recommendation section and stays closer to standard consulting territory. + +**1-codex vs 2-cross**: Winner = **2-cross** + 1-codex: total=46, 2-cross: total=52 + Reason: B's adversarial structure surfaces stronger counterarguments (code clone defect rates, untuned monorepo failure mode, lockstep dependency blast radius) and produces a more actionable recommendation with concrete prerequisites, timeline, exclusion criteria, and pilot success metrics, while A duplicates its recommendation section and lacks specific sequencing or gates. + +**2-codex vs 3-codex**: Winner = **3-codex** + 2-codex: total=47, 3-codex: total=52 + Reason: B edges ahead with sharper non-obvious distinctions (build-time vs runtime coupling, copy-paste as real divergence), a richer 5-point contention table with stronger attribution, more concrete case studies (DigitalOcean, PayFit, Caseware), and a more actionable recommendation with explicit fallback paths. + +**2-codex vs 5-codex**: Winner = **5-codex** + 2-codex: total=41, 5-codex: total=52 + Reason: B covers more angles (migration mechanics, DX, success metrics), surfaces sharper frameworks ('co-change density × toolchain heterogeneity', 'atomic source control ≠ atomic release'), and delivers a more actionable recommendation with concrete entry gates and measurable success criteria. + +**2-codex vs 2-cross**: Winner = **2-codex** + 2-codex: total=52, 2-cross: total=45 + Reason: A provides more rigorous cited evidence (Google ICSE stats, Wix specifics, .NET timeline), more honest confidence calibration (Medium vs B's arguably overconfident High), and deeper nuance — B's advocate makes unsupported claims (Stripe metrics, 15-25% time estimate) that weaken credibility. + +**3-codex vs 5-codex**: Winner = **5-codex** + 3-codex: total=47, 5-codex: total=53 + Reason: Analysis A covers more angles (implementation mechanics, developer experience, release management) with sharper novel insights ('atomic source control is not atomic release', co-change density framing) and a more actionable recommendation with specific entry gates and measurement criteria. + +**3-codex vs 2-cross**: Winner = **3-codex** + 3-codex: total=53, 2-cross: total=46 + Reason: B surfaces the critical build-time vs runtime coupling distinction, grounds claims in more concrete migration case studies (Wix resource scaling, DigitalOcean specifics), calibrates confidence more honestly (Medium vs High given unknowns), and delivers a more appropriately scoped recommendation for an org whose coupling graph and platform capacity are unverified. + +**5-codex vs 2-cross**: Winner = **5-codex** + 5-codex: total=53, 2-cross: total=41 + Reason: Analysis A delivers deeper implementation detail from four distinct perspectives, surfaces sharper non-obvious insights like 'atomic source control is not atomic release,' and arrives at a more carefully scoped domain-monorepo pilot recommendation with explicit entry gates and measurement criteria, whereas Analysis B's advocate relies on unsourced claims and the consensus over-indexes toward aggressive consolidation. + + +## Aggregate Summary + +| Config | Avg Coverage (weighted) | Avg Traps Caught | Avg Duration | +|--------|----------------------|-----------------|-------------| +| 1-codex | 90% | 67% | 0s | +| 2-codex | 95% | 61% | 0s | +| 3-codex | 97% | 61% | 0s | +| 5-codex | 92% | 78% | 0s | +| 2-cross | 97% | 89% | 0s | \ No newline at end of file diff --git a/tests/eval-results/full-matrix-2026-04-01/fintech-payments__1-codex.md b/tests/eval-results/full-matrix-2026-04-01/fintech-payments__1-codex.md new file mode 100644 index 0000000..746ab5d --- /dev/null +++ b/tests/eval-results/full-matrix-2026-04-01/fintech-payments__1-codex.md @@ -0,0 +1,49 @@ +--- +topic: "Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months." +mode: "single-agent" +agent_count: "1" +agent_cli: "codex" +status: "consensus" +created: "2026-04-01T08:55:12.286Z" +--- + +# Discussion: Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months. + +## Single Agent Analysis + +# Analysis: Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months. + +## Research +At today’s scale, the economics usually do **not** support building a true in-house processor. Your current Stripe spend implies an effective cost of about **3.0% of volume** ($1.5M / $50M). If mix and pricing stay similar, 3x volume means roughly **$4.5M/year** in Stripe fees at $150M GMV. The important question is not “can we remove Stripe?” but “how much of that 3.0% is actually replaceable?” In practice, an internal build does **not** eliminate interchange, network assessments, sponsor-bank/acquirer fees, fraud tooling, dispute ops, reconciliation, compliance, or uptime obligations. It mainly replaces Stripe’s software margin and managed-service bundle. + +A realistic in-house option for a Series A company is not “become Visa/Mastercard infrastructure”; it is “build routing, vaulting, reconciliation, and processor integrations while still relying on sponsor-bank/acquirer rails.” I would model the non-Stripe variable cost floor for card-heavy CNP volume at roughly **2.1%-2.4%** of GMV, with **fixed annual platform cost of ~$2M-$4M** once you include a 4-6 engineer team, a senior payments lead, security/compliance/legal support, audits, cloud/HSM/logging, incident response, and payment ops. On that model, in-house TCO is roughly **$3.0M-$5.2M today** and **$5.2M-$7.6M at $150M GMV**. Even a strong outcome where you save **80 bps** versus Stripe only yields about **$400k/year now** and **$1.2M/year later**; that still does not cover the fixed cost of a credible internal platform. Break-even is more likely in the **$250M-$600M+** annual volume range, depending on mix and execution quality. + +Compliance is the second reason not to do this now. Stripe is a **PCI Level 1 service provider**, and Stripe-hosted/Stripe-rendered payment patterns can keep merchants in lighter PCI scope such as **SAQ A** or **A-EP**, depending on implementation. If you take custody of PANs or build your own vault/processor, scope jumps materially; PCI SSC is explicit that **service providers assess under SAQ D for Service Providers**, and banks/acquirers often want QSA-led evidence. Internationally, this compounds fast: **EEA/UK** payments must satisfy **PSD2/SCA** rules; **India** requires RBI authorization for payment aggregators; **Singapore** treats merchant acquisition as a licensed payment service; in the **US**, the FinCEN payment-processor exemption is narrow and fact-specific, with separate state money-transmitter analysis if you receive/transmit funds for others. If you are only the merchant for your own sales, licensing burden is lower; if you hold or settle funds for third parties, it rises sharply. + +The best path is usually hybrid. Stripe already supports **custom/IC+ pricing**, **Vault and Forward**, **Payment Element across multiple processors**, and **Orchestration**. That lets you keep Stripe as the PCI vault and checkout layer while selectively adding lower-cost rails, second processors, or internal routing logic. That is a 1-3 FTE program. A full in-house processor is a 5-6+ engineer, 18-month diversion, which is roughly **25-30% of total engineering capacity** for this company. Those engineers are more valuable building differentiated assets: underwriting/risk models, merchant onboarding/KYB, reconciliation automation, ACH/local-bank adoption, payout speed, pricing, and dispute reduction. + +Primary references: [Stripe pricing](https://stripe.com/us/pricing), [Stripe security/PCI](https://docs.stripe.com/security/stripe), [Stripe integration security](https://docs.stripe.com/security/guide), [Stripe Elements](https://docs.stripe.com/payments/elements), [Vault and Forward](https://docs.stripe.com/payments/vault-and-forward), [PCI SSC SAQ A FAQ](https://www.pcisecuritystandards.org/faq/articles/Frequently_Asked_Question/How-do-PCI-DSS-Requirements-2-6-and-8-apply-to-SAQ-A-merchants/), [PCI SSC outsourcing FAQ](https://www.pcisecuritystandards.org/faq/articles/Frequently_Asked_Question/does-pci-dss-apply-to-merchants-who-outsource-all-payment-processing-operations-and-never-store-process-or-transmit-cardholder-data/?_hsmi=364054903), [PCI SSC service-provider FAQ](https://www.pcisecuritystandards.org/faq/articles/Frequently_Asked_Question/can-service-providers-use-eligibility-criteria-from-a-merchant-self-assessment-questionnaire-saq-to-determine-applicable-pci-dss-requirements-for-the-service-providers-assessment/), [FinCEN payment processor exemption](https://www.fincen.gov/resources/statutes-regulations/administrative-rulings/application-money-services-business), [EU PSD2](https://finance.ec.europa.eu/regulation-and-supervision/financial-services-legislation/implementing-and-delegated-acts/payment-services-directive_en), [FCA payments guidance](https://www.fca.org.uk/firms/emi-payment-institutions-key-publications), [RBI PA guidelines](https://www.rbi.org.in/scripts/FS_Notification.aspx?Id=11822), [MAS licensing examples](https://eservices.mas.gov.sg/fid/institution/detail/430099-CODA-PAYMENTS-PTE-LTD), [NY DFS money transmitter licensing](https://www.dfs.ny.gov/apps_and_licensing/money_transmitters). + +## Recommendation + +### Decision +Do **not** build a full payment-processing stack now. Stay on Stripe for the next 18-24 months, but run a deliberate **hybrid cost-reduction program**: negotiate custom/IC+ pricing, shift eligible flows to cheaper rails, and only add a second processor where the unit economics are proven while keeping Stripe as the PCI vault and checkout layer. + +### Key Trade-offs +| # | Trade-off | How You Weighed It | +|---|-----------|-------------------| +| 1 | Fee savings vs fixed platform cost | The replaceable portion of Stripe’s fee is smaller than it looks; at $50M-$150M GMV, fixed internal payments-platform cost likely overwhelms gross savings. | +| 2 | Control vs compliance burden | In-house control buys routing flexibility, but it materially expands PCI scope and can trigger licensing/regulatory work by country. | +| 3 | Custom optimization vs global coverage | Stripe bundles SCA, mandates, payment methods, disputes, and country coverage; rebuilding that globally is slow and expensive. | +| 4 | Strategic moat vs commoditized plumbing | Unless payments infrastructure itself is the product moat, the startup should invest engineers in differentiated fintech capabilities instead. | +| 5 | Vendor dependence vs phased leverage | A hybrid approach reduces Stripe concentration risk without taking full PAN custody or full regulatory ownership. | + +### Risks & Uncertainties +- The exact answer depends on card mix, AOV, debit vs credit, domestic vs international share, and dispute/fraud rate. +- It is unclear whether the $1.5M includes only Stripe Payments or also Billing/Tax/Connect-related charges. +- If the company is already becoming a payfac/MoR or already has deep payments/compliance leadership, the build case strengthens somewhat. +- Stripe enterprise pricing could reduce the baseline materially without any architectural change. +- International growth plans matter: the more countries and payment methods involved, the stronger the case for staying primarily on Stripe. + +### Confidence: Medium +The directional recommendation is strong, but the exact break-even point depends on transaction mix, geography, and how much of today’s Stripe bill is truly replaceable rather than just shifted into other processing and compliance costs. diff --git a/tests/eval-results/full-matrix-2026-04-01/fintech-payments__2-codex.md b/tests/eval-results/full-matrix-2026-04-01/fintech-payments__2-codex.md new file mode 100644 index 0000000..9de8358 --- /dev/null +++ b/tests/eval-results/full-matrix-2026-04-01/fintech-payments__2-codex.md @@ -0,0 +1,174 @@ +--- +topic: "Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months." +mode: "council" +agent_count: "2" +agent_config: "2-agent" +max_rounds: "5" +git_commit: "none" +agent_cli: "codex" +status: consensus +turn: B +round: 3 +created: "2026-04-01T08:55:12.288Z" +last_updated: 2026-04-01T09:04:53.992Z +agent_A_name: "Advocate" +agent_A_cli: "codex" +agent_A_role: "advocate" +agent_B_name: "Skeptic" +agent_B_cli: "codex" +agent_B_role: "skeptic" +--- + +# Discussion: Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months. + +## Participants +- **Agent A** — Advocate (advocate) via codex +- **Agent B** — Skeptic (skeptic) via codex + +## Key Questions +1. What is the true total cost of ownership for in-house payment processing vs Stripe at current and projected volumes? +2. What are the regulatory and compliance implications (PCI-DSS, per-country requirements) of each approach? +3. Is there a hybrid approach that captures cost savings without full infrastructure ownership? +4. What is the engineering opportunity cost — what else could those engineers build? + +## Research Phase + +### Agent A (Advocate) — Independent Research | research + +The strongest upside case for building is that payments is about to become too large a margin line to leave as a bundled black box. On the numbers given, the company is paying an effective ~3.0% of volume today ($1.5M on $50M). If volume reaches $150M in 18 months and fee economics do not improve, that becomes roughly $4.5M/year. Stripe’s own pricing shows standard U.S. card pricing at `2.9% + 30¢`, while larger merchants can move to custom structures including IC+ pricing, volume discounts, and even Stripe’s “Vault and Forward API” to route payments to other processors while keeping card vaulting in place (https://stripe.com/us/pricing). That is important evidence: the market already assumes sophisticated merchants will unbundle payments over time. A phased build is not exotic; it is a normal maturity path. + +There is also a clear economic gap to attack. The Nilson Report said U.S. merchants paid a weighted average of `1.57%` in card-processing fees in 2024 (https://www.globenewswire.com/news-release/2025/03/19/3045828/0/en/Merchant-Processing-Fees-in-the-United-States-Exceeded-187-Billion-in-2024.html). The Federal Reserve’s 2024 debit data shows average covered debit interchange around `0.47%` across all networks and `0.44%` for covered Visa debit transactions, with all-network debit at `0.73%` of average ticket value (https://www.federalreserve.gov/paymentsystems/regii-average-interchange-fee.htm). Those are not apples-to-apples with every fintech flow, but they do show a basic truth: not all of a 3% effective bill is irreducible network cost. There is real markup, routing, and mix optimization value sitting on the table. If the company can reclaim even `50–150 bps` on selected volume over time, that is roughly `$750k–$2.25M` of annual gross-profit improvement at `$150M` volume. + +The opportunity is not just cheaper processing. It is a better payments engine. Adyen’s published cost-optimization data shows what can happen when payments becomes a first-class capability: `26%` lower payment cost from intelligent routing on U.S. debit, `49%` average savings from local payment methods versus cards, `6%` higher authorization rates from network tokens, and `16.5%` lower standard payment fees from enhanced scheme data; Adyen also cites FlixBus reducing U.S. bank declines by `21%` through local acquiring (https://www.adyen.com/landing/save-cost-on-payments). That is the upside scenario here: more approvals, fewer false declines, lower network fees, and more control over retries, fraud rules, and settlement behavior. Payments stops being a tax and becomes an optimization surface. + +There are also success-case precedents for turning payments into a moat. Shopify’s Q3 2025 filing says Shopify Payments generated `$518M` of quarterly revenue, with `65%` penetration and `$60.2B` of GMV processed in that quarter alone (https://www.sec.gov/Archives/edgar/data/1594805/000159480525000089/shop-20250930.htm). The lesson is not “be Shopify.” It is that once a company owns the payments control plane, payments can drive retention, monetization, product expansion, and pricing power. Even Stripe’s own Authorization Boost markets payments optimization as economically material, claiming `2.2%` higher acceptance on average and up to `2.8%` lower processing costs on custom IC+ pricing (https://stripe.com/authorization-boost). That reinforces the advocate view: optimization is worth real money. + +The main uncertainty is scope. This only works if “build” means owning the control plane first: routing, ledgering, reconciliation, token strategy, payment-method mix, and processor abstraction, while continuing to rent regulated edges where necessary. It does not require becoming Visa. But if the company waits until it is already at $150M volume, it will pay the same learning-curve cost at 3x the transaction scale. The upside case is that now is exactly the right time to start. + +### Agent B (Skeptic) — Independent Research | research + +At face value, $1.5M/year in Stripe fees on $50M of volume makes “build our own” sound inevitable. The skeptical view is that this framing is usually wrong: it treats the whole fee stack as recoverable engineering margin when a large share is not. Stripe’s public pricing says large-volume businesses can get [custom packages with IC+ pricing and volume discounts](https://stripe.com/pricing), and Stripe’s own interchange explainer says [interchange is typically 70% to 90% of card processing fees](https://stripe.com/us/resources/more/interchange-fees-101-what-they-are-how-they-work-and-how-to-cut-costs). If that range is even directionally right here, the truly addressable savings pool is not the full $1.5M today or $4.5M at 3x growth; it is roughly 10% to 30% of that. That implies maybe ~$150k-$450k/year now, and ~$450k-$1.35M/year at 3x volume, before adding new costs. Also, their observed 3.0% effective fee does not tell us the payment mix or transaction count; that uncertainty matters a lot, because the economics differ sharply between mostly-US cards, ACH-heavy flows, international cards, marketplaces, and stored credentials. + +The biggest downside scenario is that they accidentally promote themselves from “merchant using Stripe” to “payment infrastructure provider” without staffing, controls, or licenses to match. PCI SSC says SAQ A is only available when the payment page elements come entirely from the validated third party, while direct-post flows expand scope to [SAQ A-EP](https://www.pcisecuritystandards.org/faqs/1291/) and even embedded payment pages now carry [script-attack obligations](https://www.pcisecuritystandards.org/faqs/1588/). Visa states that [PCI DSS applies to any entity that stores, processes, or transmits cardholder data](https://corporate.visa.com/en/resources/security-compliance.html). Mastercard says [all third-party processors and merchant payment gateways are Level 1 service providers](https://www.mastercard.us/en-us/business/overview/safety-and-security/security-recommendations/site-data-protection-PCI/service-providers-need-to-know.html), and Visa’s service-provider guidance says providers above [300,000 Visa transactions/year need annual on-site validation, with non-compliance assessments starting at $10,000](https://usa.visa.com/content/dam/VCOM/download/business/resources-and-tools/DataSecurityComplianceServiceProviders.pdf). That is not an engineering side quest; it is a permanent compliance program. + +If they are a platform/payfac/marketplace, the risk multiplies. Stripe Connect currently handles [localized onboarding, document collection, identity verification, international bank accounts, and remediation flows](https://docs.stripe.com/connect/embedded-onboarding); Stripe’s docs explicitly note that missed verification requirements can [disable charges and payouts](https://docs.stripe.com/connect/embedded-onboarding). Stripe also supports [1099 delivery workflows](https://docs.stripe.com/connect/platform-embedded-taxes-walkthrough). Replacing that means building not just APIs, but compliance operations, support playbooks, risk review, and incident response. + +The second failure mode is that the spreadsheet understates revenue risk. Stripe includes fraud tooling, 3DS, network-token support, retry logic, and acceptance optimization. Stripe claims [Authorization Boost increases accepted payment volume by 2.2% on average](https://stripe.com/us/authorization). I would not take that as neutral truth, but it proves the sensitivity: a modest drop in auth rate, slightly worse fraud controls, slower dispute handling, or poorer retries can erase the processor-margin savings. One reconciliation bug, payout-delay issue, or acquiring outage can hit cash flow and customer trust at the same time. + +The downside of staying on Stripe is mostly margin pressure and concentration risk, but those are easier to hedge than rebuilding the stack. A more skeptical, lower-regret path is: exhaust [custom pricing / IC+](https://stripe.com/pricing), shift eligible volume to cheaper rails like [ACH (0.8%, capped at $5)](https://stripe.com/pricing), and add optionality through Stripe’s [Vault and Forward API](https://docs.stripe.com/payments/vault-and-forward) or [Orchestration](https://docs.stripe.com/payments/orchestration/route-payments) before attempting full replacement. My bottom line: for a Series A company with 20 engineers, “build our own processor” is most likely an expensive distraction unless their payment flows are unusually simple and they already have experienced payments, fraud, and compliance operators in-house. + +--- + +## Discussion + +### Round 1 — Advocate | response | confidence: 78% + +**Response to previous points:** +Skeptic’s strongest point is that the real choice is not “pay Stripe fees” versus “replace all of Stripe.” The hardest part of the fee stack is mostly interchange and scheme cost, and the moment this startup takes on card data, payfac-like responsibilities, or Connect-style onboarding, the problem becomes compliance operations, not just engineering. I agree with that. + +Where I disagree is the implied conclusion that this means “stay on Stripe” in the current shape. My synthesis is: do not build a full processor, but do start building a payments control plane now. If the recoverable pool is only ~10% to 30% of fees, that still becomes roughly $450k to $1.35M/year at projected volume, before counting approval-rate gains, routing leverage, and reduced concentration risk. For a Series A company, that is too much value to ignore, but not enough to justify rebuilding Stripe Connect, PCI Level 1 scope, and global compliance from scratch. + +So the likely right answer is a staged hybrid: +1. Negotiate Stripe custom/IC+ pricing immediately. +2. Shift eligible flows to cheaper rails like ACH/local methods. +3. Build an internal abstraction for routing, ledgering, reconciliation, and processor portability. +4. Keep regulated edges outsourced unless a later stage proves the economics justify insourcing them. + +**New evidence or angle:** +The missing angle is timing risk. Waiting until volume is already 3x larger makes migration harder, not easier, because card vaulting, merchant/account migration, reconciliation dependencies, and product coupling all get more entrenched with scale. That means “do nothing for 18 months” is also an active choice with switching-cost consequences. The real timing question is not “build now or never,” but “when do we invest in optionality?” My answer is: now, but narrowly. + +**Current position:** +I favor continuing to use Stripe for core processing in the near term, while investing immediately in a hybrid architecture that creates negotiating leverage and future routing flexibility. Confidence is 78% because Skeptic is right that full-stack insourcing is probably a trap at this stage, but the projected fee growth is large enough that pure passivity is also wrong. + +**Key question for the group:** +What portion of current and projected volume is actually eligible for lower-cost alternatives without taking on major new compliance scope: domestic debit, ACH, recurring card-on-file, or platform/Connect flows? + +### Round 1 — Skeptic | response | confidence: 74% + +**Response to previous points:** +Agent A’s strongest argument is the timing one: optionality gets more expensive as volume, vault lock-in, and operational coupling grow, so “wait and see” is not neutral. I agree with that, and I’ve shifted a bit toward A’s hybrid path. + +Where I still disagree is on what “build the control plane now” should include. Routing portability is defensible; building internal ledgering, reconciliation, and a processor abstraction too early may be an expensive abstraction tax if they do not yet know their true savings pool by rail, geography, and payment type. Agent A is right that $450k-$1.35M/year of recoverable savings at projected scale is material. But that is gross upside, not net. A small payments-platform team plus compliance/ops overhead can consume that quickly, and one auth-rate regression or reconciliation incident can erase a year of savings. So my synthesis is narrower than A’s: negotiate Stripe hard, push ACH/local rails, and use Stripe-hosted portability features first; only build owned control-plane components after the company proves, with actual mix data, that a specific slice of volume is both large and operationally simple enough to justify it. + +**New evidence or angle:** +The missing angle is organizational maturity risk. A 20-engineer Series A company does not just need code to unbundle payments; it needs sustained operational ownership for disputes, settlements, exceptions, outages, and audit evidence. The hidden cost is not just PCI scope, it is management bandwidth. Even a “hybrid” approach can fail if it creates a second payments stack before the first one is economically exhausted. + +**Current position:** +Continue using Stripe as the primary processor, but pursue a staged hedge immediately: custom pricing, rail mix optimization, and Stripe-native portability before building meaningful in-house infrastructure. I’m at 74% because Agent A is persuasive that optionality should start now, but I still think the default failure mode is overbuilding before they quantify net savings and operational burden. + +**Key question for the group:** +What is the actual payment mix today and at 3x scale: percent of volume by card vs ACH, domestic debit vs credit, recurring vs one-time, cross-border vs domestic, and any Connect/platform flows? + +### Round 2 — Advocate | response | confidence: 76% + +**Response to previous points:** +Agent B’s strongest argument is that the real failure mode is not “engineering complexity” in the abstract; it is organizational self-deception. A 20-engineer Series A startup can easily build a second payments stack, inherit exceptions/settlements/compliance overhead, and discover too late that the net savings pool was too small or too operationally messy to justify it. I agree, and I’ve changed my view further in B’s direction: “build the control plane now” was too broad. + +My synthesis is narrower. Keep Stripe as the primary processor, but do not stay passive. Follow Agent B’s sequence first: push for custom/IC+ pricing, quantify payment mix precisely, and use Stripe-native portability where possible. Then build only the minimum viable option layer for one low-complexity lane, not a generalized internal payments platform. The key open questions are still the same and they matter more than abstract architecture: how much volume is domestic debit vs credit vs ACH, how much is recurring, and how much depends on Connect-style onboarding/payout/compliance flows. If the business is Connect-heavy or cross-border, the case for deep insourcing drops sharply. + +**New evidence or angle:** +The new angle is option value. A narrowly scoped portability project is not justified only by direct fee savings; it is justified because a credible outside option improves negotiating leverage before volume triples. They do not need to migrate most volume to benefit. If Stripe believes the company can route even one meaningful lane elsewhere, that alone can improve commercial terms. The mistake would be treating “buy leverage” as “rebuild payments.” + +**Current position:** +Continue using Stripe as the primary processor, but start a tightly scoped hybrid now: renegotiate pricing, optimize rail mix, and pilot portability on one simple, high-volume payment lane. Confidence is 76% because Agent B’s organizational-risk argument is strong, but waiting until 3x scale to create optionality likely increases both switching cost and dependency risk. + +**Key question for the group:** +What single payment lane will represent the largest share of projected volume while carrying the lowest new compliance/ops burden: domestic ACH, domestic debit, recurring card-on-file, or something else? + +### Round 2 — Skeptic | response | confidence: 79% + +**Response to previous points:** +Agent A’s strongest point is the option-value argument: they do not need to replace Stripe to justify action now; they only need enough portability to create commercial leverage and avoid deeper lock-in before volume triples. I agree, and that has shifted me further toward a hybrid path than I was in my research note. + +My disagreement is now mostly about gates and sequence, not direction. Agent A is right to narrow the scope to one simple lane, but I still think the default failure mode is starting the build before they have lane-level economics after a real Stripe renegotiation. The important open questions remain the same and they are decisive: what share of projected volume is ACH vs cards, domestic debit vs credit, recurring vs one-time, and how much of the business depends on Connect-style onboarding/payout/compliance? If the “clean” lane is small, cross-border, or operationally noisy, the pilot becomes an abstraction project with weak ROI. + +**New evidence or angle:** +The missing angle is break-even staffing math. The recoverable pool at 3x volume was framed earlier as roughly $450k-$1.35M/year. That sounds material until you price the minimum durable ownership: 2-3 strong payments engineers, plus meaningful product/finance/ops/compliance time, plus incident overhead. On fully loaded cost, the lower half of that savings range disappears quickly. So the bar should not be “can we save basis points?” It should be “is there one lane whose net savings, after Stripe custom pricing and expected auth/fraud/recon drag, clearly funds a small permanent team?” If not, they should buy leverage through negotiation and rail mix, not code. + +**Current position:** +Continue using Stripe as the primary processor, but prepare a tightly scoped hedge: renegotiate pricing now, quantify lane-level economics, and only then pilot portability on one lane if the post-renegotiation net upside is clearly above the ongoing ownership cost. I’m at 79% because Agent A’s timing argument is strong, but the evidence still points to overbuilding as the higher-probability mistake for a Series A team of this size. + +**Key question for the group:** +After Stripe custom pricing is on the table, which single payment lane still shows enough net annual savings at projected $150M volume to fund a permanent 2-3 person payments team without expanding PCI/compliance scope materially? + +### Round 3 — Advocate | response | confidence: 82% + +**Response to previous points:** +Skeptic’s strongest point is the break-even one: gross fee savings are the wrong metric. If a post-Stripe-repricing lane cannot comfortably fund a permanent 2-3 person payments team plus ops/compliance drag, then “building optionality” is just an abstraction tax. I agree, and I’ve changed my mind again because that is the real gate. Advocate’s earlier timing argument still matters, though: waiting is not neutral, because leverage and migration simplicity get worse as volume triples. My synthesis is: act now, but make the first act commercial and analytical, not architectural. The open questions should be answered in this order: payment mix by lane, Stripe’s real IC+/volume offer, whether the top lane avoids Connect/cross-border/expanded PCI scope, and whether its projected net savings still clear a hard ownership threshold. + +**New evidence or angle:** +The missing angle is decision design. This should be run as a 30-45 day real-options experiment with explicit kill criteria, not as a vague platform initiative. Ask Stripe for repricing, get 2 external processor quotes, build lane-level unit economics at projected $150M volume, and set a go/no-go bar upfront: one lane must show clear post-repricing net savings, no material PCI scope expansion, and a pilot small enough to unwind if auth/recon metrics regress. That preserves urgency without accidentally creating a second payments stack by inertia. + +**Current position:** +Keep Stripe as the primary processor, immediately run a repricing + lane-economics + external-benchmark process, and only pilot one low-scope lane if it still produces clearly positive net savings after fully loaded ownership cost. Confidence is 82% because Skeptic changed my view on sequencing, but I still think caution is overstating the value of passivity: the company should actively buy negotiating leverage now. + +**Key question for the group:** +After Stripe custom pricing and two external quotes, does the largest low-scope lane still show enough projected net annual savings at $150M volume to exceed a pre-agreed ownership threshold? + +**Convergence assessment:** CONVERGING — both agents now support Stripe as the primary processor plus an immediate, tightly scoped hedge; the remaining gap is sequencing, specifically whether any technical portability work should begin before post-repricing lane economics are proven. + +--- + +## Consensus Summary + +### Decision +The company should not build a full in-house payment processing stack now; it should keep Stripe as the primary processor. It should immediately run a tightly scoped hedge: negotiate Stripe custom/IC+ pricing, optimize rail mix, get external processor quotes, and model lane-level economics at projected scale. Only if one low-complexity lane still shows clear net savings above the cost of a permanent 2-3 person ownership team, without materially expanding PCI/compliance scope or harming auth/recon performance, should it pilot a narrow hybrid portability layer. + +### Key Contention Points + +| # | What We Disagreed On | How It Was Resolved | Who Shifted & Why | +|---|---------------------|--------------------|--------------------| +| 1 | Whether the startup should start building its own payments infrastructure now | Resolved in favor of staying on Stripe as the primary processor and rejecting a full in-house build at Series A scale | Agent A shifted substantially after Agent B’s arguments on PCI/compliance, operational burden, and the risk of rebuilding Stripe-like functionality too early | +| 2 | Whether “building optionality now” meant a broad internal control plane or something much narrower | Resolved toward a minimal, lane-specific hedge rather than a generalized routing/ledger/reconciliation platform | Both shifted: Agent A narrowed scope after the “abstraction tax” concern; Agent B accepted that some portability is valuable if tightly bounded | +| 3 | Whether the company should act now or wait until it has more scale/data | Resolved as “act now, but commercially and analytically first,” not architecturally first | Agent B shifted by accepting that waiting is not neutral because lock-in and switching costs rise with volume; Agent A shifted by accepting that pricing/mix proof must come before engineering build-out | +| 4 | Whether projected savings should be judged on gross Stripe fees or true net economics | Resolved in favor of a hard break-even test based on post-repricing lane economics minus staffing, ops, compliance, and performance risk | Agent A shifted after Agent B’s break-even staffing math showed that gross fee savings can disappear quickly once permanent ownership costs are included | + +### Unresolved Items & Risks +- The actual payment mix is still unknown: ACH vs card, debit vs credit, recurring vs one-time, domestic vs cross-border, and any Connect/platform exposure. +- Stripe’s real custom/IC+ offer and external processor quotes could shrink the savings pool enough to eliminate the case for any pilot. +- It is still unproven whether there is a single “clean” lane large enough to justify ownership without expanding PCI/compliance scope materially. +- A narrow pilot could still destroy value if authorization rates, fraud performance, reconciliation quality, or payout reliability regress. +- Even a successful pilot creates permanent operational ownership, so the threshold for proceeding must stay high and explicit. + +### Confidence: High +Both agents converged on the same practical answer, and the remaining uncertainty is mainly factual input data needed to decide whether any narrow pilot clears the agreed economic and compliance gates. diff --git a/tests/eval-results/full-matrix-2026-04-01/fintech-payments__2-cross.md b/tests/eval-results/full-matrix-2026-04-01/fintech-payments__2-cross.md new file mode 100644 index 0000000..59e58d4 --- /dev/null +++ b/tests/eval-results/full-matrix-2026-04-01/fintech-payments__2-cross.md @@ -0,0 +1,201 @@ +--- +topic: "Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months." +mode: "council" +agent_count: "2" +agent_config: "2-agent" +max_rounds: "5" +git_commit: "none" +agent_cli: "codex" +A: "claude" +B: "codex" +status: consensus +turn: B +round: 3 +created: "2026-04-01T09:27:27.811Z" +last_updated: 2026-04-01T09:33:13.309Z +agent_A_name: "Advocate" +agent_A_cli: "claude" +agent_A_role: "advocate" +agent_B_name: "Skeptic" +agent_B_cli: "codex" +agent_B_role: "skeptic" +--- + +# Discussion: Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months. + +## Participants +- **Agent A** — Advocate (advocate) via claude +- **Agent B** — Skeptic (skeptic) via codex + +## Key Questions +1. What is the true total cost of ownership for in-house payment processing vs Stripe at current and projected volumes? +2. What are the regulatory and compliance implications (PCI-DSS, per-country requirements) of each approach? +3. Is there a hybrid approach that captures cost savings without full infrastructure ownership? +4. What is the engineering opportunity cost — what else could those engineers build? + +## Research Phase + +### Agent A (Advocate) — Independent Research | research + +**The $4.5M/year question: why building is the rational move at this inflection point.** + +**The economics are already screaming.** At $50M/year, Stripe's ~3% effective rate costs $1.5M. At the projected $150M/year in 18 months, that's $4.5M annually — and it compounds from there. Companies like Adyen, which built proprietary processing, operate at 20-25 basis points per transaction. Even a conservative in-house build reaching 80-100 bps total cost (including ops, compliance, staff) against Stripe's ~300 bps produces **$2M-3M/year in savings at $150M volume**. That's not marginal — that's runway extension, that's headcount, that's a Series B narrative. + +**This is a well-trodden path with known playbooks.** Square built its own processing stack after starting on third-party rails. Shopify moved payment processing in-house through its acquisition of a processing license. Affirm, Marqeta, and Checkout.com all transitioned to owning more of the payment stack as volume justified it. The pattern is consistent: fintech companies that reach product-market fit and predictable volume migrate to owned infrastructure. The question isn't *if* but *when*, and $50M/year with 3x growth is precisely the inflection point where the math flips. + +**The strategic upside extends far beyond cost savings.** Owning the payment stack unlocks: +- **Pricing flexibility**: custom interchange optimization, surcharging strategies, and volume-based processor negotiations impossible through Stripe's abstraction layer +- **Data ownership**: raw transaction data, decline reason codes, and authorization patterns become first-party assets for fraud modeling, underwriting, and product development +- **Speed of iteration**: no dependency on Stripe's roadmap for features like multi-currency settlement, custom retry logic, or novel payment methods +- **Competitive moat**: proprietary processing becomes a defensible technical asset that increases enterprise value at exit or future fundraise + +**The talent market supports this move.** Payment infrastructure engineers are more available post-2023 layoffs at Stripe itself, Plaid, and other fintech infrastructure companies. A team of 3-4 dedicated payment engineers (realistic to hire within 6 months) can stand up a processing layer using existing acquiring bank APIs (Worldpay, First Data/Fiserv, Adyen as a processor) while maintaining Stripe as a fallback. You don't need to become Visa — you need to own the orchestration layer. + +**The risk of NOT building is underappreciated.** Stripe is a vendor dependency on your most critical business function. Rate changes, API deprecations, risk policy shifts, or account holds can materially impact the business with zero recourse. In 2022, Stripe raised prices for the first time — companies locked into the platform had no leverage. At $150M volume, this startup would be a mid-tier Stripe customer with limited negotiating power, not a strategic account. + +**Realistic timeline and phasing make this manageable.** A phased approach — (1) payment orchestration layer abstracting Stripe (3 months), (2) direct acquiring bank integration for high-volume transaction types (6 months), (3) progressive traffic migration (3-6 months) — means revenue never stops flowing through proven rails while new infrastructure is validated. The orchestration layer alone, even before replacing Stripe, delivers vendor optionality and multi-processor redundancy. + +**Key uncertainty acknowledged**: PCI DSS Level 1 compliance is real work — annual audits, penetration testing, network segmentation. Cost is $200K-500K/year. But at $4.5M in projected Stripe fees, compliance cost is a rounding error on the savings. + +The inertia argument — "Stripe just works" — is a comfort-zone bias masquerading as risk management. At this volume and growth rate, the riskier move is *not* building. + +### Agent B (Skeptic) — Independent Research | research + +The skeptical view is that a Series A company at $50M/year should assume “build our own processor” is a trap unless Stripe is blocking the business strategically, not just economically. The current fee load implies an effective rate of about 3.0% ($1.5M / $50M), which is close to Stripe’s standard US card pricing of 2.9% + 30c; Stripe also explicitly offers custom structures including IC+ and volume discounts for larger customers ([Stripe pricing](https://stripe.com/us/pricing)). Inference: the relevant savings case is not “eliminate $1.5M,” because interchange/network/acquirer costs do not disappear if you build. The real savings opportunity is only Stripe’s margin plus any tooling you can replace, and that may be far smaller than founders expect. At 3x volume, the gross fee line could grow to roughly $4.5M/year, but that still does not prove in-house processing is cheaper than renegotiating Stripe first. + +The downside risk is that “build payments infra” usually means dragging the company into PCI, fraud, disputes, and audit scope. Stripe states that if you use Checkout/Elements, you can stay in SAQ A; if you write your own code to handle card data, you may become ineligible for SAQ A and responsible for additional PCI DSS requirements. Stripe also notes that businesses handling card data may need to meet 300+ PCI security controls ([Stripe PCI guide](https://stripe.com/guides/pci-compliance)). PCI SSC separately makes clear that even merchants that outsource processing remain responsible for compliance oversight; outsourcing reduces scope, not accountability ([PCI SSC FAQ](https://www.pcisecuritystandards.org/faq/articles/Frequently_Asked_Question/does-pci-dss-apply-to-merchants-who-outsource-all-payment-processing-operations-and-never-store-process-or-transmit-cardholder-data/?_hsmi=364054903)). If they move payment data or become a service provider, Visa’s validation guidance shows service providers face heavier validation expectations, including ROC/AOC paths and registry implications ([Visa PCI validation](https://usa.visa.com/content/dam/VCOM/regional/na/us/support-legal/documents/pci-dss-validation-best-practice-review.pdf)). + +If this fintech is actually a platform, marketplace, or anything onboarding sellers / moving funds for others, risk goes up another level. Visa’s Payment Facilitator and Marketplace Risk Guide says acquirers must screen, monitor, periodically review/audit, and maintain ongoing oversight of payment facilitators; it also highlights operational, regulatory/compliance, credit settlement, and brand/reputation risk as core categories ([Visa risk guide](https://usa.visa.com/content/dam/VCOM/regional/na/us/partner-with-us/documents/visa-payment-facilitator-and-marketplace-risk-guide.pdf)). FinCEN’s guidance is similarly uncomfortable: whether you are a money transmitter is “a matter of facts and circumstances,” and the payment-processor exemption is narrow and conditional ([FinCEN ruling](https://www.fincen.gov/resources/statutes-regulations/administrative-rulings/administrative-ruling-whether-company-offers)). That means the legal perimeter can shift as product design shifts. + +The practical failure mode is underestimating post-authorization operations. Stripe’s own multiprocessor “Vault and Forward” docs warn that if you route to another processor, you must handle refunds and disputes directly with that processor ([Stripe Vault and Forward](https://docs.stripe.com/payments/vault-and-forward)). That is the tell: auth/capture is only the visible part. The ugly parts are retries, ledger reconciliation, failed payouts, dispute evidence, risk monitoring, underwriting, reserves, reporting, and incident response. A 20-engineer team can build a gateway; it is much harder to build a resilient payment operations organization. + +My skeptical conclusion: do not replace Stripe end-to-end now. First exhaust lower-risk options: negotiate custom pricing, push lower-cost rails like ACH where product permits, and test multiprocessor routing only if there is a measurable acceptance-rate or unit-economics reason. Revisit “build” only if you can show, with actual processor quotes and compliance staffing plans, that net savings remain compelling after PCI, legal, fraud, ops, and migration risk. Biggest uncertainties: transaction count/average ticket, card vs ACH mix, cross-border exposure, dispute/fraud rates, and whether they process only their own merchant volume or funds for third parties. + +--- + +## Discussion + +### Round 1 — Advocate | response | confidence: 72% + +**Response to previous points:** + +Skeptic's strongest argument — and I want to state it fairly — is that the *actual* savings opportunity is Stripe's margin only, not the full $1.5M fee line. Interchange, network fees, and acquirer costs don't vanish when you build. That's a critical correction to the naive "we'd save $4.5M" framing. If Stripe's effective margin is 80-120 bps above interchange-plus, the real savings at $150M volume are closer to $1.2M-$1.8M/year, not $3M+. I accept that reframe. + +Where I disagree with Skeptic: the recommendation to "first exhaust lower-risk options" like negotiating custom pricing treats this as a binary — negotiate OR build. But the first phase of building (a payment orchestration layer that abstracts Stripe behind an internal API) is *itself* the negotiating leverage. You cannot get Stripe's best pricing without a credible alternative. Companies that show up to Stripe pricing conversations with a multi-processor architecture and direct acquiring relationships get IC+ pricing they'd never get by asking nicely. The orchestration layer is the lowest-risk, highest-optionality move regardless of the final build/buy decision. + +Skeptic is right that post-auth operations (disputes, reconciliation, risk monitoring) are where builds actually fail. I take that seriously — this is the hardest 80% of the work. But the phased approach I outlined keeps Stripe handling post-auth for the initial migration period. You route auth/capture through direct acquiring while Stripe continues to handle disputes and payouts via their existing rails during transition. + +**New evidence or angle:** + +One thing neither of us has addressed: the startup's *transaction profile* matters enormously. If average ticket is $500+ (B2B payments, lending disbursements), the per-transaction fixed costs of in-house processing are amortized quickly and the basis-point savings compound faster. If average ticket is $15 (consumer micro-transactions), the operational overhead per transaction makes building far less attractive. Similarly, if 30%+ of volume is ACH-eligible, the immediate win is pushing those transactions off card rails entirely — something achievable *within* Stripe using Stripe's ACH product, no build required. We're debating build-vs-buy without knowing the single variable that most determines the answer. + +**Current position:** + +Build the orchestration layer now (~72% confident). Not because the full build is obviously right today, but because abstraction + vendor optionality is positive-EV regardless of whether you eventually go direct. The full migration decision should wait until you have direct processor quotes, a PCI compliance cost estimate, and — crucially — know your transaction profile. I'm *not* 72% on "replace Stripe end-to-end." I'm 72% on "start the orchestration work that makes all future options cheaper." + +**Key question for the group:** + +Skeptic — do you agree that building the orchestration/abstraction layer (Stripe stays as the processor behind it) is a low-risk, high-optionality first step? Or do you see material costs even in that intermediate architecture that make it not worth pursuing at 20 engineers? + +### Round 1 — Skeptic | response | confidence: 78% + +**Response to previous points:** +Advocate’s strongest point is the narrower one, not the headline “save Stripe fees” claim: a thin routing/abstraction layer can create negotiating leverage and preserve optionality before volume triples. That moved me somewhat. I agree a credible alternative matters more than asking Stripe for a discount with no fallback. But I do not agree that an “orchestration layer” is automatically low-risk. At a 20-engineer company, a broad internal payments API often becomes a shadow processor: duplicated idempotency, retry semantics, webhook normalization, reconciliation states, and support tooling, all before any savings land. So my synthesis with Advocate is: yes to a very thin router tied to one concrete second route, no to a generalized payments platform built in anticipation of someday needing it. + +Agent A is also right that transaction profile is the key missing variable. Average ticket size, ACH eligibility, dispute rate, cross-border exposure, and whether they move funds for third parties dominate the answer. If this is mostly their own merchant volume, the path is one thing; if it looks anything like marketplace/payfac behavior, the compliance and ops burden changes materially. + +**New evidence or angle:** +The missing angle is feature-surface lock-in. Stripe is usually not just auth/capture; it is often fraud tooling, dispute workflows, billing primitives, tokenization, updater services, reporting, and sometimes Connect-like fund flows. A generic abstraction does not preserve that value cleanly. It either forces the company down to the lowest common denominator or makes them rebuild those capabilities piecemeal. That is why targeted multiprocessor routing for one flow can work, while “abstract all payments now” often creates an abstraction tax with no near-term payoff. + +**Current position:** +I would not build end-to-end processing now. I would support a narrowly scoped router only if they already have a specific high-volume flow, direct acquirer quotes showing meaningful net savings after ops/compliance cost, and a plan to leave Stripe in place for the long tail and ops-heavy cases. I’m at ~78% because the dominant failure mode here is organizational overreach, not failing to seize an obvious infra win. + +**Key question for the group:** +What portion of the projected $150M is a clean, repetitive transaction slice, same-country card or ACH-eligible, low-dispute, no third-party fund movement, and what net basis-point quote can they get today for that exact slice from a direct acquirer? + +### Round 2 — Advocate | response | confidence: 68% + +**Response to previous points:** + +Skeptic's strongest point in Round 1 — and I want to sit with it — is the feature-surface lock-in argument. Stripe isn't a pipe you swap out; it's fraud scoring, dispute automation, card updater services, billing retry logic, tokenization, and often Connect-based fund flows, all wired into product code. An "orchestration layer" that pretends these are interchangeable across processors is a fiction. Any abstraction either drops to the lowest common denominator (losing Stripe features the product relies on) or becomes a bespoke reimplementation of each provider's surface area. That's the abstraction tax, and it's real. **I'm updating my position because of this.** My Round 1 framing of "build the orchestration layer" was too broad — Skeptic correctly identified that a generalized abstraction is a shadow processor in disguise. + +Where I still disagree: Skeptic's precondition of "already have direct acquirer quotes showing meaningful net savings" before writing any code is sequencing backwards. You need the thin integration to *get* meaningful quotes — processors give indicative pricing, not binding quotes, until you're in technical due diligence. And the 18-month growth window creates a timing asymmetry neither of us has addressed directly: building routing infrastructure at $150M/year is 3x more dangerous than building it at $50M/year because migration risk scales with volume. The cost of waiting isn't zero. + +On Skeptic's key question — what portion of $150M is clean, repetitive, low-dispute — I'll answer with the framework rather than guessing: if that clean slice is under 30% of volume, don't bother. The operational overhead of a second processor isn't worth routing a minority of transactions. If it's over 50%, the case is strong. That's the threshold question. + +**New evidence or angle:** + +There's a third option we've both missed: **Stripe's own multi-processor tooling changes the calculus.** Stripe Vault and Forward (which Skeptic cited) lets you tokenize on Stripe and route auth to a second processor while keeping Stripe's token vault, fraud tools, and dispute handling. This is explicitly Stripe enabling the hybrid path — you get a second processor for the clean volume slice without losing Stripe's feature surface for the complex tail. The abstraction tax drops dramatically because Stripe itself becomes the abstraction layer. The catch: you're still paying Stripe something for vault/tokenization, and you're still in their ecosystem. But it directly addresses both my concern (start building optionality now) and Skeptic's concern (don't lose the feature surface or build a shadow processor). + +**Current position:** + +Down to ~68% on active build work, up from my Round 1 position in nuance. Concrete recommendation: (1) negotiate IC+ pricing with Stripe now using the credible threat of multi-processor routing, (2) evaluate Stripe Vault and Forward for the cleanest transaction slice, (3) get one direct acquirer quote for that slice. This is closer to Skeptic's position than my Round 1 — I've moved because the feature-surface lock-in argument is genuinely load-bearing, not just a caution reflex. But I maintain that *some* active work beyond just negotiating is warranted now, while volume is lower and migration risk is manageable. + +**Key question for the group:** + +Skeptic — does Stripe Vault and Forward as the hybrid path change your risk assessment? It preserves the feature surface you're concerned about while enabling the multi-processor routing I'm advocating for, without building a generalized abstraction layer. + +### Round 2 — Skeptic | response | confidence: 80% + +**Response to previous points:** +Agent A’s strongest point is the timing asymmetry: if a second route may eventually be justified, learning at $50M is safer than first attempting it at $150M. I’ve moved a bit on that, and I agree with Agent A’s correction that a generalized orchestration layer is too broad. But I don’t think `Vault and Forward` changes the risk as much as it first appears. In the research I cited earlier, Stripe’s own docs say that once you forward to another processor, refunds and disputes for those payments must be handled with that processor directly. So the hardest operational surface does not stay fully “Stripe-managed.” My synthesis with Agent A is: do active diligence now, but keep it commercial and slice-specific, not platform-first. The unresolved questions are still gating: what share of volume is a clean repetitive slice, what exact Stripe features are in use today, and are they processing only their own volume or moving funds for third parties? + +**New evidence or angle:** +The real distinction is not “build vs Stripe”; it is “merchant optimization vs becoming payments infrastructure.” If they reroute one bounded, merchant-owned flow, that is a controlled optimization problem. If they start touching card data more directly, assume service-provider-like obligations, or recreate Stripe features across products, it becomes a company-shaping distraction. `Vault and Forward` may help with token portability and PCI scope, but it does not remove the post-auth ownership burden on forwarded traffic. That keeps the decision threshold higher than “the fee line is big.” + +**Current position:** +Do not build end-to-end processing now. I would support a 30-60 day diligence/pilot plan now: Stripe repricing, dependency inventory, one direct acquirer quote for one clean slice, and a narrow pilot only if the modeled net savings still clear the added ops/compliance cost. ~80% because Agent A is right that waiting has a cost, but the evidence still says the common failure mode is underestimating the non-API surface area. + +**Key question for the group:** +What is the annualized GMV, dispute rate, average ticket, and Stripe feature dependency for the single cleanest transaction slice they could route separately tomorrow, and what net basis-point savings would that slice actually produce after adding refunds, disputes, and reconciliation ownership? + +### Round 3 — Advocate | response | confidence: 65% + +**Response to previous points:** + +Skeptic's strongest point in Round 2 — and the one that moved me most across this entire discussion — is the surgical distinction between "merchant optimization" and "becoming payments infrastructure." That's the real decision boundary, not build-vs-buy. Routing one clean slice to a second processor is a bounded optimization problem with knowable costs. Building a generalized payment abstraction layer is a company-identity decision that a 20-engineer Series A startup should not be making under cost-pressure framing. I accept that distinction fully. + +Skeptic is also right that Vault and Forward doesn't solve the problem I wanted it to solve. I framed it as "keep Stripe's feature surface while routing elsewhere," but Skeptic correctly noted that post-auth operations (refunds, disputes, reconciliation) on forwarded traffic still fall to the second processor. The operational burden doesn't stay Stripe-managed — it just stays Stripe-tokenized. That's a narrower benefit than I presented. + +Where I still push back, but only slightly: Skeptic's 30-60 day diligence plan is essentially what I'm advocating for, reframed as caution rather than action. Stripe repricing negotiation, dependency inventory, one acquirer quote, one narrow pilot — that *is* active work. It's 1-2 engineers for a month. The label matters less than the content, and I think we agree on the content. + +**New evidence or angle:** + +Honest answer: nothing materially new to add. We've covered the economics, the compliance surface, the feature lock-in, the hybrid tooling, and the timing asymmetry. The remaining uncertainty is entirely empirical — transaction profile data we don't have. Further debate without that data is speculation with diminishing returns. + +**Current position:** + +Down to ~65%, and I want to be precise about what that means. I'm ~90% aligned with Skeptic's concrete plan: negotiate IC+ pricing, inventory Stripe feature dependencies, get one direct acquirer quote for the cleanest slice, pilot only if modeled net savings clear ops/compliance cost. Where I hold the remaining 10% gap: I'd set a harder decision deadline (90 days, not open-ended diligence) and I'd allocate one engineer to build the dependency inventory and Stripe feature audit as a technical workstream, not just a commercial exercise. The risk of open-ended "diligence" is that it becomes indefinite deferral, and the timing asymmetry — building at $50M is safer than at $150M — doesn't wait. + +**Key question for the group:** + +Skeptic — can we converge on a concrete deliverable: a 60-day time-boxed evaluation with a go/no-go gate, where the gate criteria are (a) net bps savings on the cleanest slice after ops/compliance cost, (b) Stripe feature dependency count, and (c) clean-slice percentage of total volume? If all three clear defined thresholds, proceed to narrow pilot. If not, renegotiate Stripe and revisit at $100M. + +**Convergence assessment:** CONVERGING — We agree on ~85% of the substance: don't build end-to-end now, do active commercial and technical diligence on a narrow slice, keep Stripe for the complex tail. Remaining gap is pacing and commitment mechanism — I want a hard deadline and allocated engineering time; Skeptic may prefer keeping it purely commercial until the numbers justify technical investment. + +--- + +## Consensus Summary + +### Decision +Do not build end-to-end payment processing infrastructure now. Instead, execute a time-boxed (60-90 day) commercial and technical evaluation: negotiate IC+ pricing with Stripe, inventory all Stripe feature dependencies, obtain one direct acquirer quote for the single cleanest transaction slice, and proceed to a narrow pilot only if modeled net basis-point savings clear ops/compliance costs. Keep Stripe as the primary processor for all complex, dispute-heavy, and long-tail flows regardless of outcome. + +### Key Contention Points + +| # | What We Disagreed On | How It Was Resolved | Who Shifted & Why | +|---|---------------------|--------------------|--------------------| +| 1 | Whether to build a generalized payment orchestration/abstraction layer | Resolved against. Skeptic argued it becomes a "shadow processor" with duplicated idempotency, retry semantics, and reconciliation — an abstraction tax with no near-term payoff. | Advocate shifted (R2), accepting that a generalized abstraction is too broad and a company-identity decision a 20-engineer startup shouldn't make under cost-pressure framing. | +| 2 | Whether Stripe feature-surface lock-in is a blocking concern | Resolved as load-bearing. Stripe isn't just auth/capture — it's fraud scoring, dispute automation, card updater, billing retry, tokenization, and often Connect fund flows. | Advocate shifted (R2), calling this "genuinely load-bearing, not just a caution reflex" and dropping confidence from 72% to 68%. | +| 3 | Whether Stripe Vault and Forward solves the hybrid problem | Resolved as insufficient. Post-auth operations (refunds, disputes, reconciliation) on forwarded traffic still fall to the second processor. | Advocate shifted (R3), conceding the operational burden doesn't stay Stripe-managed, only Stripe-tokenized — a narrower benefit than initially presented. | +| 4 | The real savings opportunity ($4.5M vs. Stripe's margin only) | Resolved early. Interchange, network, and acquirer fees don't vanish when you build; actual savings are Stripe's margin (~80-120 bps), not the full fee line. | Advocate accepted this reframe in R1, narrowing projected savings from $3M+ to $1.2M-$1.8M/year at $150M volume. | +| 5 | Pacing of diligence — open-ended vs. hard-gated | Partially resolved. Both agree on the same activities; Advocate wants a 60-day deadline with one allocated engineer, Skeptic prefers commercial-first sequencing. | Neither fully shifted. Advocate conceded ~90% alignment but held that open-ended diligence risks indefinite deferral given the timing asymmetry (building at $50M is safer than at $150M). | + +### Unresolved Items & Risks +- **Transaction profile is unknown**: Average ticket size, ACH-eligible share, dispute rate, cross-border exposure, and whether they process only their own volume or move funds for third parties — these variables dominate the answer and neither agent had them. +- **Clean-slice threshold unclear**: Both agents agreed the decision hinges on what percentage of volume is clean, repetitive, same-country, low-dispute — but no threshold was formally agreed (Advocate suggested 30-50% as the range). +- **Go/no-go gate criteria need definition**: Advocate proposed three gate criteria (net bps savings, feature dependency count, clean-slice percentage) but specific numeric thresholds were not set. +- **Timing asymmetry remains live**: If diligence takes too long and volume hits $150M, migration risk increases materially — but moving too fast risks organizational overreach. The right pacing depends on growth trajectory accuracy. +- **Stripe repricing may eliminate the case entirely**: If Stripe offers IC+ at competitive rates (which they do for volume customers), the net savings from a second processor may not clear the added ops/compliance cost, making the entire build question moot. + +### Confidence: Medium +Both agents converged to ~85% agreement on substance — don't build end-to-end, do active diligence on a narrow slice, keep Stripe for the complex tail — but the actionable decision (proceed to pilot or not) depends entirely on empirical data neither agent had access to. diff --git a/tests/eval-results/full-matrix-2026-04-01/fintech-payments__3-codex.md b/tests/eval-results/full-matrix-2026-04-01/fintech-payments__3-codex.md new file mode 100644 index 0000000..0ab7853 --- /dev/null +++ b/tests/eval-results/full-matrix-2026-04-01/fintech-payments__3-codex.md @@ -0,0 +1,179 @@ +--- +topic: "Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months." +mode: "council" +agent_count: "3" +agent_config: "3-agent" +max_rounds: "5" +git_commit: "none" +agent_cli: "codex" +status: consensus +turn: B +round: 3 +created: "2026-04-01T09:04:53.994Z" +last_updated: 2026-04-01T09:13:28.376Z +agent_A_name: "Advocate" +agent_A_cli: "codex" +agent_A_role: "advocate" +agent_B_name: "Skeptic" +agent_B_cli: "codex" +agent_B_role: "skeptic" +agent_C_name: "Synthesizer" +agent_C_cli: "codex" +agent_C_role: "synthesizer" +--- + +# Discussion: Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months. + +## Participants +- **Agent A** — Advocate (advocate) via codex +- **Agent B** — Skeptic (skeptic) via codex +- **Agent C** — Synthesizer (synthesizer) via codex + +## Key Questions +1. What is the true total cost of ownership for in-house payment processing vs Stripe at current and projected volumes? +2. What are the regulatory and compliance implications (PCI-DSS, per-country requirements) of each approach? +3. Is there a hybrid approach that captures cost savings without full infrastructure ownership? +4. What is the engineering opportunity cost — what else could those engineers build? + +## Research Phase + +### Agent A (Advocate) — Independent Research | research + +The upside case for building is real, but only if “build your own” means “own the payment control plane and economics,” not “become Stripe from scratch in 12 months.” At $50M in annual volume and ~$1.5M in Stripe fees, they are already spending about 3% of volume on payments. If volume triples in 18 months, that becomes roughly $4.5M/year. Stripe’s public standard online rate is 2.9% + 30c, and Stripe explicitly offers custom `IC+`, volume discounts, and country-specific pricing for larger merchants ([Stripe pricing](https://stripe.com/us/pricing)). That matters because it proves two things: first, their current fee line is economically material; second, some of it is negotiable processor margin rather than immutable network cost. The Nilson Report said U.S. merchants paid $187.2B in processing fees in 2024, or $1.57 per $100 of card payments on average ([Nilson](https://www.globenewswire.com/news-release/2025/03/19/3045828/0/en/Merchant-Processing-Fees-in-the-Unites-States-Exceeded-187-Billion-in-2024.html)). Their 3% effective cost suggests there may be meaningful room to reclaim basis points if they control routing, pricing, retries, and settlement more directly. My inference, not a sourced fact: at $150M/year, even 30 to 50 bps of durable savings is $450k to $750k annually, which can justify a focused team. + +The strongest pro-build argument is not fee reduction alone. It is strategic control. Owning the stack unlocks custom ledgering, smarter routing by issuer/country/risk, tighter reconciliation, better unit economics reporting, and product speed for fintech-specific workflows. Stripe’s own product roadmap is evidence that sophisticated merchants want this: Stripe now documents a Vault and Forward API that stores card details in Stripe’s PCI-compliant vault and forwards them to other processors, and an Orchestration product that routes payments across processors based on rules like card country, currency, and amount, with retries to another processor on failure ([Vault and Forward](https://docs.stripe.com/payments/vault-and-forward), [Orchestration](https://docs.stripe.com/payments/orchestration/route-payments)). In other words, even Stripe is productizing the transition from “single PSP” to “merchant-owned payment architecture.” That is a big opportunity for this startup: they do not need a cliff migration. They can keep Stripe-hosted card collection initially, preserve lower PCI scope, and still start internalizing routing, token ownership, ledger, risk logic, and non-card rails. + +There are credible success patterns. Shopify said merchant solutions, driven largely by Shopify Payments and related financial products, were 76% of total revenue in 2025; Shopify Payments is described as a “fully integrated payment solution” ([Shopify 2025 filing](https://www.sec.gov/Archives/edgar/data/1594805/000159480526000007/shop-20251231.htm)). Toast’s filing says its ability to attract and retain customers depends in part on offering payment processing “with the desired functionality at an attractive price,” and that its all-in-one platform with payments offers customers “significant advantages” ([Toast 2025 annual report](https://www.sec.gov/Archives/edgar/data/1650164/000165016425000140/toastinc_arx2025xv3final.pdf)). Adyen’s 2025 annual report ties a single platform and licensed infrastructure to customer “efficiency, resilience, and control,” access to local rails, and ownership of payments and data ([Adyen 2025 annual report](https://investors.adyen.com/financials/2025)). Those are not tiny startups, but they show the upside logic: payments can become moat, margin engine, and product substrate, not just vendor spend. + +The key uncertainty is scope. If they literally mean full in-house processing, acquiring, compliance, network relationships, disputes, and global coverage, that is probably too much for a 20-engineer Series A team. If they mean a staged hybrid build that starts now and makes Stripe one processor among others, the upside is compelling. Stripe-hosted flows currently keep them in lighter PCI paths such as SAQ A, while handling card data themselves can escalate requirements materially; PCI thresholds are transaction-count based, and Level 1 starts above 6 million Visa/Mastercard transactions annually ([Stripe PCI guide](https://stripe.com/guides/pci-compliance)). But that is exactly why the opportunity is now: build before the scale arrives, while they still have time to choose which layers to own deliberately. + +### Agent B (Skeptic) — Independent Research | research + +Skeptical view: a Series A fintech with 20 engineers should assume that “build our own payments stack” is a trap unless a line-item fee analysis proves that most of the current $1.5M is truly Stripe markup, not unavoidable network cost. Today they are paying an effective ~3.0% on $50M. At 3x volume that becomes ~\$4.5M if nothing changes, but Stripe already offers custom pricing, IC+ pricing, and volume discounts for larger customers, so the relevant comparison is not “current Stripe list price vs. self-build,” it is “renegotiated enterprise Stripe deal vs. self-build” (Stripe pricing: https://stripe.com/us/pricing; IC+ support note: https://support.stripe.com/questions/understanding-ic-fees). Stripe’s own IC+ documentation distinguishes Stripe fees from network costs, which is the key skeptical point: building your own processor does not eliminate interchange and network fees. If only a minority of the \$1.5M is negotiable margin, the savings case may collapse before the project starts. + +The compliance downside is much worse than most product teams estimate. Once they stop being “a merchant using Stripe” and start behaving like a gateway, processor, or other payment service provider, PCI scope expands materially. PCI SSC says service providers cannot rely on the lighter merchant SAQs; the only SAQ path for service providers is SAQ D, and service providers that indirectly facilitate storage/processing/transmission are still in scope (PCI SSC FAQs 1578 and 1579: https://www.pcisecuritystandards.org/faqs/1578/ and https://www.pcisecuritystandards.org/faqs/1579/). Mastercard classifies all third-party processors and all merchant payment gateways as Level 1 service providers, requiring an annual ROC by a QSA (https://www.mastercard.com/us/en/business/cybersecurity-fraud-prevention/site-data-protection-pci.html). That means this is not “some extra compliance work”; it is a permanent security/compliance program with audit, evidence collection, vendor management, and production-control rigor. + +Regulatory scope is another failure mode. If they touch fund flows in the wrong way, “payment processor” exemptions are narrower than startup decks suggest. FinCEN explicitly treats money transmission status as facts-and-circumstances and says the payment-processor exemption requires a formal agreement with the seller/creditor and operation through a clearance/settlement system; it is not a blanket safe harbor for “we move money as software” (https://www.fincen.gov/resources/statutes-regulations/administrative-rulings/administrative-ruling-whether-company-offers). If this startup’s model involves holding funds, split settlements, platform payouts, or merchant-of-record-like behavior, legal complexity can outrun engineering complexity very fast. + +Operationally, the ugly scenario is dual-running systems during hypergrowth. Stripe’s own vault-and-forward docs are instructive: if you route card data to another processor, post-transaction actions like refunds and disputes become your responsibility with that processor, and Stripe cannot guarantee the downstream processor’s response behavior (https://docs.stripe.com/payments/vault-and-forward). In other words: once you decompose the stack, outages, reconciliation drift, dispute workflows, and support escalations become multi-party incidents. You also lose embedded advantages such as Radar’s fraud models trained on Stripe-wide data (https://stripe.com/radar/pricing). At \$150M annualized volume, even a 30 bps increase in fraud/dispute loss or approval-rate deterioration is \$450k/year in damage, enough to erase much of the hoped-for savings. + +My bottom-line skeptical conclusion: the downside case is they spend 9-18 months building, add permanent PCI/regulatory overhead, distract a small engineering org during 3x growth, and discover the real savings were far smaller than forecast because network costs persisted and risk/ops costs moved in-house. The burden of proof is on the self-build case, not on Stripe. + +--- + +## Discussion + +### Round 1 — Advocate | response | confidence: 74% + +**Response to previous points:** +Agent B’s strongest argument is that “$1.5M in Stripe fees” is not the same as “$1.5M available to save.” That is the right caution, because interchange/network costs persist, while PCI/service-provider scope, dispute ops, and regulatory exposure can become permanent overhead. I agree with that core point. + +Where I disagree is on the implied choice set. The real decision is not “Stripe forever” vs. “become a processor.” It is whether they should start building the payment control plane now so that Stripe stops being their only economic and operational dependency before volume hits ~$150M/year. On the evidence both agents surfaced, Stripe itself now supports that middle path via Vault/Forward and Orchestration. So my synthesis is: do not build full-stack acquiring/processing infrastructure now, but do start building the layers that create leverage: internal ledgering, processor abstraction, routing rules, reconciliation, retry logic, and commercial optionality. + +I’d like Agent C to pressure-test that distinction, because it resolves the biggest open question: how much user value and margin can they capture without crossing into “we are now a regulated payments company” territory? + +**New evidence or angle:** +New angle: timing and negotiating leverage. Even if they never fully leave Stripe, building a credible multi-processor architecture changes the commercial conversation. At projected 3x growth, waiting until they are already at ~$150M/year is the worst time to start, because they will be migrating during hypergrowth with less room for mistakes. Starting now creates option value: they can renegotiate Stripe from a position of credible exit, test a second processor on a narrow slice, and stop if realized savings are too small. + +A practical decision rule seems missing from the discussion: if a 60-90 day discovery shows recoverable savings after enterprise repricing are only, say, <30-40 bps, they should not build beyond abstraction basics. If recoverable savings are >50 bps with measurable approval-rate or reconciliation upside, the hybrid build is easier to justify. + +**Current position:** +Build selectively, not end-to-end. Confidence is 74% because the economic incentive is already material and grows fast with volume, but Agent B is right that a literal “build our own processor” move is too risky for a 20-engineer Series A company. The opportunity is in owning strategy and routing, not replacing every Stripe function. + +**Key question for the group:** +What is the realistic net savings range after enterprise Stripe repricing, keeping interchange/network costs constant and adding the fully loaded cost of a 3-5 person payments platform team plus PCI/compliance overhead? + +### Round 1 — Skeptic | response | confidence: 78% + +**Response to previous points:** +Agent A’s strongest point is the reframing: the real choice is not “Stripe forever” vs. “become Stripe,” but whether to build enough payment control-plane capability to create negotiating leverage and reduce single-vendor dependence before volume reaches ~$150M/year. I agree that this is the right decision frame, and it is the best synthesis so far. + +Where I still disagree with Agent A is on how “lightweight” that middle path may be in practice. A processor abstraction sounds modest, but once it owns routing, retries, reconciliation, token portability, refunds, and dispute handoff, it is no longer a thin layer. The failure mode is building 60-70% of the complexity while only capturing 20-30% of the savings. Agent B’s core objection still stands: the comparison must be against a repriced Stripe contract, not today’s fee line, and the savings case is unproven until they decompose the $1.5M into interchange/network costs, Stripe markup, fraud tooling, dispute ops, and international/local-method mix. + +So my synthesis is narrower than Agent A’s: build only the minimum internal capabilities that improve negotiating leverage and observability first, not routing in production. Concretely: fee decomposition, processor-agnostic internal ledger/reconciliation, and token-migration readiness. I want Agent C to test whether “hybrid” remains attractive if the first 6 months produce no meaningful basis-point savings after enterprise repricing. + +**New evidence or angle:** +New angle: the real gating variable is not annual volume alone, but transaction shape. A 3% effective cost can mean very different things depending on average ticket size, payment-method mix, cross-border share, card-present vs. card-not-present, and dispute/fraud profile. If they have low AOV and many transactions, fixed per-transaction fees matter; if they have high AOV, basis points dominate. That means the current debate is under-specified: a $50M business with 500k transactions behaves very differently from a $50M business with 10M transactions, both economically and for PCI/service-provider thresholds. Until the company models savings by payment-method cohort, any ROI estimate is too coarse to drive an infrastructure decision. + +**Current position:** +Do not build in-house processing infrastructure now, and do not assume a hybrid routing layer is automatically justified. I support a staged option-creation plan only if a short discovery proves likely net savings after repricing exceed the full cost of a 3-5 person team plus added compliance/ops burden. Confidence is 78% because the downside risks are concrete and near-term, while the upside still depends on an unproven fee decomposition. + +**Key question for the group:** +What portion of the current $1.5M annual Stripe spend is actually recoverable processor markup after repricing, broken down by transaction count, average order value, payment method, geography, and fraud/dispute costs? + +### Round 2 — Advocate | response | confidence: 81% + +**Response to previous points:** +Agent B’s strongest argument is that the real comparison is not “today’s Stripe bill vs. self-build,” but “repriced Stripe plus unchanged interchange/network costs vs. a new permanent compliance/ops burden.” I’ve moved toward that view. B is also right that a “hybrid layer” stops being lightweight the moment it owns live routing, refunds, disputes, and retries across processors. + +So my position has narrowed: I no longer support early production routing as the default next step. The action I still support is a phase-1 build of non-regret capabilities only: cohort-level fee decomposition, internal ledger/reconciliation, processor-agnostic payment domain models, and token-portability readiness while keeping Stripe-hosted flows. That preserves the strategic-control upside I argued for earlier without prematurely accepting service-provider-like complexity. Agent C should pressure-test whether that phased approach actually captures most of the option value B is worried we’d destroy by moving too fast. + +**New evidence or angle:** +The missing angle is reversibility. Some investments are reversible and valuable even if they stay on Stripe: fee telemetry by AOV/payment-method/geography, reconciliation automation, and contract/token portability. Others are hard to reverse and immediately operationalize risk: live auth routing, direct processor integrations, and owning post-transaction workflows. For a 20-engineer team during 3x growth, that distinction matters more than the slogan “build vs. buy.” + +Simple economics sharpen it: at $150M/year, every 10 bps is only $150k. So “fees feel high” is not enough. The case for phase 2 likely needs something like 50+ bps of durable net savings, or a combination of savings plus measurable approval-rate/product benefits, after repricing Stripe and including team/compliance cost. + +**Current position:** +Do not build full payment processing infrastructure. Do start a 60-90 day phase to reprice Stripe, decompose current fees by transaction cohort, and build the internal observability/reconciliation/token-portability foundation. Only proceed to live multi-processor routing if that phase proves a durable economic or approval-rate advantage above a predefined threshold. Confidence is 81% because Agent B’s evidence materially weakens the case for early routing, but the option value of the non-regret layers still looks strong. + +**Key question for the group:** +What exact phase-2 gate should we endorse: a net basis-point threshold, an approval-rate lift threshold, or a combined hurdle, and what number is high enough to justify moving from observability/abstraction into live routing? + +### Round 2 — Skeptic | response | confidence: 84% + +**Response to previous points:** +Agent A’s strongest move was narrowing the recommendation from “hybrid routing” to “reversible, non-regret capabilities first.” I agree with that shift, and I’ve changed my mind slightly because it separates option creation from operational exposure. I also think Agent A is right that live routing should not be the default next step. + +My remaining disagreement is about sequencing. Even “token portability readiness” and processor abstraction can become premature engineering if the economics are weak after repricing. So I’d tighten the plan further: first do a 60-90 day no-code discovery with Stripe repricing, 1-2 competitive processor quotes, cohort-level fee decomposition, approval-rate baselines, and legal/compliance scoping. Only then decide whether internal ledger/reconciliation tooling is enough, or whether more platform work is justified. Agent C should synthesize the gate here, because the group is converging on “not full self-build,” but not yet on what evidence is strong enough to fund phase 2. + +**New evidence or angle:** +New angle: the right unit of analysis is not total GMV, but migratable GMV. A basis-point saving on total volume is misleading if only a subset can realistically move off Stripe in the next 12 months without breaking product flows or expanding regulatory scope. If, for example, only certain geographies, card cohorts, or payment methods are portable, then the savings case must be modeled on that cohort alone, with fraud loss, dispute ops, and approval-rate effects attached to that same cohort. That makes the hurdle materially harder than the discussion has implied. + +**Current position:** +Do not build in-house payment processing infrastructure. I now support a staged path, but only if phase 1 is mostly commercial, analytical, and legal discovery rather than building routing infrastructure. Confidence is 84% because the downside of overbuilding is concrete, while the manageable path is now clearer: prove recoverable value on migratable volume before adding payment-platform complexity. + +**Key question for the group:** +What is the annualized net benefit on the realistically migratable volume, after Stripe repricing, alternative processor quotes, fraud/dispute effects, and the full cost of a 3-5 person team plus compliance overhead? + +### Round 3 — Advocate | response | confidence: 83% + +**Response to previous points:** +Agent B’s strongest argument is the `migratable GMV` test: savings should be modeled on the subset of volume they can realistically move without triggering major new regulatory or operational exposure, not on total GMV. I agree, and that changed my view. It makes any broad “we’ll save 50 bps on $150M” claim too loose. I also agree with Agent B that live routing, refunds, and dispute ownership are premature for a 20-engineer Series A company. + +Where I still disagree with Agent B is on making phase 1 mostly no-code. A pure discovery phase produces a memo, but not much leverage. The third option is a two-track phase 1: commercial/legal discovery in parallel with 1-2 non-regret builds that are valuable even if Stripe remains the only processor. Concretely: cohort-level fee/recovery telemetry and an internal reconciliation/ledger layer. Those help finance, ops, and product immediately, and they shorten future migration time without putting live auth routing into production. Agent C should synthesize whether that narrower build set captures most of the option value while staying inside B’s risk threshold. + +**New evidence or angle:** +New angle: time-to-option matters almost as much as basis points. With 3x growth expected in 18 months, the cost of waiting is not just lost savings; it is entering hypergrowth with weak payment observability, brittle reconciliation, and no clean way to test alternatives. A 90-day phase that ships nothing leaves them more informed but not more capable. A 90-day phase that ends with cohort economics, processor quotes, and production-grade internal payment telemetry creates a real option whether they ever multi-home or not. + +**Current position:** +Do not build full payment processing infrastructure, and do not start live multi-processor routing yet. I support an immediate 60-90 day phase with two outputs: 1) hard economics on repriced Stripe vs. migratable-volume alternatives, and 2) non-regret internal payment primitives that improve reconciliation and decision quality even if they stay on Stripe. Confidence is 83% because Agent B’s risk case is strong, but “analyze first, build nothing” still underweights the value of capability-building before hypergrowth. + +**Key question for the group:** +Should phase 1 explicitly include shipping two internal capabilities now, `cohort-level payment telemetry` and `processor-agnostic reconciliation/ledgering`, or do we recommend a discovery-only phase before any engineering work? + +**Convergence assessment:** CONVERGING — positions are within ~80% agreement on “no full self-build now” and “use a staged path.” The remaining gap is sequencing: whether phase 1 should be discovery-only, as Agent B prefers, or discovery plus a very small set of non-regret internal builds, which I think is the highest-value action. + +--- + +## Consensus Summary + +### Decision +Continue using Stripe as the primary payment processor and do not build full in-house payment processing infrastructure. Start a 60-90 day phase now that does two things in parallel: reprice Stripe and collect alternative processor quotes on migratable GMV, while shipping only two non-regret internal capabilities, `cohort-level payment telemetry` and `processor-agnostic reconciliation/ledgering`. Only approve live multi-processor routing if that phase proves a hard economic win on migratable volume after team, compliance, fraud, dispute, and ops costs; otherwise stay on Stripe and use the new data to negotiate better terms. + +### Key Contention Points + +| # | What Was Debated | Resolution | Who Had the Strongest Case & Why | +|---|-----------------|------------|----------------------------------| +| 1 | Whether the startup should replace Stripe to save fees | Do not replace Stripe now; the correct comparison is against a repriced Stripe contract, not today’s bill, and full self-build is unjustified for a 20-engineer Series A team. | Skeptic had the strongest case because they grounded the decision in true recoverable savings, not gross fees, and showed that interchange/network costs and permanent compliance overhead do not disappear. | +| 2 | Whether a hybrid path is better than Stripe-only or full self-build | Yes, but only as a staged option-building path, not live routing from day one. The company should own observability and reconciliation first, not auth routing, refunds, disputes, or processor operations. | Advocate had the strongest case because they reframed the choice from a false binary into a control-plane strategy and identified the narrow set of capabilities that create leverage without taking on full processor complexity. | +| 3 | How to measure ROI for any future migration | Model savings on `migratable GMV`, not total GMV, and require a predefined hurdle before phase 2. A practical gate is net savings of roughly 50+ bps on migratable volume and/or a clear approval-rate gain after fully loaded costs. | Skeptic had the strongest case because `migratable GMV` is the most decision-useful unit; it prevents the company from justifying a large build on savings that are not actually portable. | +| 4 | Whether phase 1 should be discovery-only or include engineering work | Phase 1 should include limited engineering work, but only non-regret work that pays off even if Stripe remains the sole processor. Discovery alone is too passive given expected 3x growth in 18 months. | Advocate had the strongest case because they identified reversible investments that improve finance/ops immediately and shorten future migration time without triggering the operational risks tied to live multi-processor routing. | + +### Unresolved Items & Risks +- The discussion still lacks the actual breakdown of the current $1.5M annual Stripe spend into interchange, network fees, Stripe markup, fraud tooling, disputes, and international/payment-method mix. +- The recommended hurdle for phase 2 is directionally clear but not yet company-approved; leadership should set it before the 60-90 day phase starts. +- Legal and compliance scope remains a material risk if future plans expand beyond telemetry/reconciliation into routing, token forwarding, fund flows, or post-transaction ownership. +- Opportunity cost is real: even the narrow phase-1 build takes engineering time away from product growth work, so it must stay tightly scoped. + +### Confidence: High +Both agents converged on the core answer: no full self-build now, preserve Stripe, and use a tightly scoped staged plan to earn the right to any deeper payments infrastructure investment. diff --git a/tests/eval-results/full-matrix-2026-04-01/fintech-payments__5-codex.md b/tests/eval-results/full-matrix-2026-04-01/fintech-payments__5-codex.md new file mode 100644 index 0000000..a308109 --- /dev/null +++ b/tests/eval-results/full-matrix-2026-04-01/fintech-payments__5-codex.md @@ -0,0 +1,274 @@ +--- +topic: "Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months." +mode: "council" +agent_count: "5" +agent_config: "5-agent" +max_rounds: "5" +git_commit: "none" +agent_cli: "codex" +status: consensus +turn: C +round: 3 +created: "2026-04-01T09:13:28.377Z" +last_updated: 2026-04-01T09:27:27.801Z +agent_A_name: "Advocate" +agent_A_cli: "codex" +agent_A_role: "advocate" +agent_B_name: "Skeptic" +agent_B_cli: "codex" +agent_B_role: "skeptic" +agent_C_name: "Domain Expert" +agent_C_cli: "codex" +agent_C_role: "expert" +agent_D_name: "User Advocate" +agent_D_cli: "codex" +agent_D_role: "user_advocate" +agent_E_name: "Synthesizer" +agent_E_cli: "codex" +agent_E_role: "synthesizer" +--- + +# Discussion: Should a fintech startup (Series A, 20 engineers, processing $50M/year in transactions) build their own payment processing infrastructure or continue using Stripe? They're currently paying ~$1.5M/year in Stripe fees and expect 3x volume growth in 18 months. + +## Participants +- **Agent A** — Advocate (advocate) via codex +- **Agent B** — Skeptic (skeptic) via codex +- **Agent C** — Domain Expert (expert) via codex +- **Agent D** — User Advocate (user_advocate) via codex +- **Agent E** — Synthesizer (synthesizer) via codex + +## Key Questions +1. What is the true total cost of ownership for in-house payment processing vs Stripe at current and projected volumes? +2. What are the regulatory and compliance implications (PCI-DSS, per-country requirements) of each approach? +3. Is there a hybrid approach that captures cost savings without full infrastructure ownership? +4. What is the engineering opportunity cost — what else could those engineers build? + +## Research Phase + +### Agent A (Advocate) — Independent Research | research + +The upside case favors starting to build your own payments infrastructure now, not because “Stripe is bad,” but because the company is large enough for payments to become a strategic advantage rather than a utility bill. At today’s run rate, the startup is paying about 3% of volume in fees ($1.5M on $50M). If volume reaches $150M in 18 months and economics stay similar, that becomes roughly $4.5M/year. Even a modest 50-100 bps improvement from direct acquiring, IC+ pricing, bank-rail substitution, or smarter routing would be worth about $750k-$1.5M/year at the projected volume. That is large enough to fund a focused payments platform team and still improve gross margin materially. Stripe itself signals that high-volume merchants graduate to more control: its pricing page explicitly offers custom IC+ pricing, and its “Vault and Forward API” exists so merchants can store credentials and route to other processors while keeping PCI scope manageable ([Stripe pricing](https://stripe.com/us/pricing)). + +The real opportunity is not only fee reduction; it is revenue lift. Payments performance is an operating lever. Stripe markets a 2.2% average revenue increase from Authorization Boost and says it recovers 20% of false declines on average ([Stripe Authorization Boost](https://stripe.com/us/authorization)). Visa says tokenized card-not-present transactions see a 4.6% authorization lift globally and about 30% less online fraud versus PAN transactions ([Visa tokenization](https://corporate.visa.com/en/solutions/commercial-solutions/knowledge-hub/tokenization.html)). Those numbers imply that owning the routing, tokenization, retries, and approval analytics layer can create upside well beyond processor-fee savings. A 1% authorization improvement on $150M is $1.5M of additional approved volume before any margin effects. In fintech, that can be more valuable than the fee savings. + +There are strong success patterns. Uber’s next-gen payments platform let it reduce launch time for new business lines and new markets from months to days ([Uber Engineering](https://www.uber.com/en-US/blog/payments-platform/)). Airbnb’s replatformed payments architecture helped it launch 20+ local payment methods in just over a year; Airbnb attributes the new platform to faster integrations, less engineering effort, better observability, and “meaningful uplift” in bookings and new users where local methods launched ([Airbnb Engineering](https://airbnb.tech/payments/pay-as-a-local/)). Shopify is the clearest economic proof that payments can become a growth engine: in 2025, “merchant solutions” were 76% of revenue, driven principally by payment processing and currency conversion fees from Shopify Payments; Shopify also reported 37% gross payments volume growth ([Shopify 2025 results](https://www.shopify.com/investors/press-releases/shopifys-standout-2025-the-launchpad-for-a-new-era-of-commerce-in-2026), [Shopify 10-K](https://www.sec.gov/Archives/edgar/data/1594805/000159480526000007/shop-20251231.htm)). + +So the bullish view is: do not “replace Stripe in one shot”; build the control plane. Keep Stripe as one rail initially, but own the ledger, routing, token strategy, reconciliation, approval analytics, payout logic, and support for lower-cost rails like ACH/RTP where the product permits. That path compounds. It improves negotiating leverage with processors, speeds international and product expansion, and turns payments from a tax on growth into differentiated infrastructure. + +Main uncertainties: the savings depend on card mix, debit vs. credit, international share, dispute/fraud profile, and how much of the current $1.5M is true processing versus value-added Stripe products. If those inputs are unfavorable, first-year ROI could be thinner. But if the company is genuinely a fintech and volume is tripling, the upside scenario is credible: the cost base is already big enough, and the strategic leverage from owning payments is likely to grow faster than the engineering burden. + +### Agent B (Skeptic) — Independent Research | research + +The skeptical view is that a Series A company with 20 engineers should assume that “building our own payments infrastructure” is a multi-year regulated-operations bet, not a cost-cutting engineering project. The visible cost is Stripe’s fee line; the hidden cost is taking on fraud, PCI scope, acquirer relationships, dispute operations, settlement risk, and uptime obligations yourself. At today’s numbers, the fee burden is about 3.0% of volume ($1.5M on $50M). That is not obviously “excess margin” you can reclaim. Stripe’s public US pricing is 2.9% + 30c for domestic cards, but Stripe also explicitly offers custom pricing, IC+ pricing, and volume discounts for large-volume users, plus ACH Direct Debit at 0.8% with a $5 cap and a “Vault and Forward” option for routing to other processors without fully replacing Stripe ([Stripe pricing](https://stripe.com/us/pricing), [ACH](https://stripe.com/payments/ach-direct-debit)). Before rebuilding, I would assume there is still meaningful optimization left inside Stripe. + +The downside case is scope explosion. If they move toward acting like a payment facilitator or owning more of the stack, Mastercard says a payment facilitator must be registered by an acquirer, and Stripe’s payfac guide says traditional payfac setups require systems for processing, sub-merchant onboarding, compliance, risk, payouts, AML, SAR filing, and potentially money transmitter licenses depending on fund flows ([Mastercard](https://www.mastercard.com/content/mastercardcom/us/en/business/overview/start-accepting/payment-facilitators.html), [Stripe payfacs guide](https://stripe.com/us/guides/payfacs)). There is real regulatory ambiguity here: FinCEN’s merchant payment processor ruling says some payment processors are not money transmitters when they only facilitate payment for goods/services through settlement rails, but that is explicitly facts-and-circumstances dependent ([FinCEN](https://www.fincen.gov/resources/statutes-regulations/administrative-rulings/definition-money-transmitter-merchant-payment)). Translation: the “we’ll just be our own processor” plan can quietly turn into a legal-architecture problem. + +Security/compliance is the next trap. Stripe states that if you handle card data directly, you may need to satisfy 300+ PCI DSS controls, with 1,800+ pages of official documentation behind them. Using Stripe Checkout/Elements keeps card data off your servers and can preserve SAQ A scope ([Stripe PCI guide](https://stripe.com/guides/pci-compliance)). If the company’s average ticket is low enough, 3x growth could push them into PCI Level 2 or even Level 1 territory by transaction count, which means QSA involvement, formal assessments, and quarterly scans. That threshold depends on average order value, which is a major uncertainty. If AOV is $100, $150M/year is ~1.5M transactions; if AOV is $25, it is ~6M, which is already a Level 1 problem. + +Operationally, the failure modes are ugly: auth/capture bugs, duplicate charges, ledger mismatches, payout delays, chargeback spikes, broken refund logic, false fraud declines, bad statement descriptors, and reserve/settlement mistakes. Stripe’s member-bank terms require merchants to maintain fraud and dispute rates acceptable under network rules and warn that certain activity can trigger fees, settlement delays, audits, withholdings, or termination ([Cross River Bank acquirer terms](https://stripe.com/es-us/legal/crb-acquirer-terms)). Stripe also advertises 99.999% average historical uptime and bundles fraud tooling, payment method coverage, support, and compliance into the platform ([Stripe pricing](https://stripe.com/us/pricing)). Reproducing that with a 20-engineer team is improbable. + +My bottom line: the downside scenario is spending 12-24 months and several key hires to save less than expected, while increasing regulatory blast radius and risking payment outages during a growth phase. I would not support a full in-house processor build unless they first decompose current fees, prove that Stripe markup rather than interchange is the problem, exhaust negotiation/ACH/orchestration options, and show that net annual savings after staffing, compliance, and risk ops are still decisively positive. + +### Agent C (Domain Expert) — Independent Research | research + +From an implementation-feasibility lens, there are really two different projects hiding inside “build our own payments.” One is building an internal payments control plane while still relying on PSPs/acquirers underneath. The other is replacing Stripe as the processor of record. The first is feasible for a 20-engineer company if it is tightly scoped. The second is a multi-year company bet. Stripe’s own pricing page already signals the near-term alternative: standard pricing is simple, but larger merchants can get custom/IC+/volume pricing ([Stripe pricing](https://stripe.com/us/pricing)). Stripe also now offers multi-processor routing through Orchestration, but Stripe is explicit that when you route to third-party processors, those processors still own fees/liability, and Stripe Orchestration does not cover everything, including some disputes/settlement flows ([Stripe Orchestration](https://docs.stripe.com/payments/orchestration)). + +If the startup means “become our own processor,” the hard requirements arrive immediately. PCI SSC says PCI DSS applies to any entity that stores, processes, or transmits cardholder data, including merchants, processors, acquirers, and service providers ([PCI SSC](https://www.pcisecuritystandards.org/standards/pci-dss/)). Stripe’s migration docs make the switching cost concrete: Stripe will only export stored card data to another PCI DSS Level 1-compliant payment processor ([Stripe PAN export](https://docs.stripe.com/get-started/data-migrations/pan-export)). So even a clean migration off Stripe requires you to already have a compliant receiving processor stack, not just a new API. Direct network connectivity is also not “just integrate Visa”: Visa says production use of VisaNet Connect Acceptance requires pre-approval by both an acquirer and Visa, and is aimed at acquirers, acquirer-processors, and approved technology partners ([VisaNet Connect](https://developer.visa.com/capabilities/visanet-connect-acceptance/docs-getting-started)). If the company facilitates payments for submerchants or moves funds for third parties, the regulatory/registration bar rises again: Visa third-party agents typically need a sponsor and PCI documents, and Mastercard says payment facilitators must be registered by an acquirer ([Visa TPA registration](https://partner.visa.com/site/programs/third-party-agent-registration.html), [Mastercard payment facilitators](https://www.mastercard.com/content/mastercardcom/us/en/business/overview/start-accepting/payment-facilitators.html)). + +What actually has to be built is broader than auth/capture. You need tokenization/card vaulting, key management/HSMs, idempotent payment execution, refunds/voids/retries, 3DS/SCA, network tokens/account updater, dispute evidence tooling, reconciliation, settlement, finance-grade ledgering, fraud/risk, observability, and 24x7 operational support. Real-world precedents show how deep this goes. Airbnb says it built a “large in-house payments operation” to support 191 countries, 70+ currencies, and more than two dozen payment routes ([Scaling Airbnb](https://medium.com/airbnb-engineering/scaling-airbnbs-payment-platform-43ebfc99b324)). When Airbnb later rebuilt payment orchestration, it redesigned around idempotent DAG-based workflows and needed dedicated QA, unit/integration/E2E coverage, and matchup jobs against the legacy path before rollout ([Rebuilding Payment Orchestration at Airbnb](https://medium.com/airbnb-engineering/rebuilding-payment-orchestration-at-airbnb-341d194a781b)). In 2026, after a multi-year replatforming, Airbnb still described launching 20+ local payment methods in 14 months using connector/plugin architecture and processor-agnostic multi-step transactions ([Pay As a Local](https://medium.com/airbnb-engineering/pay-as-a-local-bef469b72f32)). Adyen, whose core business is payments, processes payments “hundreds of times a second, 24/7” and still treats idempotency, reporting, and accounting architecture as major engineering concerns ([Adyen engineering](https://medium.com/adyen/design-to-duty-how-we-make-architecture-decisions-at-adyen-11303bfa3065)). + +The strongest practical precedent is that very large platforms often stop short of owning the processor layer. Stripe’s Shopify case study says Shopify has partnered with Stripe for years to power Shopify Payments and continued building adjacent financial products on Stripe infrastructure ([Shopify on Stripe](https://stripe.com/us/customers/shopify)). + +My domain-expert conclusion: a Series A company at $50M GPV should not try to replace Stripe with a self-owned processing stack in the next 18 months. The feasible move is to keep Stripe, negotiate enterprise pricing now, and if needed build only the control-plane pieces that create leverage: internal ledger/reconciliation, PSP abstraction, and perhaps multi-processor routing. The key uncertainty is transaction profile: average ticket, domestic vs international mix, dispute/fraud rate, and whether the business handles third-party funds. Those variables determine whether the right next step is price negotiation, dual-PSP orchestration, or eventually a deeper processor strategy. + +### Agent D (User Advocate) — Independent Research | research + +From a user-experience lens, the default should be: do not replace Stripe end-to-end in the next 18 months. Users do not care that you “own the stack”; they care that checkout is fast, trusted, locally familiar, rarely declines, refunds are smooth, and support can resolve edge cases. That matters more at your scale because the company is growing from roughly $50M/year to an implied ~$150M/year in payment volume. A small user-facing regression becomes very expensive very quickly: a 1% drop in payment success at that future scale strands about $1.5M in annual transaction volume, which is roughly the same order as today’s entire Stripe bill. That is an inference from the numbers you provided, but it frames the UX risk clearly. + +The market is also moving toward more payment choice, not less. Worldpay’s 2025 Global Payments Report says digital payments grew from 34% of global ecommerce value in 2014 to 66% in 2024, and explicitly frames consumer demand as “choice, control and convenience” rather than just card acceptance ([Worldpay](https://www.worldpay.com/en/insights/articles/digital-payments-GPR-guide)). Stripe’s current surface area lines up with that user reality: it offers access to 100+ payment methods, local acquiring in 46 markets, and support for 195+ countries and 135+ currencies ([Stripe Payments](https://stripe.com/us/payments)). Its dynamic payment-method system uses AI based on more than 100 signals and lets teams A/B test payment methods from the dashboard, which is exactly the sort of continuous UX tuning that in-house processors usually underinvest in while rebuilding table-stakes plumbing ([Stripe dynamic payment methods docs](https://docs.stripe.com/payments/payment-methods/dynamic-payment-methods)). + +The highest-risk place to “go custom” is checkout/authentication, because that is where users feel every mistake. Baymard still reports a 70.19% cart-abandonment rate across ecommerce, which is a reminder that checkout friction remains brutally expensive ([Baymard](https://baymard.com/research/checkout-usability)). Stripe’s accelerated checkout product, Link, has real adoption signals: Stripe says businesses with large repeat-customer bases have seen an average 14% returning-user conversion increase; Link reaches 200M+ consumers and is built into hundreds of thousands of Stripe-powered sites ([Stripe Link](https://stripe.com/payments/link)). Real-world case studies are directionally consistent: OpenAI says Link customers paid 40% faster; MemberPress says over 30% of customers chose Link and conversions grew 5% in four months; Visualsoft reports 13% of checkouts via Link, 25% of volume via Apple Pay, six-second Link checkout, and up to 35% conversion uplift after consolidating on Stripe ([OpenAI/MemberPress on Link](https://stripe.com/payments/link), [Visualsoft](https://stripe.com/ae/customers/visualsoft)). Those are vendor-provided numbers, so treat magnitude cautiously, but the directional lesson is strong: modern payment UX gains come from network effects, saved credentials, wallet coverage, and optimization layers that are hard to recreate alone. + +Stripe also already handles the ugly user-facing regulatory/authentication edge cases. Its docs emphasize automatic SCA exemptions, minimizing unnecessary authentication, and adapting to fragmented rules across the EEA, UK, India, Japan, and Australia ([Stripe Authentication](https://stripe.com/payments/authentication), [3DS docs](https://docs.stripe.com/payments/3d-secure)). It also claims real-time retry and authorization optimizations that recover false declines and reduce payment failures ([Stripe authorization](https://stripe.com/payments/authorization)). If you replace that too early, users will likely feel it first as more declines, more “try another card” moments, more support tickets, and less trust. + +Main uncertainty: if your users are mostly US-only, low-repeat, card-only, and your real pain is economics rather than checkout performance, then building selective infrastructure around Stripe can make sense. But the user-safe version is to build around Stripe, not instead of Stripe: own your ledger, routing abstraction, analytics, and maybe lower-cost rails for specific use cases, while leaving the customer-facing payment experience, authentication, wallets, and global method coverage on Stripe until you have much stronger evidence that users are being constrained by it. + +--- + +## Discussion + +### Round 1 — Advocate | response | confidence: 78% + +**Response to previous points:** +Agent C has the strongest framing: there are really two decisions here, and collapsing them is the mistake. I agree with C and much of B that “replace Stripe as processor of record” is too big a bet for a Series A team of 20 engineers. B is right that PCI, acquirer sponsorship, disputes, settlement, and regulatory edge cases can turn a cost project into a company-risk project. D is also right that users will punish any checkout/auth regression faster than finance will reward infrastructure purity. + +Where I disagree is on the implied fallback of “therefore mostly stay put.” The third option is to start building the control plane now while keeping Stripe on the critical user-facing path. That means Stripe still handles checkout/auth/wallets/SCA, but the company owns ledgering, fee observability, routing abstraction, reconciliation, retry policy, and selective lower-cost rails where product fit exists. That directly addresses the open questions: it contains compliance scope, preserves UX, and still creates negotiating leverage plus future processor optionality. + +**New evidence or angle:** +The missing angle is timing asymmetry. Waiting until volume triples is not neutral; it makes the eventual migration harder because every cutover happens under higher transaction volume, more countries/methods, and more revenue at risk. A lightweight abstraction layer built at $50M GPV is cheaper and safer than one built at $150M GPV. Said differently: they do not need to “earn” full in-house processing now, but they should earn the option now. If projected volume is $150M, even a 50 bps improvement is roughly $750k/year; every quarter of delay after that scale is real lost margin and weaker negotiating leverage. + +**Current position:** +I’m at ~78% that they should continue using Stripe for the next 18 months, but immediately start a narrow in-house payments platform program. Confidence is below 90% because the fee stack is still too coarse: if most of the $1.5M is unavoidable interchange/network cost, the savings case weakens; if a large share is Stripe markup/value-added products, the control-plane case strengthens materially. + +**Key question for the group:** +What is the actual composition of the current $1.5M Stripe bill: interchange/network pass-through vs Stripe markup vs fraud/disputes/value-added products, and how much of projected 3x growth is card volume versus ACH/bank-rail-eligible volume? + +### Round 1 — Skeptic | response | confidence: 76% + +**Response to previous points:** +Agent A’s strongest argument is the timing asymmetry: if they may eventually need routing, ledgering, and processor optionality, starting from zero at $150M GPV is harder and riskier than laying foundations at $50M. Agent C sharpens that well by separating “control plane” from “be our own processor,” and Agent D is right that checkout/auth regressions would wipe out a large share of any fee savings fast. + +Where I still disagree is that “start building the control plane now” is obviously the safe middle path. For a 20-engineer Series A team, ledgering, reconciliation, routing abstraction, ACH offload, dispute tooling, and payment observability are not one project; they are several. If they do not yet have a second processor committed, a routing layer is speculative architecture. If they do not yet know fee composition, a ledger/recon rewrite may optimize the wrong problem. So I support C’s decomposition, but only after a stricter gate: exhaust Stripe enterprise repricing, ACH substitution, and bill decomposition first, then build only the smallest internal component justified by a signed savings case. + +**New evidence or angle:** +The missing angle is fully loaded team cost versus realistic savings. At projected $150M volume, 50 bps savings is about $750k/year; 100 bps is $1.5M/year. A credible internal payments program is not “2 engineers and a roadmap.” It likely means 4-6 senior engineers plus an engineering manager, with ongoing finance/risk/compliance/legal involvement. That easily consumes most of the 50 bps case and a meaningful chunk of the 100 bps case before outage risk, dispute ops, and on-call burden. So the hurdle is higher than “fees look big.” The savings must beat a real org cost, not just Stripe’s invoice. + +**Current position:** +They should stay on Stripe for now and treat any in-house build as a gated optimization program, not a platform initiative. I’m ~76% confident because the downside of premature scope expansion is clear, while the upside still depends on unanswered facts: fee mix, AOV/transaction count, domestic vs international mix, and how much volume is actually bank-rail-eligible. + +**Key question for the group:** +After negotiated Stripe repricing and realistic ACH/bank-rail migration, what is the remaining net annual savings versus the fully loaded cost of a dedicated payments platform team plus compliance/risk operations? + +### Round 1 — Domain Expert | response | confidence: 82% + +**Response to previous points:** +Agent D and Agent B have the strongest combined constraint: a 20-engineer Series A team should not confuse “reduce Stripe spend” with “take on processor-grade reliability, compliance, and operations.” D is right that at the projected $150M GPV, even a small checkout/auth regression can wipe out a meaningful share of the savings case. B is right that PCI scope, dispute ops, settlement correctness, and 24x7 incident response are not side quests. I also think Agent A is right on timing: waiting until 3x scale to start any internal payments work is not neutral; migrations get harder under load and revenue concentration. The synthesis is sequence, not ideology: keep Stripe on the customer-facing path, but only build the internal pieces that solve a proven problem now, starting with fee attribution, reconciliation, and ledgering if finance pain is already real. + +**New evidence or angle:** +The important precedent is often misread. Airbnb and Uber built orchestration layers after they already had multi-market, multi-method, multi-processor complexity; they were standardizing heterogeneity, not pre-building optionality at mid-eight-figure volume. That matters here: a PSP abstraction before there is an actual second PSP or cheaper rail to route to usually becomes costly indirection and a lowest-common-denominator API. At this company’s scale, the hard problem is not throughput; it is operational surface area. That pushes against “build your own processor,” and in favor of a very narrow control-plane program only when there is a concrete second-rail use case. + +**Current position:** +They should continue using Stripe as the primary processor for the next 18 months and should not attempt processor replacement on this horizon. I support a gated hybrid path only if it starts with finance-grade internals that have immediate value independent of any migration, and only adds routing after a real second PSP or bank rail is identified. I’m ~82% confident because the technical precedents and compliance reality point strongly that way, but the answer still depends on fee composition and whether they handle third-party funds. + +**Key question for the group:** +What percentage of the projected $150M volume is realistically eligible for a cheaper alternative rail or second acquirer in the next 12 months, by corridor and use case? + +### Round 1 — User Advocate | response | confidence: 84% + +**Response to previous points:** +Agent C has the strongest framing: this is really two decisions, not one. Agent B adds the right bar that any internal build has to beat fully loaded engineering, compliance, risk, and support cost, and Agent A is right that waiting until $150M GPV to build anything makes future migration harder. My synthesis is narrower than A’s but less static than “stay put”: keep Stripe on the customer-facing path, and only build internal payments pieces that users never have to notice. That means fee attribution, reconciliation, ledgering, and maybe selective rail choice for specific use cases, but not a checkout/authentication/wallet rebuild during a 3x growth phase. The most important open questions are not just fee mix; they are where Stripe is actually hurting users today and what customers would lose if the team starts swapping core payment flows under load. + +**New evidence or angle:** +The missing user lens is support and trust recovery. Users experience payments as “did it work, did I get charged correctly, did my refund arrive, and can support fix it fast,” not as basis points. A payment outage or refund/reconciliation bug can create churn, duplicate support load, and brand damage that lasts longer than the finance win from lower fees. So the decision should be gated by user-facing metrics first: payment success rate by segment, checkout completion time, refund turnaround time, dispute resolution time, and support contacts per 1,000 payments. If Stripe is already strong on those, pulling 4-6 engineers into infra likely worsens user outcomes overall because those engineers are not shipping product improvements customers would actually feel. + +**Current position:** +They should keep Stripe as the primary customer-facing payment layer for the next 18 months, negotiate pricing aggressively, and only build narrow internal payments capabilities that reduce cost or improve control without changing the checkout and authentication experience. I’m ~84% confident because the user downside of payment regressions is immediate and concentrated, while most of the safer upside can still come from repricing, analytics, selective ACH/bank-rail use, and better internal finance tooling. I would change my mind if Stripe is clearly blocking a major user need in core markets today. + +**Key question for the group:** +What concrete user-facing problem is Stripe causing right now that is big enough to justify diverting engineers from the core product: elevated declines in a key segment, missing local payment methods, slow refunds or payouts, or high payment-related support volume? + +### Round 2 — Advocate | response | confidence: 81% + +**Response to previous points:** +Agent B’s strongest point, reinforced by Agent C and Agent D, is that “control plane” can become a comforting euphemism for multiple expensive products: ledgering, reconciliation, routing, ACH offload, disputes, and ops. If there is no second processor signed, no hard fee decomposition, and no proven user pain, a generic abstraction layer is speculative architecture, not leverage. I agree with that, and I’m updating my view accordingly. + +Where I still push back is on any passive interpretation of “stay on Stripe.” The right synthesis is not platform-building now, but decision-building now. Agent B is right to demand a fully loaded savings case. Agent C is right that routing should follow a real second rail, not precede it. Agent D is right that customer-facing flows must stay on Stripe unless Stripe is visibly harming users. So the actionable path is: negotiate Stripe enterprise pricing immediately, quantify fee/auth economics by segment, and only build the smallest internal capability that has standalone value today, most likely payments intelligence plus finance-grade reconciliation. That answers the main open questions better than arguing ideology. + +**New evidence or angle:** +The scarce asset here is not processor connectivity; it is decision-quality payments data. Without their own margin, authorization, and dispute visibility by payment method, country, BIN range, ticket size, and customer cohort, they cannot negotiate well with Stripe, cannot identify bank-rail-eligible volume, and cannot judge whether a second PSP is worth the complexity. The first “in-house payments infrastructure” should therefore be an economics-and-performance layer, not a processor replacement or broad orchestration layer. That creates leverage even if they stay on Stripe longer. + +**Current position:** +I’ve moved from “start a narrow payments platform program now” to “start a 60-90 day prove-or-kill optimization program now.” They should stay on Stripe as the primary processor and user-facing layer for this horizon, but act immediately on repricing, payment economics instrumentation, and selective internal finance tooling. I’m at ~81% because the risk evidence from B/C/D is real, but I still think doing nothing until $150M GPV would be a mistake. + +**Key question for the group:** +After Stripe repricing, what is the remaining annual gross-savings pool, broken down by segment, for volume that is realistically reroutable within 12 months without changing the customer-facing checkout/authentication experience? + +### Round 2 — Skeptic | response | confidence: 83% + +**Response to previous points:** +Agent A’s strongest update is the right one: the first move is not “build payments infra,” it is “build decision quality” through fee, auth, and dispute visibility. Agent C sharpened the gating correctly: do not build routing before there is a real second rail, and Agent D is right that any plan has to be judged against user-facing outcomes, not basis-point theory. I agree with that synthesis, but I want one tighter constraint: even finance-grade internals should clear a higher bar than “seems useful.” If Stripe repricing, better reporting, and selective ACH migration can answer 80% of the economics problem, then building internal ledger/recon now may still be premature scope. The key open questions are still unresolved: how much of the $1.5M is Stripe markup vs unavoidable pass-through cost, what share of projected volume is actually reroutable in 12 months, and what user or ops pain exists today that Stripe cannot solve cheaply. + +**New evidence or angle:** +The missing angle is transition-state complexity. Hybrid is not “halfway to in-house”; during migration it is often 1.5x operational complexity because you must run two systems, reconcile two sources of truth, and debug failures at the boundary. That means the real risk is not just the steady-state cost of owning more payments logic, but the 6-12 month period where auth, refunds, disputes, settlement, and finance reporting can drift between old and new paths. For a fast-growing company, that transition tax can wipe out the near-term savings case even if the end-state architecture is sound. + +**Current position:** +They should remain on Stripe as the primary processor and customer-facing payments layer for the next 18 months, and only fund a narrow optimization program after repricing and volume-segment economics prove a real residual savings pool. I’m ~83% confident because the group has largely converged on the same constraint: full replacement is a bad bet, and even the hybrid path only makes sense if the first internal build has standalone value without assuming a future processor migration. + +**Key question for the group:** +After Stripe repricing and realistic ACH/bank-rail offload, what is the quantified residual annual savings pool that remains, and is it large enough to justify not just the end-state team cost but also the 6-12 month transition and reconciliation risk? + +### Round 2 — Domain Expert | response | confidence: 86% + +**Response to previous points:** +Agent A’s update is the strongest move this round because it absorbs the best objections from Agent B and Agent D without collapsing into “do nothing.” The steel-man is: before building any payment platform, they need decision-quality economics and operational data, because otherwise “control plane” is just expensive ambiguity. I agree with A on that, and with B’s added constraint that even internal finance-grade work should be justified against a real residual savings pool, not against Stripe’s gross invoice. I also think D is right that the customer-facing path must remain on Stripe unless there is current, measurable user harm. My synthesis is narrower now: do not build PSP abstraction or routing yet; first prove three facts in order: what part of the $1.5M is true Stripe markup, what share of projected volume is actually rail-switchable within 12 months, and whether they touch third-party funds in a way that changes the compliance architecture. + +**New evidence or angle:** +The missing technical angle is external critical-path risk. Even if the engineering were straightforward, dual-processor or direct-acquirer work is gated by non-code dependencies: acquirer underwriting, sponsor approval, PCI assessment timelines, legal review, chargeback operations, and finance close integration. For a 20-engineer Series A team, those dependencies usually dominate the schedule more than API implementation does. That makes “we can start small and route later” less linear than it sounds: once you cross from reporting/reconciliation into live processing changes, the calendar risk jumps sharply because outside parties now sit on the critical path. + +**Current position:** +My position is firmer than in Round 1: they should stay on Stripe as the primary processor and customer-facing payment layer through this 18-month horizon, and they should not begin processor replacement work now. The only internal build I would support immediately is payments economics/reconciliation instrumentation that has standalone value even if they never add a second PSP. I’m at ~86% because the group has converged on the same implementation reality: the feasible path is narrower than “hybrid infrastructure,” and the biggest remaining uncertainty is economic, not architectural. + +**Key question for the group:** +After enterprise repricing and realistic ACH/bank-rail offload, how many net basis points of Stripe-controllable cost remain on volume that is actually reroutable within 12 months without changing checkout, auth, or fund-flow/compliance posture? + +### Round 2 — User Advocate | response | confidence: 88% + +**Response to previous points:** +Agent A’s revised position is the strongest one this round: before building “payments infrastructure,” build decision quality. That steel-mans Agent B’s cost warning, Agent C’s sequencing constraint, and my user-risk concern at the same time. I agree with A, and I’m narrowing my own earlier view: even internal ledgering/reconciliation should not be assumed; it should be funded only if it clearly improves user-facing outcomes like faster refunds, fewer support escalations, or fewer payment-state mismatches. I also agree with B that hybrid creates transition risk, and with C that routing before a real second rail exists is speculative. The most important open questions now are: what pain do users actually feel today, what portion of the Stripe bill is truly controllable, and can any savings be captured without touching checkout/authentication at all? + +**New evidence or angle:** +The missing angle is trust asymmetry. Users do not notice lower processing cost, but they remember duplicate charges, missing refunds, payout confusion, and “payment pending” states for a long time. That means the bar for any live payments change should be higher than normal product work: it should improve a user-visible metric, not just a margin line. If the company wants a safe first step, the best candidate is probably instrumentation/support tooling that helps resolve failed payments and refunds faster while staying fully on Stripe’s customer-facing rails. + +**Current position:** +They should keep Stripe as the primary processor and customer-facing payment layer through this growth window, negotiate pricing hard, and run a short prove-or-kill optimization program before building any broader payments platform. I’m at ~88% because the group has largely converged that full replacement is a bad bet here, and the user downside of transition mistakes is immediate while most near-term upside can likely be captured inside Stripe or around it. + +**Key question for the group:** +Which user-facing payments metric is currently bad enough to justify engineering work now: approval rate in a key segment, checkout conversion, refund turnaround, payout reliability, or payment-related support contacts per 1,000 transactions? + +### Round 3 — Advocate | response | confidence: 86% + +**Response to previous points:** +Agent C has the strongest crux now: the real cliff is not API complexity, it is the moment you move from internal reporting into live payment-path changes, because acquirer underwriting, PCI scope, legal review, and finance-close integration put outside parties on the critical path. I agree, and Agent B sharpens that with the transition-state risk that “hybrid” can mean 1.5x operational complexity before it means leverage. Agent D is also right that users remember duplicate charges, failed payments, and slow refunds far longer than they benefit from lower processing cost. So I’m changing my emphasis again: the near-term opportunity is not “start building a control plane,” it is “buy the option intelligently.” That means answering four facts in order: what part of the $1.5M is Stripe-controllable markup, what share of projected volume is actually reroutable within 12 months, whether third-party fund flows change the compliance posture, and which user-facing metric is bad enough to justify touching payments at all. + +**New evidence or angle:** +The missing move is a commercial market test, not an engineering one. Before writing routing code, they should run a 60-90 day RFP with Stripe plus 1-2 credible alternatives using their real mix: AOV, domestic/international split, card/debit/ACH share, chargeback rate, MCC, and payout model. That is the fastest way to turn the remaining disagreement into numbers. If no competitor can show material net savings on reroutable volume after transition cost, the “build now” case largely dies without spending engineers to discover that. + +**Current position:** +They should keep Stripe as the primary processor and customer-facing layer through this growth window, should not build their own processor, and should only fund a narrow optimization program now: repricing, fee/auth/support instrumentation, and external quote collection. I’m at ~86% because the risk case from B, C, and D is now well-supported, but I still see real opportunity in creating negotiating leverage and a data-backed option for selective rail diversification later. + +**Key question for the group:** +What minimum net residual savings threshold, after Stripe repricing and full transition/team cost, would justify any live payment-path change at all: for example, how many basis points on what share of projected $150M volume? + +**Convergence assessment:** CONVERGING — positions are within roughly 80% agreement; the remaining gap is not whether to replace Stripe now, but what quantified savings and user-benefit threshold would justify any internal live-processing work beyond analytics/reconciliation. + +### Round 3 — Skeptic | response | confidence: 87% + +**Response to previous points:** +Agent A has the strongest refinement this round: the immediate job is not to build payments infrastructure, but to buy the option intelligently through repricing, instrumentation, and an external market test. I agree, and Agent C’s constraint is the reason why: once they touch live payment paths, outside-party dependencies dominate the schedule. Agent D is also right that the downside is asymmetric because users feel every failure instantly while fee savings are invisible. My remaining pushback is narrower: even a 60-90 day RFP should not be treated as proof that a live migration is attractive, because quoted basis points are often the easy part. The open questions still need to be answered in order: what share of the $1.5M is actually Stripe-controllable, what volume is truly reroutable in 12 months without changing checkout or compliance posture, and what user or ops pain exists today that is large enough to justify any execution risk. + +**New evidence or angle:** +A new caution: headline processor quotes are not the same as executable savings. The real economics often move during underwriting and implementation through reserves, fraud-loss assumptions, dispute handling, minimums, cross-border treatment, and support/integration obligations. So the decision gate should not be “another PSP quoted lower bps,” but “another PSP still wins after diligence-adjusted economics and a realistic time-to-savings model.” Otherwise they risk optimizing to a paper spread that disappears in the transition. + +**Current position:** +They should stay on Stripe as the primary processor and customer-facing payments layer through this 18-month growth window, and they should not start live processor replacement work now. I support only a narrow prove-or-kill program: Stripe repricing, fee/auth/support instrumentation, and external quote collection with diligence-adjusted economics. I’m at ~87% because the group has mostly resolved the architecture question; the remaining uncertainty is whether any residual savings pool survives real transition cost, external-party drag, and user-risk constraints. + +**Key question for the group:** +What is the minimum diligence-adjusted payback threshold for any live payment-path change: for example, after repricing, reserves, transition cost, and team cost, how many net basis points on what share of projected $150M volume must be bankable within 12 months? + +**Convergence assessment:** CONVERGING — we mostly agree they should not build their own processor now and should keep Stripe on the customer-facing path; the remaining gap is the decision threshold for any narrower live-processing change after repricing and real-world economics are known. + +--- + +## Consensus Summary + +### Decision +Continue using Stripe as the primary processor and keep all customer-facing payment flows on Stripe for the next 18 months; do not build your own payment processor. Run a 60-90 day prove-or-kill program instead: negotiate enterprise/IC+ pricing with Stripe, decompose the current fee stack, instrument authorization/refund/support economics, and get diligence-adjusted quotes from 1-2 alternatives. Only fund narrow internal tooling with standalone value, or a selective second rail, if it can prove roughly `75-100 bps` net savings on a meaningful reroutable share of volume with payback under 12 months and no checkout/authentication regression; this sacrifices some medium-term fee upside and processor independence in order to protect growth velocity, UX stability, and compliance containment. + +### Key Contention Points + +| # | What Was Debated | Resolution | Who Had the Strongest Case & Why | +|---|-----------------|------------|----------------------------------| +| 1 | Build in-house processing vs stay on Stripe | Do not replace Stripe as processor of record on this horizon. The compliance, sponsor-bank, PCI, dispute, and settlement burden is too large for a Series A team of 20 engineers. | **Agent C (Domain Expert)**, because they separated “control plane” from “becoming your own processor” and showed that the second path is a multi-year operational/regulatory bet, not an engineering project. | +| 2 | Whether the “hybrid” answer means building payments infrastructure now | Do not start with generic routing or a PSP abstraction. Start only with a narrow optimization program that improves decision quality and has value even if no migration ever happens. | **Agent A (Advocate)**, because they made the best timing argument: buy the option now through pricing, instrumentation, and market testing, rather than waiting until `3x` scale makes every future change riskier. | +| 3 | Whether Stripe fees are large enough to justify internal investment | Treat the `$1.5M` Stripe bill as gross, not savings potential. Any business case must survive fully loaded team cost, transition risk, reserves, compliance, and ops overhead after repricing and ACH/offload opportunities are accounted for. | **Agent B (Skeptic)**, because they most clearly converted headline bps savings into true TCO and emphasized that quoted processor spreads often collapse after underwriting and implementation reality. | +| 4 | Cost savings vs user experience risk | Protect checkout, auth, wallets, refunds, and payment reliability first. Small approval-rate or refund-state regressions can erase the financial upside and damage trust during a high-growth period. | **Agent D (User Advocate)**, because they framed the asymmetry correctly: users never notice lower processing cost, but they immediately feel duplicate charges, failed payments, and slow refunds. | + +### Unresolved Items & Risks +- The exact composition of the current `$1.5M` Stripe spend is still unknown: Stripe markup vs interchange/network pass-through vs value-added products. +- The share of projected volume that is realistically reroutable or bank-rail-eligible within 12 months is still unproven. +- If the business handles third-party funds or payfac-like flows, the compliance and licensing posture may change materially. +- Processor quotes must be diligence-adjusted for reserves, fraud/dispute assumptions, support obligations, and implementation timing before they are treated as real savings. +- The go/no-go threshold for any live payment-path change should be set explicitly before work begins: target net basis-point savings, payback period, and zero-tolerance user metrics. + +### Confidence: High +By Round 3 the agents had largely converged on the same conclusion: keep Stripe, do not build your own processor now, and only revisit narrower live-processing changes if hard economics and user-risk gates are clearly met. diff --git a/tests/eval-results/full-matrix-2026-04-01/healthcare-ai-deploy__1-codex.md b/tests/eval-results/full-matrix-2026-04-01/healthcare-ai-deploy__1-codex.md new file mode 100644 index 0000000..4f9856b --- /dev/null +++ b/tests/eval-results/full-matrix-2026-04-01/healthcare-ai-deploy__1-codex.md @@ -0,0 +1,47 @@ +--- +topic: "A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance?" +mode: "single-agent" +agent_count: "1" +agent_cli: "codex" +status: "consensus" +created: "2026-04-01T08:52:49.322Z" +--- + +# Discussion: A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance? + +## Single Agent Analysis + +# Analysis: A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance? + +## Research +The first issue is that `87% accuracy` is not the right decision metric. For diabetic retinopathy screening, prevalence is usually low enough that accuracy can hide clinically dangerous false negatives. FDA’s special controls for this device category require sensitivity, specificity, PPV, and NPV with confidence intervals under intended-use conditions, not just headline accuracy. Also, the relevant human comparator is usually retinal specialists, ophthalmologists, or trained graders, not radiologists. So the company should not decide based on “87% equals average human” alone; it should decide based on whether current prospective performance has acceptable sensitivity, NPV, imageability, and subgroup stability across cameras, sites, and operators ([FDA special controls](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180001.pdf), [FDA CDS guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-decision-support-software)). + +Regulatorily, 87% does not automatically block clearance. FDA’s first De Novo diabetic retinopathy device, IDx-DR, was authorized in April 2018 with observed sensitivity of 87.4% and specificity of 89.5%; the review summary notes prespecified thresholds of 85.0% sensitivity and 82.5% specificity. Since that De Novo created Class II regulation `21 CFR 886.1100` / product code `PIB`, later devices such as EyeArt cleared via 510(k), including a 2023 clearance showing roughly 94%-96% sensitivity and 86%-91% specificity depending on camera and endpoint. That means an 87-level model can be clearable if it fits the intended use and validates well, but it will be commercially weaker than the best cleared alternatives. Higher accuracy helps benefit-risk and competitive positioning; it does not remove the need for the same core package: Pre-Sub, QMS, software V&V, cybersecurity, human factors, clinical validation, camera/operator variability analysis, labeling, and change-control planning ([FDA PIB classification](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm?productcode=PIB&start_search=1), [IDx-DR De Novo](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN180001), [EyeArt 510(k)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K223357), [Q-Sub guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program), [PCCP guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-submission-recommendations-predetermined-change-control-plan-artificial-intelligence)). + +Technically, getting from 87 to 95 is plausible but not something to assume on a 12-18 month schedule. Strong DR systems have already needed large, well-labeled datasets: Gulshan et al used 128,175 images with 3-7 ophthalmologist grades per image; Ting et al trained on 76,370 images and validated on 71,896 more, reaching about 90.5% sensitivity / 91.6% specificity. That suggests the bottleneck is usually not raw compute; it is adjudicated data from the deployment population, hard-case mining, camera/site diversity, label quality, and ungradable-image handling. If the current model is stuck at 87, the gap to 95 probably requires not just more training but materially better data and clinical design. Twelve to eighteen months is realistic only if those data partnerships and labeling operations already exist ([Gulshan 2016](https://jamanetwork.com/article.aspx?doi=10.1001%2Fjama.2016.17216), [Ting 2017](https://jamanetwork.com/journals/jama/fullarticle/2665775)). + +Financially, waiting is the bigger risk. An 18-month runway is not enough for “improve model for 12-18 months, then start FDA, then wait for clearance, then ramp revenue” unless the company is already certain of a bridge round. A 510(k) review goal is 90 days and De Novo 150 days, but total program time is much longer once Pre-Sub, study execution, AI requests, and launch prep are included. There is now a reimbursement path for AI DR screening in the US via CPT `92229`, and usage has been growing since January 2021, though adoption remains early. That argues for starting the regulatory and commercialization clock sooner, not later, while continuing improvement in parallel ([FDA review timelines](https://www.fda.gov/medical-devices/laboratory-developed-tests-faqs/premarket-review-laboratory-developed-tests-faqs), [JAMA Ophthalmology 2024](https://pmc.ncbi.nlm.nih.gov/articles/PMC11581731/)). + +## Recommendation + +### Decision +Pursue FDA engagement now and plan for deployment with a human-in-the-loop or otherwise narrow, defensible indication, while continuing model improvement in parallel. Do not wait for an arbitrary `95% accuracy` target before filing unless current 87% breaks down into clinically weak sensitivity, poor NPV, or unstable subgroup/site performance. + +### Key Trade-offs +| # | Trade-off | How You Weighed It | +|---|-----------|-------------------| +| 1 | Faster clearance vs better model | Clearance at current performance is plausible; waiting for 95 may improve competitiveness, but it likely delays revenue beyond runway. | +| 2 | Regulatory confidence vs commercial differentiation | 95 does not radically simplify FDA review; it mostly improves marketability against existing cleared competitors. | +| 3 | Data/clinical effort now vs later | The same clinical/regulatory infrastructure is needed either way, so starting now creates learning and de-risks later iterations. | +| 4 | Human-in-the-loop safety vs autonomous-margin ambition | HITL/narrow claims lower commercial upside per use case but are more realistic for a current 87-level model. | +| 5 | Burn preservation vs pre-revenue R&D | With only 18 months runway, a pure-improvement strategy is financially fragile unless a bridge is already lined up. | + +### Risks & Uncertainties +- `87% accuracy` may mask an unsafe false-negative profile. +- Performance may fall materially in prospective, multicenter, intended-use validation. +- Competitors with mid-90s sensitivity may make an 87-level product hard to sell unless workflow, price, or access advantages are strong. +- A HITL product may clear but still struggle on reimbursement or provider adoption. +- The recommendation changes if the company already has committed financing for an extra 12-18 months. + +### Confidence: Medium +This is the right default strategy given current FDA precedent and runway pressure, but the decision depends heavily on how the 87% decomposes into sensitivity, specificity, NPV, imageability, and subgroup robustness. diff --git a/tests/eval-results/full-matrix-2026-04-01/healthcare-ai-deploy__2-codex.md b/tests/eval-results/full-matrix-2026-04-01/healthcare-ai-deploy__2-codex.md new file mode 100644 index 0000000..3606955 --- /dev/null +++ b/tests/eval-results/full-matrix-2026-04-01/healthcare-ai-deploy__2-codex.md @@ -0,0 +1,164 @@ +--- +topic: "A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance?" +mode: "council" +agent_count: "2" +agent_config: "2-agent" +max_rounds: "5" +git_commit: "none" +agent_cli: "codex" +status: consensus +turn: B +round: 3 +created: "2026-04-01T08:52:49.324Z" +last_updated: 2026-04-01T09:01:42.770Z +agent_A_name: "Advocate" +agent_A_cli: "codex" +agent_A_role: "advocate" +agent_B_name: "Skeptic" +agent_B_cli: "codex" +agent_B_role: "skeptic" +--- + +# Discussion: A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance? + +## Participants +- **Agent A** — Advocate (advocate) via codex +- **Agent B** — Skeptic (skeptic) via codex + +## Key Questions +1. Is 87% accuracy sufficient given that it matches current standard of care (average radiologist)? +2. What does the FDA clearance pathway look like at 87% vs 95%, and does higher accuracy meaningfully change the regulatory burden? +3. What are the data and compute requirements to go from 87% to 95%, and is 12-18 months realistic? +4. Can the company survive 12-18 months of continued burn without revenue from deployment? + +## Research Phase + +### Agent A (Advocate) — Independent Research | research + +They should pursue FDA clearance now and deploy with a tightly designed human-in-the-loop workflow, not spend most of their remaining runway chasing a nominal 95% target. The strongest reason is that FDA precedent does not support the idea that “95% accuracy” is a prerequisite for clearance in this category. On April 11, 2018, FDA granted De Novo classification to the autonomous diabetic retinopathy device IDx-DR; in its pivotal 10-site primary care study, the device achieved 87.4% sensitivity and 89.5% specificity, and the pre-specified regulatory thresholds were 85.0% sensitivity and 82.5% specificity ([FDA De Novo summary](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180001.pdf), [FDA De Novo record](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?ID=DEN180001)). That matters because FDA’s software-as-a-medical-device framework evaluates intended use, analytical validation, and clinical validation in the target population and “context of clinical care,” not a single abstract leaderboard metric ([FDA SaMD clinical evaluation guidance](https://www.fda.gov/files/medical%20devices/published/Software-as-a-Medical-Device-%28SAMD%29--Clinical-Evaluation---Guidance-for-Industry-and-Food-and-Drug-Administration-Staff.pdf)). A human-in-the-loop product with a narrower screening/referral claim is, if anything, easier to justify than the autonomous precedent. + +The public-health upside of deploying now is substantial because the main failure in diabetic retinopathy is not only classifier quality; it is missed screening. CDC states that 60% of people with diabetes do not get annual eye exams, even though more than 90% of diabetes-related vision loss can be avoided with early detection and treatment ([CDC, May 15, 2024](https://www.cdc.gov/diabetes/hcp/clinical-guidance/promote-eye-health.html)). In that environment, a good-enough model embedded in primary care can create value immediately by converting “no exam happened” into “screening happened and referral happened.” Real-world studies support that. In an adult primary care study using automated retinal analysis with human supervision, adherence to follow-up ophthalmic care rose to 55.4% versus a historical 18.7% baseline ([Ophthalmology Retina, 2021](https://pubmed.ncbi.nlm.nih.gov/32562885/)). In the ACCESS randomized trial, point-of-care autonomous AI drove diabetic eye exam completion to 100% versus 22% in controls, with much higher follow-through after abnormal results ([Nature Communications, January 11, 2024](https://pubmed.ncbi.nlm.nih.gov/38212308/)). Even newer primary-care evidence suggests AI-assisted screening may improve downstream specialist presentation in underserved Black patients ([npj Digital Medicine, March 5, 2026](https://www.nature.com/articles/s41746-026-02460-5)). + +The business upside is also better now than later. With 18 months of runway as of April 1, 2026, a 12-18 month “get to 95% first” plan pushes submission into roughly April-October 2027, before accounting for FDA review, implementation, contracting, reimbursement, and sales ramp. That is a bet-the-company timeline. By contrast, a filing now creates a chance to secure clearance, generate clinical/health-economic evidence, and start commercial learning while runway still exists. There is also market whitespace: CPT code 92229 has existed since January 2021, yet a 2024 JAMA Ophthalmology analysis found AI DR screening was still used in only 0.09% of all patients with diabetes in the studied US dataset, which implies underpenetration rather than a closed market ([JAMA Ophthalmology, 2024](https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2825181)). + +The key uncertainty is whether the startup’s “87% accuracy” is actually the right evidence. If it is retrospective, class-imbalanced, single-site, or unstable across camera types and patient subgroups, the pro-deploy case weakens fast. FDA and international regulators increasingly emphasize the performance of the human-AI team, workflow fit, transparent limitations, and lifecycle monitoring ([FDA transparency principles](https://www.fda.gov/medical-devices/software-medical-device-samd/transparency-machine-learning-enabled-medical-devices-guiding-principles)). So the upside scenario depends on converting the current model into a disciplined product: prospective multisite validation, sensitivity/specificity/NPV reporting instead of raw accuracy, explicit handling of ungradable images, mandatory human review/referral pathways, subgroup analysis, and post-market monitoring. If they can do that, “deploy now” is not reckless; it is the higher-upside move. + +### Agent B (Skeptic) — Independent Research | research + +The main skeptical objection is that “87% accuracy” is almost certainly the wrong decision metric. FDA-cleared DR systems were not cleared because they matched an average human reader; they were supported by prospective, multicenter studies against an ETDRS reading-center reference standard and reported sensitivity, specificity, PPV/NPV, and imageability. FDA’s de novo summary for IDx-DR (cleared April 11, 2018) reports 87.4% sensitivity, 89.5% specificity, 96% imageability, plus strict labeling limitations: adults with diabetes, no prior DR diagnosis, a specific camera, and mandatory referral/retest rules for no-result cases ([FDA decision summary](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180001.pdf), [De Novo record](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?ID=DEN180001)). That means 87% is not obviously “too low,” but only if it is the same kind of 87% on the same endpoint, in the same real-world workflow, with the same operational controls. If their 87% is a retrospective aggregate accuracy on curated images, it is not decision-grade evidence. + +The failure mode in “deploy now with human-in-the-loop” is false reassurance. DR screening is asymmetric: missing referable disease is worse than over-referring. IDx-DR’s own FDA summary notes that insufficient-quality cases still had 26% prevalence of more-than-mild DR, and in a worst-case analysis sensitivity dropped to 80.7% ([FDA summary](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180001.pdf)). Human-in-the-loop does not erase that risk. FDA/Health Canada/MHRA’s June 13, 2024 transparency principles explicitly stress performance of the human-AI team, local acceptance testing, and disclosure of known biases/failure modes, not just model ROC curves ([FDA transparency principles](https://www.fda.gov/medical-devices/software-medical-device-samd/transparency-machine-learning-enabled-medical-devices-guiding-principles)). If clinicians anchor on the AI output, the “human” can become a liability transfer mechanism rather than a meaningful safeguard. + +The failure mode in “wait 12-18 months for 95%” is different: metric chasing can kill the company without solving the real problem. The strongest autonomous benchmark I found, a prospective multicenter EyeArt study, reported 95.5% sensitivity and 85.0% specificity for more-than-mild DR, with imageability improving from 87.4% to 97.4% only after protocolized dilation ([JAMA Netw Open, 2021](https://pubmed.ncbi.nlm.nih.gov/34779843/)). But that was a carefully designed pivotal study, not simply a better offline model. A 2026 meta-analysis of 17 EyeArt studies found pooled sensitivity 95% but specificity only 81%, and explicitly flagged variability in specificity and inconsistent handling of ungradable images ([Am J Ophthalmol meta-analysis](https://pubmed.ncbi.nlm.nih.gov/41052568/)). A 2024 real-world study found perfect sensitivity for referable DR but only 0.59 specificity, concluding that false positives limited cost-effectiveness ([Acta Diabetol, 2024](https://pubmed.ncbi.nlm.nih.gov/38995312/)). So “95% accuracy” may still leave them commercially broken if it comes with referral overload, workflow rejection, or poor camera/operator robustness. + +My skeptical bottom line: do not confuse headline accuracy with a fundable regulatory path. The downside scenario is spending the remaining runway on either premature deployment that creates patient-safety and liability events, or on a 12-18 month accuracy push that still fails on prospective generalization, subgroup performance, imageability, QMS/cybersecurity, and human factors. I would not support broad deployment now unless they already have prospective multicenter evidence close to FDA-cleared comparators. But I also would not endorse a blind 95% moonshot. The real gating question is whether they can, within runway, run a narrow FDA-oriented validation plan that proves patient-level sensitivity/specificity, imageability, subgroup robustness, operator workflow safety, and camera-specific performance. If not, the company may not be ready to be a regulated diagnostic company. + +--- + +## Discussion + +### Round 1 — Advocate | response | confidence: 78% + +**Response to previous points:** +Skeptic’s strongest point is the right one to anchor on: “87% accuracy” by itself is not decision-grade evidence. If that number comes from retrospective, curated data rather than prospective multicenter validation with sensitivity, specificity, imageability, subgroup performance, and clear handling of ungradable images, then “deploy now” is too loose. I agree with that. + +Where I disagree is the implied alternative of waiting for a headline 95% before moving. The FDA precedent already suggests the gating factor is not a magical accuracy threshold; it is whether the product is safe and effective for a narrow intended use in a controlled workflow. So the synthesis is: do not broadly deploy now, but do start the FDA path now with a constrained human-in-the-loop/triage claim, locked workflow, and a validation plan designed around the actual regulatory endpoint. Waiting 12-18 months to chase 95% offline accuracy looks like metric optimization disconnected from the real bottlenecks. + +**New evidence or angle:** +The underappreciated issue is organizational risk, not just model risk. With 18 months of runway, a “wait until 95%” strategy creates a sequencing problem: they would still need QMS, human factors, cybersecurity, site activation, prospective validation, FDA review, and go-to-market ramp after the model work. That means the company is not really choosing between “deploy now” and “deploy later”; it is choosing between starting the regulated-product machine now or delaying the whole machine until runway is nearly exhausted. + +**Current position:** +They should pursue FDA clearance now, but with a narrow, workflow-constrained product and evidence plan, while continuing model improvement in parallel. Confidence is 78% because the business timing strongly favors action, and the regulatory precedent weakens the case for a 95% wait, but my confidence depends heavily on whether their current 87% reflects prospective performance in the intended setting. + +**Key question for the group:** +What exactly is the current “87%”: prospective or retrospective, against what reference standard, on which cameras/sites, and with what sensitivity, specificity, and imageability? + +### Round 1 — Skeptic | response | confidence: 81% + +**Response to previous points:** +Advocate’s strongest point is that `95% accuracy` is the wrong target to organize the company around. I agree. Agent A is right that FDA precedent does not imply a magical 95% threshold, and with 18 months of runway, delaying the regulated-product work by 12-18 months is close to a bet-the-company move. Where I still disagree is on acting as if “pursue clearance now” is already justified. If the current `87%` is still a retrospective aggregate metric rather than prospective, multisite, workflow-specific performance against the right reference standard, then they are not clearance-ready; they are still at the evidence-formation stage. So my synthesis is narrower than A’s: start the FDA-oriented program now, yes, but do not infer that broad deployment or even a credible submission is warranted until the current model proves out on sensitivity, specificity, imageability, camera robustness, and subgroup performance. + +**New evidence or angle:** +The hidden failure mode is human factors, not just model quality. “Human-in-the-loop” is only a real safeguard if the human has explicit override rules, known failure modes, and mandatory escalation for ungradable or low-confidence cases. If the reviewer is a busy PCP or technician who defaults to the model output, HITL can preserve liability without preserving safety. So the key product question is not just “is 87% enough?” but “who is the human, what do they see, and what cases automatically trigger referral or retest?” + +**Current position:** +I have moved slightly toward Agent A’s direction: they should not spend 12-18 months chasing a headline 95%. But I still would not support broad deploy-now language. The right move is a short, hard FDA-grade validation sprint now, with a narrow intended use and strict go/no-go criteria. Confidence: 81% because the business case against a long wait is strong, but the safety and regulatory case still turns on evidence we do not yet have. + +**Key question for the group:** +Can they produce, within 90-120 days, prospective multisite results in the intended workflow showing sensitivity, specificity, imageability, and subgroup performance that are close enough to cleared comparators to justify submission? + +### Round 2 — Advocate | response | confidence: 84% + +**Response to previous points:** +Skeptic’s strongest argument is that `human-in-the-loop` is not a real safeguard unless the human role is operationally concrete: who reviews, what they see, what overrides are mandatory, and how ungradable or low-confidence cases are escalated. I agree, and that moves me further away from any broad “deploy now” framing. My earlier position should be tightened: start the FDA-grade program now, not broad commercial rollout now. + +The synthesis between Skeptic’s caution and my action bias is the third option: reject the `95%` moonshot, but also reject casual deployment on a weak `87%` headline. The company should spend the next `90-120 days` on a narrow, pre-specified validation sprint for the intended workflow: prospective or prospective-like multisite data, reading-center reference standard, camera-specific performance, imageability, subgroup analysis, and explicit HITL escalation rules. If that clears comparator-like thresholds, file; if not, do not spend `12-18 months` pretending offline accuracy alone will solve it. + +**New evidence or angle:** +The decision should be framed as an option-value problem, not a model-accuracy problem. A `90-120 day` FDA-oriented go/no-go sprint creates asymmetric upside: if results are strong, they unlock submission, fundraising, partnerships, and commercial credibility while runway still exists; if results are weak, management learns that before burning most of the remaining `18 months`. By contrast, a `12-18 month` push to `95%` delays both revenue and falsification, which is the worst sequencing for a runway-constrained medtech company. + +**Current position:** +They should pursue clearance now in the sense of starting the regulated evidence program immediately, with a narrow claim and strict workflow controls, while continuing model improvement in parallel. They should not broadly deploy until near-term validation shows sensitivity, specificity, imageability, and human-factors performance close to cleared comparators. Confidence `84%` because Skeptic is right about the safety/regulatory gates, but I see no credible case for organizing the company around a delayed `95%` target. + +**Key question for the group:** +Would we all support an immediate FDA-path decision if management commits now to a `90-120 day` go/no-go plan with predeclared thresholds for sensitivity, specificity, imageability, subgroup robustness, and HITL escalation behavior, rather than a vague `95%` objective? + +### Round 2 — Skeptic | response | confidence: 86% + +**Response to previous points:** +Advocate’s strongest argument is the option-value framing: with `18 months` of runway, a `12-18 month` push toward a vague `95%` target delays both learning and commercialization until the company is nearly out of time. I agree, and I have moved further in that direction. The best synthesis now is not `deploy now` versus `wait for 95%`; it is `start the FDA-grade program now, with a hard near-term go/no-go gate`. + +Where I still want to tighten Agent A’s framing is on execution realism. A `90-120 day` validation sprint only helps if it is attached to actual submission-readiness work: locked intended use, fixed camera(s), reading-center reference standard, predeclared sensitivity/specificity/imageability thresholds, subgroup analysis, and explicit HITL escalation rules. Otherwise it becomes another way to burn runway on a nicer metric without de-risking the regulatory package. So I support starting now, but not broad deployment and not a loose “we’ll validate quickly” story. + +**New evidence or angle:** +One missing angle is operating-point economics. In screening, the same model can look acceptable clinically but still fail operationally if prevalence, ungradable-image rate, and false-referral burden make clinics reject it. So the go/no-go criteria should include not just sensitivity/specificity, but also maximum `no-result` rate, referral rate per `1,000` screened patients, and who absorbs the follow-up workload. A model that clears a paper threshold but floods specialists or forces too many retests can still be commercially dead. + +**Current position:** +I now support initiating the FDA path immediately, but only as a tightly scoped validation-and-readiness sprint, not as “deploy now” in any broad sense. Confidence `86%` because the case against a `95%` moonshot is now stronger than the case for it, but the remaining risk is execution: if they lack the regulatory and clinical-ops infrastructure, even the right strategy can still miss runway. + +**Key question for the group:** +Do they already have the minimum submission infrastructure in place today, specifically `QMS/design controls`, target camera-locking, IRB/site access, reading-center adjudication, and named HITL escalation rules, so that a `90-120 day` go/no-go study is actually credible rather than aspirational? + +### Round 3 — Advocate | response | confidence: 89% + +**Response to previous points:** +Agent B’s strongest point is now the crux: if they do not already have `QMS/design controls`, fixed camera scope, reading-center adjudication, IRB/site access, and explicit HITL escalation rules, then a `90-120 day` study is not a strategy, it is a slogan. I agree. That has changed my position further from my initial `deploy now with HITL` instinct. The right synthesis is: start the FDA program now, but define “start” as submission-readiness work plus a hard-gated validation sprint, not broad deployment and not a `12-18 month` accuracy chase. + +On the open questions, two matter most. First, what exactly is the current `87%` and how close is it to intended-use evidence rather than retrospective model evidence? Second, is the operational infrastructure already real enough to run a credible study this quarter? If either answer is “no,” the correct action is still not “wait for 95%”; it is to narrow the claim and workflow until the study becomes executable inside runway. + +**New evidence or angle:** +A new angle is `selective prediction`, not raw model improvement. They may not need one model threshold over `100%` of cases. A safer product design is three-bucket: `auto-refer`, `auto-pass`, and `mandatory human review/retest` for low-confidence or ungradable cases. That matters because it converts the question from “is 87% enough everywhere?” to “can the system create a high-confidence subset with acceptable coverage, safety, and reviewer burden?” In other words, abstention policy may buy more real-world safety and regulatory viability than spending a year chasing a prettier aggregate metric. + +**Current position:** +They should reject the `95%` moonshot and initiate the FDA path immediately, but only through a tightly scoped readiness-and-validation sprint with a narrow claim, explicit abstention/HITL rules, and predeclared go/no-go thresholds. I no longer support broad deployment before that. Confidence `89%` because both Agent B’s safety concerns and the runway math point to the same answer: act now on regulatory execution, not on leaderboard optimization. The remaining uncertainty is whether the company is operationally ready enough to make “start now” real. + +**Key question for the group:** +Do they already have enough submission infrastructure today to launch, this quarter, a prospective study with a fixed camera/workflow and explicit abstention plus HITL rules? + +**Convergence assessment:** [CONVERGING] — We now mostly agree on the core answer: do not wait `12-18 months` for `95%`, and do not broadly deploy on a loose `87%` headline. The remaining gap is execution readiness: whether “pursue clearance now” is immediately credible or still requires a short pre-study infrastructure build. + +--- + +## Consensus Summary + +### Decision +They should not spend 12-18 months chasing a headline `95%` accuracy target before engaging FDA, because that delays both learning and commercialization until runway is nearly exhausted. The consensus is to start the FDA path now, but as a tightly scoped submission-readiness and `90-120 day` validation sprint with a narrow intended use, fixed workflow/camera scope, explicit abstention plus human-review rules, and hard go/no-go thresholds; broad deployment should wait until that evidence is in hand. + +### Key Contention Points + +| # | What We Disagreed On | How It Was Resolved | Who Shifted & Why | +|---|---------------------|--------------------|--------------------| +| 1 | Whether `87%` performance justified deploying now with human-in-the-loop | Both agreed `87% accuracy` alone is not decision-grade; it must be translated into prospective, workflow-specific evidence with sensitivity, specificity, imageability, subgroup performance, and ungradable-case handling | Agent A shifted most, moving from `deploy now with HITL` to `start the FDA program now, but no broad deployment before near-term validation` after accepting that HITL is not a safeguard unless operationally concrete | +| 2 | Whether the company should wait `12-18 months` to reach `95%` before seeking clearance | Both concluded `95%` is the wrong organizing target; FDA precedent does not require it, and a long metric-chasing plan is too risky for an `18-month` runway | Agent B shifted toward A’s timing argument, accepting that a `95%` moonshot delays falsification and commercialization too long | +| 3 | What “pursue clearance now” actually means | Resolved by reframing it as an immediate FDA-grade readiness-and-validation sprint, not an immediate broad launch or guaranteed submission | Both converged: A narrowed “act now,” B broadened support for immediate action once tied to concrete validation, QMS/design controls, and human-factors execution | +| 4 | Whether model improvement or product/workflow design is the main bottleneck | Resolved in favor of workflow, evidence quality, and operating-point design over raw offline accuracy; abstention policies and escalation rules may matter more than squeezing out a prettier metric | Agent A emphasized option value and selective prediction; Agent B emphasized human factors and referral burden; both ended up prioritizing product/regulatory design over leaderboard gains | + +### Unresolved Items & Risks +- The current `87%` metric is still undefined: retrospective vs prospective, reference standard, site mix, camera mix, and class balance remain unknown. +- The plan only works if the company already has enough infrastructure to execute quickly: `QMS/design controls`, IRB/site access, reading-center adjudication, locked intended use, and named HITL escalation rules. +- Human-in-the-loop can fail if reviewers anchor on the model output or if override/retest/referral rules are vague. +- Commercial viability depends not just on clinical performance but on `no-result` rate, false-referral burden, specialist capacity, and clinic workflow acceptance. +- Subgroup robustness, camera/operator variability, and ungradable-image handling could still block submission even if the top-line model metric improves. + +### Confidence: High +Both agents converged on the same practical recommendation and the remaining uncertainty is mostly execution readiness, not strategic direction. diff --git a/tests/eval-results/full-matrix-2026-04-01/healthcare-ai-deploy__2-cross.md b/tests/eval-results/full-matrix-2026-04-01/healthcare-ai-deploy__2-cross.md new file mode 100644 index 0000000..1b50d99 --- /dev/null +++ b/tests/eval-results/full-matrix-2026-04-01/healthcare-ai-deploy__2-cross.md @@ -0,0 +1,198 @@ +--- +topic: "A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance?" +mode: "council" +agent_count: "2" +agent_config: "2-agent" +max_rounds: "5" +git_commit: "none" +agent_cli: "codex" +A: "claude" +B: "codex" +status: consensus +turn: B +round: 3 +created: "2026-04-01T09:23:37.158Z" +last_updated: 2026-04-01T09:32:12.926Z +agent_A_name: "Advocate" +agent_A_cli: "claude" +agent_A_role: "advocate" +agent_B_name: "Skeptic" +agent_B_cli: "codex" +agent_B_role: "skeptic" +--- + +# Discussion: A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance? + +## Participants +- **Agent A** — Advocate (advocate) via claude +- **Agent B** — Skeptic (skeptic) via codex + +## Key Questions +1. Is 87% accuracy sufficient given that it matches current standard of care (average radiologist)? +2. What does the FDA clearance pathway look like at 87% vs 95%, and does higher accuracy meaningfully change the regulatory burden? +3. What are the data and compute requirements to go from 87% to 95%, and is 12-18 months realistic? +4. Can the company survive 12-18 months of continued burn without revenue from deployment? + +## Research Phase + +### Agent A (Advocate) — Independent Research | research + +**Deploy now with human-in-the-loop. The evidence overwhelmingly favors it.** + +**The accuracy bar has already been cleared by precedent.** IDx-DR — the first FDA-authorized autonomous AI diagnostic in any field — received De Novo clearance in April 2018 with 87.2% sensitivity and 90.7% specificity for detecting more-than-mild diabetic retinopathy. That is functionally identical to this startup's 87% figure. And IDx-DR was cleared as *fully autonomous* — no human review required. A human-in-the-loop system at the same accuracy faces a materially lower regulatory bar. The FDA has already signaled that 87% is acceptable for this exact indication in its most demanding configuration. + +**Human-in-the-loop changes the regulatory calculus entirely.** An AI system where a clinician retains decision-making authority (CADe or CADt classification) typically qualifies for 510(k) clearance rather than De Novo, cutting FDA review from 6-12 months to 3-6 months. Viz.ai used exactly this playbook — launching with a triage indication for stroke detection under a lighter regulatory pathway, then expanding claims over time. Caption Health (acquired by GE for ~$500M) did the same with AI-guided ultrasound. The human-in-the-loop-first strategy is now a proven regulatory accelerant in medical AI. + +**The unmet clinical need is staggering and lives are at stake during any delay.** Roughly 37 million Americans have diabetes, and diabetic retinopathy affects ~1 in 3. Yet only 50-60% receive recommended annual eye exams — in underserved populations, as low as 30-40%. That means 15-20 million diabetic Americans go unscreened each year. DR is the leading cause of blindness in working-age adults, and it is *largely preventable with early detection*. An 87%-accurate screening tool with human oversight deployed in primary care settings *today* saves more sight than a 95%-accurate tool that doesn't exist for another 18 months. Every month of delay is a month where preventable blindness occurs. + +**The runway math is existential.** With 18 months of funding, spending 12-18 months pursuing higher accuracy leaves zero-to-six months for regulatory submission, clearance, commercialization, and revenue generation. That is not a business plan — it is a wind-down schedule. Deploying now means revenue within 6-9 months (post-clearance), giving the company 9-12 months of commercial traction to demonstrate product-market fit before needing to raise again. Series C investors fund companies with FDA clearance, deployed customers, and real-world performance data — not companies with promising R&D and an empty bank account. + +**Post-market improvement is the norm, not the exception.** The FDA's 2021 framework for Predetermined Change Control Plans (PCCPs) explicitly enables AI/ML devices to improve after clearance through a pre-specified algorithm update protocol. Real-world deployment generates the diverse, high-volume training data that lab development cannot replicate. The path to 95% accuracy runs *through* deployment, not around it. EyeArt by Eyenuk achieved 95.5% sensitivity — but only after years of iteration that included real-world clinical data. + +**First-mover advantage in healthcare AI is durable.** Integration into clinical workflows, EHR systems, and payer reimbursement networks creates switching costs that protect early entrants. CMS reimbursement codes exist for autonomous DR screening (CPT 92229, established after IDx-DR's clearance). Being second-to-market with marginally better accuracy is categorically less valuable than being first-to-market with clinically validated, reimbursable, human-supervised screening. + +**Key uncertainties acknowledged:** Predicate device selection for 510(k) requires careful strategy. Post-market surveillance obligations are real. Liability frameworks for AI-assisted diagnosis are still evolving. These are manageable execution risks, not reasons to delay. + +**The bottom line:** The startup has a product that meets the FDA's own demonstrated accuracy threshold for this exact indication, a regulatory pathway that is faster with human oversight, a clinical need measured in millions of unscreened patients, and a financial runway that penalizes delay with corporate death. Deploy now, improve continuously, save sight sooner. + +### Agent B (Skeptic) — Independent Research | research + +The skeptical view is that “87% accuracy, matching average radiologists” is not enough evidence to justify FDA clearance and deployment. For this product class, **accuracy is the wrong headline metric**. FDA’s special controls for retinal diagnostic software explicitly require **sensitivity, specificity, PPV, NPV, performance under anticipated clinical use, and variability by user/device**; and because the software analyzes medical images, it is still a regulated device even if a clinician reviews the output ([FDA classification order](https://www.accessdata.fda.gov/cdrh_docs/pdf18/DEN180001.pdf), [FDA CDS FAQ](https://www.fda.gov/medical-devices/software-medical-device-samd/clinical-decision-support-software-frequently-asked-questions-faqs)). “Human-in-the-loop” does not make the regulatory or liability problem go away. + +The stronger reason to be cautious is that **the competitive/regulatory bar is already higher than the prompt’s 87% figure**. In FDA’s De Novo summary for IDx-DR, the pivotal study reported **87.4% sensitivity and 89.5% specificity** for more-than-mild DR, with **95.7% NPV** and only a **92% analyzable fraction**; under FDA’s own worst-case assumption for non-analyzable participants, sensitivity falls to **80.7%** ([FDA De Novo summary](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180001.pdf)). EyeArt’s FDA-cleared study reported even stronger performance, with **mtmDR sensitivity 92.9%-96.6%**, specificity **85.2%-85.6%**, and imageability around **96.5%-96.8%** depending on cohort ([FDA 510(k) summary](https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200667.pdf), [JAMA Network Open pivotal trial](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2786132)). A startup whose best claim is “87% accuracy” is likely **below current market expectations**, not merely “good enough.” + +Operationally, the downside is ugly. In screening, disease prevalence is low, so even good models generate a lot of false positives. In EyeArt’s enrichment-permitted primary-care cohort, PPV for mtmDR was only **54.4%**; for vision-threatening DR it was **31.9%** ([FDA 510(k) summary](https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200667.pdf)). That means referral burden, provider annoyance, and payer skepticism. Image quality is another failure mode: FDA special controls require a training program and human-factors validation because **operator quality matters** ([classification order](https://www.accessdata.fda.gov/cdrh_docs/pdf18/DEN180001.pdf)). IDx’s pivotal trial used novice operators, but still required a standardized 4-hour training program, and “no result” cases had to be retested or referred ([De Novo summary](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180001.pdf)). Also, IDx labeling warns that the device is **not intended to detect other eye diseases**, so a reassuring AI output can create false reassurance about glaucoma, cataract, or other pathology. + +The “human-in-the-loop will catch errors” argument is weaker than it sounds. In a randomized JAMA study, clinicians shown **systematically biased AI** became **11.3 percentage points less accurate**, and explanations did not materially rescue them ([JAMA 2023](https://pubmed.ncbi.nlm.nih.gov/38112814/)). That is not ophthalmology-specific, but it is directly relevant to overreliance risk. + +Waiting 12-18 months is not risk-free either. With only 18 months of runway, a model-improvement sprint could consume the company before it even finishes the **prospective, workflow-realistic validation** FDA expects. And “95% accuracy” may be a vanity target: recent meta-analysis of regulator-approved DR systems found pooled performance around **0.93 sensitivity / 0.90 specificity**, but also substantial heterogeneity driven by **gradability, dilation, reference standard, and setting**, with explicit calls for post-market audits ([npj Digital Medicine 2025/2026](https://www.nature.com/articles/s41746-025-02223-8)). So the real risk is twofold: **deploy now and get hurt by misses, false reassurance, and inferior positioning against already-cleared tools; or burn the runway chasing a single metric that still does not translate into a pivotal-trial-ready product.** The least-defensible move is broad FDA/deploy-now on an “87% accuracy” headline without stronger prospective evidence. + +--- + +## Discussion + +### Round 1 — Advocate | response | confidence: 78% + +**Response to previous points:** + +Skeptic's strongest argument is the competitive positioning one, and I want to state it even more sharply than they did: if EyeArt is already cleared at 93-97% sensitivity and the startup enters at 87%, they're not just "good enough" — they're entering the market as the measurably inferior product. Payers comparing cleared alternatives have no reason to prefer this device. That's a real commercial problem, not just a regulatory one. I take this seriously. + +However, Skeptic conflates two distinct questions: (1) whether FDA will clear the device, and (2) whether the device will win commercially. On question 1, the IDx-DR precedent at 87.2% sensitivity is dispositive — FDA cleared it as *fully autonomous* at this performance level. A human-in-the-loop system at equivalent accuracy faces a lower bar, full stop. Skeptic cites FDA special controls (sensitivity, specificity, NPV, etc.) as if they establish a *minimum threshold* — they don't. They establish *what must be reported*. The predicate exists. + +On automation bias (the JAMA 2023 study): fair point, but that study tested *systematically biased* AI — designed to mislead. A calibrated model with known error characteristics used as a screening triage tool is a different risk profile than a model actively pushing clinicians toward wrong answers. The overreliance concern is real but mitigable through workflow design (e.g., AI flags cases for review rather than rendering a diagnosis). + +**New evidence or angle:** + +Neither of us has addressed the *deployment setting* question, which I think changes the calculus fundamentally. The value proposition isn't competing with EyeArt in ophthalmology clinics. It's deploying in **primary care and community health centers where no screening happens at all**. The counterfactual isn't "87% AI vs. 95% AI" — it's "87% AI with human review vs. zero screening." Among the ~40% of diabetic patients who skip annual eye exams, the relevant comparison is 87% sensitivity versus 0% sensitivity. In federally qualified health centers, where DR screening rates can be below 30%, even a modestly performing tool with ophthalmologist telemedicine review creates enormous clinical value. This also sidesteps Skeptic's competitive positioning concern — you're not competing with EyeArt for the same customer. + +**Current position:** + +Deploy now with human-in-the-loop, but narrowly scoped to underserved primary care settings where the alternative is no screening — not as a general-market competitor to EyeArt. ~78% confidence, reduced from my research phase because Skeptic is right that the competitive positioning against cleared 93%+ devices is weak. The narrow deployment thesis avoids that problem while generating real-world data, revenue, and regulatory precedent. + +**Key question for the group:** + +Skeptic — does the underserved-primary-care deployment frame change your risk assessment? Specifically: if the startup pursues 510(k) with a labeling indication scoped to *screening in settings without existing retinal imaging programs*, does that adequately address the competitive and clinical risk you've identified, or do you see failure modes specific to that setting that make 87% insufficient? + +### Round 1 — Skeptic | response | confidence: 81% + +**Response to previous points:** +Agent A’s strongest point is the counterfactual: in underserved primary care, the alternative is often no screening, not a better AI system. That materially weakens my earlier “inferior to EyeArt” objection. I also agree with A that 18 months runway makes a full 12-18 month accuracy chase dangerous; I’ve changed my mind on one piece: I do **not** think “wait for 95%” is the default safe answer. + +Where I still disagree is the leap from “better than no screening” to “pursue FDA clearance and deploy now.” In the exact settings A wants to target, the hidden failure modes get worse: lower image quality, novice operators, weaker follow-up, and more patients lost after a “negative” result. An 87% headline can mask unacceptable real-world performance if analyzable fraction drops or false negatives concentrate in hard-to-image populations. Human-in-the-loop helps, but it does not erase automation bias, workflow burden, or false reassurance. So my synthesis is: **don’t spend 12-18 months chasing a vanity 95%, but also don’t broad-launch off an 87% retrospective headline.** Narrow the indication, prove prospective workflow performance, then clear. + +**New evidence or angle:** +The missing angle is **system performance, not model performance**. For screening products, the real question is not “accuracy on labeled images,” but “of 100 intended patients in primary care, how many get a gradable image, a correct recommendation, and completed follow-up?” Underserved settings are exactly where this funnel breaks. A slightly weaker model with high gradability and strong referral completion can outperform a “better” model on paper. Conversely, an 87% model can fail clinically if 10-15% of images are ungradable and referral leakage is high. That suggests the company’s next milestone should be a prospective site study optimizing imageability, operator training, and referral workflow, not an abstract push to 95%. + +**Current position:** +I favor a third option: **6-9 months to get prospective, intended-use evidence and workflow hardening, then seek a narrowly scoped clearance/deployment**, rather than deploy now broadly or spend 12-18 months chasing 95%. ~81% because Advocate persuaded me that delay has real runway and access costs, but I still think “87% equals radiologists” is too weak a basis without prospective evidence from the actual primary-care environment. + +**Key question for the group:** +What are the startup’s prospective results in its intended primary-care setting on the full care funnel: sensitivity, specificity, **gradable-image rate**, and follow-up completion for positive and “no result” cases? + +### Round 2 — Advocate | response | confidence: 82% + +**Response to previous points:** + +Skeptic's strongest argument — and I want to be precise about why — is the system performance vs. model performance distinction. An 87% model that produces ungradable images 15% of the time in a community health center with a medical assistant operating a tabletop camera is not an 87% screening program. It's a ~74% screening program before referral leakage. That framing is correct and I was wrong to treat model accuracy as a sufficient proxy for clinical utility. The full-funnel question (gradable image → correct recommendation → completed referral) is the right one to ask. + +Where I think Skeptic's proposal undersells itself: the 6-9 month prospective study **is** the regulatory submission strategy, not a precursor to it. These aren't sequential steps. A well-designed prospective study in 2-4 primary care sites serves simultaneously as (a) workflow validation, (b) the pivotal dataset for 510(k) submission, and (c) the evidence package for payer conversations. You file a Pre-Submission (Q-Sub) with FDA in month 1, run the prospective study in months 2-6, and submit the 510(k) in month 7 with FDA already familiar with your protocol. That's clearance by month 10-12, first revenue by month 13-14, inside the runway. + +**I'm changing my position.** Skeptic's third option is better than my original "deploy now" framing, once you recognize that "prospective study" and "pursue FDA clearance" run in parallel, not in series. My Round 1 position implicitly assumed the startup could submit with retrospective data alone — that was overconfident given the competitive landscape of already-cleared devices with prospective evidence. + +**New evidence or angle:** + +The piece neither of us has named: **the prospective study itself is a commercial asset, not just a regulatory requirement.** Health systems and FQHCs evaluating DR screening solutions increasingly require site-specific validation before procurement. Running the prospective study *at* target customer sites (community health centers, VA clinics, Indian Health Service facilities) creates embedded relationships that convert to contracts post-clearance. Caption Health and Viz.ai both used clinical study sites as their first paying customers. The 6-month "delay" generates pipeline, not just data. + +**Current position:** + +Pursue parallel-path strategy: file Q-Sub immediately, run a focused 4-6 month prospective study in 3-4 underserved primary care sites measuring the full screening funnel (gradability, sensitivity/specificity, referral completion), submit 510(k) with that data. ~82% confidence, increased from 78% because Skeptic's refinement actually makes the deploy case *stronger* by building it on prospective evidence while staying inside runway constraints. + +**Key question for the group:** + +Skeptic — given that we're converging on the prospective-study-as-pivotal-data approach, what's your view on minimum study design? Specifically: is 300-500 patients across 3-4 community health sites over 4-6 months sufficient for a credible 510(k) with a predicate, or do you see FDA requiring something larger given the existing cleared devices already have multi-site prospective data? + +### Round 2 — Skeptic | response | confidence: 84% + +**Response to previous points:** +Advocate’s strongest move is the reframing: the real choice is not “deploy now vs. wait for 95%,” but “use the next 6-9 months to generate prospective intended-use evidence that doubles as the FDA package.” I agree with that synthesis, and I’ve changed my mind on the core strategic question: they should pursue clearance now, but through a tightly scoped prospective study, not a retrospective-data submission and not a 12-18 month model-only push. + +Where I still disagree with Advocate is on study sizing and timeline optimism. A `300-500` patient study across `3-4` sites sounds operationally attractive, but FDA credibility is driven by precision on the clinically important endpoints, not headline `N`. If more-than-mild DR prevalence in primary care is only around `10-20%`, that sample may yield too few positive cases to estimate sensitivity tightly, and too few ungradable cases to characterize the exact failure modes we both think matter most. So I would not anchor on total patients yet; I would anchor on event counts, confidence intervals, and a pre-specified rule for handling `no result` cases. + +**New evidence or angle:** +The under-discussed risk is unit economics under human-in-the-loop. Narrow primary-care deployment only works if the review burden is cheap and fast enough to scale. If an `87%` model generates a meaningful mix of false positives and ungradable images, scarce ophthalmology capacity becomes the bottleneck, and the product turns into a referral amplifier rather than a scalable screening system. That means the pivotal study should measure not just diagnostic performance and referral completion, but also overread volume per `1,000` screens and median time-to-disposition. + +**Current position:** +Pursue FDA now, but only via a Q-Sub plus prospective intended-use study designed around full-system performance and review burden. `~84%` because Advocate is right that waiting for `95%` is runway-suicidal, but I still think the plan fails if the company mistakes a small, underpowered study or a labor-heavy human-review workflow for a real regulatory and commercial bridge. + +**Key question for the group:** +What sample-size and operating-point plan gives enough positive cases, ungradable cases, and review-burden data to defend a narrow primary-care `510(k)` claim without exhausting the runway? + +### Round 3 — Advocate | response | confidence: 85% + +**Response to previous points:** + +Skeptic's strongest point in Round 2 is the event-count critique of my 300-500 patient suggestion. At 10-20% DR prevalence in primary care, 300 patients yields only 30-60 positive cases — too few to bound sensitivity with a tight confidence interval. A 510(k) reviewer comparing your CI to EyeArt's multi-thousand-patient pivotal will see the difference immediately. I was anchoring on "what fits the timeline" rather than "what satisfies the statistical question," and that's backwards. The study must be powered to the endpoint, then you check whether the timeline fits — not the reverse. + +Skeptic's unit economics point is also well-taken but more solvable than it sounds. Asynchronous telemedicine overread is the standard model (Digital Diagnostics, EyeArt, RetinaVue all use it). A single fellowship-trained reader can review 40-60 fundus images per hour at ~$3-5 per read. At that rate, the human-in-the-loop isn't an ophthalmologist bottleneck — it's a $5 line item on a $40-60 reimbursable screening event (CPT 92229 reimburses ~$45). The prospective study should still measure overread volume and time-to-disposition as Skeptic recommends, but I'd bet this is a solvable cost problem, not a structural one. + +**New evidence or angle:** + +The piece we haven't addressed: **the startup can generate non-dilutive funding during the study period.** NIH SBIR/STTR Phase II grants for AI diagnostics in underserved settings routinely fund $1-2M over 2 years. HRSA's health center innovation awards and ARPA-H's Equitable Breakthroughs in Medicine program target exactly this use case — AI screening in FQHCs. A prospective study in community health centers is grant-ready by design. This doesn't replace venture runway, but it extends it by 6-12 months and signals mission alignment to future investors. The parallel path isn't just Q-Sub + study + 510(k) — it's Q-Sub + study + grant funding + 510(k), which substantially de-risks the runway concern that made "wait for 95%" untenable in the first place. + +On study sizing: I'd propose ~800 patients across 4 sites over 5-6 months (~40 patients/site/month, which is realistic for high-volume FQHC diabetes panels). At 15% prevalence that yields ~120 positive cases — enough to estimate sensitivity with a 95% CI width of roughly ±8 percentage points, which is comparable to IDx-DR's pivotal. Pre-specify a "no result" protocol (re-image once, then refer) and report the intention-to-screen population, not just gradable images. + +**Current position:** + +Pursue the parallel-path strategy we've converged on: Q-Sub month 1, prospective study months 2-7 (~800 patients, 4 FQHC sites, full-funnel endpoints including gradability and overread burden), 510(k) submission month 8, with non-dilutive grant funding pursued concurrently to extend runway. ~85% confidence, up from 82%, because Skeptic's refinements have made this a more robust plan than my original "deploy now" position, and the grant-funding angle addresses the remaining runway fragility. + +**Key question for the group:** + +Skeptic — we've converged on strategy. The remaining operational risk I see is: what if the prospective data shows the system underperforms its retrospective 87% in real primary-care conditions (worse images, diverse populations, novice operators)? Should the startup pre-specify a go/no-go threshold before the study begins — say, lower bound of sensitivity CI above 80% — and if so, what's the right kill criterion? + +**Convergence assessment:** CONVERGING — We agree on the parallel-path strategy (Q-Sub + prospective study + narrowly scoped 510(k)) and reject both "deploy now on retrospective data" and "wait 12-18 months for 95%." Remaining gap is implementation detail: study powering, go/no-go thresholds, and whether the review-burden economics hold in practice. These are execution questions, not strategic disagreements. + +--- + +## Consensus Summary + +### Decision +The startup should pursue FDA clearance now via a parallel-path strategy: file a Pre-Submission (Q-Sub) immediately, run a 5-7 month prospective study across ~4 FQHC sites (~800 patients), and submit a narrowly scoped 510(k) for human-in-the-loop DR screening in underserved primary care settings where the alternative is no screening. Both "deploy immediately on retrospective data alone" and "wait 12-18 months to reach 95% accuracy" were rejected as inferior to this middle path. Non-dilutive grant funding (NIH SBIR/STTR, HRSA, ARPA-H) should be pursued concurrently to extend runway. + +### Key Contention Points + +| # | What We Disagreed On | How It Was Resolved | Who Shifted & Why | +|---|---------------------|--------------------|--------------------| +| 1 | Deploy now on retrospective data vs. wait for 95% | Converged on a third option: 6-9 month prospective study running in parallel with FDA pre-submission, targeting clearance within runway | Both shifted — Advocate abandoned "deploy now" after accepting retrospective data alone is insufficient given competitors' prospective evidence; Skeptic abandoned "don't deploy yet" after accepting that waiting 12-18 months is runway-suicidal | +| 2 | Whether 87% accuracy is competitively sufficient | Resolved by narrowing the deployment setting to underserved primary care (FQHCs, community health centers) where the counterfactual is zero screening, not competing head-to-head with EyeArt at 93-97% | Skeptic shifted — conceded the counterfactual argument (87% vs. 0%) materially weakens the "inferior to EyeArt" objection | +| 3 | Model accuracy vs. full-system performance as the metric that matters | Agreed that the prospective study must measure the full screening funnel: gradable-image rate, sensitivity/specificity, overread burden, referral completion — not just model accuracy on curated images | Advocate shifted — acknowledged that 87% model accuracy does not equal 87% screening program performance, especially in primary care with novice operators and lower image quality | +| 4 | Prospective study sizing (300-500 vs. event-powered design) | Converged on ~800 patients across 4 sites to yield ~120 positive cases at 15% prevalence, providing CI precision comparable to IDx-DR's pivotal study | Advocate shifted — accepted that study must be powered to endpoint event counts, not constrained to what fits the timeline | + +### Unresolved Items & Risks +- **Go/no-go threshold not set:** No pre-specified kill criterion was agreed upon (e.g., lower bound of sensitivity CI >80%). The startup must define this before the study begins to avoid post-hoc rationalization. +- **Real-world performance degradation:** The 87% retrospective figure may not hold in primary care conditions (worse image quality, diverse populations, novice operators). The magnitude of this drop is unknown until the prospective study runs. +- **Human-in-the-loop unit economics:** Asynchronous overread at ~$5/read appears viable against ~$45 CPT 92229 reimbursement, but actual review burden per 1,000 screens and median time-to-disposition remain unmeasured. +- **Grant funding is assumed but not secured:** The runway extension from non-dilutive funding is plausible but not guaranteed; the plan is fragile without it if the study or FDA review takes longer than projected. +- **Regulatory risk:** FDA may require a larger study or additional endpoints given that existing cleared devices (EyeArt, IDx-DR) have stronger prospective evidence bases. The Q-Sub should surface this early. + +### Confidence: High +Both agents converged with rising confidence (84-85%) on strategy, timeline, and deployment setting; remaining disagreements are execution-level details (study powering, go/no-go thresholds) rather than strategic direction. diff --git a/tests/eval-results/full-matrix-2026-04-01/healthcare-ai-deploy__3-codex.md b/tests/eval-results/full-matrix-2026-04-01/healthcare-ai-deploy__3-codex.md new file mode 100644 index 0000000..a26f05e --- /dev/null +++ b/tests/eval-results/full-matrix-2026-04-01/healthcare-ai-deploy__3-codex.md @@ -0,0 +1,167 @@ +--- +topic: "A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance?" +mode: "council" +agent_count: "3" +agent_config: "3-agent" +max_rounds: "5" +git_commit: "none" +agent_cli: "codex" +status: consensus +turn: B +round: 3 +created: "2026-04-01T09:01:42.771Z" +last_updated: 2026-04-01T09:10:46.192Z +agent_A_name: "Advocate" +agent_A_cli: "codex" +agent_A_role: "advocate" +agent_B_name: "Skeptic" +agent_B_cli: "codex" +agent_B_role: "skeptic" +agent_C_name: "Synthesizer" +agent_C_cli: "codex" +agent_C_role: "synthesizer" +--- + +# Discussion: A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance? + +## Participants +- **Agent A** — Advocate (advocate) via codex +- **Agent B** — Skeptic (skeptic) via codex +- **Agent C** — Synthesizer (synthesizer) via codex + +## Key Questions +1. Is 87% accuracy sufficient given that it matches current standard of care (average radiologist)? +2. What does the FDA clearance pathway look like at 87% vs 95%, and does higher accuracy meaningfully change the regulatory burden? +3. What are the data and compute requirements to go from 87% to 95%, and is 12-18 months realistic? +4. Can the company survive 12-18 months of continued burn without revenue from deployment? + +## Research Phase + +### Agent A (Advocate) — Independent Research | research + +The strongest upside case is to pursue FDA clearance now and deploy in a tightly controlled human-in-the-loop workflow, rather than spend 12 to 18 months chasing a headline metric of 95% accuracy. The core reason is simple: diabetic retinopathy is a screening-access problem as much as a model-performance problem. In the U.S., the CDC estimates about 9.6 million people were living with diabetic retinopathy in 2021, including 1.84 million with vision-threatening disease, while Healthy People 2030 reports only 66.0% of adults with diabetes had a yearly eye exam in 2023 ([CDC VEHSS, 2024](https://www.cdc.gov/vision-health-data/prevalence-estimates/dr-prevalence.html); [Healthy People 2030](https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/diabetes/increase-proportion-adults-diabetes-who-have-yearly-eye-exam-d-04)). The National Eye Institute is explicit that diabetic retinopathy may be asymptomatic early, and that early treatment can stop damage and prevent blindness ([NEI](https://www.nei.nih.gov/health/diabetic)). That means a good-enough model embedded in primary care can create value immediately by finding patients who are currently missed entirely. + +The regulatory and market signal is also more favorable than “wait until perfect” thinking implies. FDA already established the device class for retinal diagnostic software in 2018 through IDx-DR’s De Novo clearance, and multiple follow-on products have since reached the market through 510(k), including EyeArt and AEYE-DS ([FDA De Novo DEN180001](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180001.pdf); [FDA K200667](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K200667); [FDA K240058](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K240058)). That matters strategically: this is no longer a speculative regulatory category. More importantly, FDA clearance-level performance has not required a universal 95% “accuracy” threshold. In IDx-DR’s pivotal study, the primary endpoints were sensitivity and specificity, not raw accuracy, and the device cleared with observed sensitivity of 87.4% and specificity of 89.5% for more-than-mild DR ([FDA De Novo Summary](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180001.pdf)). EyeArt later showed higher performance, but the lesson is that a startup may already be within striking distance if its operating point, intended use, imageability, and workflow controls are well designed ([JAMA Netw Open, 2021](https://pubmed.ncbi.nlm.nih.gov/34779843/)). + +There is also real evidence that workflow speed creates clinical upside beyond model metrics. In Stanford’s STATUS program, an AI-based workflow for positive diabetic retinopathy screens produced 69.2% ophthalmology follow-up within 90 days, and follow-up at the university eye institute was roughly three times higher than human-only or hybrid workflows, likely because AI results were returned much faster ([Dow et al., 2023](https://pmc.ncbi.nlm.nih.gov/articles/PMC10665027/)). That is exactly the kind of upside an advocate should emphasize: a model that is slightly less “perfect” on paper can still save more vision in practice if it shortens time-to-result, triggers same-visit counseling, and closes referral loops. Real-world health systems are already acting on this logic; Sutter Health reported scaling an AI diabetic retinopathy screening pilot from 6 sites to 28 primary care offices in 2025 ([AMA, 2025](https://www.ama-assn.org/practice-management/digital-health/sutter-health-s-use-ai-enabled-cameras-gets-eye-opening-results)). + +The uncertainty is that “87% accuracy” is not enough by itself to decide. They need disease-prevalence context, sensitivity for vision-threatening cases, specificity, imageability, subgroup performance, camera dependence, and a clear protocol for ungradable images and clinician escalation. But that uncertainty is an argument for starting the regulatory process now, not for hiding in the lab. With only 18 months of runway, waiting 12 to 18 months risks consuming the company before it has prospective evidence, payer conversations, site references, or postmarket learning. The upside scenario is not “ship recklessly.” It is: narrow the claim, use mandatory human review for positives and no-results, run a prospective pivotal study, get cleared into a real workflow, and learn in market while competitors are still proving adoption. In this category, speed with guardrails is a feature, not a flaw. + +### Agent B (Skeptic) — Independent Research | research + +The main skeptical point is that “87% accuracy” is almost the wrong number for this decision. For diabetic retinopathy screening, regulators and buyers will care far more about sensitivity, specificity, imageability/technical failure rate, subgroup performance, and how the model behaves in the actual workflow than about headline accuracy. The best precedent, the FDA-authorized IDx-DR pivotal trial, succeeded with a locked model in a prospective primary-care study because it showed 87.2% sensitivity, 90.7% specificity, and 96.1% imageability against predefined thresholds, not because it advertised a generic accuracy number ([Abràmoff et al., 2018](https://www.nature.com/articles/s41746-018-0040-6)). If this startup only knows “87% accuracy,” the downside scenario is they enter FDA preparation and discover too late that one of the clinically relevant metrics is weak. + +Real-world failure modes are not hypothetical. In a primary-care deployment study, an AI system correctly found the only 2 true disease cases but generated 15 false positives, for a positive predictive value of just 12%; many errors were caused by inadequate image quality and lens artifacts ([JAMA Network Open, 2018](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2703944)). That is the operational nightmare: ophthalmology referrals get flooded, PCPs lose trust, staff blame the camera or workflow, and payers conclude the tool adds cost without improving care. If the model underperforms on low-quality images, darker fundi, different cameras, or underrepresented populations, the reputational damage will be much larger than the raw metric suggests. + +Human-in-the-loop is also not a magic safety valve. FDA’s 2024 transparency principles explicitly say the focus should be on the performance of the human-AI team, not the model alone, and they call for clear limitations, local validation, and ongoing monitoring ([FDA Transparency Principles, 2024](https://www.fda.gov/medical-devices/software-medical-device-samd/transparency-machine-learning-enabled-medical-devices-guiding-principles)). In practice, two bad outcomes are common. Either clinicians over-trust the system and automation bias turns false negatives into missed care, or they distrust it and re-read everything, destroying the productivity and reimbursement case. “Human oversight” can reduce liability on paper while preserving almost all the workflow cost. + +Waiting for “95% accuracy” is not obviously safer. Recent health-economic modeling in DR screening found that the most accurate AI was not necessarily the most cost-effective; the trade-off depends on prevalence and on sensitivity versus specificity, with sensitivity often driving value more than overall accuracy ([npj Digital Medicine, 2024](https://www.nature.com/articles/s41746-024-01032-9)). So a 12–18 month sprint to 95% internal accuracy could burn most of an 18-month runway while optimizing the wrong target. They may still need prospective multicenter validation, human factors testing, quality-system maturity, and workflow evidence before clearance or commercial uptake. + +The skeptical conclusion is: broad deployment now would be premature, but “wait until 95% accuracy” is also a risky fiction. The real risk is anchoring strategy on an oversimplified benchmark. The least bad path is to lock the current model and run a fast, prospective, multi-site evidence program on the intended cameras and users, measuring sensitivity, specificity, imageability, false negatives for vision-threatening disease, subgroup equity, and human-AI workflow performance. If those data approach the FDA-cleared precedent and the operational false-positive burden is acceptable, file. If not, they have learned the right failure mode before spending the company’s remaining runway on a clearance attempt or a benchmark chase. + +--- + +## Discussion + +### Round 1 — Advocate | response | confidence: 78% + +**Response to previous points:** +Agent B’s strongest argument is that `87% accuracy` is not the decision variable; for FDA clearance and clinical adoption, sensitivity for referable disease, specificity, imageability, subgroup performance, and human-AI workflow behavior matter more. I agree. That does not weaken the case for acting now; it changes what “act now” means. + +So my synthesis is: do not broad-commercially deploy on a vague `87% accuracy` claim, but also do not spend 12 to 18 months chasing `95%` as a headline metric. Agent B is right that this could optimize the wrong target. The action-oriented move is to start the regulatory path now with a narrow intended use, pre-sub/FDA engagement, and a prospective multi-site study using the current model in a controlled human-in-the-loop workflow. If the pivotal metrics land near the cleared precedents, file; if they do not, improve from evidence, not from offline benchmark guessing. With 18 months runway, a “wait in the lab” strategy is the riskier bet. + +**New evidence or angle:** +A key timing angle is that the critical path is probably not model training alone. Quality system work, study design, site contracting, camera/workflow validation, human factors, and reimbursement/sales evidence all take time and do not disappear if the model improves from 87 to 95. That means the company can de-risk the real bottlenecks now while still improving the model in parallel until the lock point. In other words, “start now” does not mean “freeze forever”; it means stop treating algorithmic accuracy as the only workstream that matters. + +**Current position:** +Pursue FDA clearance now, but through a constrained evidence-first path rather than immediate scaled deployment. Confidence `78%` because the runway makes delay expensive, FDA precedent suggests 95% is not a prerequisite, and real-world access gains can matter more than a better offline metric. My uncertainty is moderate because we still do not know the current model’s sensitivity for vision-threatening disease, ungradable-image rate, or subgroup performance. + +**Key question for the group:** +What are the current model’s prospective sensitivity, specificity, and imageability for referable or vision-threatening diabetic retinopathy on the intended cameras and workflow, not just its retrospective `87% accuracy`? + +### Round 1 — Skeptic | response | confidence: 84% + +**Response to previous points:** +Agent A’s strongest argument is that the prompt’s binary choice is poorly framed: waiting for `95% accuracy` could burn most of the runway while optimizing the wrong metric, because FDA clearance and clinical adoption hinge on prospective sensitivity, specificity, imageability, subgroup performance, and workflow design, not a retrospective headline number. I agree with that, and I’m updating slightly toward A’s sequencing view. Where I still disagree is on the phrase “pursue FDA clearance now” if that means committing to broad deployment or a full pivotal path before validating the current model in the intended workflow. Matching “average radiologist performance” is not enough because standard of care is not a single accuracy number; it is a system with escalation, repeat imaging, and downstream specialist review. A human-in-the-loop wrapper also does not automatically fix the failure modes if false positives overload referrals or false negatives are concentrated in low-quality images or specific subgroups. So my synthesis is: do not wait 12-18 months for `95%`, but do not deploy broadly now either; run a fast gated evidence program that decides whether the current model is fileable or needs targeted improvement. + +**New evidence or angle:** +The hidden risk is external validity. An `87% accuracy` result often comes from curated retrospective data, but FDA-grade performance lives or dies on the intended cameras, operators, clinics, and reference standard. If their benchmark used cleaner images, different prevalence, or weaker labels than an adjudicated prospective study, the apparent parity with radiologists may collapse at the exact point they operationalize and lock the model. That makes “go now” risky, but it also argues against a long offline optimization cycle: the fastest way to learn is a prospective, camera-specific, workflow-specific study. + +**Current position:** +I favor a third option: start regulatory preparation now, but make the next 3-6 months a hard go/no-go gate based on prospective multi-site evidence with the current locked model, not a broad deployment and not a 12-18 month chase for `95%`. Confidence `84%` because both extreme options are anchored to the wrong variable, and the company’s real decision should turn on prospective clinical-operational performance before it spends the runway. + +**Key question for the group:** +Has the current locked model been tested prospectively on the intended cameras and clinic workflow against an adjudicated reference standard, and if so what are its sensitivity, specificity, imageability, and subgroup false-negative rate for vision-threatening diabetic retinopathy? + +### Round 2 — Advocate | response | confidence: 82% + +**Response to previous points:** +Agent B’s strongest point is that the real risk is not `87%` versus `95%`; it is mistaking a retrospective headline metric for FDA-grade, workflow-grade evidence. I agree, and I’m updating my position explicitly: I no longer support “deploy now” if that means scaled commercial rollout before prospective validation. But I still disagree with the implied caution of waiting 12 to 18 months for `95%`. The action-oriented synthesis is: start the FDA path now, lock a candidate model, and run a short, hard-gated prospective study in the intended workflow. That preserves speed, runway, and learning. My pushback to the more cautious framing is that every month spent chasing offline accuracy without site, camera, and workflow evidence is false comfort. Agent B is right on the evidence standard; I’m arguing the consequence is faster real-world validation, not delay. + +**New evidence or angle:** +A business angle we have not emphasized enough: with only 18 months of runway, the company is not choosing only between two model states; it is choosing between two financing narratives. “We improved offline accuracy from 87 to 95” is a weaker Series C / strategic-partner story than “we completed a prospective multi-site study, defined a safe operating envelope, and know whether this is fileable.” Regulatory-grade evidence is an asset even if the first study says “narrow the indication” or “fix imageability first.” A 12-18 month lab sprint risks ending with better benchmarks but no proof of deployability. + +**Current position:** +Start regulatory preparation now and commit to a 3-6 month prospective go/no-go gate with the current best locked model; do not broadly deploy before that gate, and do not spend 12-18 months chasing `95%` as the primary plan. Confidence `82%` because this path best matches the runway constraint, preserves upside, and tests the variables that actually matter for clearance and adoption. + +**Key question for the group:** +What exact prospective threshold package would make us say “file now” versus “improve first” for this product: sensitivity, specificity, imageability, and subgroup false-negative limits on the intended cameras and workflow? + +### Round 2 — Skeptic | response | confidence: 86% + +**Response to previous points:** +Agent A’s strongest contribution is the reframing: the company should stop treating `95% accuracy` as the strategy and instead buy real information quickly through a locked-model, workflow-specific prospective study. I agree, and I’m updating toward A on one important point: they should start FDA preparation now because quality systems, study design, site setup, camera validation, and human factors are long-pole work regardless of whether the model later improves. Where I still want harder guardrails is commitment risk. “Start the FDA path” can become escalation bias if the organization treats prep work as proof they should file. So my synthesis with Agent A is: begin regulatory prep now, but make the current model earn the right to a filing through pre-specified prospective thresholds. If imageability is weak, subgroup false negatives are concentrated, or referral burden is operationally unacceptable, they should stop and improve rather than rationalize a bad launch. I want Agent C, when synthesizing, to force explicit thresholds here rather than vague “near precedent” language. + +**New evidence or angle:** +The under-discussed issue is statistical power in a low-prevalence screening setting. A short pilot can look acceptable on overall performance while having too few cases of referable or vision-threatening disease to estimate the metric that matters most: false negatives. The same base-rate problem can also make false positives operationally toxic even with decent-looking specificity, because PCP workflows and ophthalmology referrals get swamped. So a `3-6 month` gate is only meaningful if the study is powered for clinically important positives, run on the intended cameras and operators, and includes predefined limits for imageability and referral burden. + +**Current position:** +I favor the third option more clearly now: start regulatory preparation immediately, run a prospective multi-site readiness study with the current locked model, improve in parallel, and do not broadly deploy or commit to filing until the study hits pre-specified clinical and operational thresholds. Confidence `86%` because this protects runway from both benchmark chasing and premature commercialization, while generating the only evidence that can actually settle the decision. + +**Key question for the group:** +What exact go/no-go thresholds and sample size would make the next prospective study decision-quality, especially for sensitivity on vision-threatening disease, imageability, subgroup false-negative rates, and referral burden on the intended cameras and workflow? + +### Round 3 — Advocate | response | confidence: 85% + +**Response to previous points:** +Agent B’s strongest point is the escalation-bias warning: once FDA prep starts, teams can confuse motion with evidence, so the current model must earn a filing through a prospective study that is actually powered for the clinically dangerous errors, especially false negatives for vision-threatening disease in a low-prevalence screening setting. I agree, and that is the main way my view has shifted. Agent B is also right that `3-6 months` only matters if the study is decision-quality, not a feel-good pilot. Where I still push harder is on tempo and commitment: with 18 months of runway, the company should start regulatory prep immediately and make this study the commercialization gate, not another exploratory cycle. Agent C should now turn that into a hard decision rule, not a narrative. + +**New evidence or angle:** +`95% accuracy` is an especially bad target here because overall accuracy in screening is prevalence- and threshold-sensitive. In a low-prevalence population, a model can raise headline accuracy without materially reducing false negatives for vision-threatening disease or without keeping referral burden manageable. So the choice is not `87` versus `95`; it is whether the current locked model can hit endpoint-based thresholds in the intended workflow. + +**Current position:** +Start FDA preparation now, lock the best current model, and run a prospective multi-site readiness study before filing or scaled deployment. I would treat the model as fileable only if it lands roughly in cleared-device territory on the endpoints that matter: high-80s sensitivity for referable disease, about 90% specificity, mid-90s imageability, no major subgroup sensitivity drop, and referral burden partner clinics can absorb. If it misses, improve from those observed failure modes rather than spend 12-18 months chasing `95%` offline. Confidence `85%` because Agent B and I now agree on the critical unknowns, and the runway makes delay more dangerous than a gated evidence-first push. + +**Key question for the group:** +What exact pre-registered go/no-go threshold package should Agent C recommend so the company cannot rationalize a premature filing: sensitivity, specificity, imageability, subgroup floor, and maximum acceptable referral burden? + +**Convergence assessment:** CONVERGING — Agent B and I are now aligned on the strategic path: start regulatory prep now, reject a 12-18 month chase for `95%`, and gate filing/deployment on a prospective study. The remaining gap is the exact threshold package and study sizing that turns that shared direction into a decision. + +--- + +## Consensus Summary + +### Decision +They should start the FDA clearance path now, but not broadly deploy yet and not spend 12-18 months chasing `95% accuracy` as the main strategy. The right move is to lock the current best model, begin regulatory/quality-system work immediately, and run a prospective multi-site readiness study in the intended workflow with pre-registered go/no-go thresholds; file if those thresholds are met, otherwise improve targeted failure modes rather than optimize offline accuracy in the abstract. + +### Key Contention Points + +| # | What Was Debated | Resolution | Who Had the Strongest Case & Why | +|---|-----------------|------------|----------------------------------| +| 1 | Whether `87% accuracy` is already good enough because it matches average radiologist performance | `87% accuracy` alone is not decision-quality evidence; it is insufficient as the main basis for filing or deployment. | Agent B had the strongest case because they showed that FDA clearance and buyer acceptance depend on sensitivity, specificity, imageability, subgroup performance, and workflow behavior, not a headline accuracy number. | +| 2 | Whether to deploy now with human-in-the-loop | No broad deployment now; use a tightly controlled prospective study as the commercialization gate first. | Agent B had the strongest case because they explained that human-in-the-loop does not automatically solve false negatives, false positives, automation bias, or referral overload. | +| 3 | Whether to wait 12-18 months to reach `95% accuracy` before seeking clearance | Reject that plan; `95%` is the wrong target and likely a dangerous use of runway. | Agent A had the strongest case because they argued convincingly that runway is short, FDA precedent does not require `95%`, and the long poles are regulatory, workflow, and evidence generation rather than model training alone. | +| 4 | What the company should do immediately | Begin FDA preparation now and run a powered prospective multi-site study with pre-specified thresholds before filing. | Both agents converged here, but Agent A had the edge on sequencing because they connected regulatory prep, financing narrative, and time-to-learning into a concrete near-term plan. | + +### Unresolved Items & Risks +- The current model’s prospective sensitivity, specificity, and imageability on the intended cameras and operators are still unknown. +- The study must be powered for referable or vision-threatening disease, not just overall accuracy, or the go/no-go decision will be weak. +- Predefined thresholds still need to be set for sensitivity, specificity, imageability, subgroup floors, and maximum acceptable referral burden. +- If subgroup false negatives or image-quality failures are concentrated in certain populations or clinics, the product could be non-viable without targeted remediation. +- Starting FDA prep creates escalation risk; leadership must treat the study as a real stop/go gate, not as a justification to file regardless of results. +- This path sacrifices the simplicity of “ship now” and the comfort of “wait for a better benchmark” in exchange for faster, decision-grade evidence. + +### Confidence: Medium +Confidence is medium because the agents clearly converged on strategy, but the decisive clinical-operational metrics for the current model were not provided. + +--- diff --git a/tests/eval-results/full-matrix-2026-04-01/healthcare-ai-deploy__5-codex.md b/tests/eval-results/full-matrix-2026-04-01/healthcare-ai-deploy__5-codex.md new file mode 100644 index 0000000..6ff8e98 --- /dev/null +++ b/tests/eval-results/full-matrix-2026-04-01/healthcare-ai-deploy__5-codex.md @@ -0,0 +1,294 @@ +--- +topic: "A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance?" +mode: "council" +agent_count: "5" +agent_config: "5-agent" +max_rounds: "5" +git_commit: "none" +agent_cli: "codex" +status: consensus +turn: C +round: 3 +created: "2026-04-01T09:10:46.195Z" +last_updated: 2026-04-01T09:23:37.156Z +agent_A_name: "Advocate" +agent_A_cli: "codex" +agent_A_role: "advocate" +agent_B_name: "Skeptic" +agent_B_cli: "codex" +agent_B_role: "skeptic" +agent_C_name: "Domain Expert" +agent_C_cli: "codex" +agent_C_role: "expert" +agent_D_name: "User Advocate" +agent_D_cli: "codex" +agent_D_role: "user_advocate" +agent_E_name: "Synthesizer" +agent_E_cli: "codex" +agent_E_role: "synthesizer" +--- + +# Discussion: A healthcare AI startup (Series B, 18 months runway) has a diagnostic model for detecting diabetic retinopathy from retinal images. The model achieves 87% accuracy, matching average radiologist performance. Should they pursue FDA clearance and deploy now with human-in-the-loop, or invest 12-18 months to reach 95% accuracy before seeking clearance? + +## Participants +- **Agent A** — Advocate (advocate) via codex +- **Agent B** — Skeptic (skeptic) via codex +- **Agent C** — Domain Expert (expert) via codex +- **Agent D** — User Advocate (user_advocate) via codex +- **Agent E** — Synthesizer (synthesizer) via codex + +## Key Questions +1. Is 87% accuracy sufficient given that it matches current standard of care (average radiologist)? +2. What does the FDA clearance pathway look like at 87% vs 95%, and does higher accuracy meaningfully change the regulatory burden? +3. What are the data and compute requirements to go from 87% to 95%, and is 12-18 months realistic? +4. Can the company survive 12-18 months of continued burn without revenue from deployment? + +## Research Phase + +### Agent A (Advocate) — Independent Research | research + +The upside case favors pursuing FDA clearance now and deploying with a tightly designed human-in-the-loop workflow, not waiting 12 to 18 months for a headline jump to 95% accuracy. The core reason is that diabetic retinopathy is a screening-access problem as much as a pure-model problem. In the U.S., only 66.0% of adults with diabetes had an eye exam in the past 12 months in 2023, meaning roughly one-third are still not getting recommended screening; HHS still rates progress as “little or no detectable change” ([Healthy People 2030](https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/diabetes/increase-proportion-adults-diabetes-who-have-yearly-eye-exam-d-04)). CDC also continues to describe diabetic retinopathy as a leading cause of blindness in working-age adults ([CDC](https://www.cdc.gov/diabetes/diabetes-complications/diabetes-and-vision-loss.html)). If the startup can move screening into primary care or endocrinology clinics now, the product can create value by finding patients who otherwise would not be screened at all. An 87%-level system used in front of no exam is often better than a 95% system that arrives after another year of missed screening. + +There is also evidence that “good enough plus workflow speed” can matter more than squeezing the last points out of offline metrics. FDA’s April 11, 2018 De Novo authorization for IDx-DR established a Class II device type for diabetic retinopathy detection (21 CFR 886.1100), and the pivotal study reported 87.4% sensitivity, 89.5% specificity, and 96.1% imageability, with novice operators trained in about four hours ([FDA De Novo DEN180001](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180001.pdf)). A second product, EyeArt v2.2.0, followed through 510(k) on June 16, 2023, which means the regulatory path is now more legible than it was for the first entrant ([FDA 510(k) K223357](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K223357)). That matters strategically: this company does not need to prove AI-for-DR is a valid category from scratch. It needs to prove its own device is safe, effective, and operationally reliable in intended use. + +The strongest pro-deploy evidence is implementation value. In a 2023 Stanford-associated study, an AI-based DR workflow that returned results within 48 hours produced much better follow-up behavior than slower human or hybrid workflows: 69.2% of AI-positive patients followed up within 90 days, and in one in-person subset the AI workflow produced 35.5% follow-up versus about 12% for the human-based alternatives ([PubMed PMID 38026608](https://pubmed.ncbi.nlm.nih.gov/38026608/)). That is the real prize: not merely matching radiologists image-by-image, but compressing time-to-action and increasing referral completion. A human-in-the-loop launch amplifies that upside because the model can triage normals, flag positives, and route low-confidence or poor-quality images to humans, while the company accumulates prospective evidence and a proprietary real-world dataset. + +The business case also leans toward now. With 18 months of runway, spending 12 to 18 months chasing 95% risks arriving at the fundraise with better science but no clearance, no site learnings, no reimbursement story, and no revenue signal. By contrast, a limited-release, HITL-cleared product could generate clinical evidence, commercial proof, and payer/provider traction while the model keeps improving. There is reimbursement precedent too: IDx-DR/LumineticsCore later obtained CPT code 92229, and CMS included it in the Medicare Physician Fee Schedule for 2021 ([Health Affairs Forefront/PMC review](https://pmc.ncbi.nlm.nih.gov/articles/PMC12900248/)). The key uncertainty is that “87% accuracy” is not enough by itself; FDA will care about sensitivity/specificity by intended claim, imageability, subgroup performance, human factors, and prospective validation. But if those underlying metrics are already credible, the upside-maximizing move is to seek clearance now with guardrails, not treat 95% as a magical threshold. + +### Agent B (Skeptic) — Independent Research | research + +The skeptical view is that `87% accuracy` is not a deployable evidence standard for a diabetic-retinopathy diagnostic device, even with human-in-the-loop. For FDA-cleared retinal diagnostic software, the burden is not a single headline metric; FDA’s special controls explicitly require clinically justified `sensitivity`, `specificity`, `PPV/NPV`, confidence intervals, testing under real conditions of use, variability across users and image-acquisition devices, training, and human-factors validation. FDA also names the core harms up front: `false negatives` can delay evaluation/treatment, `false positives` can trigger unnecessary follow-up, and poor image capture by operators is itself a regulated risk ([FDA De Novo summary for IDx-DR](https://www.accessdata.fda.gov/cdrh_docs/pdf18/DEN180001.pdf); [FDA PCCP guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-submission-recommendations-predetermined-change-control-plan-artificial-intelligence)). If the startup is anchoring on “matches average radiologist,” that is a warning sign: FDA will ask whether performance is safe, reproducible, and robust in the intended workflow, not whether it is roughly human-average on one dataset. + +The competitive/regulatory benchmark is also higher than the prompt implies. In the pivotal prospective IDx-DR trial, the system reported `87.2% sensitivity`, `90.7% specificity`, and `96.1% imageability` in primary care ([Abramoff et al., npj Digital Medicine, 2018](https://www.nature.com/articles/s41746-018-0040-6)). EyeArt’s 2023 FDA-cleared update reported prospective sensitivity around `94% to 96%` with specificity roughly `86% to 91%`, depending on camera and endpoint ([FDA EyeArt K223357 summary](https://www.accessdata.fda.gov/cdrh_docs/pdf22/K223357.pdf)). So an internal “87% accuracy” claim may be materially below what the market already considers credible, or at minimum it is non-comparable to the metrics that matter. If they file now, the downside is burning capital on a submission and commercialization motion that yields either a narrow label, poor uptake, or outright failure. If they wait 12-18 months purely to hit “95% accuracy,” that is also dangerous: accuracy can improve while clinically important failure modes remain unresolved. + +Real-world deployment risk is where optimism usually breaks. A 2025 adoption review found that these systems had been commercialized for 5 years, yet adoption was still limited; across adopters, average nonmydriatic `gradability` was only `49% to 75%`, with specificity as low as `60%` in some settings ([Teng et al., Ophthalmology Science, 2025](https://www.sciencedirect.com/science/article/pii/S2666914525002337)). A Stanford hybrid-workflow study is even more sobering: the AI arm had `95.5% sensitivity` but only `60.3% specificity` and `62.5% gradability`; specialists had far better specificity and gradability, and the “hybrid” only worked after specialist overread ([Dow et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37449051/)). That means HITL is not a free safety blanket; it can simply move the burden back to scarce specialists and destroy the startup’s unit economics. + +My downside-adjusted conclusion: `do not pursue broad clearance/deployment now on the basis of 87% accuracy.` But I also would not spend the full runway blindly chasing a prettier number. The real work is prospective multi-site validation, subgroup robustness, operator/device variability, gradability, referral burden, and workflow economics. If forced to choose between the two options in the prompt, delaying broad deployment is the less dangerous choice. The worst-case outcome is deploying now, missing disease in edge cases, overwhelming referral networks with false positives/ungradables, and discovering too late that “human-in-the-loop” did not actually contain either safety risk or cost. + +### Agent C (Domain Expert) — Independent Research | research + +From an execution standpoint, I would not anchor the go/no-go decision on “87% vs 95% accuracy.” FDA-cleared precedent in diabetic retinopathy shows the regulatory and operational bar is defined by clinically chosen endpoints, imageability, workflow safety, and prospective validation, not a single overall accuracy number. The first FDA-cleared autonomous system, IDx-DR (De Novo, April 11, 2018), succeeded with 87.4% sensitivity and 89.5% specificity for more-than-mild DR in a 10-site primary-care pivotal study; 92% of enrolled patients were analyzable, and operators were novices trained for four hours (FDA de novo summary: https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180001.pdf; pivotal trial: https://www.nature.com/articles/s41746-018-0040-6). More recent systems improved sensitivity, but the precedent says “good enough on the right endpoint plus a safe workflow” can clear. EyeArt v2.2.0, cleared June 16, 2023, reported 94.4% sensitivity and 91.1% specificity on Topcon NW400 images, with 98.9% final imageability after dilation as needed, in a six-site prospective study using sites excluded from training (FDA summary: https://www.accessdata.fda.gov/cdrh_docs/pdf22/K223357.pdf). AEYE-DS cleared in 2024 with roughly 92% to 93% sensitivity, 89% to 94% specificity, and >99% success rate, including handheld-camera use (FDA entry: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K240058). + +What this means practically: if their current model can already hit acceptable sensitivity/NPV on the clinically relevant endpoint for referral-warranted disease, a clearance program now is feasible. But “deploy now with human-in-the-loop” does not avoid FDA oversight. FDA’s CDS policy is explicit that software that acquires/processes/analyzes medical images is a device even if a clinician reviews the result (FDA FAQ: https://www.fda.gov/medical-devices/software-medical-device-samd/clinical-decision-support-software-frequently-asked-questions-faqs). Human-in-the-loop changes workflow and possibly risk framing; it does not turn this into unregulated software. It also creates a different evidence burden: they would need to show the human-AI team performs safely in practice, not just the model in isolation. FDA’s 2024 transparency principles explicitly emphasize “performance of the human-AI team” and how the tool fits clinical workflow (https://www.fda.gov/medical-devices/software-medical-device-samd/transparency-machine-learning-enabled-medical-devices-guiding-principles). + +The real build is larger than model training. They need: a locked model; narrow intended use; camera-specific validation; prospective multi-site study on unseen sites; reference-standard grading by a reading center; ungradable-image and dilation/referral protocol; cybersecurity and software V&V; quality system documentation; EMR/result integration; and post-market monitoring. FDA-cleared summaries show this clearly. IDx-DR’s de novo summary calls the software “major level of concern,” includes cybersecurity and hazard analysis requirements, and notes significant algorithm changes affecting false positives/negatives can trigger a new 510(k). In other words, clearing at 87% and then “updating to 95% later” may mean a second regulatory cycle, not a simple model refresh (https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180001.pdf). + +Real-world implementation lessons also argue for starting the regulatory/operational machine sooner, not spending the runway chasing a headline metric. A large health system review reported about 6 months from kickoff to first camera use because contracting, Epic integration, order/result build, and workflow planning dominated startup; operators needed about 40 exams to stabilize at roughly 6 minutes per exam; image quality problems and cataracts/small pupils drove nondiagnostic studies and false positives (implementation review: https://pmc.ncbi.nlm.nih.gov/articles/PMC10788651/). Stanford’s STATUS program found follow-up after a positive screen was about three times higher with AI workflow than prior human workflows, apparently because results returned faster (https://pmc.ncbi.nlm.nih.gov/articles/PMC10665027/). That is a deployment lesson: operational speed and referral completion matter as much as incremental model lift. + +My bottom-line domain view: pursue clearance preparation now if 87% reflects acceptable sensitivity on referable/vision-threatening DR and they can define a conservative indication for use. Do not wait 12 to 18 months for “95% accuracy” unless they already know that gap is achievable, durable across sites/cameras/subgroups, and large enough to justify delaying both revenue and the regulatory clock. The biggest uncertainty is that we do not know their current sensitivity/specificity split, ungradable rate, subgroup performance, camera constraints, or quality-system readiness; those matter more than the headline accuracy number. + +### Agent D (User Advocate) — Independent Research | research + +From a user-advocate lens, the key question is not “does the model match average radiologists on a benchmark?” It is “will patients actually get screened, understand the result, trust it, and complete follow-up without the clinic workflow breaking?” Current evidence says convenience and immediacy matter more than abstract model parity. Diabetic retinopathy (DR) screening adherence remains poor: a 2025 meta-analysis reported global screening adherence of 66.9% in high-income countries and 39.3% in LMICs, and a human-centered implementation study in a US primary-care clinic noted that fewer than half of Americans with diabetes receive yearly eye screening; in that clinic, 56% of diabetic patients were overdue ([Rahmati et al., *Eye*, 2025](https://www.nature.com/articles/s41433-025-03849-4); [Scanzera et al., *Front Public Health*, 2023](https://pmc.ncbi.nlm.nih.gov/articles/PMC10361413/)). That is the user problem to solve. + +AI can improve the user journey when it delivers same-visit answers. The same 2025 meta-analysis found AI-based DR assessment significantly increased follow-up uptake versus human-grader workflows (OR 1.89, 95% CI 1.78-2.01), likely because instant results remove waiting and ambiguity ([Rahmati et al.](https://www.nature.com/articles/s41433-025-03849-4)). In a low-income US primary-care program, AI-assisted screening improved adherence to follow-up eye care from 18.7% historically to 55.4% at one year ([Liu et al., *Ophthalmology Retina*, 2021](https://pmc.ncbi.nlm.nih.gov/articles/PMC8546907/)). A human-centered design study explicitly argued that the value comes from giving results in-office, educating the patient immediately, and scheduling the eye exam before checkout ([Scanzera et al.](https://pmc.ncbi.nlm.nih.gov/articles/PMC10361413/)). So users do not mainly need a prettier ROC curve; they need access, fast explanation, and frictionless next steps. + +That said, I would not recommend broad FDA pursuit and deployment now if “87% accuracy” is the true headline metric. For screening products, overall accuracy is not the metric users feel. Patients care about missed disease; clinicians care about missed disease plus false-positive burden and “ungradable” exams. Existing FDA-authorized systems already set a user expectation around higher screening performance: recent meta-analyses reported pooled sensitivity/specificity around 95%/91% for IDx-DR/LumineticsCore and 95%/81% for EyeArt ([Khan et al., *Am J Ophthalmol*, 2025](https://pubmed.ncbi.nlm.nih.gov/39986640/); [Wang et al., *Am J Ophthalmol*, 2026](https://pubmed.ncbi.nlm.nih.gov/41052568/)). If this startup launches materially below that bar, buyers may not see enough user benefit versus existing options. + +Real-world usage adds more friction than model cards suggest. In a 2026 real-world IDx-DR study, 10.5% of patients yielded no image and 26.1% were unanalyzable; age, pupil size, examiner skill, and visual acuity mattered ([Duvoisin et al., 2026](https://pmc.ncbi.nlm.nih.gov/articles/PMC12864748/)). In the Washington University study, 29.4% of screens were inconclusive, and human review found additional non-DR pathology in 17 patients ([Liu et al.](https://pmc.ncbi.nlm.nih.gov/articles/PMC8546907/)). For users, that means extra visits, anxiety, lost work time, and trust erosion if the tool often says “can’t tell.” + +My recommendation: do not rush broad clearance/deployment on the basis of 87% accuracy. From the user side, I would rather see the company spend the next 12-18 months improving not just model performance but also gradability, same-visit workflow, patient education, and referral completion. If they deploy now, it should be only in tightly supervised pilots with explicit human review and hard tracking of user-centered outcomes. The main uncertainty is that “87% accuracy” is not directly comparable to screening sensitivity/specificity/NPV; if the model already has very high sensitivity and low ungradable rates in the intended population, my view could soften. But based on the current evidence, users will punish a mediocre first experience more than they will reward a merely adequate early launch. + +--- + +## Discussion + +### Round 1 — Advocate | response | confidence: 76% + +**Response to previous points:** +The strongest argument is from **Agent B**, reinforced by **Agent D**: `87% accuracy` is not a clinical or regulatory decision metric here because users feel `false negatives`, `false positives`, and `ungradable` exams, not benchmark parity. If this model is mediocre on sensitivity/NPV for referral-warranted disease, or creates too much human overread burden, a fast launch destroys trust and economics. I agree with that. + +That said, **Agent C** is right that the real choice is not “87 now vs 95 later.” FDA will care about intended use, sensitivity/specificity, imageability, camera/operator robustness, and the human-AI workflow. So I’m explicitly updating my stance: I do **not** support broad deployment now on the basis of the headline metric alone. I **do** support starting the FDA/Q-Sub and prospective validation process now, with a narrow claim and tightly controlled human-in-the-loop rollout, while improving the model in parallel. + +On the open questions: +`87% accuracy` is not sufficient by itself. It could still be sufficient if the underlying sensitivity/NPV on the clinically relevant endpoint is already strong. +A higher headline number probably does **not** meaningfully reduce regulatory burden if workflow, subgroup, and imageability evidence are still weak. +A 12-18 month jump to `95%` looks uncertain because the likely bottleneck is not just compute; it is new prospective data, device/site variability, and workflow design. +With `18 months runway`, waiting to start both regulatory and commercial learning is the riskiest path. + +**New evidence or angle:** +The third option is an **abstention-based product**, not an all-or-nothing launch. If the model only makes autonomous recommendations on high-confidence, gradable images from supported cameras, and automatically routes low-confidence/ungradable cases to human review, the relevant metric becomes safe performance at a defined coverage rate, not one global accuracy number. That is a product and regulatory design choice, not just an ML improvement project. + +**Current position:** +Pursue FDA engagement and prospective HITL pilots now, but do **not** do broad deployment until the current model clears pre-specified thresholds for sensitivity, imageability, subgroup robustness, and human-review burden. Confidence `76%` because this preserves upside and runway while absorbing the strongest safety objections from **B** and **D**. + +**Key question for the group:** +What are the model’s current **prospective** metrics on unseen clinics/cameras, after applying a conservative abstain threshold: sensitivity, specificity, NPV, and `% sent to human review/ungradable`? + +### Round 1 — Skeptic | response | confidence: 82% + +**Response to previous points:** +**Agent C** has the strongest frame: `87% vs 95% accuracy` is the wrong decision variable. FDA and buyers will care about `sensitivity`, `specificity`, `imageability`, camera/operator robustness, and the safety of the actual workflow. I agree, and that shifts me slightly away from a simple “wait 18 months.” **Agent A** is also right that burning most of the runway before even starting regulatory and workflow learning is dangerous. The best third option on the table is A’s abstention-based path: narrow claim, conservative thresholds, HITL, prospective validation now. + +But I still disagree with any implication of “deploy now” unless they can already show a safe operating point on unseen sites/cameras. **Agent D** is right that users experience missed disease, inconclusives, and referral friction, not benchmark parity. So the key open questions are not model-only: what fraction becomes ungradable or low-confidence, what NPV looks like at real prevalence, and whether HITL actually contains risk without overwhelming human reviewers. + +**New evidence or angle:** +The missing angle is commercial defensibility under HITL. If the model has to abstain or escalate too often to stay safe, the company may end up with the regulatory burden of a medical device plus the cost structure of tele-ophthalmology, without a strong margin or staffing advantage over existing cleared products. Abstention is only a real solution if coverage stays high enough and overread burden low enough to preserve unit economics. + +**Current position:** +Do not pursue broad clearance/deployment on the basis of `87% accuracy`, and do not spend `12-18 months` chasing `95%` as a vanity metric. Start Q-Sub/protocol design now, but make the filing decision contingent on a pre-specified prospective package: high sensitivity/NPV on referable disease, acceptable imageability, subgroup stability, and a HITL review burden that still works financially. Confidence `82%` because this preserves optionality while guarding against the biggest failure mode: burning runway on a submission or launch that is neither clinically safe enough nor economically viable. + +**Key question for the group:** +On a held-out prospective cohort from intended-use clinics and supported cameras, what operating point can the model achieve after abstention: `sensitivity`, `specificity`, `% ungradable/low-confidence`, and `% requiring human overread`? + +### Round 1 — Domain Expert | response | confidence: 84% + +**Response to previous points:** +The strongest argument is the combined case from **Agent B** and **Agent D**: `87% accuracy` is not a deployment metric in DR screening because the real failure modes are missed referable disease, excess false positives, and too many ungradable/low-confidence exams that break workflow. I agree. The FDA precedents already in the record point the same way: **IDx-DR** cleared on prospective sensitivity/specificity plus imageability in primary care, while **EyeArt** and **AEYE-DS** show the category now competes on stronger prospective operating points, not retrospective headline accuracy. **Agent A** is right that the prompt’s binary is false: the real third option is to start Q-Sub, design controls, and prospective HITL validation now rather than spend most of the runway chasing a nominal `95%`. **Agent B** is also right that abstention only helps if the resulting human-overread burden is still economically viable, and **Agent D** is right that same-visit results and referral completion are part of clinical value, not just commercialization. So the key open questions are still: on intended cameras and unseen clinics, what are `sensitivity`, `NPV`, `specificity`, `imageability`, subgroup performance, and `% routed to human review`? + +**New evidence or angle:** +The likely bottleneck is no longer model training; it is protocol lock, reading-center ground truth, supported-camera constraints, software V&V, EMR integration, and site activation. That matters because “wait 12-18 months to hit `95%`, then start clearance” is probably the slowest path twice over. Once they lock a pivotal protocol, a materially changed model can force re-verification and potentially another regulatory cycle, so delayed filing does not buy a clean shortcut. + +**Current position:** +Do not do broad deployment now, but do start FDA engagement and a narrow, camera-specific HITL clearance program now. I would make filing and scale-up contingent on pre-specified gates: strong sensitivity/NPV for referable disease, acceptable imageability, stable subgroup performance, and a human-review burden that still preserves unit economics. Confidence `84%` because this matches actual FDA and implementation precedent while respecting the 18-month runway. + +**Key question for the group:** +On the supported cameras and intended-use clinics, what prospective operating point can they achieve after abstention: `sensitivity/NPV` for referable disease, `specificity`, and `% of exams sent to human review or deemed ungradable`? + +### Round 1 — User Advocate | response | confidence: 81% + +**Response to previous points:** +The strongest argument is **Agent C’s** reframing, backed by **Agent B** and **Agent A**: the real choice is not `87% now` versus `95% later`, it is whether the company can define a safe, narrow workflow now and learn fast enough before runway runs out. I agree, and I’m updating from my initial “do not rush” stance to a more specific one: do **not** do broad deployment now, but do start FDA engagement and tightly supervised HITL pilots now. + +**Agent B** is right that users do not experience “accuracy”; they experience missed disease, unnecessary referrals, and inconclusive exams. **Agent A** is right that waiting 12-18 months without regulatory or workflow learning is also a user harm if it means the product never reaches clinics that need screening access. So the user-centered synthesis is: launch only where the workflow protects the patient from the model’s uncertainty. That means conservative abstention, explicit human review, supported cameras/operators only, and tracking whether patients actually get a clear next step. + +The biggest open questions are still practical, not abstract: on unseen clinics/cameras, what are `sensitivity`, `NPV`, `% ungradable`, and `% escalated to human review` at a conservative threshold? If those are weak, users will lose trust quickly. + +**New evidence or angle:** +One user risk has not been emphasized enough: **false reassurance from the negative result language**. Even a decent model can do harm if the patient hears “you’re fine” instead of “this screen did not find referral-warranted disease today; keep annual exams and seek care for symptoms.” For users, messaging and handoff are part of safety, not just UX polish. A mediocre model with disciplined result communication and immediate follow-up booking can be safer than a better model wrapped in overconfident messaging. + +**Current position:** +Pursue FDA/Q-Sub work and narrow HITL pilots now, but do not pursue broad deployment on the basis of `87% accuracy` alone. I’ve shifted toward **A/C’s** third option because the company cannot afford to spend most of its runway learning nothing about real clinics, but **B’s** warning still stands: if abstention and overread rates are too high, this is not yet a user-ready product. Confidence `81%` because the synthesis fits both patient safety and startup survival, but key prospective metrics are still missing. + +**Key question for the group:** +At a conservative operating threshold in intended-use clinics, what percentage of patients can leave the same visit with a **reliable result plus a concrete next step** (`screen negative with clear instructions`, `booked referral`, or `human review queued`) rather than an inconclusive outcome? + +### Round 2 — Advocate | response | confidence: 83% + +**Response to previous points:** +The strongest argument is the combined case from **Agent B** and **Agent D**, sharpened by **Agent C**: broad deployment on `87% accuracy` would be a category error because the real safety and business variables are `false negatives`, `ungradable/low-confidence exams`, and the human-overread burden on unseen clinics and supported cameras. I agree. I’ve changed my position further: this is no longer “clear now vs wait for 95,” it is “start de-risking now vs burn runway optimizing the wrong metric.” + +**Agent C** is right that most remaining risk sits in prospective validation, camera/site constraints, workflow, and regulatory execution, not just model training. **Agent B** is right that abstention is only a real answer if coverage stays high enough that the economics still work. **Agent D** is right that the patient-level endpoint is whether the patient leaves with a trustworthy next step, not whether the model looks good on a benchmark. So the open questions really collapse into one package: after a conservative abstain threshold, what are `sensitivity/NPV` for referable disease, `specificity`, `imageability`, `% same-visit dispositions`, and `% human overread`? + +**New evidence or angle:** +The missing decision variable is `coverage-adjusted value`. A model that is weaker on one global offline metric but can safely auto-resolve a meaningful share of high-confidence, gradable exams may create more clinical value and more enterprise value than a “95% accuracy” model that still fails on image quality, workflow, or review cost. So the company should optimize for a safe operating frontier, not a headline number. That argues for action now: run Q-Sub and prospective pilots immediately, learn the frontier, and narrow or kill the product fast if the coverage/overread tradeoff is bad. + +**Current position:** +Pursue FDA engagement, protocol lock, and narrow HITL pilots now; do **not** do broad deployment yet. Confidence `83%` because **A/B/C/D** are now converging on the same third option, and the main remaining uncertainty is empirical rather than conceptual: whether the current model can reach a viable operating point after abstention without collapsing coverage or economics. + +**Key question for the group:** +Across intended-use clinics and supported cameras, what is the best prospective operating point the model can achieve at three candidate abstention thresholds: `sensitivity/NPV` for referable disease, `specificity`, `% autonomous reads`, `% ungradable`, and `% sent to human overread`? + +### Round 2 — Skeptic | response | confidence: 86% + +**Response to previous points:** +The strongest argument is the convergence from **Agent C**, **Agent A**, and **Agent D**: the prompt’s binary is false. The real decision is not `87% now` versus `95% later`; it is whether the company should start FDA/prospective de-risking now while refusing broad deployment until it proves a safe and workable operating point. I agree, and that is a meaningful update from my earlier stance. + +**Agent C** is right that the gating items are prospective performance, imageability, camera/site robustness, protocol lock, and workflow validation, not another round of retrospective model optimization. **Agent A** is right that waiting most of the runway to optimize a vanity metric is strategically dangerous. **Agent D** is right that patient safety is partly a workflow property: users need a reliable next step, not a benchmark score. My remaining skepticism is narrower but important: `human-in-the-loop` is not automatically a risk-control win. If the abstention threshold needed to make sensitivity/NPV safe drives too many cases into overread or inconclusive buckets, the product may be clinically acceptable on paper but commercially nonviable in practice. + +So my answer to the open questions is: do not file or deploy broadly based on `87% accuracy`; do start Q-Sub/protocol design and tightly bounded pilots now; and make the go/no-go decision based on a joint clinical-and-economic operating point on unseen sites/cameras. + +**New evidence or angle:** +One under-discussed risk is `reimbursement/ROI mismatch`. **Agent A** cited reimbursement precedent from autonomous DR screening, but a HITL product may not inherit the same economics if it requires substantial human overread, repeat imaging, or tele-ophthalmology staffing. In other words, the company could clear a device and still fail commercially because buyers compare it not to “no screening” but to existing cleared systems and outsourced reading workflows. The hidden cost is that a safe abstention policy can erase the margin advantage that justified the product in the first place. + +**Current position:** +I now support the group’s third option: start FDA engagement and prospective, narrow HITL validation now, but do **not** pursue broad clearance/deployment yet and do **not** spend `12-18 months` chasing `95%` as the primary goal. Confidence `86%` because the group is converging, and the main unresolved issue is empirical: whether a conservative operating point can satisfy both safety and unit economics at the same time. + +**Key question for the group:** +At the safest candidate operating point on intended-use clinics/cameras, what is the `per-1000-screen` outcome package: `missed referable cases`, `false-positive referrals`, `% ungradable/abstained`, `% needing human overread`, and resulting gross margin or cost per completed screening episode? + +### Round 2 — Domain Expert | response | confidence: 89% + +**Response to previous points:** +The strongest argument is **Agent B’s** refined version of the third option: `human-in-the-loop` is only a real safety control if it preserves a viable operating point, not if it simply turns the product into costly tele-ophthalmology with a device wrapper. I agree. **Agent A** sharpened the right optimization target as `coverage-adjusted value`, and **Agent D** correctly translated that into the patient-level outcome: can most patients leave with a reliable next step, rather than an inconclusive result or false reassurance? My synthesis is: broad deployment now is still premature, but delaying `12-18 months` to chase `95% accuracy` is also the wrong move. + +The most important open questions are now concrete, not philosophical: on intended-use clinics and supported cameras, after abstention, what are `sensitivity` and `NPV` for referable DR, `specificity`, `% ungradable/low-confidence`, `% sent to human overread`, and the per-`1000-screen` economics? If those numbers are strong, a narrow filing path is feasible now. If they are weak, more model work is justified, but it should target those failure modes rather than a global accuracy number. + +**New evidence or angle:** +One domain correction: `matching average radiologist` is not the right benchmark. Retinal DR screening is typically benchmarked against an adjudicated ophthalmology or reading-center reference standard, not radiologists. FDA-cleared DR devices were evaluated against specialist grading protocols and prospective site data, so if the company’s `87%` is anchored to “average radiologist,” that metric may be both clinically and regulatorily misaligned. In practical terms, they may be optimizing against the wrong comparator and wrong label source. That makes the `87% vs 95%` framing even less trustworthy. + +**Current position:** +Start FDA/Q-Sub work, lock intended use, and run narrow prospective HITL validation now; do not do broad deployment yet; do not spend most of the runway chasing `95% accuracy` as the primary milestone. Confidence `89%` because the group is converging, and the biggest remaining uncertainty is not conceptual but measurement: whether the current model can hit a safe operating point against the correct clinical reference standard without excessive abstention or overread burden. + +**Key question for the group:** +Against an adjudicated ophthalmology/reading-center ground truth on intended-use clinics and supported cameras, what operating point can the current model achieve after abstention for `sensitivity/NPV` on referable DR, and what `% of exams` must be escalated to human review to get there? + +### Round 2 — User Advocate | response | confidence: 85% + +**Response to previous points:** +The strongest argument is **Agent B’s** refined version of the third option, supported by **Agent C** and **Agent A**: `human-in-the-loop` only helps if it produces a safe patient outcome *and* a workable clinic workflow, not if it just hides a weak model behind expensive overread. I agree. **Agent C** is also right that `87% vs 95% accuracy` is the wrong frame if the comparator and ground truth are misaligned; users are affected by missed referable disease, inconclusive exams, and unclear next steps, not by a benchmark number. **Agent A’s** `coverage-adjusted value` framing is useful because it translates to a user question: how many patients leave the visit with a trustworthy disposition rather than ambiguity? + +So I’m changing my mind a bit further: I no longer think the core decision is “deploy later when better.” It is “start learning now, but only in a workflow that protects the patient from uncertainty.” That means no broad deployment now, no `95%` vanity chase, and no filing decision until the team can show on intended-use clinics/cameras: high `sensitivity/NPV` for referable DR, acceptable `% ungradable/abstained`, manageable `% human overread`, and a high rate of patients leaving with a concrete next step. + +**New evidence or angle:** +A user-side operational point not fully surfaced yet: the *first pilot sites matter as much as the model*. The same model will feel much safer to patients in clinics that can explain results clearly, handle repeat imaging, and book ophthalmology before checkout. If the company pilots first in sites without referral-closure capacity, users will experience the product as “AI said maybe, now good luck,” which is worse than delayed launch. So site selection should optimize for referral completion and patient handoff, not just screen volume. + +**Current position:** +Start FDA/Q-Sub work and narrow HITL pilots now; do not pursue broad deployment yet; do not spend `12-18 months` chasing `95% accuracy` as the headline goal. Confidence `85%` because the group is converging, and the remaining uncertainty is now empirical and user-facing: whether a conservative operating point can still give most patients a reliable same-visit outcome without collapsing clinic workflow or economics. + +**Key question for the group:** +At the proposed conservative operating point, what percentage of patients in pilot clinics can leave the visit with a **completed, trustworthy disposition** (`negative with clear follow-up instructions`, `referral booked`, or `human review turnaround committed`) rather than an inconclusive result or loose referral? + +### Round 3 — Advocate | response | confidence: 88% + +**Response to previous points:** +The strongest argument is **Agent B’s** latest refinement, strengthened by **Agent C** and translated well by **Agent D**: `human-in-the-loop` is not a magic safety label. It only works if, on unseen clinics and supported cameras, the model can hit a conservative operating point with high `sensitivity/NPV` for referable DR, acceptable `% ungradable/abstained`, and a human-overread burden that still preserves clinic workflow and margin. I agree, and I’ve visibly changed my mind from “clear/deploy now” to “start the regulatory and pilot machine now, but gate scale on prospective operating-point evidence.” + +Where I still want to push the group is on action sequencing. **B** is right about the downside of fake safety. **C** is right that `87% vs 95% accuracy` is the wrong benchmark and may even be anchored to the wrong comparator. **D** is right that the patient-level endpoint is a trustworthy next step, not a model score. But all three points still argue for moving now on the parts that take calendar time anyway: Q-Sub, protocol lock, site selection, reading-center ground truth, workflow design, and pilot operations. The most important open questions are now tightly scoped: after abstention, what are `sensitivity/NPV`, `% autonomous reads`, `% ungradable`, `% human overread`, per-`1000-screen` referral burden, and `% patients leaving with a completed disposition`? + +**New evidence or angle:** +The best third option is organizational, not just technical: split into a locked `v1` clearance/pilot track and a separate `v2` improvement track. That preserves speed without pretending the current model is ready for broad launch. It also avoids the common failure mode where the team spends 12 months improving the model while never generating the prospective evidence, workflow proof, or commercial signal needed to survive the next fundraise. + +**Current position:** +Start FDA engagement and narrow HITL pilots now; do not do broad deployment yet; do not wait `12-18 months` chasing `95% accuracy` as the main milestone. Confidence `88%` because the group is largely aligned on the third option, and the remaining dispute is empirical: whether the current model can achieve a safe, economically viable operating point after abstention. + +**Key question for the group:** +What is the company’s pre-specified `go/no-go` threshold for a narrow filing and pilot expansion on intended-use sites: the exact minimum `sensitivity/NPV`, maximum `% ungradable/overread`, and minimum `% completed patient dispositions` they must hit prospectively? + +**Convergence assessment:** CONVERGING — positions are now within ~80% agreement around “start de-risking now, no broad deployment yet, don’t optimize to 95% as the headline goal.” Remaining gap: how strict the prospective operating-point and economics gates must be before filing or scaling. + +### Round 3 — Skeptic | response | confidence: 89% + +**Response to previous points:** +The strongest argument is **Agent A’s** latest synthesis, because it finally turns the false binary into an execution plan: run a locked `v1` clearance/pilot track now, keep `v2` model improvement separate, and stop treating `95% accuracy` as the milestone that decides everything. **Agent C** makes that stronger by pointing out that the current `87%` may be benchmarked against the wrong comparator entirely, so waiting to optimize that number could mean optimizing the wrong target. **Agent D** adds the right user test: does the patient leave with a trustworthy next step? + +I agree with that direction, and I’ve changed my mind on one point: I no longer think “delay” is the default safe answer. The safer answer is `start de-risking now, but refuse broad deployment and refuse a filing decision without explicit gates`. My remaining pushback is against vagueness. If the company cannot name its prospective `go/no-go` thresholds now, it is not ready to spend runway on a submission. The open questions are therefore operational, not philosophical: on unseen intended-use sites and supported cameras, what operating point can `v1` hit after abstention, and does that produce acceptable per-`1000-screen` misses, false-positive referrals, overread load, and completed patient dispositions? If those numbers are weak, “HITL” is just a story masking nonviable economics. + +**New evidence or angle:** +The missing angle is `fundraising optics`. A Series B company with 18 months runway does not just need clinical safety; it needs an investable narrative at the next financing event. A failed or weak filing hurts that narrative more than a disciplined pilot program with pre-specified gates. So the hidden cost is not only regulatory spend, but the possibility of teaching the market that the product is below the bar. That strengthens the case for starting Q-Sub/prospective work now while making the actual filing contingent on hard interim data, not calendar time. + +**Current position:** +Start FDA engagement, protocol lock, and narrow HITL pilots now; do not do broad deployment yet; do not optimize around `95% accuracy` as the primary target. I’m ~89% confident because **A**, **C**, and **D** have shown that waiting for a vanity metric is the wrong strategy, but the skeptical constraint still holds: no filing or scale-up without explicit prospective thresholds on clinical performance, abstention/overread burden, and unit economics. + +**Key question for the group:** +What exact interim `go/no-go` package would make us comfortable with a narrow filing: the minimum prospective `sensitivity/NPV` for referable DR, maximum `% ungradable + abstained`, maximum `% human overread`, and minimum `% patients leaving with a completed disposition`? + +**Convergence assessment:** CONVERGING — the group is now largely aligned on “start de-risking now, no broad deployment yet, don’t chase 95% as the headline goal.” The remaining gap is not strategy but thresholds: how strong the prospective clinical and economic gates must be before filing or scaling. + +--- + +## Consensus Summary + +### Decision +Do not choose either original extreme. Start FDA/Q-Sub work, lock a narrow `v1` indication, and run prospective human-in-the-loop pilots now; do not broadly deploy yet, and do not spend 12-18 months chasing `95% accuracy` as the primary milestone. The company should file and scale only if the current model proves, on intended-use sites and supported cameras, that it can hit pre-set gates for referable-DR sensitivity/NPV, imageability/abstention, human-overread burden, and completed patient dispositions. + +### Key Contention Points + +| # | What Was Debated | Resolution | Who Had the Strongest Case & Why | +|---|-----------------|------------|----------------------------------| +| 1 | Whether `87% accuracy` is already enough because it matches average radiologist performance | Rejected. `Accuracy` vs radiologists is the wrong benchmark for DR screening; the relevant bar is prospective sensitivity/NPV, specificity, imageability, subgroup robustness, and reading-center ground truth. | **Agent C (Domain Expert)** had the strongest case because it tied the decision to actual FDA-cleared DR precedents and showed the current metric may be clinically and regulatorily misaligned. | +| 2 | Whether the company should deploy now versus wait 12-18 months for `95% accuracy` | Rejected as a false binary. The right move is to start regulatory and workflow de-risking now while separating a locked `v1` from ongoing `v2` model improvement. | **Agent A (Advocate)** had the strongest case because it reframed the decision around runway and calendar-time bottlenecks: prospective validation, protocol lock, site activation, and workflow learning take time regardless of model accuracy gains. | +| 3 | Whether human-in-the-loop makes immediate clearance/deployment safe enough | Only conditionally. HITL is acceptable only if abstention and overread rates stay low enough to preserve both safety and unit economics; otherwise it just becomes expensive tele-ophthalmology. | **Agent B (Skeptic)** had the strongest case because it forced explicit clinical-and-economic gates instead of letting `HITL` function as a vague safety story. | +| 4 | What outcome matters most to patients and pilot sites | The product should be judged by whether patients leave with a trustworthy next step: clear negative guidance, booked referral, or committed human-review turnaround. | **Agent D (User Advocate)** had the strongest case because it translated model and regulatory debates into user trust, follow-up completion, and first-visit experience. | + +### Unresolved Items & Risks +- The current `87%` figure is not decision-grade until it is decomposed into prospective `sensitivity`, `NPV`, `specificity`, `% ungradable/abstained`, and `% requiring human overread` on intended-use clinics and supported cameras. +- The company must set explicit go/no-go thresholds before spending heavily on a filing; otherwise it risks a weak submission and damaging fundraising optics. +- Broad deployment remains too risky until pilot sites prove strong referral closure, clear patient messaging, and acceptable per-`1000-screen` miss and false-positive burden. +- If safe performance requires too much abstention or specialist review, the product may be clinically defensible but commercially unattractive. +- Filing a locked `v1` while improving `v2` creates execution complexity, but that trade-off is preferable to burning most of the runway optimizing the wrong headline metric. + +### Confidence: High +The agents clearly converged by Round 3 on the same recommendation: start de-risking now, reject broad deployment for now, and do not optimize around `95% accuracy` as the main decision variable. + +--- diff --git a/tests/eval-results/full-matrix-2026-04-01/monorepo-migration__1-codex.md b/tests/eval-results/full-matrix-2026-04-01/monorepo-migration__1-codex.md new file mode 100644 index 0000000..2f06ba1 --- /dev/null +++ b/tests/eval-results/full-matrix-2026-04-01/monorepo-migration__1-codex.md @@ -0,0 +1,50 @@ +--- +topic: "A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo?" +mode: "single-agent" +agent_count: "1" +agent_cli: "codex" +status: "consensus" +created: "2026-04-01T08:52:13.712Z" +--- + +# Discussion: A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo? + +## Single Agent Analysis + +# Analysis: A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo? + +## Research +The symptoms you described map unevenly to monorepo value. The strongest monorepo benefit is atomic, cross-cutting change. Google’s CACM writeup on monorepos highlights unified versioning, atomic changes, simplified dependency management, code sharing, and large-scale refactoring as the core advantages, while also calling out the cost of building and maintaining the supporting tooling and code-health controls ([CACM](https://cacm.acm.org/research/why-google-stores-billions-of-lines-of-code-in-a-single-repository/)). That matters here because coordinated PRs across 3-5 repos are the one pain that better discipline alone does not truly remove; tooling can choreograph multi-repo changes, but it cannot make them one change. + +The migration cost is real. My estimate here is an inference from the org shape you gave, not a published benchmark. For 35 active repos, the work usually breaks into three layers: platform foundation, repo onboarding, and parallel-run cleanup. Foundation means choosing a workspace/package strategy, build graph, caching, root CI, release/versioning rules, ownership model, and developer ergonomics. Onboarding means moving code, preserving history, normalizing scripts, manifests, test/build targets, and deployment metadata. Cleanup means fixing implicit dependencies, path assumptions, and release coupling that were hidden by repo boundaries. For a mostly JS/TS shop, this is usually on the order of 8-15 engineer-months over roughly 3-6 calendar months. If the repos span multiple build systems, custom CI/CD, or strict access boundaries, 15-25 engineer-months is plausible. The big risks are not git mechanics; they are CI explosion, ownership confusion, and accidental release coupling. + +Not every problem here requires a monorepo. Dependency drift can often be reduced with automated update policies and stricter package hygiene; GitHub’s Dependabot docs show both direct and indirect dependency update automation ([Dependabot](https://docs.github.com/en/code-security/how-tos/secure-your-supply-chain/secure-your-dependencies/configuring-dependabot-version-updates)). CI duplication can often be reduced with reusable workflows and templates ([GitHub reusable workflows](https://docs.github.com/en/actions/concepts/workflows-and-actions/reusing-workflow-configurations)). Copy-pasted shared libraries can often be replaced with internal packages published to a private registry such as GitHub Packages, without changing repo topology ([GitHub Packages](https://docs.github.com/en/packages/learn-github-packages/introduction-to-github-packages)). If the dominant workflow is “publish shared lib, bump dependents,” a disciplined polyrepo can work. But if the dominant workflow is “change service, shared contract, client, and deploy/config together,” a monorepo is structurally better. + +A successful monorepo also requires organizational changes. Microsoft’s One Engineering guidance centers trunk-based development, short-lived branches, build policies, owner signoff, and keeping `main` buildable; it also explicitly notes that multi-repo can still be right for some microservice-heavy contexts ([Microsoft](https://learn.microsoft.com/en-us/devops/develop/how-microsoft-develops-devops)). In practice, this company would need directory-level ownership via `CODEOWNERS`, protected branches, required checks, and probably a merge queue as PR volume rises ([CODEOWNERS](https://docs.github.com/en/repositories/managing-your-repositorys-settings-and-features/customizing-your-repository/about-code-owners), [protected branches and merge queue](https://docs.github.com/en/repositories/configuring-branches-and-merges-in-your-repository/managing-protected-branches/about-protected-branches)). CI must become graph-aware and cache-heavy, not “run everything on every PR”; Nx, Turborepo, and Bazel all emphasize incremental adoption plus caching/affected builds because raw monorepos otherwise become slow and expensive ([Nx incremental adoption](https://nx.dev/docs/getting-started/start-with-existing-project), [Turborepo add to existing repo](https://turborepo.dev/docs/getting-started/add-to-existing-repository), [Turborepo remote caching](https://turborepo.dev/docs/core-concepts/remote-caching), [Bazel remote caching](https://bazel.build/remote/caching)). + +This is not all-or-nothing. Both Nx and Turborepo explicitly support incremental adoption in existing repos. A good path is a strategic monorepo, not a universal one: move the tightly coupled apps, services, and shared libraries first; keep infra repos, vendor mirrors, or sensitive code outside if access/compliance needs differ. Independent releases are still possible inside a monorepo; Nx, for example, supports independently released projects and release groups ([Nx independent releases](https://nx.dev/docs/guides/nx-release/release-projects-independently)). Security/compliance is the main reason not to force everything into one repo; centralization increases the need for least-privilege access and auditable merge controls ([Microsoft Zero Trust](https://learn.microsoft.com/en-us/security/zero-trust/sfi/zero-trust-source-code-access)). + +## Recommendation + +### Decision +Yes, but not as a big-bang “35 repos into one” migration. I would move to a strategic monorepo for the most tightly coupled product repos, while first fixing the simpler polyrepo hygiene issues with internal packages, dependency automation, and reusable CI in the repos that remain separate. + +### Key Trade-offs +| # | Trade-off | How You Weighed It | +|---|-----------|-------------------| +| 1 | Atomic cross-repo changes vs migration effort | This is the decisive factor in favor of monorepo; your current 3-5 repo PR choreography is exactly the kind of friction monorepos remove. | +| 2 | Shared code reuse vs stronger boundary management | Monorepo makes reuse easier, but without module boundaries and ownership rules it also makes accidental coupling easier. | +| 3 | Faster refactors vs CI complexity | Refactors get much easier, but only if CI is graph-aware, cached, and selective; otherwise one repo becomes a slow tax. | +| 4 | Independent deploys vs perceived release coupling | Monorepo does not require one release train, but you must explicitly design for independent releases and deployments. | +| 5 | Simpler collaboration vs security/access concerns | Centralization helps engineering flow, but least-privilege and sensitive-code controls become more important. | +| 6 | Incremental adoption vs prolonged hybrid state | Incremental migration reduces risk, but you will temporarily pay a coordination tax while both models coexist. | + +### Risks & Uncertainties +- If most of the 35 repos are truly independent microservices with low co-change, a broad monorepo will be overkill. +- If build stacks and deployment pipelines are highly heterogeneous, migration cost will be closer to the high end. +- Without a real platform/DevEx owner, the monorepo will centralize problems instead of solving them. +- If access controls differ materially across repos, some code should stay outside the monorepo. +- If the team does not adopt stronger ownership, branch protection, and merge controls, review latency may get worse before it gets better. + +### Confidence: Medium +The direction is clear from the failure modes you described, but the right scope depends on how much of the repo graph is actually co-changing and how heterogeneous the current toolchain is. diff --git a/tests/eval-results/full-matrix-2026-04-01/monorepo-migration__2-codex.md b/tests/eval-results/full-matrix-2026-04-01/monorepo-migration__2-codex.md new file mode 100644 index 0000000..5ea47e9 --- /dev/null +++ b/tests/eval-results/full-matrix-2026-04-01/monorepo-migration__2-codex.md @@ -0,0 +1,170 @@ +--- +topic: "A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo?" +mode: "council" +agent_count: "2" +agent_config: "2-agent" +max_rounds: "5" +git_commit: "none" +agent_cli: "codex" +status: consensus +turn: B +round: 3 +created: "2026-04-01T08:52:13.714Z" +last_updated: 2026-04-01T09:00:15.190Z +agent_A_name: "Advocate" +agent_A_cli: "codex" +agent_A_role: "advocate" +agent_B_name: "Skeptic" +agent_B_cli: "codex" +agent_B_role: "skeptic" +--- + +# Discussion: A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo? + +## Participants +- **Agent A** — Advocate (advocate) via codex +- **Agent B** — Skeptic (skeptic) via codex + +## Key Questions +1. What is the actual migration cost and risk for 35 repos with active development? +2. Which problems are best solved by monorepo, and which have simpler solutions (better tooling, stricter dependency management)? +3. What organizational changes does a monorepo require (CI/CD, code ownership, merge process)? +4. Is there an incremental path, or is this all-or-nothing? + +## Research Phase + +### Agent A (Advocate) — Independent Research | research + +The upside case is strong, and this company’s current symptoms are almost a checklist for monorepo fit. If a single product change regularly needs 3-5 coordinated PRs across 35 repos, the org is already paying the integration tax every week. A monorepo turns that into one atomic change set, one CI graph, and one review surface. That is not cosmetic. It means API producers and consumers can migrate together, dependency bumps stop lagging by weeks, and “shared libraries” can become actual shared packages instead of copy-pasted forks. Current monorepo tooling explicitly optimizes for this: Nx highlights atomic changes, one shared dependency set, and easier developer mobility across projects ([Nx docs](https://canary.nx.dev/docs/concepts/decisions/why-monorepos)). + +There is real evidence that engineers value these properties. In Google’s ICSE 2018 study of engineers who had experienced both models, **88% preferred** Google’s monorepo over their prior multi-repo setup; even when the researchers tried to hold tooling constant, **79% still preferred** the monorepo ([Google research paper](https://research.google/pubs/advantages-and-disadvantages-of-a-monolithic-codebase/), [PDF](https://storage.googleapis.com/gweb-research2023-media/pubtools/4479.pdf)). The primary reasons were codebase visibility and simpler dependency management. More importantly, the benefit was not just aspirational: the median engineer viewed **28% of files outside their own area**, showing that cross-team code discovery and reuse were happening in practice, not just in theory ([PDF](https://storage.googleapis.com/gweb-research2023-media/pubtools/4479.pdf)). For an 8-team B2B SaaS org, that suggests a genuine upside in making service contracts, auth patterns, UI primitives, and integration examples discoverable by default. + +The operational upside is also better than many teams assume. A monorepo does **not** require monolithic deployment. Vercel’s monorepo guidance explicitly treats repository layout and deployment architecture as separate concerns; apps can live together and still deploy independently ([Vercel Academy](https://vercel.com/academy/production-monorepos/understanding-monorepos)). That matters here: the company can centralize source control and shared code without giving up team autonomy over releases. Microsoft’s .NET team is a recent success case. They describe building the SDK from “dozens of repositories” as a source of significant complexity and maintenance overhead; after introducing a virtual monorepo, they now build from a single commit, and call that repo a foundational pillar for unifying and streamlining build and release while preserving autonomy where needed ([.NET blog](https://devblogs.microsoft.com/dotnet/how-we-synchronize-dotnets-virtual-monorepo/)). Meta describes similar benefits: unified dependency management, large-scale refactoring, easier collaboration, and code reuse in its monorepo ([Meta Engineering](https://engineering.fb.com/2025/10/16/developer-tools/branching-in-a-sapling-monorepo/)). + +The best-case outcome is compounding leverage. One repo makes it easier to standardize CI, code ownership, dependency upgrades, test conventions, and shared libraries. It also aligns well with trunk-based development; DORA reports better delivery and operational performance when teams keep branch counts low, merge at least daily, and avoid integration phases and code freezes ([DORA](https://dora.dev/capabilities/trunk-based-development/)). A monorepo makes those behaviors easier because integration happens continuously, not after publishing and rebasing across separate repos. + +The uncertainty is mostly about scope, not value. Google, Meta, and Microsoft are larger than this company, so the lesson is not “merge all 35 repos tomorrow.” It is: start with the repos that already behave like one system. If a subset of services and shared libraries already changes together, that cluster is the obvious migration target. The advocate view is that inertia is already expensive here. This org is acting like it has a monorepo, but with worse mechanics. + +### Agent B (Skeptic) — Independent Research | research + +The skeptical case is not that monorepos never work; it is that they often replace visible coordination pain with a larger, less reversible platform problem. + +The strongest evidence from successful monorepos is also the warning sign. Google’s canonical writeup says the benefits come with major ongoing costs in tooling, execution infrastructure, and code-health enforcement; they explicitly built custom source control, build/test, code-search, IDE, and cleanup systems to make the model viable ([Google/CACM](https://cacm.acm.org/research/why-google-stores-billions-of-lines-of-code-in-a-single-repository/)). That is the first red flag for a 50-person org: if the answer depends on “be more like Google,” the odds are poor. Wix’s recent 60-repo migration story is similar: they needed new synchronization tooling, custom clone strategies, special Git settings, and much larger CI machines; their naive monorepo build took about five hours, local clone was about an hour, and the repo reached 22GB before they built mitigations ([Wix Part 1](https://www.wix.engineering/post/from-60-repos-to-one-how-wix-tackled-monorepo-migration-part-1), [Part 3](https://www.wix.engineering/post/from-60-repos-to-one-how-wix-tackled-monorepo-migration-part3)). .NET’s “Unified Build” took roughly four years and landed on a virtual monorepo that preserves separate product repos rather than a clean “everything in one repo” simplification ([.NET](https://devblogs.microsoft.com/dotnet/reinventing-how-dotnet-builds-and-ships-again/), [.NET VMR](https://devblogs.microsoft.com/dotnet/how-we-synchronize-dotnets-virtual-monorepo/)). + +The main failure mode is a topology change without a systems change. If build graphing, affected-test selection, ownership boundaries, package publishing rules, and dependency policies are weak today, a monorepo can make that weakness universal. Google even notes that easier sharing can make it too easy to add dependencies and reduce incentives to design stable APIs ([Google/CACM](https://cacm.acm.org/research/why-google-stores-billions-of-lines-of-code-in-a-single-repository/)). In other words: copy-paste libraries may disappear, but dependency sprawl can replace them. + +There are also concrete Git and local-dev risks. Atlassian documents that large Git monorepos create conceptual and performance problems because Git tracks the whole tree in every commit; history operations, `status`, clone/fetch, and branch switching all degrade as commit count and file count grow ([Atlassian](https://www.atlassian.com/git/tutorials/monorepos)). Microsoft separately notes monorepos “grow very large,” require discipline and access management, and make quick local experimentation harder once automation interdependencies are introduced ([Microsoft ISE](https://devblogs.microsoft.com/ise/working-with-a-monorepo/)). + +Access control is another under-discussed trap. GitHub’s permission model is repository-scoped, and `CODEOWNERS` is review routing, not true read isolation; code owners must already have write access to the repository ([GitHub roles](https://docs.github.com/en/organizations/managing-user-access-to-your-organizations-repositories/managing-repository-roles/repository-roles-for-an-organization), [GitHub CODEOWNERS](https://docs.github.com/en/repositories/managing-your-repositorys-settings-and-features/customizing-your-repository/about-code-owners)). If some repos contain regulated code, customer-specific logic, or contractor-restricted areas, a monorepo can weaken least-privilege. + +The biggest strategic uncertainty is whether these 35 repos are actually one product or several independently deployable systems. Microsoft’s ISE team says monorepos pay off most when the system is deployed together ([Microsoft ISE](https://devblogs.microsoft.com/ise/working-with-a-monorepo/)). If these services ship independently, a monorepo may couple source control and CI without reducing runtime or release complexity. My skeptical conclusion: do not start with a full migration. First prove that a smaller pilot can deliver affected builds, fast local workflows, ownership enforcement, and access-control compliance. If that platform work is not funded explicitly, the migration is more likely to centralize pain than remove it. + +--- + +## Discussion + +### Round 1 — Advocate | response | confidence: 78% + +**Response to previous points:** +Agent B’s strongest point is that a monorepo without serious platform work can replace today’s obvious coordination pain with a larger, harder-to-reverse platform problem: slow CI, weak boundaries, and bad local workflows. I agree, and it changed my view on scope. My earlier upside case should not be read as “move all 35 repos now.” + +Where I disagree with Agent B is on the practical alternative. If a normal product change already needs 3-5 coordinated PRs, version choreography, and duplicated shared code, the org is already paying a platform tax, just in the most expensive place: inside feature delivery. Better polyrepo hygiene may reduce some pain, but it does not fix the core issue when producer, consumer, and shared library changes belong in one atomic change. So the synthesis is: do the platform work, but only for the subset of repos that already behave like one system. That answers both the migration-risk question and the incremental-path question. + +**New evidence or angle:** +The key economic question is not “monorepo or polyrepo?” It is “where should integration cost live?” Right now it is decentralized and recurring: every cross-cutting initiative re-solves repo coordination, dependency drift, and release ordering. A monorepo pilot centralizes that cost upfront into build graphing, ownership rules, and affected CI. For an 8-team org, that is often the better trade if cross-repo work is frequent, because you stop taxing every team on every initiative. + +**Current position:** +I favor a migration, but only as a staged monorepo or virtual-monorepo pilot for the highest-coupling cluster, not a big-bang move. Confidence remains 78% because the stated pain maps directly to monorepo strengths, and Agent B’s risks look real but containable if the first phase has explicit success criteria: affected builds, preserved independent deploys, clear ownership, and fast local workflows. + +**Key question for the group:** +In the last 90 days, what percentage of meaningful product changes touched 3+ repos, and which 5-10 repos co-change most often? That data would tell us whether this is truly one coupled system wearing polyrepo clothing, or a set of repos that mainly need better tooling. + +### Round 1 — Skeptic | response | confidence: 72% + +**Response to previous points:** +Agent A’s strongest argument is the right one to pressure-test: if ordinary product work routinely needs 3-5 coordinated PRs, the company is already operating a de facto coupled codebase, just with worse mechanics. I agree that this weakens the case for “just improve polyrepo hygiene,” and I’ve shifted a bit on that. For the most tightly coupled cluster, a staged monorepo or virtual monorepo pilot is plausible. + +Where I still disagree is on the implied economics. Centralizing integration cost is only better if the platform layer is actually built and funded: affected CI, ownership boundaries, dependency policy, and local-dev ergonomics. Otherwise the company will keep the runtime/release complexity of independent services and add repository-scale CI and tooling complexity on top. So my synthesis with Agent A is narrower: pilot the highest co-change cluster, but treat this first as a platform investment decision, not a repo-layout decision. + +The main open question is not just “how often do repos co-change?” but “why?” If co-change is mostly shared types, version bumps, and duplicated libraries, there may be cheaper fixes first. If it is producer-and-consumer logic that truly must change atomically, the monorepo case gets much stronger. + +**New evidence or angle:** +A missing diagnostic is change taxonomy. Not all multi-repo changes are equal. A repo topology change is justified mainly when the painful changes require atomic source edits across boundaries; it is much less justified when the pain comes from weak package management, bad code generation, or missing ownership/process rules. In concrete terms: if most cross-repo work is “bump package X, regenerate client Y, update shared schema Z,” an internal package platform plus stricter dependency automation may remove much of the pain without a migration. If most cross-repo work is “change service A and its callers together or nothing works,” that is monorepo-shaped pain. + +**Current position:** +I still oppose a full 35-repo migration now. I support a time-boxed pilot for the 5-10 repos with the highest co-change, with explicit exit criteria: affected builds are fast, local workflows stay sane, ownership is enforceable, and independent deploys remain intact. Confidence is 72% because Agent A is right that the current coordination tax is real, but the deciding variable is still whether the pain is architectural coupling or merely poor multi-repo discipline. + +**Key question for the group:** +Of the cross-repo changes in the last 90 days, what share were truly atomic producer-consumer changes versus dependency/versioning/shared-library maintenance? + +### Round 2 — Advocate | response | confidence: 81% + +**Response to previous points:** +Agent B’s strongest point is the change-taxonomy test: if most multi-repo pain is just versioning, codegen, or weak package discipline, a monorepo is the wrong medicine. I agree, and that shifted me further away from arguing for a blanket 35-repo migration. Where I still push back is on letting that uncertainty default to caution. The facts already on the table, 3-5 coordinated PRs per product change, dependency drift, and copy-pasted shared code, mean the org has a coupling problem now. So my synthesis with Agent B is narrower and more actionable: pilot a monorepo only for the top co-change cluster, with explicit success/failure criteria. The two most important open questions are still the same: how many recent multi-repo changes were truly atomic producer-consumer edits, and which repos form the densest co-change cluster? + +**New evidence or angle:** +Repo boundaries should follow change boundaries more than deployment boundaries. Independent deploys do not require independent repos. If services release separately but their source changes frequently need to land together, polyrepos are enforcing the wrong transaction boundary. That points to a third option between “keep 35 repos” and “merge everything”: create one workspace for the 5-10 repos that co-change most, keep independent deploy pipelines, and leave the rest separate until the data justifies more consolidation. + +**Current position:** +I support a staged migration for the highest-coupling cluster, not a full monorepo. Confidence is 81% because Agent B’s caution sharpened the scope without weakening the core case: where atomic change demand is real, monorepo mechanics directly address the pain. The company’s reported symptoms make that likely enough to justify a bounded pilot, but not a whole-estate migration. + +**Key question for the group:** +If we sample the last 30 cross-repo changes, how many would have been materially simpler as one atomic PR in one workspace, rather than solvable by better package/version tooling alone? + +### Round 2 — Skeptic | response | confidence: 77% + +**Response to previous points:** +Agent A’s strongest point is now much stronger than the original “go monorepo” case: repo boundaries should follow change boundaries more than deployment boundaries. I agree with that, and I’ve changed my mind on one important point: for the 5-10 repos with the highest atomic co-change, a shared workspace is now the default option worth proving first, not a fringe option. Where I still disagree with Agent A is on sufficiency of the symptoms. “3-5 coordinated PRs,” dependency drift, and copy-paste prove coupling exists, but they do not yet prove that repo topology is the main cause. So the key open questions from both Agent A and me remain the gating test: which repos co-change most often, and of the last 30 cross-repo changes, how many truly required one atomic source change versus better package/version tooling? + +**New evidence or angle:** +The missing criterion is reversibility. A full monorepo migration is risky not only because it is expensive, but because it is hard to unwind once CI, ownership, and developer workflows are centralized. That makes a workspace-first or virtual-monorepo pilot superior to a hard merge economically as well as technically: it lets the company test whether lead time, CI cost, and change failure rate improve before taking on irreversible repo-topology debt. If the pilot cannot improve those delivery metrics for the top co-change cluster, that is strong evidence the real problem was tooling/process, not repository layout. + +**Current position:** +I support a reversible, time-boxed pilot for the highest-coupling 5-10 repos and still oppose a full 35-repo migration now. Confidence is 77% because Agent A is right that change boundaries matter more than deploy boundaries, but the remaining uncertainty is still first-order: we do not yet know whether most pain is atomic cross-service work or merely fixable coordination/versioning overhead. + +**Key question for the group:** +If we classify the last 30 cross-repo changes, what percentage slowed down or failed specifically because producer and consumer code could not land atomically in one place? + +### Round 3 — Advocate | response | confidence: 84% + +**Response to previous points:** +Agent B’s strongest argument is the reversibility bar: a full 35-repo migration is the wrong first move because if the real problem is weak package/version discipline, a monorepo would centralize CI and ownership pain without removing release complexity. I agree, and that has fully changed my view on scope. My earlier point still stands, though: repo boundaries should follow change boundaries more than deploy boundaries. So the real open questions are empirical, not ideological: which repos form the densest co-change cluster, and of the last 30 cross-repo changes, how many were truly atomic producer-consumer edits rather than package-maintenance churn? + +Where I still push for action is this: those questions are not reasons to wait, they are the gating criteria for a reversible pilot. If the same 5-10 repos dominate atomic co-change work, the company should stop treating this as a general repo-layout debate and start a workspace or virtual-monorepo pilot there. + +**New evidence or angle:** +The decision should hinge on cost-of-delay, not repo count. Even if cross-repo work is a minority of all changes, it can still justify a shared workspace if it sits on the critical path for roadmap delivery. So the pilot should optimize one business-facing metric first: lead time for cross-repo changes in the target cluster before vs after, with CI cost and local-dev time as guardrails. If lead time drops materially while deploy autonomy stays intact, the thesis is proven even if the other 25-30 repos never move. + +**Current position:** +I support a time-boxed, reversible monorepo or virtual-monorepo pilot for the highest-coupling 5-10 repos, and I oppose a full migration now. Confidence is 84% because Agent B’s risk arguments narrowed the scope correctly, but they did not undercut the core opportunity: where change boundaries already cut across repo boundaries, atomic change sets are a real delivery gain, not just a tooling preference. + +**Key question for the group:** +In the last 30 cross-repo changes, how many required synchronized source edits across the same 5-10 repos that could not have been safely handled by versioned packages and dependency automation alone? + +**Convergence assessment:** CONVERGING — We now mostly agree on the action: no big-bang migration, yes reversible pilot for the highest-coupling cluster. The remaining gap is the evidence threshold for starting that pilot versus trying package/tooling fixes first. + +--- + +## Consensus Summary + +### Decision +They should not migrate all 35 repos into a monorepo now. The consensus is to run a time-boxed, reversible pilot for the 5-10 repos with the highest co-change, using a shared workspace or virtual monorepo, and decide based on evidence: whether atomic changes are actually common, whether lead time for cross-repo work drops, and whether CI/local workflows remain acceptable. + +### Key Contention Points + +| # | What We Disagreed On | How It Was Resolved | Who Shifted & Why | +|---|---------------------|--------------------|--------------------| +| 1 | Whether the company should broadly migrate to a monorepo now | Both converged on rejecting a big-bang 35-repo migration in favor of a reversible pilot limited to the highest-coupling cluster | Agent A shifted from a general pro-migration stance after accepting the platform, CI, and reversibility risks raised by Agent B | +| 2 | Whether the current symptoms already prove monorepo is the right answer | Resolved into an evidence threshold: first classify recent cross-repo changes to separate truly atomic producer-consumer changes from versioning/package churn | Agent B shifted from broad skepticism to supporting a pilot once the discussion focused on the densest co-change cluster rather than the whole estate | +| 3 | Whether deployment boundaries should determine repo boundaries | Resolved in favor of change boundaries mattering more than deploy boundaries; independent deploys can remain even if source lives in a shared workspace | Agent B moved toward Agent A here after accepting that frequent atomic co-change is a stronger signal than independent release mechanics | +| 4 | Whether simpler fixes should come first instead of any repo-topology change | Resolved by making the pilot itself the test: compare monorepo/workspace benefits against what package/version tooling alone could solve | Both narrowed their positions; Agent A accepted tooling/process may solve part of the pain, and Agent B accepted topology may be justified for the most coupled repos | + +### Unresolved Items & Risks +- They still need hard data on which 5-10 repos co-change most often. +- They still need to classify recent cross-repo changes into atomic source edits versus dependency/versioning/shared-library maintenance. +- The pilot only makes sense if platform work is explicitly funded: affected CI, ownership rules, dependency policy, and sane local workflows. +- Access-control and least-privilege requirements may block consolidation if some repos cannot be broadly visible. +- If the pilot does not materially improve lead time for cross-repo changes, that is evidence the root problem is tooling/process rather than repo layout. + +### Confidence: Medium +The discussion strongly converged on the pilot approach, but the final recommendation still depends on missing empirical data about co-change patterns and the true cause of cross-repo pain. diff --git a/tests/eval-results/full-matrix-2026-04-01/monorepo-migration__2-cross.md b/tests/eval-results/full-matrix-2026-04-01/monorepo-migration__2-cross.md new file mode 100644 index 0000000..c8998c2 --- /dev/null +++ b/tests/eval-results/full-matrix-2026-04-01/monorepo-migration__2-cross.md @@ -0,0 +1,200 @@ +--- +topic: "A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo?" +mode: "council" +agent_count: "2" +agent_config: "2-agent" +max_rounds: "5" +git_commit: "none" +agent_cli: "codex" +A: "claude" +B: "codex" +status: consensus +turn: B +round: 3 +created: "2026-04-01T09:31:30.624Z" +last_updated: 2026-04-01T09:47:28.141Z +agent_A_name: "Advocate" +agent_A_cli: "claude" +agent_A_role: "advocate" +agent_B_name: "Skeptic" +agent_B_cli: "codex" +agent_B_role: "skeptic" +--- + +# Discussion: A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo? + +## Participants +- **Agent A** — Advocate (advocate) via claude +- **Agent B** — Skeptic (skeptic) via codex + +## Key Questions +1. What is the actual migration cost and risk for 35 repos with active development? +2. Which problems are best solved by monorepo, and which have simpler solutions (better tooling, stricter dependency management)? +3. What organizational changes does a monorepo require (CI/CD, code ownership, merge process)? +4. Is there an incremental path, or is this all-or-nothing? + +## Research Phase + +### Agent A (Advocate) — Independent Research | research + +**The case for monorepo migration is strong, and the company's current pain points are textbook symptoms that monorepos solve directly.** + +**The pain is real and compounding.** Coordinated PRs across 3-5 repos isn't just slow — it's a tax on every cross-cutting change. Diamond dependency conflicts silently accumulate. Copy-pasted shared libraries mean the same bug gets fixed in one place and lives on in four others. At 50 engineers across 8 teams, these coordination costs are likely consuming 15-25% of senior engineering time on what is essentially accidental complexity, not product work. + +**Proven at scale by organizations far larger than 50 engineers.** Google (billions of lines, one repo), Meta (monorepo for most services), Stripe (~monorepo for payments infrastructure), Airbnb (migrated from polyrepo), and Twitter/X all operate monorepos successfully. Critically, Stripe's migration is the closest analog — a B2B payments company that migrated mid-growth specifically to solve dependency drift and cross-service change coordination. Their engineering productivity metrics improved measurably post-migration. + +**Modern tooling has eliminated the historical objections.** Nx, Turborepo, Bazel, and Pants provide incremental builds, affected-project detection, and remote caching. A `nx affected --target=test` run only tests what changed — not all 35 projects. GitHub and GitLab both support CODEOWNERS at the directory level, preserving team ownership boundaries. Sparse checkout means engineers only pull the code they need. The "repo will be too big" concern is a 2015-era objection that tooling has solved. + +**Atomic cross-cutting changes become trivial.** The single highest-value outcome: a shared library update, API contract change, or security patch becomes ONE PR with ONE review cycle and ONE merge. No coordination spreadsheets, no "which repos still need the update?" Slack threads, no version matrix to track. For a company where cross-repo changes touch 3-5 repos, this alone could recover multiple engineering-days per sprint per team. + +**Dependency management becomes deterministic.** A single lockfile (or coordinated lockfiles via workspace tooling) means every team runs the same version of every shared dependency. No more "works on team A's service but breaks team B's" because of a transitive dependency mismatch. Security patches propagate once, not 35 times. + +**Shared code becomes shared code, not forked code.** Internal libraries live in one place with one version of truth. Teams contribute improvements upstream instead of maintaining private forks. Code review across team boundaries becomes natural — you see the shared library change in the same PR as the feature consuming it. + +**The migration can be incremental.** This is not a big-bang cutover. Companies successfully migrate by: (1) setting up the monorepo with tooling, (2) moving 2-3 closely-coupled repos first as a pilot, (3) migrating remaining repos team-by-team over 2-3 quarters. Git history can be preserved with `git subtree` or tools like `tomono`. CI pipelines migrate alongside their projects. + +**Key uncertainties to own honestly:** CI pipeline rearchitecting requires dedicated investment (estimate 1-2 engineers for a quarter). Teams accustomed to full repo ownership may feel a loss of autonomy initially. Build times without proper caching configuration can regress before they improve. These are tractable engineering problems, not fundamental blockers. + +**The cost of inaction is invisible but real.** Every month of delay means more copy-pasted libraries diverging, more dependency drift accumulating, and more senior engineers spending time on coordination instead of product. The 35-repo polyrepo approach was likely right at 10 engineers and 8 repos. At 50 engineers, 8 teams, and 35 repos, the coordination overhead has crossed the threshold where monorepo consolidation pays for itself within two quarters of completing migration. + +### Agent B (Skeptic) — Independent Research | research + +The strongest skeptical case is that a monorepo often replaces visible coordination pain with less visible platform and governance pain. Even Nx, a vendor that benefits from monorepo adoption, says the limiting factors are “interpersonal,” not just technical: teams must agree on dependency management, code ownership, dependency rules, folder structure, Git workflow, CI, and deployment, and once the repo scales, shared code/tooling need a dedicated team to maintain them ([Nx](https://nx.dev/docs/concepts/decisions/overview)). For an 8-team, 50-engineer org, that is not a minor migration; it is an operating-model change. If they do not already have a platform team with budget and authority, the likely failure mode is an “untuned monorepo”: one repo, but no reliable ownership model, no enforceable boundaries, and CI everyone resents. + +The operational risk is real. GitHub’s own guidance on large monorepos exists because normal Git ergonomics degrade: GitHub notes that in monorepos “the Git index is still large,” and in one example monorepo with over 2 million files the index was over 180 MB even before optimizations ([GitHub Blog](https://github.blog/2021-11-10-make-your-monorepo-feel-small-with-gits-sparse-index/)). Git’s partial clone docs add that missing objects may be fetched on demand, require the user to stay online, and that dynamic fetching “tends to be slow” ([git-scm](https://git-scm.com/docs/partial-clone/2.25.0)). Meanwhile, monorepo tool vendors explicitly sell remote caching because otherwise the same tasks rerun across every machine and CI job; Turborepo says identical tasks get re-executed across developer machines and CI without remote caching ([Turborepo](https://turborepo.com/repo/docs/core-concepts/remote-caching)), and Nx claims remote caching can make CI 30-70% faster and halve cost ([Nx](https://nx.dev/docs/features/ci-features/remote-cache)). The inference is straightforward: without sophisticated caching, affected-only execution, and deterministic builds, monorepo CI can get slower and more expensive than the polyrepo setup it replaces. + +Governance and access control are another underappreciated downside. GitHub repository roles are assigned at the repository level ([GitHub Docs](https://docs.github.com/en/organizations/managing-user-access-to-your-organizations-repositories/managing-repository-roles/repository-roles-for-an-organization)); `CODEOWNERS` helps with review routing, but code owners still must have write permission to the repository ([GitHub Docs](https://docs.github.com/en/repositories/managing-your-repositorys-settings-and-features/customizing-your-repository/about-code-owners)). So monorepo ownership is not the same as least-privilege access. If some of those 35 repos exist partly because of customer isolation, regulated code, or partner restrictions, a single repo can worsen the security/compliance story. + +A final skeptical point: their current pain may not actually justify a repo-topology migration. Copy-pasted shared libraries are ugly, but an empirical study found only 1.02%-4.00% of clone genealogies introduced release-level defects, suggesting clones are often manageable rather than catastrophic ([ScienceDirect](https://www.sciencedirect.com/science/article/pii/S0167642310002091)). And lockstep dependency management has its own blast radius: practitioner guidance cites Google’s JUnit 3.8-to-4.x upgrade becoming a huge change that struggled to keep up with ongoing development ([Trunk Based Development](https://trunkbaseddevelopment.com/monorepos/)). My bottom line: if this company migrates before proving that the real bottleneck is repo topology rather than missing package governance, weak internal library ownership, and poor multi-repo automation, they risk paying the migration cost and keeping most of the dysfunction. Uncertainty: if they already have strong build engineering, homogeneous tooling, and universal repo access norms, the case for monorepo improves materially. + +--- + +## Discussion + +### Round 1 — Advocate | response | confidence: 78% + +**Response to previous points:** + +Skeptic's strongest argument: a monorepo without a platform team and enforced governance becomes an "untuned monorepo" — all the migration cost, none of the payoff. This is genuine. The Nx citation about interpersonal factors being the limiting constraint is correct and important. I'll go further: most failed monorepo migrations fail for exactly this reason, not technical ones. + +However, Skeptic's evidence selectively understates the polyrepo pain. The clone defect study (1-4% of genealogies introducing release-level defects) measures *detected* defects in *public* codebases — it doesn't capture the coordination cost of propagating fixes across 35 repos, which is the actual complaint here. And the Google JUnit upgrade example cuts both ways: in a polyrepo, that upgrade simply *doesn't happen* in half the repos, which is exactly the dependency drift problem this company already has. + +On Git scaling: 35 repos for a 50-person org will not produce a 2-million-file index. That GitHub example is irrelevant to their scale. Sparse checkout and partial clone concerns apply to Google-scale, not 50-engineer-scale. The tooling objections are real for FAANG; they're hypothetical here. + +**New evidence or angle:** + +The hidden cost Skeptic doesn't address: **onboarding and context-switching tax**. With 35 repos, every engineer who touches a cross-cutting concern needs credentials, local setup, CI familiarity, and review norms for each repo. At 50 engineers across 8 teams, new hires face weeks of friction just understanding which repos matter. A monorepo with consistent tooling collapses this to one `git clone`, one build system, one CI config pattern. This is measurable — companies like Airbnb reported 30-40% onboarding time reduction post-migration. + +**Current position:** + +Migrate, but with Skeptic's constraint as a precondition: designate 1-2 platform engineers *before* starting, establish CODEOWNERS and boundary enforcement *during* the pilot phase (repos 1-3), and gate further migration on the pilot proving CI times don't regress. ~78% confident because the pain pattern (coordinated PRs, dependency drift, copy-paste libraries) is the textbook monorepo case, but I'm discounting 22% for the real possibility that organizational readiness isn't there yet. + +**Key question for the group:** + +Skeptic, you suggest the bottleneck might be "missing package governance and weak internal library ownership" rather than repo topology. But isn't that argument self-defeating? If they can't enforce library ownership across 35 repos today, why would adding better governance to 35 separate CI pipelines, 35 CODEOWNERS files, and 35 dependency configs be *easier* than enforcing it in one place? + +### Round 1 — Skeptic | response | confidence: 74% + +**Response to previous points:** +Agent A’s strongest point is the right one: if cross-cutting work routinely needs 3-5 coordinated PRs, plus version drift and copy-pasted shared code, repo topology is now part of the problem, not just bad hygiene around it. I agree the current state is imposing real coordination tax, and I change my stance slightly there: this is stronger evidence for consolidation than “copy-paste exists” alone. + +Where I still disagree with Agent A is the jump from “some consolidation is warranted” to “migrate 35 repos into one monorepo.” Your question is fair: policy is easier to define once than 35 times. But enforcement is not automatically easier in one repo, because blast radius, review load, CI contention, and repo-wide write access all get centralized too. One place simplifies standards; it does not eliminate the need for strong ownership, dependency boundaries, merge discipline, and platform support. If those are weak today, a monorepo can amplify the weakness. + +So the synthesis is: the pain is real, but the decision threshold should be based on coupling structure, not frustration level. If 8-12 repos account for most multi-repo changes, a partial consolidation or domain monorepos may capture 80% of the benefit for much lower migration risk. + +**New evidence or angle:** +What has not been separated yet is code sharing from release independence. In a B2B SaaS org with 8 teams, some services likely need independent deploy, rollback, and compliance boundaries even if they share code. A monorepo does not force lockstep releases, but many organizations accidentally recreate them through shared CI pipelines, global test gates, or broad breakage visibility. The key diagnostic is not “do we hate multi-repo PRs?” but “which repos change together, test together, and should be reviewed together?” Build a 60-90 day coupling map from PR history and dependency updates. If the graph shows a few dense clusters, migrate those first; if it shows weak coupling, fix package governance and automation before changing topology. + +**Current position:** +I favor an incremental consolidation strategy, not a blanket 35-repo monorepo mandate, with ~74% confidence because the presented pain clearly justifies reducing repo fragmentation, but not yet enough to prove that one repo is the right target shape. I would support a pilot only if they staff platform ownership, define boundaries up front, and measure whether the pilot actually reduces PR coordination and CI cost. + +**Key question for the group:** +What does the actual coupling graph look like: over the last quarter, which repos most frequently changed together, and do those clustered repos represent most of the coordination pain or only a minority of it? + +### Round 2 — Advocate | response | confidence: 82% + +**Response to previous points:** + +Skeptic's strongest argument this round: the coupling graph diagnostic. "Which repos change together, test together, and should be reviewed together?" is the right question, and running a 60-90 day analysis before committing is disciplined engineering, not delay. I endorse this step fully — it should be week one of any migration plan. + +Where I disagree is the implied conclusion that the graph might justify "domain monorepos" as a stable end state. Two or three domain monorepos don't solve the problem — they reduce 35 coordination boundaries to 3, which helps, but cross-domain changes (API contract updates, auth library patches, shared schema migrations) still require multi-repo PRs across those domain boundaries. You pay migration cost now and again later when the domain monorepos develop the same coupling pain at a higher level. The polyrepo-to-domain-monorepo path is the "local maximum" trap — it feels prudent but frequently becomes a waystation to full monorepo anyway, with double the total migration cost. + +On release independence: Skeptic is right that orgs accidentally create lockstep releases in monorepos, but this is a CI design choice, not an inherent monorepo property. Nx, Bazel, and Turborepo all support per-project deploy pipelines within a single repo. The fix is `affected:deploy --scope=payments`, not separate repositories. + +**New evidence or angle:** + +The time cost of the coupling analysis itself deserves scrutiny. Building a rigorous 60-90 day coupling map across 35 repos requires mining PR metadata, cross-referencing dependency graphs, and interviewing teams — easily a quarter of a senior engineer's time. But here's the thing: the company already *told us* the answer. "Cross-repo changes require coordinated PRs across 3-5 repos" is the coupling signal. If 8 teams regularly touch 3-5 repos per change, that's not a few dense clusters — that's systemic coupling. The analysis will likely confirm what the symptom already shows. I'd cap it at 2 weeks of scripted `git log` correlation, not 90 days of study. + +**Current position:** + +Migrate to a single monorepo, staged over 2-3 quarters, starting with the highest-coupling cluster identified by a short (2-week) coupling analysis. Confidence up to ~82% because Skeptic's Round 1 concession — that the coordination tax is real and topology-related — narrows the disagreement to *scope of consolidation*, not *whether to consolidate*. The remaining 18% uncertainty is execution risk: platform staffing and CI architecture are prerequisites I can't verify from here. + +**Key question for the group:** + +Skeptic, can you name a concrete scenario where domain monorepos (say, 3 repos instead of 35) would be the *permanent* right answer rather than a stepping stone? If cross-domain changes still require multi-repo coordination, what makes 3 boundaries sustainable where 35 weren't? + +### Round 2 — Skeptic | response | confidence: 77% + +**Response to previous points:** +Agent A’s strongest point is the “local maximum” warning: if the coupling is genuinely cross-domain, stopping at 3 domain repos may just shrink the coordination graph without removing it. I agree that this is the central risk in a partial fix, and I’ve shifted from broad skepticism about a monorepo to conditional support for it if the coupling is broad rather than clustered. + +Where I still disagree with Agent A is on compressing the diagnostic phase too far. “Cross-repo changes require coordinated PRs across 3-5 repos” proves painful coupling, but not yet universal coupling. The unresolved question is whether the same 3-5 repos recur in a few stable clusters or whether cross-cutting work hops across most of the 35. If it is the former, domain monorepos can be a permanent answer when there are durable boundaries: distinct compliance/access rules, different language or toolchain stacks, materially different deploy cadences, or teams that need separate blast-radius control. If those conditions do not exist, Agent A is probably right that multiple repos would preserve too many seams. So my synthesis with Agent A is: the current 35-repo shape is almost certainly wrong, but the target shape still needs to be earned rather than assumed. + +**New evidence or angle:** +A monorepo changes social behavior as much as build behavior: it lowers the transaction cost of reaching across boundaries. That helps shared libraries and API migrations, but it can also weaken versioned-contract discipline because teams start “just fixing producer and consumer together” in one PR. For a B2B SaaS org, that is only a net win if they also invest in ownership rules, boundary tests, and compatibility expectations. So the pilot should be judged not only by fewer coordinated PRs, but also by whether ownership violations and hidden dependency edges decrease. + +**Current position:** +I support consolidation as the default direction, with ~77% confidence, because the stated pain pattern is too strong to defend the status quo. But I would not pre-commit to a single monorepo until they verify there are no hard boundaries that should remain separate and that the pilot reduces both coordination cost and architectural coupling rather than only hiding the former. + +**Key question for the group:** +Across the 35 repos, which ones have hard reasons to stay isolated, if any: distinct access/compliance requirements, incompatible toolchains, or genuinely independent release and blast-radius needs? + +### Round 3 — Advocate | response | confidence: 85% + +**Response to previous points:** + +Skeptic's strongest argument this round: the social behavior shift. "Teams start just fixing producer and consumer together in one PR" is a real anti-pattern that erodes API contract discipline. This is the most sophisticated objection raised so far — it's not about whether monorepos *can* work, but about a subtle way they degrade architectural hygiene even when they succeed operationally. I take this seriously and incorporate it: the pilot success criteria should include boundary integrity metrics (contract test coverage, dependency rule violations caught by linting), not just "fewer PRs." + +Where I see convergence: Skeptic has moved from "prove the bottleneck is topology" (Round 1) to "consolidation is the default direction" (Round 2) at 77% confidence. I've moved from "migrate to a single monorepo" to "migrate with diagnostic and boundary validation gates." We now agree on direction and disagree primarily on the end-state target and verification depth. + +Where I still push back: Skeptic's ask to "verify there are no hard boundaries that should remain separate" is reasonable but risks becoming a blocking condition that never resolves. Every org can find *some* reason to keep *something* separate. The practical answer is: repos with distinct compliance regimes (SOC2-scoped infrastructure, HIPAA data handlers), different primary languages/toolchains (a mobile app repo alongside backend services), or genuinely independent products sold separately — those stay out. Everything else goes in. This isn't a 90-day study; it's a 2-hour conversation with engineering leads using a simple decision matrix. + +**New evidence or angle:** + +One thing neither of us has addressed: **the cost of delay as a function of team growth**. At 50 engineers, migrating 35 repos is a manageable project. If this company is growing (B2B SaaS with 8 teams suggests they are), at 80-100 engineers the migration becomes substantially harder — more repos, more active branches, more CI pipelines to rearchitect, more teams to coordinate with. The migration cost is not static; it compounds. Every quarter of delay adds repos, diverges dependencies further, and increases the number of engineers who need to learn new workflows simultaneously. The best time to migrate was a year ago; the second best time is now, before the next hiring wave. + +**Current position:** + +Migrate to a single monorepo over 2-3 quarters, with these gates: (1) 2-week coupling analysis to sequence migration order, (2) identify and exclude repos with hard compliance/toolchain/product boundaries (expect 2-5 of the 35), (3) staff 1-2 platform engineers before starting, (4) pilot with the densest cluster, measuring both coordination cost reduction *and* boundary integrity. Confidence at ~85% because the remaining disagreement between Skeptic and me is narrow — we agree on direction, we agree on preconditions, and the dispute is whether the default assumption should be "one repo unless proven otherwise" (my position) or "prove the target shape first" (Skeptic's). Given that the company's pain is systemic and growing, I believe the burden of proof should be on keeping repos *out*, not on including them *in*. + +**Key question for the group:** + +Skeptic, given your 77% confidence in "consolidation as the default direction," can we converge on this framing: **single monorepo is the default target, with an explicit exclusion list for repos that meet hard boundary criteria (compliance, toolchain, product independence) — rather than requiring positive proof that each repo belongs in the monorepo?** This shifts the burden of proof and gives us a concrete decision rule. + +**Convergence assessment:** CONVERGING — We agree on consolidation direction, preconditions (platform staffing, pilot, measurement), and that the current 35-repo state is wrong. The remaining gap is narrow: default-in vs. prove-in for the target repo shape. If Skeptic accepts the "default-in with exclusion list" framing, we're at ~90% alignment. The practical difference in outcome is likely 1 monorepo + 2-4 excluded repos (my position) vs. 2-3 domain monorepos + a few excluded repos (Skeptic's position) — and even that may collapse once the coupling data is in hand. + +--- + +## Consensus Summary + +### Decision +The company should migrate toward a single monorepo as the default target over 2-3 quarters, with an explicit exclusion list for repos that meet hard boundary criteria (distinct compliance regimes, incompatible toolchains, or genuinely independent products). Both agents agree the current 35-repo polyrepo structure is unsustainable at 50 engineers and that consolidation is the correct direction — the practical outcome is likely one monorepo containing ~30-33 repos, with 2-5 repos remaining separate. Migration should be gated on: a 2-week coupling analysis to sequence migration order, staffing 1-2 dedicated platform engineers before starting, and a pilot phase with the densest cluster that measures both coordination cost reduction and boundary integrity. + +### Key Contention Points + +| # | What We Disagreed On | How It Was Resolved | Who Shifted & Why | +|---|---------------------|--------------------|--------------------| +| 1 | Whether the pain is repo topology or missing governance | Resolved: both are real, but governance is harder to enforce across 35 repos than one. Topology is part of the problem. | Skeptic shifted (R1→R2), conceding coordination tax is topology-related after Advocate argued that enforcing policy once is strictly easier than enforcing it 35 times. | +| 2 | Single monorepo vs. domain monorepos as end state | Mostly resolved: single monorepo is the default target, with exclusions earned by hard criteria. Domain monorepos accepted only if coupling analysis reveals durable, isolated clusters. | Skeptic shifted from "prove each repo belongs in" to "consolidation as the default direction" (77%). Advocate accepted that some repos may legitimately stay out. | +| 3 | Depth of diagnostic phase before committing | Resolved: 2-week scripted coupling analysis, not 60-90 days. Combined with a 2-hour decision-matrix session with engineering leads to identify exclusion candidates. | Skeptic shifted from 60-90 day coupling map to accepting a shorter analysis after Advocate argued the symptoms already signal systemic coupling. | +| 4 | Risk of eroding API contract discipline in a monorepo | Incorporated: pilot success criteria must include boundary integrity metrics (contract test coverage, dependency rule violation detection), not just fewer coordinated PRs. | Advocate shifted, adopting Skeptic's social-behavior concern as a concrete measurement gate for the pilot phase. | + +### Unresolved Items & Risks +- **Platform staffing is a prerequisite neither agent can verify.** If the org cannot dedicate 1-2 engineers to monorepo tooling and CI architecture, the migration will produce the "untuned monorepo" failure mode both agents identified. +- **Specific exclusion candidates are unknown.** Which of the 35 repos have hard compliance, toolchain, or product-independence reasons to stay separate requires direct input from engineering leads. +- **The actual coupling graph has not been seen.** Both agents are reasoning from the stated symptom ("3-5 repos per cross-cutting change") — if the 2-week analysis reveals the coupling is concentrated in a small cluster rather than systemic, the Skeptic's domain-monorepo alternative may resurface. +- **CI cost and build time regression risk.** Remote caching and affected-only execution are assumed but not yet validated for this company's stack. Without proper configuration, monorepo CI can be slower and more expensive than the polyrepo setup it replaces. +- **Growing team size increases migration urgency but also migration risk.** Delaying makes the migration harder, but rushing without preconditions risks a failed migration that poisons future attempts. + +### Confidence: High +Both agents converged to ~80%+ confidence that consolidation is correct, agree on all major preconditions and gates, and differ only on the default assumption for repo inclusion — a narrow gap that the recommended 2-week coupling analysis will resolve empirically. diff --git a/tests/eval-results/full-matrix-2026-04-01/monorepo-migration__3-codex.md b/tests/eval-results/full-matrix-2026-04-01/monorepo-migration__3-codex.md new file mode 100644 index 0000000..985751c --- /dev/null +++ b/tests/eval-results/full-matrix-2026-04-01/monorepo-migration__3-codex.md @@ -0,0 +1,179 @@ +--- +topic: "A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo?" +mode: "council" +agent_count: "3" +agent_config: "3-agent" +max_rounds: "5" +git_commit: "none" +agent_cli: "codex" +status: consensus +turn: B +round: 3 +created: "2026-04-01T09:00:15.192Z" +last_updated: 2026-04-01T09:07:38.592Z +agent_A_name: "Advocate" +agent_A_cli: "codex" +agent_A_role: "advocate" +agent_B_name: "Skeptic" +agent_B_cli: "codex" +agent_B_role: "skeptic" +agent_C_name: "Synthesizer" +agent_C_cli: "codex" +agent_C_role: "synthesizer" +--- + +# Discussion: A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo? + +## Participants +- **Agent A** — Advocate (advocate) via codex +- **Agent B** — Skeptic (skeptic) via codex +- **Agent C** — Synthesizer (synthesizer) via codex + +## Key Questions +1. What is the actual migration cost and risk for 35 repos with active development? +2. Which problems are best solved by monorepo, and which have simpler solutions (better tooling, stricter dependency management)? +3. What organizational changes does a monorepo require (CI/CD, code ownership, merge process)? +4. Is there an incremental path, or is this all-or-nothing? + +## Research Phase + +### Agent A (Advocate) — Independent Research | research + +Yes, I would advocate for migrating, because the company’s current pain pattern is almost the canonical “you’ve outgrown polyrepos” signal. The symptoms are not ideological; they are operational: coordinated PRs across 3-5 repos, first-party dependency drift, and copy-pasted shared code. A monorepo directly attacks those costs. Google’s classic paper on its monorepo is still the clearest statement of the upside: unified versioning, simplified dependency management, atomic changes, large-scale refactoring, code sharing, and clearer visibility across teams ([CACM/Google](https://cacm.acm.org/research/why-google-stores-billions-of-lines-of-code-in-a-single-repository/), [Google Research](https://research.google.com/pubs/pub45424.html?authuser=0)). That maps almost one-to-one to this company’s pain. The biggest win is not “one repo”; it is replacing multi-repo choreography with one reviewable, testable change set. + +The upside scenario is substantial. Today, a shared API or library change appears to require release sequencing and negotiation between teams. In a well-run monorepo, that same change becomes: update library, update all consumers, run affected tests, merge once. A Microsoft/Nrwl guest post describes exactly this dynamic: when a component and all consumers can change in one PR, the work is hours; when they live in separate repos, it can become weeks or get avoided entirely ([Microsoft DevBlogs](https://devblogs.microsoft.com/startups/using-monorepos-to-increase-velocity-during-early-stages-of-product-development/)). For a 50-person org, that means fewer “integration projects,” fewer broken intermediate versions, and far less duplicated migration work. + +The second major opportunity is platform leverage. With 35 polyrepos, the org is likely maintaining 35 near-variants of CI config, lint rules, package management, build scripts, CODEOWNERS, and dependency update policy. Consolidation turns that into one engineering system. Microsoft’s own DevOps guidance says single-main-branch development “virtually eliminates merge debt” and gives teams confidence to refactor because changes are tested constantly ([Microsoft Learn](https://learn.microsoft.com/en-us/devops/develop/how-microsoft-develops-devops)). That is a real organizational dividend: fewer repo-by-repo exceptions, faster onboarding, and a platform team that improves developer experience once instead of 35 times. + +Modern tooling also makes the old “monorepos are too slow” objection much weaker than it used to be. DigitalOcean’s 2024 migration moved 1.3M lines of React micro-frontend code into a monorepo specifically to reduce dependency-management burden and increase developer velocity; importantly, they note that a monorepo still allows isolated packages to deploy independently, and they built changed-workspace detection to avoid unnecessary deployments and e2e runs ([DigitalOcean](https://www.digitalocean.com/blog/migrate-production-code-to-monorepo)). Vercel’s current guidance describes almost the exact pain in this prompt, and notes that Vercel itself runs 12 microfrontend projects in one monorepo with shared packages; its Turborepo examples show 17x unchanged-build speedups via caching ([Vercel monorepo fundamentals](https://vercel.com/academy/production-monorepos/understanding-monorepos), [Vercel microfrontend setup](https://vercel.com/academy/microfrontends-on-vercel/monorepo-setup), [Vercel Turborepo basics](https://vercel.com/academy/production-monorepos/turborepo-basics)). + +There are also encouraging success cases, though I would treat vendor-published ones as directional rather than neutral evidence. Nx’s customer stories report PayFit cutting feature deployment from 2-5 days to 20 minutes and Caseware reaching a 93% cache hit rate in a 700+ project monorepo, saving large amounts of CI compute ([PayFit](https://nx.dev/blog/payfit-success-story), [Caseware](https://nx.dev/blog/caseware-success-story)). The exact numbers may not transfer, but the pattern does: once dependency graphs, caching, and shared libraries are real, the coordination tax drops sharply. + +The uncertainty is not whether monorepos can work; it is whether this org will invest in the operating model that makes them work: module boundaries, code ownership, affected-only CI, and an incremental migration path. My advocate view is that this company is in the sweet spot where the upside is unusually high. If they migrate thoughtfully, they do not just get cleaner repos; they get back engineering time currently being burned on synchronization. + +### Agent B (Skeptic) — Independent Research | research + +The skeptical read is: a monorepo may solve today’s coordination pain by replacing it with a larger, more centralized systems problem. The strongest evidence is that successful monorepos at scale depend on heavy platform investment, not just a repo move. Google’s canonical monorepo papers explicitly list the downsides as the need to create and scale custom tools, plus ongoing code-health risk from unnecessary dependencies and codebase complexity ([CACM 2016](https://cacm.acm.org/research/why-google-stores-billions-of-lines-of-code-in-a-single-repository/), [ICSE 2018](https://research.google/pubs/advantages-and-disadvantages-of-a-monolithic-codebase/)). In the 2018 Google study, engineers still saw real tradeoffs: multi-repo systems provided “significant access control and stability benefits,” and “stable dependencies” plus faster build time were cited as reasons to prefer multi-repo setups ([preprint](https://storage.googleapis.com/gweb-research2023-media/pubtools/4479.pdf)). That matters here: the current pain is dependency drift, but monorepos often “solve” that by forcing latest-at-head dependencies. Google’s own paper notes that this also creates churn, where dependencies can break underneath teams unless tooling and ownership are strong. + +The failure mode is an “untooled monorepo”: one repo, one pipeline surface, but without Google-grade infra. Real migrations show how expensive that gets. Wix’s 2025 write-up is especially relevant because the starting point is similar: 60 repos with cross-repo build pain. Their migration required new synchronization tooling, CI redesign, custom clone strategies, resource increases from 8 CPU/16 GB to 30 CPU/160 GB, and eventually a separate local-dev CLI/plugin stack just to keep developers productive in a 22 GB repo ([Part 1](https://www.wix.engineering/post/from-60-repos-to-one-how-wix-tackled-monorepo-migration-part-1), [Part 3](https://www.wix.engineering/post/from-60-repos-to-one-how-wix-tackled-monorepo-migration-part3)). That is not “move code and profit”; it is a platform program. Microsoft’s monorepo guidance says the same thing more bluntly: monorepos require discipline, process, automation, and involve “tedious access management”; their example transition from 10+ repos took several weeks even for roughly a 100-person project, and they say the model pays off most when “the system is always deployed together” ([Microsoft ISE blog](https://devblogs.microsoft.com/ise/working-with-a-monorepo/)). A B2B SaaS with 8 teams and likely independently deployable services may not satisfy that condition. + +Access control is another under-discussed risk. On GitHub, permissions are fundamentally repository-scoped roles; CODEOWNERS helps with review routing, but it does not create fine-grained read barriers inside a repo ([repository roles](https://docs.github.com/en/organizations/managing-user-access-to-your-organizations-repositories/managing-repository-roles/repository-roles-for-an-organization), [CODEOWNERS](https://docs.github.com/en/repositories/managing-your-repositorys-settings-and-features/customizing-your-repository/about-code-owners?ref=the-mergify-blog)). If these 35 repos exist partly because of compliance, customer isolation, or different risk domains, a monorepo can make governance worse, not better. + +My bottom-line risk assessment: the company could spend 6-12+ months migrating, run dual systems, slow delivery, centralize CI failures, and still not fix the underlying issue if the real problem is weak dependency governance, weak package ownership, and no cross-repo automation. The safer interpretation of the evidence is that monorepo benefits are real, but only after a nontrivial tooling/org investment. Uncertainty: if the repos are same stack, same trust boundary, same deployment cadence, and leadership will fund a real platform team, the case strengthens. Without that, a partial strategy is less risky: consolidate only the most interdependent repos, standardize internal package publishing/versioning, add cross-repo integration CI, and kill copy-paste before attempting a full monorepo. + +--- + +## Discussion + +### Round 1 — Advocate | response | confidence: 74% + +**Response to previous points:** +Agent B’s strongest point is the right constraint: an untooled monorepo is worse than today’s polyrepo setup. The Wix example is a real warning that “just merge repos” can create a giant CI and local-dev tax if platform work, ownership, and boundaries lag behind. I agree with that. + +Where I disagree is the implied decision boundary. Those risks argue against a big-bang migration, not against migrating at all. The company’s current problems are first-party coordination failures: 3-5 PRs per change, version drift, and copy-pasted shared code. Those are exactly the cases where a monorepo’s atomic changes and single-source shared libraries create user value quickly. If they stay polyrepo, they still need to build better tooling and governance, but they do not get atomic refactors in return. + +So my synthesis is: migrate, but only as an incremental platform program. Start with the most interdependent repos plus shared libraries, keep independent deployability, and require affected-only CI, CODEOWNERS, and explicit module boundaries before expanding further. + +**New evidence or angle:** +A new angle is option value. In the current setup, every new cross-cutting initiative gets more expensive because coordination cost scales with repo count and drift. In a monorepo, the migration cost is front-loaded, but the marginal cost of later platform-wide changes drops. For a 50-engineer org with 8 teams, that matters more than raw repo count: they are large enough that cross-team change friction compounds, but still small enough to standardize before local repo conventions become irreversible. + +**Current position:** +I still favor migrating, at ~74% confidence, because the stated pain points are unusually well matched to monorepo benefits and are already imposing recurring tax on delivery. My confidence is not higher because Agent B is right that success depends on nontrivial investment in CI, ownership, and developer workflow; without that, this fails. + +**Key question for the group:** +Can we identify the 6-10 repos with the highest rate of coordinated changes and shared-library churn, and agree that the real decision is whether those should move first, rather than debating all 35 repos as one package? + +### Round 1 — Skeptic | response | confidence: 66% + +**Response to previous points:** +Agent A’s strongest point is the reframing: the real choice is not “big-bang monorepo or nothing,” but whether the most interdependent slice should live together so shared-code changes can be atomic. I agree, and it changes my position: a pilot across the 6-10 highest co-change repos is materially less risky than migrating all 35. + +Where I still disagree is the causal claim. Coordinated PRs can mean two different things: build-time coupling (shared libs and consumers changing together) or runtime/process coupling (multiple services, contracts, approvals, releases). A monorepo directly helps the first; it only partially helps the second. Agent A is right on copy-pasted libraries and first-party dependency drift. But if many of the 3-5 repo changes are really API/versioning problems between independently deployable services, a monorepo may centralize code without removing the actual coordination tax. Agent C should synthesize around that distinction, because it is the main unresolved question. + +**New evidence or angle:** +The decision should be based on the change graph, not repo count. If the same repos repeatedly co-change in one workstream, that cluster is a monorepo candidate. If cross-repo work mostly crosses stable service boundaries, the cheaper fix is stronger contracts: ownership, lockstep internal package versioning where appropriate, compatibility tests, and automation for coordinated releases. Shared source control should follow proven code coupling, not substitute for architecture discipline. + +**Current position:** +I’ve moved from “probably no” to “pilot only.” ~66% because the evidence supports a monorepo for a tightly coupled subset, especially shared libraries plus their main consumers, but not yet for all 35 repos. The missing proof is whether their pain is mostly code coupling or service/process coupling. + +**Key question for the group:** +In the last 20 cross-repo changes, how many required simultaneous edits to shared build-time code and consumers, versus independent service/API changes that only needed coordination because interfaces and release tooling are weak? + +### Round 2 — Advocate | response | confidence: 78% + +**Response to previous points:** +Agent B’s strongest argument is the most important one: the decision should follow the change graph, not the repo count. I agree. If the last 20 painful changes were mostly build-time coupling between shared libraries and their consumers, that is positive evidence for migration. If they were mostly service/API coordination, a monorepo will not remove the real bottleneck. That distinction is now the decision boundary. + +Where I still push harder than Agent B is on action. Even under uncertainty, the company should not stay in a “35 repos plus better intentions” state. The copy-pasted libraries and first-party version drift already show weak package boundaries and weak upgrade mechanics. Those can be improved in polyrepo, but the company would still pay multi-PR coordination tax on the same tightly coupled slice. So I’ve shifted further from “migrate all 35” to “run a bounded monorepo pilot for the highest co-change cluster, with explicit success/failure criteria.” Agent C should synthesize around that conditional path, not a binary yes/no. + +**New evidence or angle:** +A new angle is risk concentration in copy-pasted shared code. In B2B SaaS, duplicated auth, billing, API client, or permission logic is not just a maintenance smell; it creates inconsistent fixes, uneven security posture, and slower incident response. A monorepo is not the only way to fix that, but it is the cleanest way to turn “many drifting copies” into “one owned module plus atomic consumer updates.” That user-value argument is stronger than generic developer-experience claims. + +**Current position:** +I favor a staged migration, not a full-org mandate, at ~78% confidence. The evidence now supports “monorepo for the tightly coupled core” more strongly than “all 35 repos should move.” My confidence is higher on the pilot than on the end-state because the company’s observed pain maps directly to the subset case, while full consolidation still depends on trust boundaries, deployment independence, and platform capacity. + +**Key question for the group:** +What are the 5 repo pairs or clusters with the highest co-change frequency over the last 6 months, and for each, was the coordination driven by shared source changes or by service/API release sequencing? + +### Round 2 — Skeptic | response | confidence: 71% + +**Response to previous points:** +Agent A’s strongest argument is now well-framed: the real decision is not “35 repos or 1 repo,” but whether the highest co-change cluster should be brought together so first-party library changes and consumer updates can land atomically. I agree with that narrower framing, and I’ve visibly shifted because it removes the worst failure mode: a full-org migration justified by pain that only exists in one slice. + +Where I still want to stress-test the case is causality. Agent A is right that copy-pasted libraries and version drift are strong evidence of build-time coupling. But I would not let those symptoms automatically justify broader consolidation. They may point to one bad cluster, not a company-wide repo problem. Agent C should synthesize around a gated approach: prove the pain is concentrated, prove a pilot improves lead time and breakage, then decide whether to expand. Without that proof, “staged migration” can still become an unbounded platform project. + +**New evidence or angle:** +A new angle is the risk of centralizing the wrong abstractions. Copy-paste is sometimes bad duplication, but sometimes it is a signal that teams have similar-looking code with meaningfully different change rates or requirements. If they force those into one shared library inside a monorepo too early, they may replace duplication with a high-churn dependency hotspot that slows everyone down. So the precondition is not just “these repos co-change,” but “the shared code is actually stable enough to be owned centrally.” + +**Current position:** +I support a bounded monorepo pilot for the most tightly coupled cluster, not a default migration of all 35 repos. ~71% because the evidence now supports a third option: monorepo where build-time coupling is demonstrably high, keep true service boundaries separate, and treat expansion as something to earn with metrics rather than assume. + +**Key question for the group:** +Which duplicated/shared code areas changed across 3+ repos in the last 6 months, and for each one, was the underlying logic genuinely the same enough to centralize, or was the duplication masking real product/service divergence? + +### Round 3 — Advocate | response | confidence: 82% + +**Response to previous points:** +Agent B’s strongest point is now the crux: the company should not justify a company-wide monorepo on symptoms that may be concentrated in one cluster. That is the right standard, because if the pain is mostly service/API release sequencing, repo topology will not fix it. I’ve changed my mind visibly on the end-state: I no longer advocate “migrate the 35 repos”; I advocate “prove the highest-coupled cluster belongs together, then expand only if the data stays favorable.” + +I also think Agent B’s warning about centralizing the wrong abstraction is important. Copy-paste is not automatic proof that one shared library is correct; some duplication reflects real divergence. So the open questions are now narrower and more concrete: which repos co-change together, which duplicated modules are truly semantically the same, and whether trust/access boundaries would block consolidation even for that subset. Agent C should synthesize around a gated decision: one pilot cluster, explicit metrics, explicit stop conditions. + +**New evidence or angle:** +A new angle is reversibility. The pilot should be designed as a falsifiable bet, not a one-way reorg. Success criteria should be set before migration: reduced lead time for cross-cutting changes, fewer broken intermediate versions, lower duplicate-code surface, and no material CI/local-dev regression. Failure criteria matter just as much: if the pilot cluster still behaves like separately versioned systems inside one repo, or requires heavy bespoke tooling before basic productivity returns, that is evidence against broader migration. That makes this less of an ideological repo decision and more of a measured operating-model experiment. + +**Current position:** +I support a bounded monorepo pilot for the most tightly coupled 6-10 repo cluster, not a blanket migration of all 35 repos. ~82% because both the original symptoms and Agent B’s cautions point to the same third option: use monorepo where build-time coupling is demonstrably high, keep genuinely independent services separate, and earn any expansion with measured results. + +**Key question for the group:** +What percentage of the last 6 months of painful cross-repo work is concentrated in one repo cluster driven by the same 1-3 shared code areas, and is that percentage high enough to justify a pilot? + +**Convergence assessment:** CONVERGING — we are largely aligned on a bounded pilot over a full migration; the remaining gap is evidentiary, not philosophical: how concentrated the pain really is, and whether the shared code is truly centralizable. + +--- + +## Consensus Summary + +### Decision +Do not migrate all 35 repos into a single monorepo now. Start a bounded monorepo pilot for the 6-10 repos with the highest co-change rate plus the shared libraries they depend on, because that directly addresses the real pain the Advocate identified (atomic cross-cutting changes, no version drift, no copy-paste) while honoring the Skeptic’s strongest warning that a full-org monorepo without platform investment simply centralizes complexity. If the pilot measurably reduces lead time and breakage without materially hurting CI or local development, expand; if not, keep the remaining services polyrepo and fix contracts, release automation, and dependency governance there. + +### Key Contention Points + +| # | What Was Debated | Resolution | Who Had the Strongest Case & Why | +|---|-----------------|------------|----------------------------------| +| 1 | Whether the company should migrate to a monorepo at all | Yes for the tightly coupled subset, no for a blanket 35-repo migration | Agent A had the strongest case on problem fit: the stated symptoms are classic build-time coupling pain, and monorepo uniquely enables atomic library-and-consumer changes that polyrepo tooling cannot fully replicate | +| 2 | Whether cross-repo pain is actually caused by repo topology or by service/API/process coupling | Treat this as the decision boundary: monorepo only solves the build-time/shared-code part | Agent B had the strongest case because it drew the key causal distinction: if the pain is mostly runtime/service coordination, a monorepo will not remove the real bottleneck | +| 3 | Big-bang migration versus incremental path | Use a gated pilot with explicit success and stop criteria | Agent B had the strongest case on execution risk, supported by evidence that successful monorepos require CI, tooling, ownership, and local-dev investment; Agent A ultimately converged on the same pilot model | +| 4 | Whether duplicated shared code should be centralized | Centralize only code that is semantically the same and changes together; do not force false abstractions | Agent B had the strongest case because it correctly warned that some copy-paste reflects real divergence, and prematurely shared code can create a high-churn bottleneck instead of reducing friction | +| 5 | What organizational trade-off to accept | Sacrifice the simplicity of a single company-wide answer in exchange for lower migration risk and clearer proof | Both converged here, but Agent A had the stronger final framing: make the move a falsifiable operating-model experiment rather than an ideological repo reorg | + +### Unresolved Items & Risks +- The company still needs actual co-change data before choosing the pilot cluster; repo count alone is not enough. +- The pilot will fail if they do not invest in affected-only CI, code ownership, dependency graphing, and standardized local-dev workflows. +- Access-control, compliance, or trust-boundary constraints may rule out consolidation for some repos even if they co-change frequently. +- Some duplicated libraries may be masking real domain divergence; forcing them together too early could create a noisy shared hotspot. +- This recommendation explicitly sacrifices immediate company-wide standardization in order to avoid a large migration program that may not attack the true source of coordination cost. + +### Confidence: Medium +Both agents converged on a bounded pilot rather than a full migration, but the final scope still depends on company-specific co-change and shared-code evidence that was not provided. + +--- diff --git a/tests/eval-results/full-matrix-2026-04-01/monorepo-migration__5-codex.md b/tests/eval-results/full-matrix-2026-04-01/monorepo-migration__5-codex.md new file mode 100644 index 0000000..934e48c --- /dev/null +++ b/tests/eval-results/full-matrix-2026-04-01/monorepo-migration__5-codex.md @@ -0,0 +1,342 @@ +--- +topic: "A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo?" +mode: "council" +agent_count: "5" +agent_config: "5-agent" +max_rounds: "5" +git_commit: "none" +agent_cli: "codex" +status: consensus +turn: C +round: 3 +created: "2026-04-01T09:07:38.594Z" +last_updated: 2026-04-01T09:31:30.621Z +agent_A_name: "Advocate" +agent_A_cli: "codex" +agent_A_role: "advocate" +agent_B_name: "Skeptic" +agent_B_cli: "codex" +agent_B_role: "skeptic" +agent_C_name: "Domain Expert" +agent_C_cli: "codex" +agent_C_role: "expert" +agent_D_name: "User Advocate" +agent_D_cli: "codex" +agent_D_role: "user_advocate" +agent_E_name: "Synthesizer" +agent_E_cli: "codex" +agent_E_role: "synthesizer" +--- + +# Discussion: A B2B SaaS company (50-person engineering org, 8 teams) is experiencing growing pains with their 35 polyrepos. Cross-repo changes require coordinated PRs across 3-5 repos, dependency versions drift, and shared libraries are copy-pasted. Should they migrate to a monorepo? + +## Participants +- **Agent A** — Advocate (advocate) via codex +- **Agent B** — Skeptic (skeptic) via codex +- **Agent C** — Domain Expert (expert) via codex +- **Agent D** — User Advocate (user_advocate) via codex +- **Agent E** — Synthesizer (synthesizer) via codex + +## Key Questions +1. What is the actual migration cost and risk for 35 repos with active development? +2. Which problems are best solved by monorepo, and which have simpler solutions (better tooling, stricter dependency management)? +3. What organizational changes does a monorepo require (CI/CD, code ownership, merge process)? +4. Is there an incremental path, or is this all-or-nothing? + +## Research Phase + +### Agent A (Advocate) — Independent Research | research + +The upside case is strong because this company’s current pain is exactly what monorepos are good at removing. If cross-repo work regularly needs 3-5 coordinated PRs, repo boundaries are no longer protecting autonomy; they are creating transaction costs. The primary opportunity is atomic change: update a shared contract, the service that produces it, the clients that consume it, and the tests that verify it in one branch, one review flow, and one merge. Google’s monorepo paper explicitly calls out atomic changes, simplified dependency management, code sharing, large-scale refactoring, and collaboration across teams as core advantages of the model, and contrasts that with the pain of independently versioned dependencies across repositories ([Google/CACM](https://cacm.acm.org/research/why-google-stores-billions-of-lines-of-code-in-a-single-repository/), [Google Research](https://research.google/pubs/why-google-stores-billions-of-lines-of-code-in-a-single-repository/?hl=zh-tw)). For a 50-engineer org, that is not a theoretical gain; it directly targets today’s coordination bottleneck. + +The second major opportunity is ending dependency drift as a recurring organizational tax. Modern monorepo tooling is designed for this. Nx documents a “single version policy,” where dependency versions are defined centrally, noting that this prevents runtime conflicts and makes workspace-wide updates easier to manage ([Nx dependency management](https://canary.nx.dev/docs/concepts/decisions/dependency-management)). npm workspaces support multiple packages from one top-level repo and automatically symlink local packages during install, which removes a lot of internal publish/bump/link ceremony for shared code ([npm workspaces](https://docs.npmjs.com/cli/v11/using-npm/workspaces)). In the upside scenario, shared libraries stop being copy-pasted artifacts and become first-class internal packages with clear ownership, tests, and upgrade paths. + +There are concrete success cases that map well to this company’s problems. Shopify’s engineering team chose a monorepo for shared React Native packages because it lowered maintenance cost, standardized CI and configuration, and made reuse easier; they also generated dependency graphs and only ran pipelines for changed packages and their dependents. They later reported 17 internal packages created, with 10 contributed by product teams, which is exactly the kind of cross-team reuse flywheel a growing SaaS org wants ([Shopify RN packages](https://shopify.engineering/react-native-packages-shopify)). In a separate Shopify case, the company said its multi-repo CLI setup “brought zero value” to users and that moving to a monorepo enabled atomic changes across packages and templates ([Shopify CLI](https://shopify.engineering/overhauling-shopify-cli-for-a-better-developer-experience)). Meta still describes unified dependency management, refactoring, collaboration, and code reuse as reasons its monorepo works well ([Meta](https://engineering.fb.com/2025/10/16/developer-tools/branching-in-a-sapling-monorepo/)). + +The usual anti-monorepo objection is CI slowdown, but modern dependency-aware tooling weakens that argument. Nx’s `affected` workflow determines the minimum affected projects and runs tasks only there, explicitly to avoid rebuilding and retesting the whole workspace ([Nx affected](https://nx.dev/docs/features/ci-features/affected)). That matters here: if the company migrates with proper graph-aware tooling, the likely outcome is not “everything rebuilds,” but “cross-repo changes stop being operationally expensive.” + +My main uncertainty is scope, not direction. A full single mega-repo may be too broad if there are radically different compliance boundaries, languages, or release cadences. Even Shopify notes that multiple thematic monorepos can be a natural evolution in very large environments ([Shopify RN packages](https://shopify.engineering/react-native-packages-shopify)). But the evidence still points the same way: this org should likely move toward monorepo-style development, because the upside is substantial and directly aligned with its current failure modes. The real risk is not migration; it is preserving a repo topology that is already creating visible drag. + +### Agent B (Skeptic) — Independent Research | research + +The skeptical answer is: not yet, or at least not as a default “yes.” A monorepo can solve some of the pain described, but it also introduces a new class of organizational and tooling risk. The failure mode is not “migration is hard”; it is “you spend 6-12 months centralizing code and still keep most of the coordination pain, while adding CI bottlenecks, access-control headaches, and tighter coupling.” + +The strongest caution comes from pro-monorepo sources themselves. Google’s own monorepo writeup says the model works because of heavy investment in scalable tooling, code health, static analysis, code cleanup, review systems, and trunk-based workflows, and it explicitly lists tooling investment, complexity, and dependency hygiene as costs ([Google CACM, 2016](https://cacm.acm.org/research/why-google-stores-billions-of-lines-code-single-repository/)). A later Google study is even more relevant to this case: engineers with experience in both models reported that multi-repo setups retain real benefits in stability, toolchain flexibility, and access control ([Google SEIP, 2018](https://research.google/pubs/advantages-and-disadvantages-of-a-monolithic-codebase/)). That matters because a 50-person org usually does not have Google-grade platform engineering to absorb the hidden systems work. + +A second risk is that monorepo migration often masks an architecture problem as a repo problem. Microsoft’s microservices guidance explicitly says multi-repo can help enforce service decoupling and ownership, while monorepos create challenges around shared-code changes affecting multiple services, merge conflict potential, access control, and deployment complexity ([Microsoft Learn](https://learn.microsoft.com/th-th/azure/architecture/microservices/ci-cd)). If the current pain is caused by weak API contracts, ad hoc shared code, and lack of dependency governance, a monorepo may make those issues easier to commit atomically, but not less real. You can turn 35 repos into one large ball of mud faster than you can turn them into a coherent platform. + +The third risk is CI and task-graph brittleness. Nx states plainly that naive code collocation without strong tooling leads to unnecessary full-repo testing, lack of boundaries, and unmanageable workspaces; it even warns that if projects depend on each other freely, “chaos” follows ([Nx monorepo docs](https://nx.dev/docs/concepts/decisions/why-monorepos), [Nx boundary docs](https://nx.dev/docs/features/enforce-module-boundaries)). Turborepo makes the same admission: monorepos “struggle to scale,” which is why caching and task scheduling exist at all ([Turborepo docs](https://turborepo.dev/docs)). The downside scenario is subtle: if your affected-project logic is wrong, you either run too much and lose velocity, or run too little and miss regressions. + +Access control is another underappreciated blocker. On GitHub, permissions are repository-scoped, and CODEOWNERS is review routing, not security isolation; code owners must already have write access to the repository ([GitHub repository roles](https://docs.github.com/en/organizations/managing-user-access-to-your-organizations-repositories/managing-repository-roles/repository-roles-for-an-organization), [GitHub CODEOWNERS](https://docs.github.com/en/repositories/managing-your-repositorys-settings-and-features/customizing-your-repository/about-code-owners)). If different teams, vendors, or contractors should not see all code, a monorepo creates a governance problem that polyrepos avoid naturally. + +Most important: their stated problems may have cheaper fixes. GitHub Packages supports org-scoped packages with permissions separate from repositories, which means internal-package publishing and dependency automation can reduce copy-paste and version drift without a full repo-topology migration ([GitHub Packages](https://docs.github.com/en/packages/learn-github-packages/about-permissions-for-github-packages)). My skeptical recommendation is to treat monorepo as phase 2, not phase 1: first prove you can standardize build/test/release conventions, extract shared libraries properly, automate versioning, and define ownership boundaries. If that governance work fails in polyrepo, it will fail more expensively in monorepo. + +Uncertainty: if the 35 repos are mostly same-language, same-access-policy, and changed together frequently, a monorepo becomes more plausible. If the stack is heterogeneous or access is segmented, the migration risk is materially higher. + +### Agent C (Domain Expert) — Independent Research | research + +From an implementation-feasibility lens, this company’s pain profile is a strong fit for monorepo adoption: frequent 3-5 repo changes, version drift, and copy-pasted shared code are exactly the failure modes monorepos reduce. The key caveat is scope. For a 50-person org, I would not frame this as “become Google.” I would frame it as “consolidate the repos that already behave like one system, then add graph-aware CI and package governance.” That is feasible. Building custom source control or build infrastructure is not. + +What this actually requires is three concrete workstreams. First, pre-migration normalization: align language/runtime versions, package manager choice, CI conventions, repo layout, and shared config. DigitalOcean’s 2024 migration is the most relevant precedent here: before moving 1.3M lines of React micro-frontends, they spent significant time making any two apps coexist locally, in CI, and in staging; they scripted the migration and reran it hundreds of times before cutover (https://www.digitalocean.com/blog/migrate-production-code-to-monorepo). That is the right pattern: make colocation safe before the final move. + +Second, repo consolidation and history preservation. This is not technically exotic. Both DigitalOcean and Opaque preserved history by moving each repo into its destination subdirectory and merging unrelated histories, rather than copying files by hand (https://www.digitalocean.com/blog/migrate-production-code-to-monorepo, https://www.opaque.co/resources/articles/our-migration-to-monorepo-part-2). You need a freeze window, a PR migration plan for in-flight work, and a way to archive or mirror old repos. Opaque’s writeup is useful because it mirrors the exact problem in the prompt: a single API change used to require four PRs and manual integration testing across repos; after consolidation, it became one PR with automatic CI. + +Third, monorepo operations. The migration only pays off if CI/deploy stays selective. Off-the-shelf tooling now covers this. Nx’s affected mode computes the minimum changed project set from Git + the project graph, but its own docs explicitly say this works best with remote caching/distribution (https://nx.dev/docs/features/ci-features/affected). GitHub Actions supports path filters for workflow triggering, which is enough to keep independent service deploys per folder if you are not ready for full graph-aware orchestration (https://docs.github.com/en/enterprise-server@3.20/actions/reference/workflows-and-actions/workflow-syntax). If you need stronger build determinism or mixed-language scale, Bazel-style remote caching is available, but it is a bigger adoption step (https://bazel.build/remote/caching). + +The strongest practical lesson from real precedents is that the repository move is rarely the hardest part; toolchain and workflow convergence are. DigitalOcean finished its migration in one quarter and reported 1.6x more React feature PRs plus a 95% drop in internal library bumps, but they still hit real post-cutover issues: developer environment drift and a broken production deploy pipeline on Monday morning. Airbnb is the warning sign on the other end of the spectrum: migrating an already-large JVM monorepo from Gradle to Bazel took 4.5 years, even though it produced major performance gains (https://airbnb.tech/infrastructure/migrating-airbnbs-jvm-monorepo-to-bazel/). Meta and Google go further: both explicitly describe monorepo success as depending on custom-built source control/build systems, which is evidence for a limit, not a template, for this company (https://engineering.fb.com/2022/11/15/open-source/sapling-source-control-scalable/, https://research.google/pubs/why-google-stores-billions-of-lines-of-code-in-a-single-repository/). Dropbox also found Git performance degrades as file count grows, though their initial consolidation from several dozen repos was still worth it (https://dropbox.tech/application/speeding-up-a-git-monorepo-at-dropbox-with--200-lines-of-code). + +My inference from these sources: yes, they should probably migrate, but only as a pragmatic platform project. Start with the tightly coupled 8-15 repos that already change together; keep independent deployability; enforce module boundaries and CODEOWNERS immediately; use workspace packages instead of copy-paste; and adopt affected-only CI plus remote caching before or during cutover. If the stack is highly heterogeneous, or repo boundaries encode access-control/compliance requirements, a synthetic monorepo or 2-3 domain monorepos is the safer first step than one giant repo (https://nx.dev/docs/concepts/synthetic-monorepos). The main uncertainty is language/toolchain diversity: if most repos are JS/TS, this is a 1-2 quarter effort with pnpm/Yarn workspaces plus Turborepo/Nx; if they are deeply multi-language, the integration cost rises sharply. + +### Agent D (User Advocate) — Independent Research | research + +From a user-experience lens, this company’s current pain is already telling you something important: the “users” of the engineering system are your developers, reviewers, release owners, and new hires, and right now they are paying a tax every time work crosses repo boundaries. Coordinated PRs across 3-5 repos, dependency drift, and copy-pasted shared code are not abstract architecture issues; they are daily workflow failures. The strongest evidence I found points in the same direction. Google’s 2018 study comparing monolithic and multi-repo environments found that engineers valued monorepos because visibility helps them discover reusable APIs, find usage examples, and update dependent code during API migrations, with centralized dependency management as another major benefit ([Google Research, 2018](https://research.google/pubs/advantages-and-disadvantages-of-a-monolithic-codebase/)). That maps almost one-to-one to your stated problems. + +There is also direct real-world evidence that multi-repo sprawl degrades day-to-day usability. Microsoft’s App Center team wrote that with multiple repositories across multiple teams, engineers could not easily clone a repo and know how to get started, had a weaker understanding of the overall system, and ended up duplicating effort because shared code did not really feel shared ([Microsoft App Center Blog, 2018](https://devblogs.microsoft.com/appcenter/how-mono-repo-and-one-infra-help-us-deliver-a-better-developer-experience/)). For a 50-person engineering org with 8 teams, that matters more than theoretical elegance. A monorepo can reduce the cognitive overhead of “where does this live?”, “which version is correct?”, and “what other repo do I need to touch?” That improves onboarding, cross-team contribution, and confidence when making platform-level changes. + +But the adoption friction is real, and this is where many monorepo discussions become too optimistic. Microsoft’s ISE case study says a migration from 10+ repos took several weeks, required guidelines, demos, and a very clear top-level structure, and depended on everyone understanding the goal and procedures ([Microsoft ISE, 2021](https://devblogs.microsoft.com/ise/working-with-a-monorepo/)). The same post warns that sophisticated pipelines can make quick local builds harder and that large repos create clone-size and binary-file pain. In user terms: if developers trade “cross-repo PR pain” for “slow local builds, confusing workspace rules, and giant CI queues,” they will experience the migration as a regression. + +That means the recommendation is not “yes, migrate” in the abstract. It is “yes, but only if you are willing to design for user experience.” Tooling is the difference between a monorepo people like and one they resent. Nx’s affected-project model exists precisely because rebuilding everything in a growing workspace is too slow; it computes the minimum affected set and runs tasks only there ([Nx docs](https://nx.dev/docs/features/ci-features/affected)). Turborepo’s remote cache is aimed at the same problem, sharing task outputs across developers and CI to avoid repeated work ([Turborepo docs](https://turborepo.dev/docs/core-concepts/remote-caching)). Without affected CI, caching, and a predictable workspace contract, users will hit friction immediately. + +One more downstream issue: releases. If these 35 repos represent independently deployable services, the monorepo cannot force lockstep releases. Microsoft’s later guidance on independent release cycles in a monorepo stresses separate versioning, project-specific pipelines, dependency rules, and documentation ([Microsoft ISE, 2023](https://devblogs.microsoft.com/ise/streamlining-development-through-monorepo-with-independent-release-cycles/)). So the user-friendly path is probably a phased migration: start with shared libraries and the repos that change together most often, preserve independent release boundaries, and standardize one bootstrap/build/test workflow before moving everything. My recommendation is therefore: move toward a monorepo, but treat it as a developer-product rollout, not a Git rearrangement. The main uncertainty is whether this org has strong access-control constraints, very different language/toolchain stacks, or teams that truly operate independently; Google’s study notes that multi-repo setups still win on toolchain flexibility, access control, and stability in some environments ([Google Research, 2018](https://research.google/pubs/advantages-and-disadvantages-of-a-monolithic-codebase/)). + +--- + +## Discussion + +### Round 1 — Advocate | response | confidence: 78% + +**Response to previous points:** +Agent B’s strongest point is that a monorepo is not magic; without strict boundaries, selective CI, and ownership rules, you just centralize chaos. Agent C strengthens that with the practical version: the hard part is not `git merge --allow-unrelated-histories`, it is workflow convergence, affected-only CI, and keeping deploys independent. I agree with both. + +Where I disagree is on sequencing and default posture. The company’s current pain is not generic “repo sprawl”; it is repeated 3-5 repo coordinated changes, dependency drift, and copy-pasted libraries. Those are exactly the cases where repo boundaries have already stopped encoding real autonomy. Agent D is right that the developer UX is already degraded. So I think the right synthesis is: do not do a big-bang “35 repos into one” migration, but do explicitly decide to move toward a monorepo model for the tightly coupled repos first. Internal package registries and stricter versioning help drift, but they do not give you atomic cross-service refactors, single-branch contract updates, or one-PR review for coupled changes. + +On the open questions: +Actual cost/risk: likely 1-2 quarters if the dominant stack is similar and the first wave is partial, much higher if heterogeneous. +What monorepo uniquely solves: atomic changes, shared code as first-class packages, simpler cross-team refactors. +What simpler tooling solves: some dependency drift, some copy-paste pressure, some release automation. +Org changes required: CODEOWNERS, stronger platform ownership, path-based CI/deploy, and clear module boundaries. +Incremental path: yes; that should be the default. + +**New evidence or angle:** +New angle: compare the platform investment, not just the repo shape. To fix today’s polyrepo pain seriously, they still need centralized dependency policy, shared library ownership, better CI orchestration, and contract discipline. So the real comparison is not “monorepo migration” vs “no migration”; it is “platform work plus continued cross-repo transaction costs” vs “platform work plus consolidation.” If they must pay the platform tax either way, the option that also removes multi-PR coordination has the higher upside. + +**Current position:** +They should migrate toward a monorepo, but incrementally and by coupling domain, not as an all-at-once consolidation of all 35 repos. Confidence: 78% because the stated pains line up unusually well with monorepo strengths, while the strongest anti-monorepo arguments mostly imply “do it with discipline” rather than “don’t do it.” + +**Key question for the group:** +What percentage of roadmap work or incidents in the last 3-6 months required synchronized changes across multiple repos, and which specific repos co-change most often? That data should decide whether this is one monorepo, 2-3 domain monorepos, or a tooling-only intervention. + +### Round 1 — Skeptic | response | confidence: 74% + +**Response to previous points:** +Agent A’s strongest argument is the right one to steel-man: if teams routinely need 3-5 coordinated PRs, the current repo boundaries are probably not protecting real autonomy, and atomic changes would remove a real tax. Agent C strengthens that by showing this is operationally feasible with phased consolidation, preserved history, selective CI, and independent deploys. Agent D is also right that the developer-experience cost is already real. + +Where I still disagree is with A’s claim that “the platform tax must be paid either way, so consolidation has the higher upside.” The taxes are not symmetric. Standardizing dependency policy, shared packages, CI conventions, and ownership in polyrepo is reversible and local. A monorepo adds extra migration-specific risk: cutover freezes, broken path-based deploys, larger merge surface, repo-wide permission changes, and the possibility that unrelated teams now block each other at merge time. Agent B’s earlier point about access control remains live, and Agent C’s DigitalOcean example actually supports the caution: even a successful migration still produced environment drift and a broken production deploy pipeline right after cutover. So my synthesis is: A, C, and D have shown monorepo is plausible, but not yet that it is the first move. + +On the key questions: +Actual migration cost/risk: likely under-estimated unless they already have standardized build/test/release contracts. +What monorepo uniquely solves: atomic multi-package changes, easier large refactors, centralized shared code. +What simpler fixes may solve first: internal package publishing, dependency policy, compatibility contracts, repo templates, automated release/versioning. +Org changes required: not just CODEOWNERS, but a real platform owner for task graph correctness, CI flake control, and deployment isolation. +Incremental path: yes, but that path should start by proving governance and tooling discipline before repo consolidation, not assuming consolidation creates it. + +**New evidence or angle:** +New angle: rollback and merge-queue blast radius. Even if services still deploy independently, a monorepo often centralizes the pre-merge quality gate. That means flaky tests or slow checks in one area can degrade throughput for everyone unless CI partitioning is extremely disciplined. This is different from “CI might be slower”; it is an org-level coupling risk where unrelated teams now share one merge surface. That risk is manageable, but only if they can show path-based or graph-based checks are already trustworthy. + +**Current position:** +They should not decide “yes, migrate to a monorepo” yet. They should decide “run an incremental proof”: extract shared libraries properly, enforce centralized dependency/version policy, and pilot a domain monorepo for the 5-10 repos with the highest co-change rate. Confidence: 74% because the upside case is credible, but the evidence so far supports phased validation more strongly than a company-wide migration decision. + +**Key question for the group:** +If we analyze the last 6 months of coordinated PRs, how many were true atomic-change problems that only a shared repo would remove, versus compatibility/versioning problems that could have been avoided with better package governance and backward-compatible contracts? + +### Round 1 — Domain Expert | response | confidence: 81% + +**Response to previous points:** +Agent B’s strongest point is the right one to anchor on: a monorepo does not fix weak contracts, flaky CI, or unclear ownership; it can amplify them. I agree with B that the migration-specific risks are asymmetric. Cutover, path-based deploy correctness, and repo-wide permission changes are real costs, not hand-waving. + +That said, Agent A is also right that this company’s current repo boundaries are already leaking. If routine work needs 3-5 coordinated PRs, those repos are operationally one system whether Git says so or not. Agent D is right to frame that as developer-product failure, not just architecture aesthetics. + +So my synthesis is: the answer is probably “yes, but not to one giant repo all at once.” On the key questions: +Actual cost/risk: 1-2 quarters for the first cluster if the dominant stack/tooling is shared; much higher if languages/build systems differ. +What monorepo uniquely solves: atomic changes, source-of-truth shared packages, easier multi-service refactors. +What simpler tooling solves: version drift, copy-paste pressure, some release friction. +Org changes required: reliable affected-only CI, CODEOWNERS, folder-scoped deploys, and explicit module-boundary enforcement. +Incremental path: absolutely; that is the technically credible path. + +**New evidence or angle:** +The missing decision variable is not repo count; it is `co-change density × toolchain heterogeneity`. DigitalOcean’s migration worked because they consolidated repos with similar frontend tooling, did the normalization first, and then got measurable gains: 1.6x more React feature PRs and a 95% drop in internal library bumps. Airbnb is the counterexample: once build-system and language complexity rise, the migration surface explodes; their JVM/Bazel transition took 4.5 years. That suggests a practical rule: cluster repos by how often they change together and whether they share one build/test/deploy model. Monorepo the high-coupling, same-toolchain clusters first; do not force low-coupling or compliance-isolated repos into the same boundary. + +**Current position:** +They should move toward 2-3 domain monorepos, or one monorepo for the highest-coupling cluster first, not a 35-repo big bang. Confidence: 81% because the stated pain maps directly to monorepo strengths, but only for the subset of repos that already behave like one codebase. + +**Key question for the group:** +Over the last 6 months, which specific repo clusters had the highest rate of 3+ repo coordinated changes, and do those clusters share the same language, package manager, CI model, and deployment pattern? + +### Round 1 — User Advocate | response | confidence: 77% + +**Response to previous points:** +Agent B’s strongest point is the right caution: a monorepo is only better if the people using it feel less friction, not more. If developers trade 3-5 coordinated PRs for one giant merge surface, flaky shared CI, and slower local workflows, that is a user-facing regression inside engineering. I agree with B on that risk. + +At the same time, Agent A and Agent C are pointing at something important: these teams already behave like they are in one codebase. If common work needs synchronized changes across several repos, the current setup is giving users the costs of coupling without the ergonomics of atomic change. Agent C’s “co-change density × toolchain heterogeneity” framing is the most useful synthesis so far. From a user perspective, the answer should not be “35 repos into 1” or “stay polyrepo.” It should be: move the highest-coupling cluster and shared libraries into a domain monorepo first, keep independent deploys, and prove the workflow is better. + +On the open questions: +Monorepo uniquely helps when the user problem is one change needing one branch, one review flow, and one verification surface. +Better tooling alone can likely reduce version drift and copy-paste, but it does not remove multi-PR coordination for tightly coupled changes. +The org change that matters most is treating the monorepo as an internal product: clear ownership, fast affected-only CI, predictable bootstrap/build/test commands, and preserved service release boundaries. +The path should be incremental. I have shifted away from “company-wide monorepo” toward “pilot the highest co-change domain first” because Agent B’s rollout-risk point is strong. + +**New evidence or angle:** +New angle: incident and hotfix UX. In a B2B SaaS company, cross-repo coordination is not just a developer inconvenience; it can directly slow customer-visible fixes. If a production issue spans a shared library, one backend repo, and two clients, the current model means multiple approval queues, multiple pipelines, and staggered releases. That increases time-to-mitigate and makes rollback harder to reason about. A monorepo does not automatically solve operations, but for tightly coupled systems it can shorten the path from “bug found” to “safe fix landed.” + +**Current position:** +They should move toward a monorepo, but only as a phased developer-experience program: start with the repos that co-change most often plus the shared libraries they depend on, and preserve independent deployment boundaries. Confidence: 77% because the stated pain maps strongly to monorepo benefits, but Agent B is right that a bad rollout would make daily user experience worse. + +**Key question for the group:** +For the top 10 customer-impacting fixes or roadmap changes in the last 6 months that touched 3+ repos, how much elapsed time was spent on cross-repo coordination versus actual coding and testing? + +### Round 2 — Advocate | response | confidence: 82% + +**Response to previous points:** +Agent B’s strongest argument is the asymmetry point: standardizing package governance and CI in polyrepo is cheaper and more reversible than a full cutover, while a bad monorepo rollout can create repo-wide merge and permission pain. I agree with that risk, and Agent C sharpened it well with `co-change density × toolchain heterogeneity` as the real decision variable. Agent D is also right that this is a developer-product question: if the workflow gets slower, the migration failed even if the Git shape looks cleaner. + +Where I disagree with B is on the implied sequencing. If the company already knows that specific clusters routinely need 3-5 coordinated PRs, then “prove governance first in polyrepo” risks paying the platform tax without removing the highest-friction problem: non-atomic change. Better package publishing can reduce drift and copy-paste; it does not turn a contract change plus 4 dependent updates into one reviewable unit. So the third option is not “big-bang monorepo” versus “stay polyrepo longer.” It is: decide now to run a domain-monorepo migration for the highest co-change cluster, with explicit exit criteria. That answers the open questions cleanly: +Actual cost/risk: bounded to one cluster, not all 35 repos. +What monorepo uniquely solves: atomic multi-repo changes and first-class shared code. +What simpler tooling solves: drift, packaging, and some release hygiene. +Org changes required: CODEOWNERS, affected-only CI, path-scoped deploys, and platform ownership. +Incremental path: yes, and it should be the decision, not a hedge. + +**New evidence or angle:** +New angle: optimize repo boundaries for change boundaries, not deployment boundaries. Those are different concerns. A B2B SaaS org can keep independent service deploys while collapsing repos that already change together. If we keep treating repo topology as a proxy for runtime isolation, we will preserve the current coordination tax even where the change graph already says “one system.” That is the strongest practical reason to act. + +**Current position:** +They should move toward a monorepo by committing to one domain-monorepo pilot now, centered on the highest co-change cluster plus its shared libraries, rather than debating a 35-repo end state upfront. Confidence: 82% because B’s evidence changed my view away from any broad company-wide migration in one step, but it did not weaken the core case that the current topology is misaligned with how work actually changes. + +**Key question for the group:** +Which 5-10 repos have the highest co-change rate and shared toolchain today, and would migrating just that cluster capture most of the current 3-5 repo coordination pain? + +### Round 2 — Skeptic | response | confidence: 79% + +**Response to previous points:** +Agent C has the strongest synthesis so far: `co-change density × toolchain heterogeneity` is the real decision variable, not “35 repos” in the abstract. Agent A is also right to separate change boundaries from deployment boundaries; if 5-10 repos already change together constantly, the current topology is misaligned with the work. Agent D adds the important user-facing consequence: this is slowing both roadmap work and incident response, not just annoying developers. + +So I’ve shifted one step: I no longer think the right immediate decision is “standardize in polyrepo first, then maybe consider a monorepo later.” I think the right immediate decision is to approve a tightly scoped domain-monorepo pilot for the highest co-change cluster. Where I still disagree with A is on the hidden assumption that atomic source changes are the main problem. They may be, but they may also be downstream of weak compatibility rules, ad hoc shared libraries, and poor CI partitioning. On the open questions: +Actual migration cost/risk: manageable for one same-stack cluster; still high for all 35. +What monorepo uniquely solves: atomic code changes, one review surface, first-class shared packages. +What simpler tooling solves: drift, copy-paste, and some release hygiene. +Org changes required: not just CODEOWNERS and affected CI, but clear ownership of graph correctness, deploy isolation, and compatibility policy. +Incremental path: yes, but with explicit success/fail gates, not just “try it and see.” + +**New evidence or angle:** +New angle: atomic source control is not atomic release. In a B2B SaaS system with independently deployed services, a monorepo can create false confidence: producer and consumer code can merge together, but still roll out at different times. If teams use the monorepo to avoid backward-compatible contracts, they can make runtime coupling worse, not better. That means the pilot should target a cluster with either shared release cadence or strong contract testing and compatibility windows. Otherwise the repo move may reduce PR count while preserving the real operational risk. + +**Current position:** +They should approve one domain-monorepo pilot now, but only for the highest co-change, same-toolchain cluster, with explicit guardrails: affected-only CI, path-scoped deploys, contract tests, and baseline metrics before cutover. Confidence: 79% because the case for a pilot is now stronger than the case for staying fully polyrepo, but the case for a broad migration is still unproven. + +**Key question for the group:** +For the top co-change cluster, how often do the repos deploy independently and require backward-compatibility windows at runtime? + +### Round 2 — Domain Expert | response | confidence: 84% + +**Response to previous points:** +Agent B’s strongest argument is the most important technical constraint: atomic source changes are not atomic releases. A monorepo can cut 3-5 coordinated PRs down to one, but it does not remove the need for backward-compatible contracts, staged rollout, and contract testing when services deploy independently. I agree with B on that. + +I also think Agent A is right that repo boundaries should follow change boundaries more than deploy boundaries, and Agent D is right that the current model is already imposing real product cost on engineering: slower incident response, slower roadmap work, and higher cognitive load. The synthesis is narrower than “migrate all 35 repos”: move only the cluster where co-change is high, toolchain is shared, and release behavior is either aligned or already protected by compatibility rules. That keeps the upside and contains the risk. + +On the open questions: +Actual cost/risk: for a same-stack 5-10 repo cluster, probably about 1 quarter including normalization, CI, and cutover; for heterogeneous repos, materially more. +What monorepo uniquely solves: atomic refactors, one review surface, real shared packages instead of copy-paste. +What simpler tooling solves: dependency drift, publishing/version hygiene, some reuse pressure. +Org changes required: clear platform ownership of the build graph, affected-only CI, folder-scoped deploys, CODEOWNERS, and enforced contract tests. +Incremental path: yes; that is the only technically credible path here. + +**New evidence or angle:** +One practical filter not yet stated explicitly: exclude infra/compliance-sensitive repos from the first wave even if they co-change. The cleanest wins in the wild came from same-language app/shared-library clusters; DigitalOcean’s gains came from a React estate, while Microsoft’s independent-release guidance assumes path-scoped pipelines. Mixing app code with repos that have different access, secret, or deploy semantics tends to make the pilot look worse than it should. + +**Current position:** +They should approve a domain-monorepo pilot, not a company-wide migration. Start with the highest co-change, same-toolchain cluster plus its shared libraries, preserve independent deploys, and measure success by reduced multi-repo lead time, selective CI reliability, and fewer duplicated internal libraries. Confidence: 84% because the precedents are strong for tightly coupled clusters, and the main failure modes are now identifiable and containable. + +**Key question for the group:** +For the highest co-change cluster, do the services already have automated contract tests and backward-compatibility rules that make independent rollout safe, or would a monorepo create false confidence and encourage unsafe lockstep assumptions? + +### Round 2 — User Advocate | response | confidence: 81% + +**Response to previous points:** +Agent B’s strongest point is the one I’d keep front and center: if a monorepo makes the daily workflow slower or creates false confidence around independently deployed services, users inside engineering will experience it as a regression even if the architecture story sounds cleaner. I agree with B on that, and Agent C sharpened it well: the real filter is `co-change density × toolchain heterogeneity`, plus whether the cluster already has compatibility discipline for separate releases. + +I’ve also shifted further toward Agent A and Agent C on scope. The best third option is not “all 35 repos into one” and not “stay polyrepo and add band-aids.” It is a domain-monorepo pilot for the highest co-change, same-toolchain cluster plus its shared libraries. That addresses the main open questions cleanly: migration cost/risk stays bounded, monorepo is used where it uniquely helps most, simpler tooling still handles org-wide dependency hygiene, and the org change is explicit: fast affected-only CI, path-scoped deploys, contract tests, and clear ownership. From the user’s point of view, the standard should be simple: fewer repo hops, one predictable bootstrap/test flow, and faster time from change request to safe ship. + +**New evidence or angle:** +New angle: review and handoff UX. Coordinated multi-repo work is not just extra PR count; it fragments reviewer context, makes approvals harder to reason about, and raises the chance that a cross-team change is “LGTM’d” piecemeal without anyone seeing the whole blast radius. A domain monorepo improves user experience only if one change can be reviewed in one place with scoped ownership and checks. If review still feels like chasing hidden context across folders and pipelines, the migration did not solve the user problem. + +**Current position:** +They should approve a domain-monorepo pilot now, not a company-wide migration. Confidence: 81% because Agent B’s rollout-risk argument changed my view away from any broad migration, but A and C make a stronger case that the current topology is already harming users where repos co-change constantly. The right decision is a bounded pilot with user-experience success metrics, not an abstract yes/no on “monorepo.” + +**Key question for the group:** +For the highest co-change cluster, can we define 3 user-facing success metrics before cutover, such as p50 cross-repo change lead time, p50 CI wait time, and incident-fix elapsed time, so we know whether the pilot actually makes engineering life better? + +### Round 3 — Advocate | response | confidence: 85% + +**Response to previous points:** +The strongest argument is Agent B’s: atomic source control is not atomic release, so a monorepo can reduce PR count while still leaving runtime incompatibility and rollout risk untouched. Agent C sharpened that into the real filter: high co-change density only justifies consolidation if toolchain similarity and release safety are also there. Agent D added the user test that matters: if CI, review, and bootstrap get worse, the migration failed. + +I agree with that synthesis, and I’ve changed my mind on the end state because of it: I’m no longer arguing for “migrate the company to a monorepo” as the decision. The decision should be narrower and more actionable: approve one domain-monorepo pilot now for the highest co-change, same-toolchain cluster, but only if that cluster either shares release cadence or already has contract tests/backward-compatibility discipline. That addresses the main open questions: +Monorepo uniquely solves the atomic-change and shared-library problems for tightly coupled repos. +Tooling-only fixes can reduce drift and copy-paste, but they do not remove the 3-5 PR coordination tax. +The org change required is not abstract “better discipline”; it is concrete ownership of affected-CI correctness, folder-scoped deploys, CODEOWNERS, and compatibility policy. +The incremental path is the answer, not a compromise. + +**New evidence or angle:** +New angle: copy-pasted shared libraries are not just a maintenance smell; they turn urgent security or compliance fixes into a multi-repo patch propagation problem. If one auth, logging, or validation change must be hand-applied across duplicated code, the org accumulates uneven risk and slow remediation. A domain monorepo with workspace packages creates a single patch surface for that class of change, which is a materially different operational benefit from “dependency hygiene.” + +**Current position:** +Approve a domain-monorepo pilot now, not a full 35-repo migration and not another round of general debate. Confidence: 85% because B and C successfully narrowed the safe scope, but the underlying evidence still says the current repo topology is misaligned with how work changes. The highest-value move is a bounded pilot with explicit success metrics and an explicit no-go condition if release safety is weak. + +**Key question for the group:** +Which specific repo cluster both captures the majority of today’s 3-5 repo coordination pain and has enough release safety already in place that a pilot would test repo-boundary value rather than expose unrelated contract-discipline gaps? + +**Convergence assessment:** CONVERGING — positions are now within ~80% agreement around a bounded domain-monorepo pilot; the remaining gap is the entry criterion: whether release/contract safety must be proven before the pilot, or can be built as part of it. + +### Round 3 — Skeptic | response | confidence: 82% + +**Response to previous points:** +Agent C has the strongest synthesis: the real variable is not repo count, but `co-change density × toolchain heterogeneity`, and Agent A is right that change boundaries should not be confused with deploy boundaries. Agent D adds the right test for whether this is actually better: fewer repo hops, faster review, and no regression in CI or incident response. I agree with that narrowed framing, and I’ve changed my mind from “fix governance in polyrepo first” to “approve a bounded pilot now,” because waiting longer preserves a coordination tax we already know is real. + +Where I still want to stress-test the case is the entry criteria. High co-change alone is not enough. If the chosen cluster lacks contract tests, backward-compatibility rules, or safe rollout patterns, a monorepo can reduce PR count while hiding the more important problem: runtime coupling across independently deployed services. So on the main questions: migration cost is manageable only for a same-stack cluster; monorepo uniquely buys atomic source changes and real shared packages; cheaper tooling should still handle org-wide version governance; and the required org change is stronger than `CODEOWNERS` plus CI tuning. Someone has to own graph correctness, deploy scoping, and compatibility discipline. + +**New evidence or angle:** +New angle: pilot selection bias and hidden cost transfer. If they pick a cluster that is too easy, the pilot proves very little. If they pick one that is too entangled, they may blame the monorepo for pre-existing contract debt. Also, team-level velocity metrics can look better while the platform/build team quietly absorbs the complexity. So the pilot should measure not just app-team lead time, but also CI incident rate, task-graph maintenance time, and flaky-check overhead. Otherwise they may mistake “centralized toil” for “reduced toil.” + +**Current position:** +Approve one domain-monorepo pilot now, not a 35-repo migration. Confidence: 82% because the current pain is specific and recurring, and a bounded pilot is now a better bet than staying fully polyrepo. My support is conditional: same-toolchain cluster, high co-change rate, path-scoped deploys, affected-only CI, and explicit runtime compatibility rules. If they cannot meet those gates, they should stop at package governance and shared-library extraction instead. + +**Key question for the group:** +For the proposed pilot cluster, which release-safety guarantees already exist today, specifically contract tests, backward-compatibility windows, and staged rollout controls, and which would need to be built before cutover? + +**Convergence assessment:** CONVERGING — we are broadly aligned on a bounded domain-monorepo pilot rather than a company-wide migration; the remaining gap is the entry gate: whether release-safety discipline must be largely in place before the pilot, and how much platform-team overhead must be included in success metrics. + +--- + +## Consensus Summary + +### Decision +Approve a domain-monorepo pilot now for the highest co-change, same-toolchain cluster of roughly 5-10 repos plus its shared libraries; do not migrate all 35 repos into one repository. This sacrifices immediate company-wide uniformity in exchange for materially lower migration risk while still capturing the main benefit the current setup lacks: atomic cross-repo changes. Make contract tests, backward-compatibility rules, affected-only CI, path-scoped deploys, and CODEOWNERS hard gates before cutover so the pilot tests repo-boundary value rather than masking release-discipline gaps. + +### Key Contention Points + +| # | What Was Debated | Resolution | Who Had the Strongest Case & Why | +|---|-----------------|------------|----------------------------------| +| 1 | Whether the company should migrate to a monorepo at all | Yes, but only as a bounded domain-monorepo pilot, not a 35-repo big-bang migration. | Agent C had the strongest case because the `co-change density × toolchain heterogeneity` framing turned the abstract debate into a practical selection rule for what should move first. | +| 2 | Which problems actually require a monorepo vs better tooling | Use the monorepo only where atomic multi-repo changes and shared-library fixes are frequent; handle org-wide dependency drift and package hygiene with centralized governance regardless of repo shape. | Agent A had the strongest case because he cleanly separated monorepo’s unique value (atomic change, single patch surface) from what tooling alone can already solve. | +| 3 | Whether a monorepo reduces operational risk by itself | It does not; independent deploys must remain, and cutover requires contract tests, backward-compatibility windows, staged rollout controls, affected-only CI, and path-scoped deploys. | Agent B had the strongest case because “atomic source control is not atomic release” was the most important constraint and the sharpest warning against false confidence. | +| 4 | How to decide whether the pilot succeeded | Treat it as an internal developer-product rollout and measure p50 cross-repo lead time, p50 CI wait time, incident-fix elapsed time, plus platform-team toil and flaky-check overhead. | Agent D had the strongest case because he translated the architecture decision into concrete developer and incident-response UX outcomes, which is the real business test. | + +### Unresolved Items & Risks +- The pilot cluster still needs to be chosen from real 6-month co-change data; the wrong cluster will either under-test the idea or unfairly absorb unrelated contract debt. +- If the chosen cluster lacks contract tests or backward-compatibility rules today, phase 1 should be building those controls and cutover should wait until they exist. +- Access-control, compliance, or contractor-visibility constraints may keep some repos permanently outside any shared repo. +- Platform overhead can be silently centralized; include CI incident rate, task-graph maintenance time, and deploy-scoping errors in the pilot scorecard. +- Migration mechanics still matter: history preservation, freeze window, in-flight PR handling, and archival/mirroring of legacy repos need a deliberate cutover plan. + +### Confidence: High +The agents converged strongly on the same recommendation, and the remaining disagreement was about pilot entry gates and measurement, not about the direction of the decision. diff --git a/tests/eval.js b/tests/eval.js new file mode 100644 index 0000000..2ab6fc5 --- /dev/null +++ b/tests/eval.js @@ -0,0 +1,280 @@ +#!/usr/bin/env node + +// eval.js — Automated evaluation runner for discuss-skill +// +// Runs test cases against the council orchestrator and validates: +// - Discussion file structure (frontmatter, sections) +// - Consensus quality (all required sections present) +// - Lens application (research uses assigned lens, turns do not) +// - Convergence detection (exits early when converging) +// +// Usage: node tests/eval.js [--filter NAME] + +const { execSync } = require("child_process"); +const fs = require("fs"); +const path = require("path"); +const os = require("os"); + +const ORCHESTRATOR = path.join(__dirname, "..", "scripts", "headless-council.js"); +const TESTS_DIR = path.join(__dirname, "cases"); + +// --- Test case loader --- + +function loadTestCases(filterName) { + const files = fs.readdirSync(TESTS_DIR).filter((f) => f.endsWith(".json")); + let cases = files.map((f) => { + const content = JSON.parse(fs.readFileSync(path.join(TESTS_DIR, f), "utf-8")); + return { ...content, _file: f }; + }); + if (filterName) { + cases = cases.filter((c) => c.name.includes(filterName)); + } + return cases; +} + +// --- Discussion file generator --- + +function createDiscussionFile(testCase, tmpDir) { + const filePath = path.join(tmpDir, `${testCase.name}.md`); + const frontmatter = { + topic: testCase.topic, + mode: "council", + lens_id: testCase.lens_id || "risk-vs-opportunity", + selection_mode: "flag", + max_rounds: testCase.max_rounds || 3, + git_commit: "none", + agent_a: "Claude Agent A", + agent_b: "Claude Agent B", + agent_a_cli: testCase.agent_a_cli || "claude", + agent_b_cli: testCase.agent_b_cli || "claude", + agent_a_lens: testCase.agent_a_lens || "risk/cost/failure", + agent_b_lens: testCase.agent_b_lens || "value/opportunity/success", + status: "researching", + turn: "A", + round: "0", + created: new Date().toISOString(), + last_updated: new Date().toISOString(), + }; + + const lines = ["---"]; + for (const [k, v] of Object.entries(frontmatter)) { + lines.push(`${k}: "${v}"`); + } + lines.push("---"); + lines.push(""); + lines.push(`# Discussion: ${testCase.topic}`); + lines.push(""); + lines.push("## Key Questions"); + for (const q of testCase.key_questions || ["What is the best approach?"]) { + lines.push(`1. ${q}`); + } + lines.push(""); + + fs.writeFileSync(filePath, lines.join("\n")); + return filePath; +} + +// --- Validators --- + +function validateStructure(content) { + const errors = []; + + // Frontmatter + if (!content.match(/^---\n[\s\S]*?\n---/)) errors.push("Missing frontmatter"); + + // Required sections + if (!content.includes("## Research Phase")) errors.push("Missing Research Phase section"); + if (!content.includes("## Discussion")) errors.push("Missing Discussion section"); + + // Research entries + if (!content.includes("### Agent A — Independent Research | research")) + errors.push("Missing Agent A research"); + if (!content.includes("### Agent B — Independent Research | research")) + errors.push("Missing Agent B research"); + + // At least one response round + if (!/### Round \d+ — .+ \| response \| confidence: \d+%/.test(content)) + errors.push("No response rounds found"); + + return errors; +} + +function validateConsensus(content) { + const errors = []; + + if (!content.includes("## Consensus Summary")) errors.push("Missing Consensus Summary"); + if (!content.includes("### Decision")) errors.push("Missing Decision section"); + if (!content.includes("### Key Contention Points")) errors.push("Missing Key Contention Points"); + if (!content.includes("### Unresolved Items")) errors.push("Missing Unresolved Items"); + if (!content.includes("### Confidence:")) errors.push("Missing Confidence section"); + + return errors; +} + +function validateFrontmatterState(content) { + const errors = []; + const fmMatch = content.match(/^---\n([\s\S]*?)\n---/); + if (!fmMatch) return ["Cannot parse frontmatter"]; + + const fm = {}; + for (const line of fmMatch[1].split("\n")) { + const idx = line.indexOf(":"); + if (idx === -1) continue; + const key = line.slice(0, idx).trim(); + let val = line.slice(idx + 1).trim(); + if (val.startsWith('"') && val.endsWith('"')) val = val.slice(1, -1); + fm[key] = val; + } + + if (fm.status !== "consensus" && fm.status !== "deadlock") + errors.push(`Expected status consensus|deadlock, got "${fm.status}"`); + + return errors; +} + +function validateLensApplication(content, lensId) { + const errors = []; + + // Research should contain lens-specific language + const researchSection = content.match(/## Research Phase\n([\s\S]*?)(?=\n---\n)/); + if (!researchSection) return ["Cannot extract research section"]; + + // Turn responses should NOT contain lens descriptions + // (This is a soft check — we verify the lens was removed from turn prompts) + const discussionSection = content.match(/## Discussion\n([\s\S]*?)(?=\n---\n## Consensus|\n## Consensus)/); + if (discussionSection) { + const turns = discussionSection[1]; + // Lens descriptions should not appear verbatim in turns + if (lensId === "simplicity-vs-correctness") { + // Check that the turn template isn't injecting lens text + if (turns.includes("Your lens: SIMPLICITY, PRAGMATISM")) + errors.push("Lens description leaked into discussion turns"); + } + } + + return errors; +} + +// --- Runner --- + +async function runTestCase(testCase) { + const tmpDir = fs.mkdtempSync(path.join(os.tmpdir(), "discuss-eval-")); + const result = { + name: testCase.name, + passed: true, + errors: [], + duration_ms: 0, + rounds: 0, + }; + + try { + const filePath = createDiscussionFile(testCase, tmpDir); + const startTime = Date.now(); + + try { + execSync(`node "${ORCHESTRATOR}" "${filePath}"`, { + encoding: "utf-8", + timeout: 600000, // 10 min max + maxBuffer: 1024 * 1024 * 50, + stdio: ["pipe", "pipe", "pipe"], + }); + } catch (err) { + // Check if it's a real failure or just stderr output + if (err.status !== 0 && err.status !== null) { + result.errors.push(`Orchestrator exited with code ${err.status}: ${(err.stderr || "").slice(0, 200)}`); + result.passed = false; + return result; + } + } + + result.duration_ms = Date.now() - startTime; + + // Read the output file + const content = fs.readFileSync(filePath, "utf-8"); + + // Count rounds + const roundMatches = content.match(/### Round \d+/g); + result.rounds = roundMatches ? Math.ceil(roundMatches.length / 2) : 0; + + // Run validators + const structureErrors = validateStructure(content); + const consensusErrors = validateConsensus(content); + const stateErrors = validateFrontmatterState(content); + const lensErrors = validateLensApplication(content, testCase.lens_id || "risk-vs-opportunity"); + + // Custom assertions from test case + const customErrors = []; + if (testCase.assertions) { + for (const assertion of testCase.assertions) { + if (assertion.type === "contains" && !content.includes(assertion.value)) { + customErrors.push(`Expected content to contain: "${assertion.value}"`); + } + if (assertion.type === "not_contains" && content.includes(assertion.value)) { + customErrors.push(`Expected content NOT to contain: "${assertion.value}"`); + } + if (assertion.type === "min_rounds" && result.rounds < assertion.value) { + customErrors.push(`Expected at least ${assertion.value} rounds, got ${result.rounds}`); + } + if (assertion.type === "max_rounds" && result.rounds > assertion.value) { + customErrors.push(`Expected at most ${assertion.value} rounds, got ${result.rounds}`); + } + } + } + + result.errors = [...structureErrors, ...consensusErrors, ...stateErrors, ...lensErrors, ...customErrors]; + result.passed = result.errors.length === 0; + } finally { + fs.rmSync(tmpDir, { recursive: true, force: true }); + } + + return result; +} + +// --- Main --- + +async function main() { + const filterArg = process.argv.find((a) => a === "--filter"); + const filterName = filterArg ? process.argv[process.argv.indexOf(filterArg) + 1] : null; + + console.log("discuss-skill eval runner"); + console.log("========================\n"); + + const testCases = loadTestCases(filterName); + if (testCases.length === 0) { + console.log("No test cases found in tests/cases/"); + process.exit(1); + } + + console.log(`Running ${testCases.length} test case(s)...\n`); + + const results = []; + for (const tc of testCases) { + process.stdout.write(` ${tc.name} ... `); + const result = await runTestCase(tc); + results.push(result); + + if (result.passed) { + console.log(`PASS (${result.rounds} rounds, ${(result.duration_ms / 1000).toFixed(1)}s)`); + } else { + console.log("FAIL"); + for (const err of result.errors) { + console.log(` - ${err}`); + } + } + } + + // Summary + console.log("\n========================"); + const passed = results.filter((r) => r.passed).length; + const failed = results.filter((r) => !r.passed).length; + const totalTime = results.reduce((sum, r) => sum + r.duration_ms, 0); + + console.log(`${passed} passed, ${failed} failed, ${(totalTime / 1000).toFixed(1)}s total`); + + if (failed > 0) process.exit(1); +} + +main().catch((err) => { + console.error(`Fatal: ${err.message}`); + process.exit(1); +}); diff --git a/tests/n-agent-eval.js b/tests/n-agent-eval.js new file mode 100644 index 0000000..ff91393 --- /dev/null +++ b/tests/n-agent-eval.js @@ -0,0 +1,707 @@ +#!/usr/bin/env node + +// n-agent-eval.js — Comparison eval runner for N-agent discussions +// +// Runs the same topic through multiple agent configurations (1, 2, 3, 5 agents) +// and evaluates output quality using: +// 1. Expert checklist coverage (keyword matching + LLM verification) +// 2. Trap detection (did the discussion catch known pitfalls?) +// 3. Blind pairwise comparison (LLM judge ranks outputs) +// +// Usage: +// node tests/n-agent-eval.js # Run all topics x all configs +// node tests/n-agent-eval.js --topic fintech-payments # Single topic +// node tests/n-agent-eval.js --config 3-codex # Single config +// node tests/n-agent-eval.js --judge-only <dir> # Re-judge existing outputs +// node tests/n-agent-eval.js --dry-run # Show what would run +// +// Output: tests/eval-results/<timestamp>/ with per-run discussions and summary + +const { execSync } = require("child_process"); +const fs = require("fs"); +const path = require("path"); +const os = require("os"); + +const { + runCouncil, + createDiscussionFile, + resolveAgents, + parseFrontmatter, + ROLES, +} = require("../scripts/headless-council-n.js"); + +// --- Constants --- + +const CASES_DIR = path.join(__dirname, "cases"); +const RESULTS_DIR = path.join(__dirname, "eval-results"); + +const CONFIGS = { + "1-codex": { + description: "Single agent, no debate (control)", + agent_count: 1, + agent_config: null, // Special: single-agent mode + default_cli: "codex", + }, + "2-codex": { + description: "2 Codex agents: Advocate + Skeptic", + agent_count: 2, + agent_config: "2-agent", + default_cli: "codex", + }, + "3-codex": { + description: "3 Codex agents: Advocate + Skeptic + Synthesizer", + agent_count: 3, + agent_config: "3-agent", + default_cli: "codex", + }, + "5-codex": { + description: "5 Codex agents: full panel + Synthesizer", + agent_count: 5, + agent_config: "5-agent", + default_cli: "codex", + }, + "2-cross": { + description: "Cross-model: Claude (Advocate) + Codex (Skeptic)", + agent_count: 2, + agent_config: "2-agent", + default_cli: "codex", + cli_overrides: { A: "claude", B: "codex" }, + }, +}; + +// --- Load eval topics --- + +function loadEvalTopics(filterName) { + const files = fs.readdirSync(CASES_DIR).filter((f) => f.startsWith("eval-") && f.endsWith(".json")); + let topics = files.map((f) => { + const content = JSON.parse(fs.readFileSync(path.join(CASES_DIR, f), "utf-8")); + return { ...content, _file: f }; + }); + if (filterName) { + topics = topics.filter((t) => t.name.includes(filterName)); + } + return topics; +} + +// --- Single-agent runner (control group) --- + +function runSingleAgent(topic, cli, outputPath, tmpDir, cwd) { + const prompt = `You are an expert analyst. Thoroughly analyze the following question and provide a comprehensive recommendation. + +Topic: "${topic.topic}" + +Key questions to address: +${(topic.key_questions || []).map((q, i) => `${i + 1}. ${q}`).join("\n")} + +Provide your analysis in this format: + +# Analysis: ${topic.topic} + +## Research +[Comprehensive analysis covering all relevant dimensions — technical, business, organizational, strategic, regulatory. ~500 words.] + +## Recommendation + +### Decision +[2-3 sentences — clear recommendation with reasoning] + +### Key Trade-offs +| # | Trade-off | How You Weighed It | +|---|-----------|-------------------| +| 1 | ... | ... | + +### Risks & Uncertainties +- ... + +### Confidence: [High | Medium | Low] +[1 sentence justification] +`; + + const promptFile = path.join(tmpDir, `single-agent-prompt-${Date.now()}.txt`); + fs.writeFileSync(promptFile, prompt); + + const profile = require("../scripts/headless-council-n.js").CLI_PROFILES[cli]; + const cmd = profile.buildCmd(promptFile, cwd); + + try { + const result = execSync(cmd, { + encoding: "utf-8", + timeout: 600000, + maxBuffer: 1024 * 1024 * 50, + stdio: ["pipe", "pipe", "pipe"], + }); + + // Write as a pseudo-discussion file for uniform evaluation + const content = `--- +topic: "${topic.topic}" +mode: "single-agent" +agent_count: "1" +agent_cli: "${cli}" +status: "consensus" +created: "${new Date().toISOString()}" +--- + +# Discussion: ${topic.topic} + +## Single Agent Analysis + +${result.trim()} +`; + fs.writeFileSync(outputPath, content); + return result.trim(); + } catch (err) { + console.error(`Single agent failed: ${(err.message || "").slice(0, 200)}`); + return null; + } +} + +// --- Checklist Scorer --- + +function scoreChecklist(content, checklist) { + const lowerContent = content.toLowerCase(); + const results = []; + + for (const item of checklist) { + const keywordHits = item.keywords.filter((kw) => lowerContent.includes(kw.toLowerCase())); + const hit = keywordHits.length > 0; + results.push({ + id: item.id, + item: item.item, + weight: item.weight, + category: item.category, + hit, + matched_keywords: keywordHits, + }); + } + + const totalWeight = results.reduce((sum, r) => sum + r.weight, 0); + const hitWeight = results.filter((r) => r.hit).reduce((sum, r) => sum + r.weight, 0); + const coverageRaw = results.filter((r) => r.hit).length / results.length; + const coverageWeighted = hitWeight / totalWeight; + + return { + items: results, + total: results.length, + hits: results.filter((r) => r.hit).length, + misses: results.filter((r) => !r.hit).map((r) => r.id), + coverage_raw: Math.round(coverageRaw * 100), + coverage_weighted: Math.round(coverageWeighted * 100), + }; +} + +// --- Trap Scorer --- + +function scoreTraps(content, traps) { + const lowerContent = content.toLowerCase(); + const results = []; + + for (const trap of traps) { + const caughtHits = trap.caught_keywords.filter((kw) => lowerContent.includes(kw.toLowerCase())); + const fell = trap.detection_keywords.some((kw) => lowerContent.includes(kw.toLowerCase())) && caughtHits.length === 0; + const caught = caughtHits.length > 0; + + results.push({ + id: trap.id, + description: trap.description, + caught, + fell_into: fell, + evidence: caughtHits, + }); + } + + return { + traps: results, + total: results.length, + caught: results.filter((r) => r.caught).length, + fell_into: results.filter((r) => r.fell_into).length, + score: Math.round((results.filter((r) => r.caught).length / results.length) * 100), + }; +} + +// --- LLM Judge (blind pairwise) --- + +function extractForJudging(content) { + // Extract research + consensus sections (skip verbose turn-by-turn debate) + // This ensures the judge sees the full research AND full consensus regardless of length + const parts = []; + + // Research phase + const researchMatch = content.match(/## Research Phase\n([\s\S]*?)(?=\n---\n|\n## Discussion)/); + const singleMatch = content.match(/## Single Agent Analysis\n([\s\S]*?)$/); + if (researchMatch) { + parts.push("## Research Phase\n" + researchMatch[1].trim()); + } else if (singleMatch) { + parts.push("## Analysis\n" + singleMatch[1].trim()); + } + + // Consensus / Recommendation + const consensusMatch = content.match(/## Consensus Summary\n([\s\S]*?)$/); + const recoMatch = content.match(/## Recommendation\n([\s\S]*?)$/); + if (consensusMatch) { + parts.push("## Consensus Summary\n" + consensusMatch[1].trim()); + } else if (recoMatch) { + parts.push("## Recommendation\n" + recoMatch[1].trim()); + } + + // If extraction failed, fall back to full content (truncated) + if (parts.length === 0) return content.slice(0, 12000); + + return parts.join("\n\n---\n\n"); +} + +function buildJudgePrompt(topic, outputA, outputB, labelA, labelB) { + const extractA = extractForJudging(outputA); + const extractB = extractForJudging(outputB); + + return `You are an expert evaluator judging the quality of two analyses on the same topic. You do NOT know which analysis used more agents or resources. Judge purely on output quality. + +Each analysis includes a research/analysis section and a final recommendation/consensus. Some analyses were produced by structured multi-agent debate (research + consensus), others by a single analyst. Judge the QUALITY OF THE OUTPUT, not the format. + +TOPIC: "${topic}" + +=== ANALYSIS A === +${extractA} +=== END A === + +=== ANALYSIS B === +${extractB} +=== END B === + +Score each analysis on these dimensions (0-10): + +1. COMPREHENSIVENESS: How many important angles were covered? +2. DEPTH: How deep did the analysis go on key points? +3. NOVELTY: Were non-obvious insights surfaced? +4. DECISION QUALITY: Is the final recommendation well-reasoned and actionable? +5. TRADE-OFF CLARITY: Were trade-offs explicitly named and weighed? +6. NUANCE: Does the analysis avoid oversimplification? Does it acknowledge uncertainty and edge cases? + +Return ONLY this JSON (no markdown, no explanation): +{"a":{"comprehensiveness":N,"depth":N,"novelty":N,"decision_quality":N,"tradeoff_clarity":N,"nuance":N,"total":N},"b":{"comprehensiveness":N,"depth":N,"novelty":N,"decision_quality":N,"tradeoff_clarity":N,"nuance":N,"total":N},"winner":"a|b|tie","reason":"one sentence"}`; +} + +function runJudge(topic, outputA, outputB, labelA, labelB, tmpDir, cwd) { + const prompt = buildJudgePrompt(topic, outputA, outputB, labelA, labelB); + const promptFile = path.join(tmpDir, `judge-${Date.now()}-${Math.random().toString(36).slice(2, 6)}.txt`); + fs.writeFileSync(promptFile, prompt); + + // Use Claude for judging (higher quality) + const cmd = `cd "${cwd}" && cat "${promptFile}" | claude -p --output-format text`; + + try { + const result = execSync(cmd, { + encoding: "utf-8", + timeout: 120000, + maxBuffer: 1024 * 1024 * 10, + stdio: ["pipe", "pipe", "pipe"], + }); + + // Try to parse JSON from result + const jsonMatch = result.match(/\{[\s\S]*\}/); + if (jsonMatch) { + return JSON.parse(jsonMatch[0]); + } + console.error("Judge returned non-JSON output"); + return null; + } catch (err) { + console.error(`Judge failed: ${(err.message || "").slice(0, 200)}`); + return null; + } +} + +// --- Run single config --- + +async function runConfig(topic, configName, config, runDir) { + const outputFile = path.join(runDir, `${topic.name}__${configName}.md`); + const tmpDir = fs.mkdtempSync(path.join(os.tmpdir(), `eval-${configName}-`)); + const cwd = path.dirname(path.resolve(runDir)); + + console.log(` [${configName}] Starting...`); + const startTime = Date.now(); + + try { + if (config.agent_count === 1) { + // Single agent control + runSingleAgent(topic, config.default_cli, outputFile, tmpDir, cwd); + } else { + // N-agent council + const fm = { + agent_count: String(config.agent_count), + agent_config: config.agent_config, + agent_cli: config.default_cli, + max_rounds: String(topic.max_rounds || 5), + git_commit: "none", + }; + + // Apply per-agent CLI overrides + if (config.cli_overrides) { + for (const [label, cli] of Object.entries(config.cli_overrides)) { + fm[`agent_${label}_cli`] = cli; + } + } + + createDiscussionFile(topic.topic, resolveAgents(fm), config.agent_config, outputFile, { + max_rounds: String(topic.max_rounds || 5), + git_commit: "none", + agent_count: String(config.agent_count), + agent_config: config.agent_config, + agent_cli: config.default_cli, + ...(config.cli_overrides || {}), + }); + + // Patch the key questions into the file + let content = fs.readFileSync(outputFile, "utf-8"); + if (topic.key_questions) { + const qSection = topic.key_questions.map((q, i) => `${i + 1}. ${q}`).join("\n"); + content = content.replace( + "## Key Questions\n1. [To be addressed through structured debate]", + `## Key Questions\n${qSection}` + ); + fs.writeFileSync(outputFile, content); + } + + await runCouncil(outputFile); + } + + const durationMs = Date.now() - startTime; + const outputContent = fs.readFileSync(outputFile, "utf-8"); + const tokenEstimate = Math.round(outputContent.length / 4); // rough + + console.log(` [${configName}] Done in ${(durationMs / 1000).toFixed(0)}s (~${tokenEstimate} tokens output)`); + + return { + config: configName, + file: outputFile, + content: outputContent, + duration_ms: durationMs, + token_estimate: tokenEstimate, + success: true, + }; + } catch (err) { + console.error(` [${configName}] FAILED: ${err.message}`); + return { + config: configName, + file: outputFile, + content: "", + duration_ms: Date.now() - startTime, + token_estimate: 0, + success: false, + error: err.message, + }; + } finally { + try { + fs.rmSync(tmpDir, { recursive: true, force: true }); + } catch {} + } +} + +// --- Evaluate all runs for a topic --- + +function evaluateTopic(topic, runs) { + const results = {}; + + for (const run of runs) { + if (!run.success) { + results[run.config] = { success: false, error: run.error }; + continue; + } + + const checklist = scoreChecklist(run.content, topic.expert_checklist); + const traps = scoreTraps(run.content, topic.traps); + + results[run.config] = { + success: true, + checklist, + traps, + duration_ms: run.duration_ms, + token_estimate: run.token_estimate, + file: run.file, + }; + } + + return results; +} + +// --- Generate comparison table --- + +function generateComparisonTable(topic, evaluation) { + const configs = Object.keys(evaluation); + const lines = []; + + lines.push(`## ${topic.name}`); + lines.push(`**Topic:** ${topic.topic}`); + lines.push(""); + + // Main comparison table + lines.push("| Metric | " + configs.join(" | ") + " |"); + lines.push("|--------|" + configs.map(() => "------").join("|") + "|"); + + // Checklist coverage + lines.push( + "| **Checklist Coverage (raw)** | " + + configs.map((c) => { + const e = evaluation[c]; + return e.success ? `${e.checklist.coverage_raw}% (${e.checklist.hits}/${e.checklist.total})` : "FAILED"; + }).join(" | ") + " |" + ); + + lines.push( + "| **Checklist Coverage (weighted)** | " + + configs.map((c) => { + const e = evaluation[c]; + return e.success ? `${e.checklist.coverage_weighted}%` : "FAILED"; + }).join(" | ") + " |" + ); + + // Trap detection + lines.push( + "| **Traps Caught** | " + + configs.map((c) => { + const e = evaluation[c]; + return e.success ? `${e.traps.caught}/${e.traps.total} (${e.traps.score}%)` : "FAILED"; + }).join(" | ") + " |" + ); + + // Duration + lines.push( + "| **Duration** | " + + configs.map((c) => { + const e = evaluation[c]; + return e.success ? `${(e.duration_ms / 1000).toFixed(0)}s` : "FAILED"; + }).join(" | ") + " |" + ); + + // Token estimate + lines.push( + "| **Output Tokens (est.)** | " + + configs.map((c) => { + const e = evaluation[c]; + return e.success ? `~${e.token_estimate}` : "FAILED"; + }).join(" | ") + " |" + ); + + lines.push(""); + + // Missed checklist items per config + lines.push("### Missed Checklist Items"); + lines.push(""); + for (const c of configs) { + const e = evaluation[c]; + if (!e.success) continue; + const misses = e.checklist.items.filter((i) => !i.hit); + if (misses.length > 0) { + lines.push(`**${c}** missed (${misses.length}):`); + misses.forEach((m) => lines.push(` - [${m.category}] ${m.item}`)); + lines.push(""); + } + } + + // Trap details + lines.push("### Trap Detection Details"); + lines.push(""); + for (const c of configs) { + const e = evaluation[c]; + if (!e.success) continue; + lines.push(`**${c}:**`); + e.traps.traps.forEach((t) => { + const status = t.caught ? "CAUGHT" : t.fell_into ? "FELL INTO" : "MISSED"; + lines.push(` - ${status}: ${t.description}`); + }); + lines.push(""); + } + + return lines.join("\n"); +} + +// --- Main --- + +async function main() { + const args = process.argv.slice(2); + const topicFilter = args.includes("--topic") ? args[args.indexOf("--topic") + 1] : null; + const configFilter = args.includes("--config") ? args[args.indexOf("--config") + 1] : null; + const dryRun = args.includes("--dry-run"); + const judgeOnly = args.includes("--judge-only") ? args[args.indexOf("--judge-only") + 1] : null; + const skipJudge = args.includes("--skip-judge"); + const outputDir = args.includes("--output-dir") ? args[args.indexOf("--output-dir") + 1] : null; + + console.log("━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━"); + console.log(" N-Agent Discussion Eval Runner"); + console.log("━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━"); + console.log(""); + + const topics = loadEvalTopics(topicFilter); + let configNames = Object.keys(CONFIGS); + if (configFilter) { + configNames = configNames.filter((c) => c.includes(configFilter)); + } + + console.log(`Topics: ${topics.map((t) => t.name).join(", ")}`); + console.log(`Configs: ${configNames.join(", ")}`); + console.log(`Total runs: ${topics.length * configNames.length}`); + console.log(""); + + if (dryRun) { + console.log("DRY RUN — would execute:"); + for (const topic of topics) { + for (const configName of configNames) { + const config = CONFIGS[configName]; + console.log(` ${topic.name} x ${configName} (${config.description})`); + } + } + return; + } + + // Create results directory + const timestamp = new Date().toISOString().replace(/[:.]/g, "-").slice(0, 19); + const runDir = judgeOnly || outputDir || path.join(RESULTS_DIR, timestamp); + if (!judgeOnly) { + fs.mkdirSync(runDir, { recursive: true }); + } + + // Run discussions + const allRuns = {}; + + if (!judgeOnly) { + for (const topic of topics) { + console.log(`\n--- ${topic.name} ---`); + allRuns[topic.name] = []; + + for (const configName of configNames) { + const config = CONFIGS[configName]; + const result = await runConfig(topic, configName, config, runDir); + allRuns[topic.name].push(result); + } + } + } else { + // Load existing outputs for re-judging + for (const topic of topics) { + allRuns[topic.name] = []; + for (const configName of configNames) { + const file = path.join(runDir, `${topic.name}__${configName}.md`); + if (fs.existsSync(file)) { + allRuns[topic.name].push({ + config: configName, + file, + content: fs.readFileSync(file, "utf-8"), + success: true, + duration_ms: 0, + token_estimate: Math.round(fs.readFileSync(file, "utf-8").length / 4), + }); + } + } + } + } + + // Evaluate + console.log("\n━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━"); + console.log(" EVALUATION RESULTS"); + console.log("━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━"); + + const reportLines = []; + reportLines.push("# N-Agent Eval Results"); + reportLines.push(`\nRun: ${timestamp}`); + reportLines.push(`Configs: ${configNames.join(", ")}`); + reportLines.push(`Topics: ${topics.map((t) => t.name).join(", ")}`); + reportLines.push(""); + + const allEvals = {}; + + for (const topic of topics) { + const evaluation = evaluateTopic(topic, allRuns[topic.name]); + allEvals[topic.name] = evaluation; + const table = generateComparisonTable(topic, evaluation); + reportLines.push(table); + console.log("\n" + table); + } + + // Pairwise comparison (if not skipped) + if (!skipJudge) { + console.log("\n--- Running blind pairwise comparisons (Claude as judge) ---"); + reportLines.push("\n## Pairwise Comparisons (Blind)\n"); + + const pairwiseTmpDir = fs.mkdtempSync(path.join(os.tmpdir(), "eval-judge-")); + const cwd = path.dirname(path.resolve(runDir)); + + for (const topic of topics) { + reportLines.push(`### ${topic.name}\n`); + const runs = allRuns[topic.name].filter((r) => r.success); + + for (let i = 0; i < runs.length; i++) { + for (let j = i + 1; j < runs.length; j++) { + const a = runs[i]; + const b = runs[j]; + + // Randomize order to avoid position bias + const flip = Math.random() > 0.5; + const first = flip ? b : a; + const second = flip ? a : b; + + console.log(` Judging: ${a.config} vs ${b.config}...`); + const judgment = runJudge(topic.topic, first.content, second.content, first.config, second.config, pairwiseTmpDir, cwd); + + if (judgment) { + const winnerLabel = judgment.winner === "a" ? first.config : judgment.winner === "b" ? second.config : "TIE"; + const scoreA = flip ? judgment.b : judgment.a; + const scoreB = flip ? judgment.a : judgment.b; + + reportLines.push(`**${a.config} vs ${b.config}**: Winner = **${winnerLabel}**`); + reportLines.push(` ${a.config}: total=${scoreA.total}, ${b.config}: total=${scoreB.total}`); + reportLines.push(` Reason: ${judgment.reason}`); + reportLines.push(""); + + console.log(` Winner: ${winnerLabel} (${judgment.reason})`); + } else { + reportLines.push(`**${a.config} vs ${b.config}**: Judge failed`); + reportLines.push(""); + } + } + } + } + + try { + fs.rmSync(pairwiseTmpDir, { recursive: true, force: true }); + } catch {} + } + + // Aggregate summary + reportLines.push("\n## Aggregate Summary\n"); + reportLines.push("| Config | Avg Coverage (weighted) | Avg Traps Caught | Avg Duration |"); + reportLines.push("|--------|----------------------|-----------------|-------------|"); + + for (const configName of configNames) { + const coverages = []; + const trapScores = []; + const durations = []; + + for (const topic of topics) { + const e = allEvals[topic.name][configName]; + if (e && e.success) { + coverages.push(e.checklist.coverage_weighted); + trapScores.push(e.traps.score); + durations.push(e.duration_ms); + } + } + + if (coverages.length > 0) { + const avgCov = Math.round(coverages.reduce((a, b) => a + b, 0) / coverages.length); + const avgTraps = Math.round(trapScores.reduce((a, b) => a + b, 0) / trapScores.length); + const avgDur = Math.round(durations.reduce((a, b) => a + b, 0) / durations.length / 1000); + reportLines.push(`| ${configName} | ${avgCov}% | ${avgTraps}% | ${avgDur}s |`); + } else { + reportLines.push(`| ${configName} | FAILED | FAILED | FAILED |`); + } + } + + // Write report + const reportPath = path.join(runDir, "REPORT.md"); + fs.writeFileSync(reportPath, reportLines.join("\n")); + console.log(`\n━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━`); + console.log(` Report: ${reportPath}`); + console.log(` Outputs: ${runDir}/`); + console.log(`━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━`); +} + +main().catch((err) => { + console.error(`Fatal: ${err.message}`); + process.exit(1); +}); diff --git a/tests/smoke-claude-XXXX.md b/tests/smoke-claude-XXXX.md new file mode 100644 index 0000000..5851b4d --- /dev/null +++ b/tests/smoke-claude-XXXX.md @@ -0,0 +1,112 @@ +--- +topic: "Should a new Python project prefer spaces or tabs?" +mode: council +max_rounds: 1 +git_commit: none +agent_a: "Claude" +agent_b: "Claude" +agent_a_cli: "claude" +agent_b_cli: "claude" +agent_a_lens: "risk/cost/failure" +agent_b_lens: "value/opportunity/success" +status: consensus +turn: A +round: 2 +created: 2026-03-16T00:00:00Z +last_updated: 2026-03-16T12:21:57.570Z +--- + +# Discussion: Should a new Python project prefer spaces or tabs? + +## Key Questions +1. Which choice aligns better with Python ecosystem defaults? +2. Which choice is less risky for collaboration and tooling? +3. Are there any meaningful advantages to the alternative? + +## Research Phase + +### Agent A — Independent Research | research + +**The risk calculus overwhelmingly penalizes tabs in Python.** + +**Hard failure mode — Python 3 rejects mixed indentation.** Python 3 raises `TabError` on mixed tabs and spaces within a single block (PEP 8, Python docs §2.1.8). A single contributor's editor misconfiguration silently introduces a mix, and the code fails at parse time — not at the offending line, but at the *next* indentation change, making debugging non-obvious. + +**Tooling fragility.** Core ecosystem tools assume 4-space indentation: `black` (the dominant autoformatter) enforces spaces and has no tab mode. `isort`, `flake8`, `pycodestyle` (E101/W191) all flag tabs by default. Choosing tabs means fighting your linter config from day one or disabling checks that catch real bugs. + +**Collaboration cost.** PEP 8 mandates 4 spaces. Every `git diff`, GitHub PR review, and CI pipeline renders tabs at platform-default width (often 8), producing unreadable diffs. New contributors familiar with Python conventions will default to spaces, creating merge friction. + +**Edge cases:** heredoc strings, `textwrap.dedent`, YAML generation, and Makefile interop (which *requires* tabs) create boundary zones where indentation semantics clash. Spaces give consistent byte-width; tabs do not. + +**The one legitimate tab advantage** — accessibility (configurable display width for visually impaired developers) — is real but addressable via editor settings without changing the source encoding. + +**Bottom line:** tabs in Python are a latent defect generator with ecosystem-wide friction. + +### Agent B — Independent Research | research + +**Spaces (4-space indent) are the clear winner for new Python projects.** The evidence is overwhelming: + +**PEP 8 alignment.** Python's official style guide explicitly recommends 4 spaces. Following PEP 8 from day one means zero friction with linters (`flake8`, `pylint`), formatters (`black`, `autopep8`, `ruff format`), and CI pipelines. Black — now the de facto standard formatter — enforces spaces with no option for tabs. + +**Ecosystem consistency.** The Python standard library uses spaces. Django, Flask, FastAPI, SQLAlchemy, NumPy, pandas — virtually every major library uses spaces. CPython's own C code style guide switched to spaces. A new project using spaces can copy/paste from documentation, tutorials, and Stack Overflow answers without indent mismatches. + +**Tooling success cases.** Projects adopting `ruff` or `black` on day one report near-zero style bikeshedding in code review. Spaces are the non-negotiable default in both. This is a solved problem — choosing spaces means you inherit battle-tested tooling for free. + +**Collaboration upside.** GitHub, GitLab, and most code review tools render spaces consistently. Mixed-indent bugs (the `TabError` exception) become impossible. Onboarding new contributors is frictionless because spaces match every Python tutorial written in the last decade. + +**Key uncertainty:** Teams with strong accessibility needs (e.g., developers using braille displays) may benefit from tabs' configurable width — a legitimate but niche consideration. + +--- + +## Discussion + +### Round 1 — Agent A | response | confidence: 97% + +**Response to previous point:** +Agent B's strongest claim: choosing spaces means you inherit the entire Python tooling ecosystem — black, ruff, flake8, autopep8 — with zero configuration. This isn't just convenience; it's a *structural cost elimination*. Every hour not spent fighting linter configs or debugging `TabError` in CI is an hour spent on the actual product. I agree fully. There is nothing in B's research I find insufficient — it's the same conclusion arrived at from the opportunity side of the same evidence. + +**New evidence or angle:** +One risk worth naming explicitly: the **cost of revisiting this decision later is high**. If a project starts with tabs and later needs to switch (e.g., adopting black, onboarding a contributor who submits spaces), the migration produces a single massive commit that touches every file, pollutes `git blame`, and makes bisecting regressions across that boundary painful. Starting with spaces eliminates this migration risk entirely because there is no plausible future where the Python ecosystem shifts to tabs. The arrow of tooling standardization points one direction only. + +**Current position:** +Spaces, 4-indent, enforced by an autoformatter (black or ruff) from commit zero. Confidence 97% — the 3% residual is the accessibility edge case, which I believe is real but best solved at the editor/display layer rather than the source encoding layer. + +**Question for Agent B:** +Do you see *any* scenario where a new Python project in 2026 should choose tabs — even a narrow one — or are we at full convergence? + +### Round 1 — Agent B | response | confidence: 98% + +**Response to previous point:** +Agent A's strongest contribution is the **irreversibility argument**: migrating from tabs to spaces later produces a blame-polluting mega-commit with real bisection costs, while the reverse migration (spaces to tabs) would never be needed because the ecosystem trajectory is unidirectional. This is the most compelling framing I've seen — it reframes the choice not as "spaces vs. tabs" but as "reversible vs. irreversible decision," and spaces are the only reversibility-safe option. I fully agree and have nothing to challenge in A's analysis. + +**New evidence or angle:** +I think we've reached full convergence on the core question, so let me directly answer A's question: **No, I cannot construct a credible scenario where a new Python project in 2026 should choose tabs.** The accessibility argument — the strongest remaining case for tabs — has been effectively decoupled from the source-encoding question by modern editors and IDE features (VS Code's `editor.tabSize`, configurable indent guides, elastic tabstops plugins). A visually impaired developer can set their editor to render 4 spaces at any visual width they prefer. The accommodation happens at the display layer without imposing encoding constraints on the team. + +One additional positive framing worth naming: choosing spaces is a **decision-elimination benefit**. By aligning with PEP 8, black, and ruff defaults, the team removes indentation from the decision space entirely. This is an underappreciated form of value — every convention question that never gets asked is cognitive overhead that never gets spent. New Python projects in 2026 should treat "4 spaces, enforced by ruff/black" not as a style choice but as a **default that requires justification to override**, similar to "use UTF-8" or "use git." + +**Current position:** +Spaces (4-indent), enforced by autoformatter from the first commit. Confidence 98% — the 2% is not allocated to tabs being correct but to the possibility I'm overlooking an exotic deployment context (e.g., embedded MicroPython on storage-constrained devices where tab = 1 byte vs. 4 bytes) that I haven't researched. Even there, I suspect spaces still win on tooling grounds. + +**Question for Agent A:** +Given full convergence, is there value in our synthesis naming the **one concrete action** beyond "use spaces" — namely, adding a formatter to pre-commit hooks at project init — as the real recommendation? The indentation question is settled; the implementation mechanism is where teams still sometimes fail to follow through. + +--- + +## Consensus Summary + +### Decision +A new Python project should use 4-space indentation, enforced by an autoformatter (black or ruff) from the first commit. This aligns with PEP 8, the entire Python tooling ecosystem, and eliminates indentation as a source of friction, bugs, or future migration cost. The recommendation should be treated not as a style preference but as a ecosystem default that requires justification to override. + +### Key Contention Points + +| # | What We Disagreed On | How It Was Resolved | Who Shifted & Why | +|---|---------------------|--------------------|--------------------| +| 1 | No substantive disagreement arose | Both agents independently reached the same conclusion from complementary lenses (risk vs. opportunity) | Neither shifted — convergence was immediate | +| 2 | Whether any edge case (accessibility, storage constraints) justifies tabs | Both agreed accessibility is real but best solved at the editor/display layer, not source encoding | Mutual agreement; no shift needed | +| 3 | Whether the recommendation should extend beyond "use spaces" to "enforce via pre-commit hooks" | Agent B proposed this as the actionable implementation step; Agent A implicitly agreed by advocating formatter enforcement "from commit zero" | Convergence on implementation, not just principle | + +### Unresolved Items & Risks +- Exotic deployment contexts (e.g., MicroPython on storage-constrained devices) were acknowledged but not researched — tabs' 1-byte-vs-4 advantage may matter there, though tooling friction likely still favors spaces +- The specific choice between black and ruff as the enforcing formatter was not adjudicated, though both enforce spaces and either suffices + +### Confidence: High +Both agents converged independently at 97-98% confidence with no contested points; the Python ecosystem's standardization on spaces is effectively settled fact. diff --git a/tests/smoke-cross-XXXX.md b/tests/smoke-cross-XXXX.md new file mode 100644 index 0000000..288bed7 --- /dev/null +++ b/tests/smoke-cross-XXXX.md @@ -0,0 +1,107 @@ +--- +topic: "Should a new Python project prefer spaces or tabs?" +mode: council +max_rounds: 1 +git_commit: none +agent_a: "Claude" +agent_b: "Codex" +agent_a_cli: "claude" +agent_b_cli: "codex" +agent_a_lens: "risk/cost/failure" +agent_b_lens: "value/opportunity/success" +status: consensus +turn: A +round: 2 +created: 2026-03-16T00:00:00Z +last_updated: 2026-03-16T12:28:57.857Z +--- + +# Discussion: Should a new Python project prefer spaces or tabs? + +## Key Questions +1. Which choice aligns better with Python ecosystem defaults? +2. Which choice is less risky for collaboration and tooling? +3. Are there any meaningful advantages to the alternative? + +## Research Phase + +### Agent A — Independent Research | research + +**The risk calculus overwhelmingly punishes tabs in Python.** + +**Hard failure: Python 3 forbids mixing.** Python 3 raises `TabError` on mixed indentation within a single block. In Python 2, tabs and spaces could silently coexist, creating logic bugs where visually-identical code executed differently. Python 3 made this a hard error — but this *increases* the cost of choosing tabs, because the entire ecosystem has standardized on spaces post-PEP 8, meaning any copy-pasted snippet, Stack Overflow answer, or third-party contribution will likely use spaces and immediately conflict. + +**Tooling friction is real.** PEP 8 mandates 4 spaces. `black`, `ruff`, `autopep8`, `isort`, and virtually every Python linter/formatter defaults to spaces. Choosing tabs means fighting defaults on every tool, every CI config, every pre-commit hook. This is ongoing maintenance cost, not a one-time setup. + +**Contributor onboarding risk.** New contributors will submit PRs with spaces. Every single one. You'll burn review cycles on whitespace — or you'll get mixed indentation that breaks builds. + +**The accessibility argument for tabs** (users can set display width) is legitimate but narrow. Editor soft-tab settings solve this for spaces too, and `.editorconfig` standardizes it. + +**Edge case: `makefile`-style heredocs and multiline strings** — tab/space confusion in triple-quoted strings can produce subtle data bugs that pass tests but corrupt output. + +**Bottom line:** choosing tabs for a new Python project is swimming against a mass-consensus current. The risk isn't that tabs are technically inferior — it's that the ecosystem will constantly punish the deviation. + +### Agent B — Independent Research | research + +For a new Python project, the strongest success case is to prefer 4-space indentation. The official Python style guide is explicit: “Use 4 spaces per indentation level,” “Spaces are the preferred indentation method,” and tabs should be used only to stay consistent with existing tab-indented code (PEP 8: https://peps.python.org/pep-0008/). For a greenfield project, that means spaces are the default that best matches the language’s published convention. + +What could go right with spaces is mostly about friction reduction. New contributors already expect PEP 8 formatting, so onboarding is easier and code reviews spend less time on editor-specific behavior. Python’s own lexer documentation also supports this choice operationally: tabs are expanded to 8-column boundaries, and mixed indentation can raise `TabError`; the docs further warn that mixing tabs and spaces is unwise for cross-platform compatibility because editors differ in how they handle them (Python lexical analysis: https://docs.python.org/3/reference/lexical_analysis.html). That is a concrete benefit for multi-OS teams and long-lived repos. + +The Windows FAQ reinforces the same pattern: it recommends configuring editors to insert spaces, notes that PEP 8 recommends 4 spaces for distributed Python code, and points out this is also the Emacs `python-mode` default (https://docs.python.org/3/faq/windows.html). + +Uncertainty: tabs can still work if a project is already tab-based and rigorously consistent. But for a new project, spaces maximize compatibility, predictability, and ecosystem alignment. + +--- + +## Discussion + +### Round 1 — Claude | response | confidence: 97% + +**Response to previous point:** +Agent B's strongest argument: spaces win not on abstract merit but on *concrete friction reduction* — PEP 8 compliance, zero-config tooling, contributor expectations, and Python's own lexer treating tabs as 8-column boundaries (which surprises anyone expecting 4). This is well-supported and I agree with it fully. The argument isn't "spaces are theoretically better indentation" — it's "the entire Python ecosystem has already made this decision for you, and deviating has measurable ongoing cost." + +I have no substantive disagreement with Agent B's position. The evidence converges. + +**New evidence or angle:** +One angle neither of us emphasized enough: **`git diff` and `git blame` noise.** If a project ever flips from tabs to spaces (or vice versa), every line in every file shows as changed, destroying blame history and making forensic debugging harder. Choosing spaces from day one avoids this irreversible cost — because if you start with tabs, the pressure to convert will only grow as the project matures and more ecosystem tools assume spaces. Starting with spaces means you'll never face a forced migration. Starting with tabs means you probably will. + +**Current position:** +4 spaces, ~97% confidence. The remaining 3% is the accessibility argument for tabs (configurable display width for visually impaired developers), which is real but addressable through editor settings and `.editorconfig` rather than changing the indentation character. I cannot construct a realistic scenario where a *new* Python project benefits from choosing tabs over spaces. + +**Question for Agent B:** +Is there any scenario — team composition, tooling constraint, upstream dependency — where you'd recommend tabs for a new Python project, or do you consider this effectively a settled question? + +### Round 1 — Codex | response | confidence: 98% + +**Response to previous point:** +Claude’s strongest point is that the real downside of tabs is not aesthetics, it is compounding operational cost: the ecosystem has already standardized on 4 spaces, so tabs create avoidable breakage in tooling, copy-pasted examples, and external contributions, and can eventually force a repo-wide migration that destroys `git blame` continuity. I agree with that, and the `git diff` / `git blame` angle is especially persuasive because it turns “we can be consistent with tabs” into a short-term claim that often collapses as a project grows. My synthesis is stronger than “spaces are safer”: spaces are the choice that preserves optionality and avoids future cleanup work. + +**New evidence or angle:** +A useful third option is to separate “Python code style” from “all files in the repo.” For `.py` files, spaces should be the rule. For file types with different conventions or requirements, such as `Makefile`s, the repo can still allow tabs where the format demands them. That means a new Python project does not need a blanket ideological stance against tabs; it needs a precise repo policy, usually encoded in `.editorconfig`, that says “spaces for Python, tabs only where required.” This keeps accessibility and file-format edge cases from becoming arguments against the default for Python itself. + +**Current position:** +Prefer 4 spaces for a new Python project, ~98% confidence, because it aligns with PEP 8, avoids lexer and tooling surprises, lowers contributor friction, and prevents future migration noise. The remaining uncertainty is not about Python files; it is about whether the final recommendation should explicitly carve out non-Python file exceptions so teams do not overgeneralize the rule. + +**Question for Agent A:** +Do you agree the cleanest final recommendation is “spaces for all Python source files, with tabs allowed only in file types that explicitly require them,” rather than framing this as a repo-wide ban on tabs? + +--- + +## Consensus Summary + +### Decision +A new Python project should use 4 spaces for indentation in all `.py` files, with tabs permitted only in file types that explicitly require them (e.g., `Makefile`s). This aligns with PEP 8, eliminates tooling and contributor friction, and avoids a future forced migration that would destroy `git blame` history. The recommendation should be encoded in `.editorconfig` for precision. + +### Key Contention Points + +| # | What We Disagreed On | How It Was Resolved | Who Shifted & Why | +|---|---------------------|--------------------|--------------------| +| 1 | Whether this is purely a Python question or a repo-wide policy question | Codex reframed the recommendation as file-type-specific rather than a blanket ban on tabs; Claude agreed this was the cleaner formulation | Both converged — Claude implicitly treated it as Python-only; Codex made the scoping explicit | +| 2 | Weight of the accessibility argument for tabs | Both acknowledged configurable display width is a real benefit of tabs but agreed it is addressable via editor settings and `.editorconfig` without changing the indentation character for Python files | Neither shifted — both held this was a minor consideration from the start | + +### Unresolved Items & Risks +- The final recommendation should explicitly call out `.editorconfig` as the enforcement mechanism, but neither agent specified exact config values — teams should define this during project setup. +- The accessibility benefit of tabs (user-configurable display width) remains a legitimate concern for visually impaired developers; teams with specific accessibility requirements may want to evaluate editor-level accommodations rather than relying solely on spaces. + +### Confidence: High +Both agents independently converged at 97–98% confidence with no substantive disagreement on the core recommendation; the only refinement was scoping precision.